[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fH-JbYHZfvFcNtzeRHpfK-cJJyGsTaT0LtWC0r_1ImLA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Johns Hopkins University",[4],1777,false,392,86,6443120,158,1163,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Hypertension",40,{"name":18,"count":19},"Obesity",31,{"name":21,"count":22},"Asthma",29,{"name":24,"count":25},"HIV",26,{"name":27,"count":25},"Depression",{"name":29,"count":30},"HIV Infections",24,{"name":32,"count":33},"Stroke",22,{"name":35,"count":33},"Tuberculosis",[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03730649","Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure","2025-03-01","Sulforaphane",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03101891","Renal Anhydramnios Fetal Therapy","2025-03-10","Isotonic fluid",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05695196","Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant","2025-05-06","nasal microbiota transplant",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05324982","Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants","2025-12","Oral Placebo",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05895929","The Role of IL5 in Epithelial Cell Integrity","2025-12-31","Mepolizumab",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06089707","Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl","2026-01-01","Naloxone Nasal Spray",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04620759","Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","2026-03-02","Psilocybin",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05741658","The Fontan Dapagliflozin Pilot Study","2026-04","Dapagliflozin 10mg Tab",{"nctId":78,"briefTitle":79,"date":80,"intervention":71},"NCT06407635","A Study of Psilocybin for PTSD","2026-05",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT05378100","Ketamine for Multiple Sclerosis Fatigue","2026-05-21","Ketamine",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,170,233,278,318,357,375,402,420,443,461,479,501,528,546,564,588,613,660,732,769,861,909,945,967,989,1011,1033,1061,1083,1110,1128,1146,1174,1192,1210,1236,1254,1272,1298,1325,1351,1378,1396,1414,1434,1452,1478,1503,1532,1560,1843,1960,2009,2043,2079,2190,2232,2267,2319,2350,2390,2426,2458,2483,2508,2530,2552,2578,2596,2614,2632,2655,2679,2703,2727,2751,2776,2794,2818,2841,2859,2877,2902,2920,2946,2969,2994,3012,3036,3062,3087,3105,3134,3158,3185,3203,3274,3317,3362,3405,3465,3506,3541,3567,3612,3647,3676,3698,3716,3738,3762,3780,3806,3824,3851,3869,3892,3917,3940,3970,3994,4012,4030,4048,4066,4084,4102,4120,4138,4156,4174,4192,4210,4228,4250,4273,4307,4337,4358,4376,4394,4418,4441,4465,4498,4525,4550,4576,4594,4612,4639,4663,4681,4707,4725,4752,4776,4794,4861,4932,4983,5030,5057,5085,5122,5156,5190,5215,5246,5271,5289,5307,5331,5349,5367,5392,5410,5434,5460,5478,5502,5527,5545,5567,5592,5610,5636,5654,5677,5705,5723,5746,5773,5796,5814,5838,5862,5889,5907,5925,5943,5966,5991,6009,6033,6051,6069,6091,6115,6133,6151,6169,6193,6216,6240,6263,6286,6304,6327,6351,6374,6398,6421,6439,6463,6481,6499,6525,6547,6570,6591,6615,6633,6656,6679,6697,6720,6747,6770,6788,6812,6836,6854,6884,6902,6920,6943,6961,6979,6997,7021,7039,7061,7085,7164,7197,7229,7253,7271,7294,7312,7336,7360,7385,7409,7439,7457,7475,7497,7521,7547,7572,7590,7612,7635,7653,7677,7700,7724,7742,7768,7786,7804,7822,7840,7858,7876,7900,7918,7942,7960,7984,8002,8020,8045,8063,8088,8110,8133,8151,8206,8251,8286,8327,8361,8391,8424,8458,8490,8522,8554,8585,8617,8646,8676,8715,8746,8782,8804,8836,8861,8879,8897,8922,8940,8958,8976,8994,9016,9039,9062,9080,9102,9126,9150,9175,9197,9220,9244,9262,9284,9308,9331,9352,9370,9388,9414,9435,9457,9480,9503,9530,9548,9572,9599,9617,9641,9664,9688,9706,9728,9750,9773,9794,9812,9837,9859,9881,9907,9931,9949,9973,9991,10009,10027,10045,10069,10093,10116,10138,10160,10185,10208,10231,10255,10280,10298,10316,10334,10357,10375,10393,10415,10433,10456,10479,10497,10519,10542,10565,10587,10609,10635,10653,10671,10693,10719,10742,10760,10783,10808,10826,10849,10874,10899,10917,10935,10953,10978,10996,11014,11032,11050,11068,11090,11113,11136,11161,11179,11197,11222,11245,11266,11293,11311,11336,11354,11380,11407,11431,11453,11478,11500,11524,11542,11560,11584,11605,11627,11649,11673,11691,11709,11732,11754,11772,11790,11808,11826,11844,11862,11884,11902,11927,11949,11975,11993,12011,12029,12047,12065,12089,12111,12132,12154,12175,12199,12224,12242,12260,12281,12299,12317,12347,12369,12402,12435,12466,12488,12506,12524,12542,12560,12578,12600,12625,12649,12671,12693,12716,12738,12762,12780,12802,12829,12851,12873,12897,12919,12943,12965,12989,13007,13025,13047,13071,13089,13107,13130,13151,13169,13190,13215,13233,13251,13269,13291,13312,13337,13355,13379,13401,13419,13443,13461,13484,13502,13529,13547,13565,13590,13614,13643,13661,13679,13697,13715,13737,13761,13783,13806,13824,13842,13863,13886,13904,13922,13943,13967,13985,14009,14027,14045,14067,14092,14110,14128,14146,14175,14203,14227,14255,14280,14306,14331,14354,14372,14396,14420,14443,14467,14489,14510,14528,14552,14576,14594,14627,14645,14663,14681,14699,14717,14735,14753,14776,14794,14812,14830,14848,14870,14888,14917,14943,14961,14988,15006,15024,15042,15060,15083,15146,15183,15213,15251,15289,15321,15353,15380,15413,15439,15464,15497,15526,15559,15589,15622,15652,15674,15698,15716,15734,15762,15780,15805,15827,15850,15872,15897,15915,15937,15960,15986,16004,16022,16040,16064,16082,16100,16118,16142,16160,16183,16205,16230,16248,16274,16292,16310,16332,16354,16378,16396,16420,16438,16456,16478,16500,16526,16544,16565,16590,16620,16647,16665,16683,16704,16726,16744,16768,16791,16814,16837,16861,16879,16903,16921,16944,16969,16992,17010,17034,17057,17075,17093,17117,17140,17158,17183,17206,17231,17249,17272,17295],{"intervention":95,"totalTrials":96,"cells":97},"Methylphenidate",5,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":127,"PHASE3":129,"PHASE4":144,"NA":168},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":126,"soonestReadout":120},[103,115],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT03652740","Effects of Commonly Used Medications on Mood and Choice","COMPLETED",[88],"2024-02-01","2018-10-02",25,[112],"Healthy",[95,114],"Nicotine",{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":16,"conditions":123,"interventions":125},"NCT06355414","Psilocybin in Chronic Low Back Pain and Depression","RECRUITING",[88],"2026-07-30","2026-08-30","2024-04-22",[124,27],"Chronic Low-back Pain",[71,95],1,{"trials":128,"activeCount":100},[],{"trials":130,"activeCount":100},[131],{"nctId":132,"briefTitle":133,"status":106,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT03185065","Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis",[90],"2019-11-21","2017-10-04",141,[139],"Fatigue in Multiple Sclerosis",[141,142,95,143],"Amantadine","Modafinil","Placebos",{"trials":145,"activeCount":126,"soonestReadout":161},[146,157],{"nctId":147,"briefTitle":148,"status":149,"phases":150,"primaryCompletion":151,"completion":152,"start":153,"enrollment":100,"conditions":154,"interventions":156},"NCT06077669","Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD","WITHDRAWN",[91],"2028-12","2029-01","2024-04-16",[155],"ADHD",[95],{"nctId":158,"briefTitle":159,"status":118,"phases":160,"primaryCompletion":161,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":167},"NCT04781972","Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD",[91],"2028-11-30","2029-04-30","2021-07-27",30,[166],"ADHD - Combined Type",[95],{"trials":169,"activeCount":100},[],{"intervention":143,"totalTrials":96,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":201,"PHASE4":207,"NA":231},{"trials":173,"activeCount":100},[],{"trials":175,"activeCount":100},[],{"trials":177,"activeCount":100},[178,189],{"nctId":179,"briefTitle":180,"status":106,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT04082442","Evolocumab in Patients With Acute MI",[89],"2024-10-25","2019-09-01",100,[186],"Acute Coronary Syndrome",[188,143],"Evolocumab",{"nctId":190,"briefTitle":191,"status":106,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":199},"NCT04287062","Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder",[89],"2025-08-15","2020-11-20",138,[197,198],"Sleep Disturbance","Opioid-use Disorder",[200,143],"Suvorexant",{"trials":202,"activeCount":100},[203],{"nctId":132,"briefTitle":133,"status":106,"phases":204,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":205,"interventions":206},[90],[139],[141,142,95,143],{"trials":208,"activeCount":126,"soonestReadout":213},[209,220],{"nctId":210,"briefTitle":211,"status":118,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"NCT03935295","Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis",[91],"2026-12-31","2020-09-03",90,[217],"Adolescent Idiopathic Scoliosis",[219,143],"AbobotulinumtoxinA",{"nctId":221,"briefTitle":222,"status":106,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT00245518","Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy",[91],"2008-09","2005-06",39,[228],"Hot Flashes",[230,143],"Isoflavone",{"trials":232,"activeCount":100},[],{"intervention":234,"totalTrials":235,"cells":236},"Nicotine Replacement Product",3,{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":276},{"trials":238,"activeCount":100},[],{"trials":240,"activeCount":100},[],{"trials":242,"activeCount":100},[],{"trials":244,"activeCount":100},[],{"trials":246,"activeCount":126,"soonestReadout":271},[247,257,267],{"nctId":248,"briefTitle":249,"status":106,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":96,"conditions":254,"interventions":256},"NCT06289192","Testing C-Raven, a Virtual Tobacco Cessation Intervention, in the Community",[91],"2024-08-23","2024-08-27","2024-04-30",[255],"Tobacco Dependence",[234],{"nctId":258,"briefTitle":259,"status":106,"phases":260,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":266},"NCT06545669","C-Raven, a Virtual Tobacco Cessation Intervention in the Community",[91],"2025-10-17","2026-01-16","2024-10-30",10,[255],[234],{"nctId":268,"briefTitle":269,"status":118,"phases":270,"primaryCompletion":271,"completion":272,"start":273,"enrollment":164,"conditions":274,"interventions":275},"NCT07220356","C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics",[91],"2026-06-30","2027-06-30","2025-12-10",[255],[234],{"trials":277,"activeCount":100},[],{"intervention":279,"totalTrials":280,"cells":281},"Ublituximab",2,{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":316},{"trials":283,"activeCount":100},[],{"trials":285,"activeCount":100},[286],{"nctId":287,"briefTitle":288,"status":106,"phases":289,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":297},"NCT02276963","Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses",[88],"2017-07","2019-02-15","2016-01",6,[295,296],"Neuromyelitis Optica","Neuromyelitis Optica Spectrum Disorder",[279],{"trials":299,"activeCount":100},[],{"trials":301,"activeCount":100},[],{"trials":303,"activeCount":126,"soonestReadout":308},[304],{"nctId":305,"briefTitle":306,"status":118,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT07389590","Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis",[91],"2028-10","2029-03","2026-02-10",50,[313],"Multiple Sclerosis",[279,315],"Ocrelizumab",{"trials":317,"activeCount":100},[],{"intervention":319,"totalTrials":280,"cells":320},"Acetaminophen",{"EARLY_PHASE1":321,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":355},{"trials":322,"activeCount":100},[323],{"nctId":324,"briefTitle":325,"status":106,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":332},"NCT02366065","Does Oral Acetaminophen Lower Intraocular Pressure?",[87],"2016-05","2015-01",11,[331],"Glaucoma",[319],{"trials":334,"activeCount":100},[],{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":100},[],{"trials":340,"activeCount":126,"soonestReadout":345},[341],{"nctId":342,"briefTitle":343,"status":118,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":352},"NCT06434233","Opioid Use After Laparoscopic Salpingectomy",[91],"2026-11","2024-04-25",120,[349,350,351],"Opioid Use","Post-operative Pain","Sterility, Female",[319,353,354],"Ibuprofen","Oxycodone",{"trials":356,"activeCount":100},[],{"intervention":219,"totalTrials":126,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":373},{"trials":360,"activeCount":100},[],{"trials":362,"activeCount":100},[],{"trials":364,"activeCount":100},[],{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":126,"soonestReadout":213},[369],{"nctId":210,"briefTitle":211,"status":118,"phases":370,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":371,"interventions":372},[91],[217],[219,143],{"trials":374,"activeCount":100},[],{"intervention":376,"totalTrials":126,"cells":377},"Transdermal estrogen",{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":400},{"trials":379,"activeCount":100},[],{"trials":381,"activeCount":100},[],{"trials":383,"activeCount":100},[],{"trials":385,"activeCount":100},[],{"trials":387,"activeCount":126,"soonestReadout":392},[388],{"nctId":389,"briefTitle":390,"status":118,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":398},"NCT05704036","Estrogen Supplementation and Bone Health in Women With CF",[91],"2027-01","2023-05-02",75,[396,397],"Cystic Fibrosis","Hypoestrogenism",[376,399],"Progesterone",{"trials":401,"activeCount":100},[],{"intervention":399,"totalTrials":126,"cells":403},{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":412,"NA":418},{"trials":405,"activeCount":100},[],{"trials":407,"activeCount":100},[],{"trials":409,"activeCount":100},[],{"trials":411,"activeCount":100},[],{"trials":413,"activeCount":126,"soonestReadout":392},[414],{"nctId":389,"briefTitle":390,"status":118,"phases":415,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":416,"interventions":417},[91],[396,397],[376,399],{"trials":419,"activeCount":100},[],{"intervention":421,"totalTrials":126,"cells":422},"Osilodrostat",{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":441},{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":100},[],{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":126,"soonestReadout":151},[433],{"nctId":434,"briefTitle":435,"status":118,"phases":436,"primaryCompletion":151,"completion":309,"start":437,"enrollment":264,"conditions":438,"interventions":440},"NCT07247058","Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)",[91],"2026-02-02",[439],"Mild Autonomous Cortisol Secretion (MACS)",[421],{"trials":442,"activeCount":100},[],{"intervention":353,"totalTrials":126,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":459},{"trials":446,"activeCount":100},[],{"trials":448,"activeCount":100},[],{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"trials":454,"activeCount":126,"soonestReadout":345},[455],{"nctId":342,"briefTitle":343,"status":118,"phases":456,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":457,"interventions":458},[91],[349,350,351],[319,353,354],{"trials":460,"activeCount":100},[],{"intervention":354,"totalTrials":126,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":477},{"trials":464,"activeCount":100},[],{"trials":466,"activeCount":100},[],{"trials":468,"activeCount":100},[],{"trials":470,"activeCount":100},[],{"trials":472,"activeCount":126,"soonestReadout":345},[473],{"nctId":342,"briefTitle":343,"status":118,"phases":474,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":475,"interventions":476},[91],[349,350,351],[319,353,354],{"trials":478,"activeCount":100},[],{"intervention":76,"totalTrials":126,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":489,"NA":499},{"trials":482,"activeCount":100},[],{"trials":484,"activeCount":100},[],{"trials":486,"activeCount":100},[],{"trials":488,"activeCount":100},[],{"trials":490,"activeCount":126,"soonestReadout":75},[491],{"nctId":73,"briefTitle":74,"status":492,"phases":493,"primaryCompletion":75,"completion":494,"start":495,"enrollment":22,"conditions":496,"interventions":498},"ENROLLING_BY_INVITATION",[91],"2026-06","2023-11-08",[497],"Heart Failure",[76],{"trials":500,"activeCount":100},[],{"intervention":502,"totalTrials":126,"cells":503},"Dupilumab - Discontinuation",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":526},{"trials":505,"activeCount":100},[],{"trials":507,"activeCount":100},[],{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":126,"soonestReadout":518},[514],{"nctId":515,"briefTitle":516,"status":118,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":164,"conditions":521,"interventions":523},"NCT06116526","Dupilumab De-escalation in Pediatric Atopic Dermatitis",[91],"2027-04-01","2027-04-30","2024-04-01",[522],"Atopic Dermatitis",[502,524,525],"Dupilumab - Dose Reduction","Dupilumab - Standard Dose",{"trials":527,"activeCount":100},[],{"intervention":524,"totalTrials":126,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":544},{"trials":531,"activeCount":100},[],{"trials":533,"activeCount":100},[],{"trials":535,"activeCount":100},[],{"trials":537,"activeCount":100},[],{"trials":539,"activeCount":126,"soonestReadout":518},[540],{"nctId":515,"briefTitle":516,"status":118,"phases":541,"primaryCompletion":518,"completion":519,"start":520,"enrollment":164,"conditions":542,"interventions":543},[91],[522],[502,524,525],{"trials":545,"activeCount":100},[],{"intervention":525,"totalTrials":126,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":556,"NA":562},{"trials":549,"activeCount":100},[],{"trials":551,"activeCount":100},[],{"trials":553,"activeCount":100},[],{"trials":555,"activeCount":100},[],{"trials":557,"activeCount":126,"soonestReadout":518},[558],{"nctId":515,"briefTitle":516,"status":118,"phases":559,"primaryCompletion":518,"completion":519,"start":520,"enrollment":164,"conditions":560,"interventions":561},[91],[522],[502,524,525],{"trials":563,"activeCount":100},[],{"intervention":565,"totalTrials":126,"cells":566},"Elucirem",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":575,"NA":586},{"trials":568,"activeCount":100},[],{"trials":570,"activeCount":100},[],{"trials":572,"activeCount":100},[],{"trials":574,"activeCount":100},[],{"trials":576,"activeCount":126,"soonestReadout":581},[577],{"nctId":578,"briefTitle":579,"status":118,"phases":580,"primaryCompletion":581,"completion":581,"start":582,"enrollment":110,"conditions":583,"interventions":585},"NCT05954559","High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment",[91],"2026-12","2025-08-01",[584],"Myocardial Fibrosis",[565],{"trials":587,"activeCount":100},[],{"intervention":589,"totalTrials":126,"cells":590},"sertraline 50 mg daily",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":599,"NA":611},{"trials":592,"activeCount":100},[],{"trials":594,"activeCount":100},[],{"trials":596,"activeCount":100},[],{"trials":598,"activeCount":100},[],{"trials":600,"activeCount":126,"soonestReadout":605},[601],{"nctId":602,"briefTitle":603,"status":118,"phases":604,"primaryCompletion":605,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":610},"NCT06704594","Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder",[91],"2029-07-01","2025-05-14",288,[609],"Premenstrual Dysphoric Disorder (PMDD)",[589],{"trials":612,"activeCount":100},[],{"intervention":315,"totalTrials":614,"cells":615},4,{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":649},{"trials":617,"activeCount":100},[],{"trials":619,"activeCount":100},[],{"trials":621,"activeCount":100},[],{"trials":623,"activeCount":100},[],{"trials":625,"activeCount":126,"soonestReadout":308},[626,630,640],{"nctId":305,"briefTitle":306,"status":118,"phases":627,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":628,"interventions":629},[91],[313],[279,315],{"nctId":631,"briefTitle":632,"status":106,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":264,"conditions":637,"interventions":639},"NCT04261790","Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis",[91],"2024-10-31","2024-11-01","2020-08-01",[638],"Multiple Sclerosis, Relapsing-Remitting",[315],{"nctId":641,"briefTitle":642,"status":106,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":264,"conditions":647,"interventions":648},"NCT03853746","Short-term B-cell Depletion in Relapsing Multiple Sclerosis",[91],"2024-03-01","2024-07-01","2019-04-01",[313],[315],{"trials":650,"activeCount":100},[651],{"nctId":652,"briefTitle":653,"status":106,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":110,"conditions":658,"interventions":659},"NCT03873389","Ocrelizumab Effects on the Metabolome in MS",[],"2023-06-22","2023-12-05","2019-06-12",[313],[315],{"intervention":661,"totalTrials":614,"cells":662},"Tacrolimus",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":728,"NA":730},{"trials":664,"activeCount":100},[],{"trials":666,"activeCount":100},[],{"trials":668,"activeCount":100},[],{"trials":670,"activeCount":235,"soonestReadout":581},[671,681,692,708],{"nctId":672,"briefTitle":673,"status":118,"phases":674,"primaryCompletion":581,"completion":581,"start":675,"enrollment":676,"conditions":677,"interventions":679},"NCT05252754","Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis",[90],"2023-01-18",4874,[678],"Post-ERCP Acute Pancreatitis",[661,680],"Rectal Indomethacin",{"nctId":682,"briefTitle":683,"status":118,"phases":684,"primaryCompletion":685,"completion":686,"start":687,"enrollment":16,"conditions":688,"interventions":690},"NCT05646992","Uterus Transplantation to Treat Infertility",[89,90],"2033-02-28","2043-02-28","2023-03-01",[689],"Uterine Factor Infertility",[661,691],"Imuran",{"nctId":693,"briefTitle":694,"status":106,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT00275509","Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch",[90],"2010-06","2007-01",56,[700],"Kidney Failure, Chronic",[702,703,704,661,705,706,707],"Thymoglobulin","Daclizumab","Mycophenolate mofetil","Dexamethasone","Prednisone","Cytogam",{"nctId":709,"briefTitle":710,"status":118,"phases":711,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":726},"NCT02395497","Human Penile Allotransplantation",[89,90],"2034-06","2039-06","2014-06",60,[717,718,719,720,721,722,723,724,725],"Amputation","Wounds and Injuries","Amputation, Traumatic","Urologic Surgical Procedures, Male","Amputation, Traumatic\u002FSurgery","Penis\u002FTransplantation","Penis\u002FSurgery","Penis\u002FInjuries","Congenital Anomaly, Male Genitalia",[727,661],"Monoclonal Antibody",{"trials":729,"activeCount":100},[],{"trials":731,"activeCount":100},[],{"intervention":733,"totalTrials":280,"cells":734},"Cannabidiol",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":747,"PHASE3":749,"PHASE4":765,"NA":767},{"trials":736,"activeCount":100},[],{"trials":738,"activeCount":126,"soonestReadout":581},[739],{"nctId":740,"briefTitle":741,"status":118,"phases":742,"primaryCompletion":581,"completion":581,"start":743,"enrollment":16,"conditions":744,"interventions":746},"NCT05015439","Cannabidiol (CBD) in Adults With ASD",[88],"2023-04-20",[745],"Autism Spectrum Disorder",[733],{"trials":748,"activeCount":100},[],{"trials":750,"activeCount":126,"soonestReadout":756},[751],{"nctId":752,"briefTitle":753,"status":754,"phases":755,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":764},"NCT07148843","Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving","NOT_YET_RECRUITING",[89,90],"2030-10","2030-10-31","2026-08-01",105,[761,762,763],"Alcohol Use Disorder (AUD)","Withdrawal From Addictive Substance; Detoxification","Craving",[733],{"trials":766,"activeCount":100},[],{"trials":768,"activeCount":100},[],{"intervention":770,"totalTrials":293,"cells":771},"Rifampin",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":833,"PHASE4":848,"NA":859},{"trials":773,"activeCount":100},[],{"trials":775,"activeCount":100},[],{"trials":777,"activeCount":100},[778,793,808,820],{"nctId":779,"briefTitle":780,"status":106,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":787},"NCT02256696","Assessing PA-824 for Tuberculosis (the APT Trial)",[89],"2022-05-01","2015-04-29",157,[786],"Pulmonary Tuberculosis",[788,770,789,790,791,792],"PA-824","Rifabutin","Pyrazinamide","Ethambutol","Isoniazid",{"nctId":794,"briefTitle":795,"status":106,"phases":796,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":802},"NCT03174184","Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin\u002FClavulanate in Adults With Pulmonary TB",[89],"2022-05-13","2017-08-23",112,[801],"Tuberculosis, Pulmonary",[770,803,804,805,806,807],"MEROPENEM 2 grams TID","MEROPENEM 1 gram TID","MEROPENEM 3 grams QD","Amoxicillin\u002FClavulanate Potassium 500 MG-125 MG Oral","Amoxicillin\u002FClavulanate Potassium 875 MG-125 MG Oral",{"nctId":809,"briefTitle":810,"status":106,"phases":811,"primaryCompletion":812,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":817},"NCT00814671","Study of Daily Rifapentine for Pulmonary Tuberculosis",[89],"2013-06","2014-09","2010-04",153,[35],[818,819,770],"Rifapentine 450","Rifapentine 600",{"nctId":821,"briefTitle":822,"status":106,"phases":823,"primaryCompletion":824,"completion":824,"start":825,"enrollment":22,"conditions":826,"interventions":827},"NCT01594827","Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)",[89],"2017-12-30","2012-10",[396],[828,770,829,830,831,832],"Inhaled Vancomycin","Trimethoprim\u002FSulfamethoxazole","Doxycycline","Mupirocin Intranasal Creme","4% chlorhexidine gluconate liquid skin cleanser",{"trials":834,"activeCount":126,"soonestReadout":839},[835],{"nctId":836,"briefTitle":837,"status":118,"phases":838,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":845},"NCT06253715","Shortened Regimen for Drug-susceptible TB in Children",[90],"2027-09-30","2025-01-15",860,[35,801,843,844],"Tuberculosis, Lymph Node","Mycobacterium Tuberculosis",[792,770,790,791,846,847],"Rifapentine","Moxifloxacin",{"trials":849,"activeCount":100},[850],{"nctId":851,"briefTitle":852,"status":149,"phases":853,"primaryCompletion":854,"completion":854,"start":855,"enrollment":100,"conditions":856,"interventions":858},"NCT02547116","Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis",[91],"2021-12","2020-12",[396,857],"MRSA",[770],{"trials":860,"activeCount":100},[],{"intervention":862,"totalTrials":235,"cells":863},"Varenicline",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":879,"PHASE4":894,"NA":907},{"trials":865,"activeCount":100},[],{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":100},[870],{"nctId":871,"briefTitle":872,"status":873,"phases":874,"primaryCompletion":290,"completion":290,"start":875,"enrollment":96,"conditions":876,"interventions":878},"NCT02683161","Pre to Postoperative Smoking Cessation","TERMINATED",[89],"2015-10",[877,18],"Cigarette Smoking",[862],{"trials":880,"activeCount":126,"soonestReadout":885},[881],{"nctId":882,"briefTitle":883,"status":118,"phases":884,"primaryCompletion":885,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":891},"NCT05413122","Evaluating Smoking Cessation Interventions for PWH in South Africa",[89,90],"2027-08-31","2023-11-27",660,[889,24,890],"Smoking Cessation","Comorbidities and Coexisting Conditions",[862,892,893],"Nicotine patch","Nicotine gum",{"trials":895,"activeCount":100},[896],{"nctId":897,"briefTitle":898,"status":106,"phases":899,"primaryCompletion":900,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":906},"NCT00944554","Relapse Prevention With Varenicline",[91],"2011-05","2008-10",104,[904,889,905],"Recurrence","Substance-Related Disorders",[862],{"trials":908,"activeCount":100},[],{"intervention":847,"totalTrials":235,"cells":910},{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":924,"PHASE3":935,"PHASE4":941,"NA":943},{"trials":912,"activeCount":100},[],{"trials":914,"activeCount":100},[915],{"nctId":916,"briefTitle":917,"status":873,"phases":918,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":923},"NCT00460759","Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine",[88],"2008-08-24","2007-06",15,[844],[847,846],{"trials":925,"activeCount":100},[926],{"nctId":927,"briefTitle":928,"status":106,"phases":929,"primaryCompletion":930,"completion":224,"start":931,"enrollment":932,"conditions":933,"interventions":934},"NCT00082173","Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis",[89],"2007-09","2004-10",170,[35],[847],{"trials":936,"activeCount":126,"soonestReadout":839},[937],{"nctId":836,"briefTitle":837,"status":118,"phases":938,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":939,"interventions":940},[90],[35,801,843,844],[792,770,790,791,846,847],{"trials":942,"activeCount":100},[],{"trials":944,"activeCount":100},[],{"intervention":790,"totalTrials":280,"cells":946},{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":957,"PHASE4":963,"NA":965},{"trials":948,"activeCount":100},[],{"trials":950,"activeCount":100},[],{"trials":952,"activeCount":100},[953],{"nctId":779,"briefTitle":780,"status":106,"phases":954,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":955,"interventions":956},[89],[786],[788,770,789,790,791,792],{"trials":958,"activeCount":126,"soonestReadout":839},[959],{"nctId":836,"briefTitle":837,"status":118,"phases":960,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":961,"interventions":962},[90],[35,801,843,844],[792,770,790,791,846,847],{"trials":964,"activeCount":100},[],{"trials":966,"activeCount":100},[],{"intervention":791,"totalTrials":280,"cells":968},{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":979,"PHASE4":985,"NA":987},{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":100},[],{"trials":974,"activeCount":100},[975],{"nctId":779,"briefTitle":780,"status":106,"phases":976,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":977,"interventions":978},[89],[786],[788,770,789,790,791,792],{"trials":980,"activeCount":126,"soonestReadout":839},[981],{"nctId":836,"briefTitle":837,"status":118,"phases":982,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":983,"interventions":984},[90],[35,801,843,844],[792,770,790,791,846,847],{"trials":986,"activeCount":100},[],{"trials":988,"activeCount":100},[],{"intervention":792,"totalTrials":280,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":1001,"PHASE4":1007,"NA":1009},{"trials":992,"activeCount":100},[],{"trials":994,"activeCount":100},[],{"trials":996,"activeCount":100},[997],{"nctId":779,"briefTitle":780,"status":106,"phases":998,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":999,"interventions":1000},[89],[786],[788,770,789,790,791,792],{"trials":1002,"activeCount":126,"soonestReadout":839},[1003],{"nctId":836,"briefTitle":837,"status":118,"phases":1004,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":1005,"interventions":1006},[90],[35,801,843,844],[792,770,790,791,846,847],{"trials":1008,"activeCount":100},[],{"trials":1010,"activeCount":100},[],{"intervention":846,"totalTrials":280,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1021,"PHASE3":1023,"PHASE4":1029,"NA":1031},{"trials":1014,"activeCount":100},[],{"trials":1016,"activeCount":100},[1017],{"nctId":916,"briefTitle":917,"status":873,"phases":1018,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":1019,"interventions":1020},[88],[844],[847,846],{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":126,"soonestReadout":839},[1025],{"nctId":836,"briefTitle":837,"status":118,"phases":1026,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":1027,"interventions":1028},[90],[35,801,843,844],[792,770,790,791,846,847],{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":100},[],{"intervention":893,"totalTrials":280,"cells":1034},{"EARLY_PHASE1":1035,"PHASE1":1047,"PHASE2":1049,"PHASE3":1051,"PHASE4":1057,"NA":1059},{"trials":1036,"activeCount":100},[1037],{"nctId":1038,"briefTitle":1039,"status":149,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":100,"conditions":1043,"interventions":1045},"NCT05060965","Inpatient Smoking Cessation Pilot Program",[87],"2023-04","2019-10-01",[1044],"Tobacco Use Cessation",[1046,893,892],"Nicotine lozenge",{"trials":1048,"activeCount":100},[],{"trials":1050,"activeCount":100},[],{"trials":1052,"activeCount":126,"soonestReadout":885},[1053],{"nctId":882,"briefTitle":883,"status":118,"phases":1054,"primaryCompletion":885,"completion":885,"start":886,"enrollment":887,"conditions":1055,"interventions":1056},[89,90],[889,24,890],[862,892,893],{"trials":1058,"activeCount":100},[],{"trials":1060,"activeCount":100},[],{"intervention":892,"totalTrials":280,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1069,"PHASE2":1071,"PHASE3":1073,"PHASE4":1079,"NA":1081},{"trials":1064,"activeCount":100},[1065],{"nctId":1038,"briefTitle":1039,"status":149,"phases":1066,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":100,"conditions":1067,"interventions":1068},[87],[1044],[1046,893,892],{"trials":1070,"activeCount":100},[],{"trials":1072,"activeCount":100},[],{"trials":1074,"activeCount":126,"soonestReadout":885},[1075],{"nctId":882,"briefTitle":883,"status":118,"phases":1076,"primaryCompletion":885,"completion":885,"start":886,"enrollment":887,"conditions":1077,"interventions":1078},[89,90],[889,24,890],[862,892,893],{"trials":1080,"activeCount":100},[],{"trials":1082,"activeCount":100},[],{"intervention":1084,"totalTrials":126,"cells":1085},"Dolutegravir 50mg Tab",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1106,"NA":1108},{"trials":1087,"activeCount":100},[],{"trials":1089,"activeCount":100},[],{"trials":1091,"activeCount":100},[],{"trials":1093,"activeCount":126,"soonestReadout":1098},[1094],{"nctId":1095,"briefTitle":1096,"status":118,"phases":1097,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT06497465","Dolutegravir\u002FLamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment",[90],"2028-01-31","2029-01-31","2025-09-18",150,[35,24],[1084,1104,1105],"Dolutegravir\u002FLamivudine 50 MG-300mg Oral Tablet [DOVATO]","Dolutegravir plus Tenofovir disoproxil fumarate",{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":100},[],{"intervention":1104,"totalTrials":126,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1124,"NA":1126},{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":126,"soonestReadout":1098},[1120],{"nctId":1095,"briefTitle":1096,"status":118,"phases":1121,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":1122,"interventions":1123},[90],[35,24],[1084,1104,1105],{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"intervention":1105,"totalTrials":126,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1142,"NA":1144},{"trials":1131,"activeCount":100},[],{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":126,"soonestReadout":1098},[1138],{"nctId":1095,"briefTitle":1096,"status":118,"phases":1139,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":1140,"interventions":1141},[90],[35,24],[1084,1104,1105],{"trials":1143,"activeCount":100},[],{"trials":1145,"activeCount":100},[],{"intervention":1147,"totalTrials":126,"cells":1148},"Bedaquiline",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1170,"NA":1172},{"trials":1150,"activeCount":100},[],{"trials":1152,"activeCount":100},[],{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":126,"soonestReadout":1161},[1157],{"nctId":1158,"briefTitle":1159,"status":118,"phases":1160,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1165,"interventions":1167},"NCT06568484","Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB",[89,90],"2027-07","2027-09","2026-05-08",2530,[1166],"Tuberculosis, Latent",[1147,1168,1169],"Isoniazid, rifapentine","Levofloxacin",{"trials":1171,"activeCount":100},[],{"trials":1173,"activeCount":100},[],{"intervention":1168,"totalTrials":126,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1188,"NA":1190},{"trials":1177,"activeCount":100},[],{"trials":1179,"activeCount":100},[],{"trials":1181,"activeCount":100},[],{"trials":1183,"activeCount":126,"soonestReadout":1161},[1184],{"nctId":1158,"briefTitle":1159,"status":118,"phases":1185,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1186,"interventions":1187},[89,90],[1166],[1147,1168,1169],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"intervention":1169,"totalTrials":126,"cells":1193},{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1200,"PHASE4":1206,"NA":1208},{"trials":1195,"activeCount":100},[],{"trials":1197,"activeCount":100},[],{"trials":1199,"activeCount":100},[],{"trials":1201,"activeCount":126,"soonestReadout":1161},[1202],{"nctId":1158,"briefTitle":1159,"status":118,"phases":1203,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1204,"interventions":1205},[89,90],[1166],[1147,1168,1169],{"trials":1207,"activeCount":100},[],{"trials":1209,"activeCount":100},[],{"intervention":1211,"totalTrials":126,"cells":1212},"Aspirin 81mg",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1232,"NA":1234},{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":100},[],{"trials":1220,"activeCount":126,"soonestReadout":581},[1221],{"nctId":1222,"briefTitle":1223,"status":118,"phases":1224,"primaryCompletion":581,"completion":581,"start":1225,"enrollment":1226,"conditions":1227,"interventions":1229},"NCT05265299","Trial to Determine Effective Aspirin Dose in COPD",[90],"2023-05-16",48,[1228],"Pulmonary Disease, Chronic Obstructive",[1211,1230,1231],"Aspirin 162 mg","Aspirin 325mg",{"trials":1233,"activeCount":100},[],{"trials":1235,"activeCount":100},[],{"intervention":1230,"totalTrials":126,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1250,"NA":1252},{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":126,"soonestReadout":581},[1246],{"nctId":1222,"briefTitle":1223,"status":118,"phases":1247,"primaryCompletion":581,"completion":581,"start":1225,"enrollment":1226,"conditions":1248,"interventions":1249},[90],[1228],[1211,1230,1231],{"trials":1251,"activeCount":100},[],{"trials":1253,"activeCount":100},[],{"intervention":1231,"totalTrials":126,"cells":1255},{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1268,"NA":1270},{"trials":1257,"activeCount":100},[],{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":126,"soonestReadout":581},[1264],{"nctId":1222,"briefTitle":1223,"status":118,"phases":1265,"primaryCompletion":581,"completion":581,"start":1225,"enrollment":1226,"conditions":1266,"interventions":1267},[90],[1228],[1211,1230,1231],{"trials":1269,"activeCount":100},[],{"trials":1271,"activeCount":100},[],{"intervention":1273,"totalTrials":126,"cells":1274},"Triamcinolone 0.1%",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1281,"PHASE4":1294,"NA":1296},{"trials":1276,"activeCount":100},[],{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":126,"soonestReadout":1287},[1283],{"nctId":1284,"briefTitle":1285,"status":754,"phases":1286,"primaryCompletion":1287,"completion":1288,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1293},"NCT07228104","Use of Steroid Injections to Prevent the Recurrence of Tracheal Stenosis in Idiopathic Subglottic Stenosis",[90],"2031-01-01","2032-01","2026-06-01",226,[1292],"Idiopathic Subglottic Stenosis",[1273],{"trials":1295,"activeCount":100},[],{"trials":1297,"activeCount":100},[],{"intervention":1299,"totalTrials":126,"cells":1300},"N-acetylcysteine",{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1321,"NA":1323},{"trials":1302,"activeCount":100},[],{"trials":1304,"activeCount":100},[],{"trials":1306,"activeCount":100},[],{"trials":1308,"activeCount":126,"soonestReadout":1314},[1309],{"nctId":1310,"briefTitle":1311,"status":1312,"phases":1313,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1320},"NCT05537220","Oral N-acetylcysteine for Retinitis Pigmentosa","ACTIVE_NOT_RECRUITING",[90],"2029-05","2030-05","2023-10-11",485,[1319],"Retinitis Pigmentosa",[1299],{"trials":1322,"activeCount":100},[],{"trials":1324,"activeCount":100},[],{"intervention":1326,"totalTrials":126,"cells":1327},"Absence epilepsy medications",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1334,"PHASE4":1347,"NA":1349},{"trials":1329,"activeCount":100},[],{"trials":1331,"activeCount":100},[],{"trials":1333,"activeCount":100},[],{"trials":1335,"activeCount":126,"soonestReadout":1340},[1336],{"nctId":1337,"briefTitle":1338,"status":118,"phases":1339,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":16,"conditions":1342,"interventions":1346},"NCT04274179","Ketogenic Diet for New-Onset Absence Epilepsy",[90],"2028-05-01","2020-08-10",[1343,1344,1345],"Absence Epilepsy","Ketogenic Dieting","Epilepsy, Absence",[1326],{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"intervention":1352,"totalTrials":126,"cells":1353},"Emetine Hydrochloride 6mg",{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1374,"NA":1376},{"trials":1355,"activeCount":100},[],{"trials":1357,"activeCount":100},[],{"trials":1359,"activeCount":100},[],{"trials":1361,"activeCount":126,"soonestReadout":1366},[1362],{"nctId":1363,"briefTitle":1364,"status":754,"phases":1365,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1372},"NCT07016321","Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)",[89,90],"2029-03-01","2029-05-03","2026-05-01",600,[1371],"Dengue",[1352,1373],"Emetine Hydrochloride 12mg",{"trials":1375,"activeCount":100},[],{"trials":1377,"activeCount":100},[],{"intervention":1373,"totalTrials":126,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1392,"NA":1394},{"trials":1381,"activeCount":100},[],{"trials":1383,"activeCount":100},[],{"trials":1385,"activeCount":100},[],{"trials":1387,"activeCount":126,"soonestReadout":1366},[1388],{"nctId":1363,"briefTitle":1364,"status":754,"phases":1389,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":1369,"conditions":1390,"interventions":1391},[89,90],[1371],[1352,1373],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[],{"intervention":691,"totalTrials":126,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":100},[],{"trials":1401,"activeCount":100},[],{"trials":1403,"activeCount":100},[],{"trials":1405,"activeCount":126,"soonestReadout":685},[1406],{"nctId":682,"briefTitle":683,"status":118,"phases":1407,"primaryCompletion":685,"completion":686,"start":687,"enrollment":16,"conditions":1408,"interventions":1409},[89,90],[689],[661,691],{"trials":1411,"activeCount":100},[],{"trials":1413,"activeCount":100},[],{"intervention":66,"totalTrials":126,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1430,"NA":1432},{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":100},[],{"trials":1421,"activeCount":100},[],{"trials":1423,"activeCount":126,"soonestReadout":65},[1424],{"nctId":63,"briefTitle":64,"status":118,"phases":1425,"primaryCompletion":65,"completion":65,"start":1426,"enrollment":110,"conditions":1427,"interventions":1429},[90],"2024-01-09",[1428],"Opioid Use Disorder",[66],{"trials":1431,"activeCount":100},[],{"trials":1433,"activeCount":100},[],{"intervention":727,"totalTrials":126,"cells":1435},{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1448,"NA":1450},{"trials":1437,"activeCount":100},[],{"trials":1439,"activeCount":100},[],{"trials":1441,"activeCount":100},[],{"trials":1443,"activeCount":126,"soonestReadout":712},[1444],{"nctId":709,"briefTitle":710,"status":118,"phases":1445,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":1446,"interventions":1447},[89,90],[717,718,719,720,721,722,723,724,725],[727,661],{"trials":1449,"activeCount":100},[],{"trials":1451,"activeCount":100},[],{"intervention":1453,"totalTrials":126,"cells":1454},"Cysview",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1474,"NA":1476},{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":126,"soonestReadout":1467},[1463],{"nctId":1464,"briefTitle":1465,"status":118,"phases":1466,"primaryCompletion":1467,"completion":1468,"start":1469,"enrollment":1470,"conditions":1471,"interventions":1473},"NCT06525571","Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection",[90],"2027-01-04","2028-01-04","2024-12-20",200,[1472],"Bladder Cancer",[1453],{"trials":1475,"activeCount":100},[],{"trials":1477,"activeCount":100},[],{"intervention":1479,"totalTrials":126,"cells":1480},"Continuous DOAC therapy",{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1485,"PHASE3":1487,"PHASE4":1499,"NA":1501},{"trials":1482,"activeCount":100},[],{"trials":1484,"activeCount":100},[],{"trials":1486,"activeCount":100},[],{"trials":1488,"activeCount":126,"soonestReadout":1493},[1489],{"nctId":1490,"briefTitle":1491,"status":118,"phases":1492,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1495,"conditions":1496,"interventions":1498},"NCT05836987","The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation",[90],"2029-07-31","2023-07-13",5350,[1497],"Atrial Fibrillation",[1479],{"trials":1500,"activeCount":100},[],{"trials":1502,"activeCount":100},[],{"intervention":1504,"totalTrials":126,"cells":1505},"Secretin",{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1528,"NA":1530},{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[],{"trials":1511,"activeCount":100},[],{"trials":1513,"activeCount":126,"soonestReadout":151},[1514],{"nctId":1515,"briefTitle":1516,"status":118,"phases":1517,"primaryCompletion":151,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1527},"NCT02000089","The Cancer of the Pancreas Screening-5 CAPS5)Study",[90],"2029-06","2014-01-06",9000,[1522,1523,1524,1525,1526],"Pancreas Cancer","Peutz-Jeghers Syndrome (PJS)","Gene Mutation","Germline Mutation Carrier","Lynch Syndrome",[1504],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[],{"intervention":680,"totalTrials":280,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":100},[],{"trials":1539,"activeCount":100},[],{"trials":1541,"activeCount":126,"soonestReadout":581},[1542],{"nctId":672,"briefTitle":673,"status":118,"phases":1543,"primaryCompletion":581,"completion":581,"start":675,"enrollment":676,"conditions":1544,"interventions":1545},[90],[678],[661,680],{"trials":1547,"activeCount":100},[],{"trials":1549,"activeCount":100},[1550],{"nctId":1551,"briefTitle":1552,"status":106,"phases":1553,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1558},"NCT02116309","Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis",[92],"2016-12-02","2014-08",948,[678],[680,1559],"Epinephrine",{"intervention":71,"totalTrials":1561,"cells":1562},27,{"EARLY_PHASE1":1563,"PHASE1":1609,"PHASE2":1745,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1564,"activeCount":614,"soonestReadout":1569},[1565,1576,1587,1599],{"nctId":1566,"briefTitle":1567,"status":1312,"phases":1568,"primaryCompletion":1569,"completion":1570,"start":1571,"enrollment":1572,"conditions":1573,"interventions":1575},"NCT05546658","Effects of Psilocybin in Obsessive Compulsive Disorder",[87],"2026-09-12","2027-09-12","2022-11-28",35,[1574],"Obsessive-Compulsive Disorder",[71],{"nctId":1577,"briefTitle":1578,"status":754,"phases":1579,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1583,"interventions":1585},"NCT07565493","Psilocybin Administration With 5-HT1a Blockade",[87],"2028-06-15","2026-06-15",18,[1584],"Psychedelic Effects in Healthy Volunteers",[1586,71],"Pindolol",{"nctId":1588,"briefTitle":1589,"status":118,"phases":1590,"primaryCompletion":1591,"completion":213,"start":1592,"enrollment":1593,"conditions":1594,"interventions":1598},"NCT04123314","Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease",[87],"2026-09-30","2021-03-24",20,[1595,27,1596,1597],"Depressive Symptoms","Alzheimer Disease","Mild Cognitive Impairment",[71],{"nctId":1600,"briefTitle":1601,"status":118,"phases":1602,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":30,"conditions":1606,"interventions":1608},"NCT06656702","Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis",[87],"2027-01-30","2027-07-01","2025-04-09",[1607],"Amyotrophic Lateral Sclerosis",[71],{"trials":1610,"activeCount":1744,"soonestReadout":80},[1611,1620,1640,1650,1658,1667,1675,1682,1695,1708,1719,1731,1740],{"nctId":1612,"briefTitle":1613,"status":106,"phases":1614,"primaryCompletion":1615,"completion":743,"start":1616,"enrollment":33,"conditions":1617,"interventions":1619},"NCT04052568","Effects of Psilocybin in Anorexia Nervosa",[88],"2022-01-05","2019-08-26",[1618],"Anorexia Nervosa",[71],{"nctId":1621,"briefTitle":1622,"status":118,"phases":1623,"primaryCompletion":1624,"completion":1625,"start":1626,"enrollment":1593,"conditions":1627,"interventions":1639},"NCT07053917","Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability",[88],"2027-02","2027-03","2026-02-09",[32,1628,1629,1630,1631,1632,1633,1634,1635,1636,1637,1638],"Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and\u002For Hemiparesis Following Stroke","Middle Cerebral Artery Stroke",[71],{"nctId":1641,"briefTitle":1642,"status":106,"phases":1643,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":394,"conditions":1647,"interventions":1648},"NCT00802282","Psilocybin and Spiritual Practice",[88],"2014-02","2014-05","2009-08",[112],[1649],"psilocybin",{"nctId":1651,"briefTitle":1652,"status":106,"phases":1653,"primaryCompletion":1654,"completion":1654,"start":1655,"enrollment":30,"conditions":1656,"interventions":1657},"NCT02243813","Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion",[88],"2024-05-31","2015-03",[112],[71],{"nctId":1659,"briefTitle":1660,"status":118,"phases":1661,"primaryCompletion":345,"completion":581,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1666},"NCT06660381","Psilocybin-assisted Treatment for Cannabis Use Disorder",[88],"2024-11-08",12,[1665],"Cannabis Use Disorder",[71],{"nctId":1668,"briefTitle":1669,"status":149,"phases":1670,"primaryCompletion":55,"completion":55,"start":1671,"enrollment":100,"conditions":1672,"interventions":1674},"NCT05562973","Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder",[88],"2025-01",[1673],"Post-Traumatic Stress Disorder",[71],{"nctId":78,"briefTitle":79,"status":1312,"phases":1676,"primaryCompletion":80,"completion":1677,"start":1678,"enrollment":1593,"conditions":1679,"interventions":1681},[88],"2027-05","2024-06-07",[1680],"Post Traumatic Stress Disorder",[71],{"nctId":1683,"briefTitle":1684,"status":106,"phases":1685,"primaryCompletion":1686,"completion":1645,"start":1687,"enrollment":264,"conditions":1688,"interventions":1694},"NCT01988311","Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",[88],"2014-01","2013-05",[71,1689,1690,1691,1692,1693],"Hallucinogens","Pharmacologic Actions","Central Nervous System Agents","Therapeutic Uses","Psychotropic Drugs",[1649],{"nctId":1696,"briefTitle":1697,"status":118,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":311,"conditions":1702,"interventions":1703},"NCT06772753","Investigation of Psychedelic Effects in Psychoactive Substances",[88],"2027-06","2027-12","2025-02-05",[1584],[71,85,1704,1705,1706,1707],"Dextromethorphan","Dimethyltryptamine","Methylenedioxymethamphetamine","Tetrahydrocannabinol",{"nctId":1709,"briefTitle":1710,"status":118,"phases":1711,"primaryCompletion":1712,"completion":1713,"start":1714,"enrollment":16,"conditions":1715,"interventions":1717},"NCT06989957","Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)",[88],"2028-08","2029-08","2025-09-17",[1716],"Posttraumatic Stress Disorder",[71,71,1718,1718],"MDMA",{"nctId":1720,"briefTitle":1721,"status":106,"phases":1722,"primaryCompletion":1723,"completion":1724,"start":1725,"enrollment":1593,"conditions":1726,"interventions":1730},"NCT05305105","Effects of Psilocybin in Post-Treatment Lyme Disease",[88],"2024-10-26","2025-04-07","2022-07-01",[1727,1728,1729],"Post-Treatment Lyme Disease","Chronic Lyme Disease","Lyme Disease, Chronic",[71],{"nctId":1732,"briefTitle":1733,"status":492,"phases":1734,"primaryCompletion":1735,"completion":1712,"start":1736,"enrollment":184,"conditions":1737,"interventions":1739},"NCT07180108","PRoMiSS: Psilocybin and the Role of Music in Set and Setting",[88],"2028-06","2025-08-12",[71,1738],"Music Intervention",[71],{"nctId":116,"briefTitle":117,"status":118,"phases":1741,"primaryCompletion":120,"completion":121,"start":122,"enrollment":16,"conditions":1742,"interventions":1743},[88],[124,27],[71,95],7,{"trials":1746,"activeCount":96,"soonestReadout":70},[1747,1756,1767,1776,1785,1792,1801,1809,1820,1830],{"nctId":1748,"briefTitle":1749,"status":106,"phases":1750,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1561,"conditions":1753,"interventions":1755},"NCT03181529","Effects of Psilocybin in Major Depressive Disorder",[89],"2020-12-02","2017-08-10",[1754],"Major Depressive Disorder",[71],{"nctId":1757,"briefTitle":1758,"status":106,"phases":1759,"primaryCompletion":1760,"completion":1761,"start":1762,"enrollment":698,"conditions":1763,"interventions":1766},"NCT00465595","Psychopharmacology of Psilocybin in Cancer Patients",[89],"2014-12","2016-12","2007-04",[1595,1764,1765],"Anxiety","Cancer",[1649],{"nctId":1768,"briefTitle":1769,"status":106,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":1773,"conditions":1774,"interventions":1775},"NCT02971605","Persisting Effects of Psilocybin",[88,89],"2018-08-21","2017-07-01",13,[112],[71],{"nctId":1777,"briefTitle":1778,"status":149,"phases":1779,"primaryCompletion":1780,"completion":1781,"start":1782,"enrollment":100,"conditions":1783,"interventions":1784},"NCT05242029","Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use",[89],"2024-02","2024-12","2023-12",[1428],[71],{"nctId":68,"briefTitle":69,"status":1312,"phases":1786,"primaryCompletion":70,"completion":1787,"start":1788,"enrollment":215,"conditions":1789,"interventions":1791},[89],"2027-03-30","2021-04-14",[1754,1790],"Alcohol Use Disorder",[71],{"nctId":1793,"briefTitle":1794,"status":118,"phases":1795,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":164,"conditions":1799,"interventions":1800},"NCT05301608","Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought",[88,89],"2026-07-01","2026-11-01","2022-03-03",[112],[71],{"nctId":1802,"briefTitle":1803,"status":118,"phases":1804,"primaryCompletion":1805,"completion":1314,"start":1806,"enrollment":215,"conditions":1807,"interventions":1808},"NCT06067737","Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder",[89],"2028-07","2024-02-08",[1428],[71,71],{"nctId":1810,"briefTitle":1811,"status":754,"phases":1812,"primaryCompletion":1735,"completion":151,"start":494,"enrollment":1593,"conditions":1813,"interventions":1817},"NCT07610135","Psilocybin Efficacy With or Without Pimavanserin Pretreatment",[88,89],[1814,1815,1816,112],"Mood (Psychological Function)","Well Being","Mood",[71,1818,1819],"Pimavanserin","Inactive Placebo",{"nctId":1821,"briefTitle":1822,"status":118,"phases":1823,"primaryCompletion":581,"completion":1677,"start":1824,"enrollment":1825,"conditions":1826,"interventions":1828},"NCT05452772","5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder",[89],"2023-11-01",66,[1827],"Tobacco Use Disorder",[71,1829],"Niacin",{"nctId":1831,"briefTitle":1832,"status":149,"phases":1833,"primaryCompletion":1805,"completion":1805,"start":1834,"enrollment":100,"conditions":1835,"interventions":1836},"NCT06005662","Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder",[89],"2027-04",[1428],[71],{"trials":1838,"activeCount":100},[],{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[],{"intervention":1844,"totalTrials":329,"cells":1845},"Cannabis",{"EARLY_PHASE1":1846,"PHASE1":1859,"PHASE2":1941,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1847,"activeCount":100},[1848],{"nctId":1849,"briefTitle":1850,"status":106,"phases":1851,"primaryCompletion":1852,"completion":1852,"start":1853,"enrollment":1854,"conditions":1855,"interventions":1857},"NCT03204305","Brain Imaging of Cannabinoid Receptors",[87],"2020-03-31","2017-09-14",28,[1665,1856],"Cannabis Dependence, Continuous",[1858,1844],"11C-OMAR",{"trials":1860,"activeCount":614,"soonestReadout":392},[1861,1869,1881,1890,1899,1909,1918,1925,1933],{"nctId":1862,"briefTitle":1863,"status":106,"phases":1864,"primaryCompletion":1865,"completion":1865,"start":1866,"enrollment":1582,"conditions":1867,"interventions":1868},"NCT03676166","Pharmacokinetic and Pharmacodynamic Effects of Smoked and Vaporized Cannabis",[88],"2017-01-17","2016-06-16",[1844],[1844],{"nctId":1870,"briefTitle":1871,"status":106,"phases":1872,"primaryCompletion":1873,"completion":1874,"start":1875,"enrollment":1876,"conditions":1877,"interventions":1879},"NCT03122691","Differences in Cannabis Impairment and Its Measurement Due to Route of Administration",[88],"2019-06-11","2020-02-01","2018-05-01",23,[1878],"Behavioral Pharmacology of Cannabis",[1880],"cannabis",{"nctId":1882,"briefTitle":1883,"status":754,"phases":1884,"primaryCompletion":1604,"completion":1604,"start":758,"enrollment":16,"conditions":1885,"interventions":1889},"NCT06351540","Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance",[88],[1886,1887,1888],"Cannabis Use","Impaired Driving","Cognitive Impairment",[1844],{"nctId":1891,"briefTitle":1892,"status":754,"phases":1893,"primaryCompletion":1518,"completion":1894,"start":1581,"enrollment":1895,"conditions":1896,"interventions":1898},"NCT07214155","Effects of Various Cannabis Strains on Perceptual, Subjective and Objective Use Outcomes",[88],"2029-09",70,[1897],"Cannabis Intoxication",[1844],{"nctId":1900,"briefTitle":1901,"status":118,"phases":1902,"primaryCompletion":1903,"completion":1700,"start":1904,"enrollment":215,"conditions":1905,"interventions":1907},"NCT06293040","Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment",[88],"2027-08","2024-09-26",[1897,1906],"Alcohol Intoxication",[1844,1908],"Alcohol",{"nctId":1910,"briefTitle":1911,"status":106,"phases":1912,"primaryCompletion":1913,"completion":1914,"start":1915,"enrollment":25,"conditions":1916,"interventions":1917},"NCT04124432","Behavioral Pharmacology of Cannabis and Nicotine",[88],"2023-07-24","2023-08-31","2020-09-15",[1844,114],[1844,114],{"nctId":1919,"briefTitle":1920,"status":106,"phases":1921,"primaryCompletion":193,"completion":193,"start":1922,"enrollment":715,"conditions":1923,"interventions":1924},"NCT04931095","The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment",[88],"2022-02-17",[1897,1906],[1844,1908],{"nctId":1926,"briefTitle":1927,"status":106,"phases":1928,"primaryCompletion":1929,"completion":1929,"start":1687,"enrollment":25,"conditions":1930,"interventions":1932},"NCT01798186","Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation",[88],"2013-08",[1931],"Cannabis Toxicology",[1844],{"nctId":1934,"briefTitle":1935,"status":118,"phases":1936,"primaryCompletion":392,"completion":392,"start":1937,"enrollment":1938,"conditions":1939,"interventions":1940},"NCT05602649","The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles",[88],"2024-07-10",80,[1886],[1844],{"trials":1942,"activeCount":126,"soonestReadout":1947},[1943],{"nctId":1944,"briefTitle":1945,"status":118,"phases":1946,"primaryCompletion":1947,"completion":1948,"start":1949,"enrollment":1593,"conditions":1950,"interventions":1951},"NCT07216690","Pregnenolone as a Treatment for Cannabis Intoxication",[89],"2028-01-01","2029-01-01","2026-04-24",[1897],[1844,1952,1953],"Pregnenolone 250 mg","Pregnenolone 500 mg",{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"intervention":85,"totalTrials":614,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1970,"PHASE3":1990,"PHASE4":1992,"NA":2007},{"trials":1963,"activeCount":100},[],{"trials":1965,"activeCount":126,"soonestReadout":1699},[1966],{"nctId":1696,"briefTitle":1697,"status":118,"phases":1967,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":311,"conditions":1968,"interventions":1969},[88],[1584],[71,85,1704,1705,1706,1707],{"trials":1971,"activeCount":126,"soonestReadout":84},[1972,1982],{"nctId":1973,"briefTitle":1974,"status":106,"phases":1975,"primaryCompletion":1976,"completion":1976,"start":1977,"enrollment":1582,"conditions":1978,"interventions":1980},"NCT03500289","Ketamine for Treatment of MS Fatigue",[88,89],"2019-08-30","2018-08-10",[313,1979],"Fatigue",[85,1981],"Midazolam",{"nctId":82,"briefTitle":83,"status":1312,"phases":1983,"primaryCompletion":84,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1989},[89],"2026-10-01","2023-01-01",110,[1988],"Multiple Sclerosis Fatigue",[85,1981],{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[1994],{"nctId":1995,"briefTitle":1996,"status":873,"phases":1997,"primaryCompletion":1998,"completion":1999,"start":2000,"enrollment":614,"conditions":2001,"interventions":2004},"NCT03305055","RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain",[91],"2018-03-28","2018-04-21","2017-12-16",[2002,2003,1716],"Acute Pain","Wound Care",[2005,2006],"ketamine","Fentanyl",{"trials":2008,"activeCount":100},[],{"intervention":2010,"totalTrials":280,"cells":2011},"AGB101",{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":280,"soonestReadout":2032},[2018,2028],{"nctId":2019,"briefTitle":2020,"status":118,"phases":2021,"primaryCompletion":1677,"completion":2022,"start":2023,"enrollment":715,"conditions":2024,"interventions":2027},"NCT06919926","Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults",[89],"2028-05","2025-04-17",[2025,2026],"Hippocampal Overactivity","Dementia",[2010],{"nctId":2029,"briefTitle":2030,"status":118,"phases":2031,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":164,"conditions":2034,"interventions":2036},"NCT05824728","Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis",[89],"2026-09","2023-09-28",[2035],"Parkinson Disease Psychosis",[2010],{"trials":2038,"activeCount":100},[],{"trials":2040,"activeCount":100},[],{"trials":2042,"activeCount":100},[],{"intervention":2044,"totalTrials":280,"cells":2045},"Autologous Skin Fibroblasts",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":100},[],{"trials":2051,"activeCount":280,"soonestReadout":2066},[2052,2062],{"nctId":2053,"briefTitle":2054,"status":118,"phases":2055,"primaryCompletion":2056,"completion":2056,"start":2057,"enrollment":311,"conditions":2058,"interventions":2061},"NCT03947450","Autologous Volar Fibroblast Injection Into the Stump Site of Amputees",[89],"2028-04-01","2019-09-05",[717,2059,2060],"Skin Wound","Stem Cell",[2044],{"nctId":2063,"briefTitle":2064,"status":118,"phases":2065,"primaryCompletion":2066,"completion":2067,"start":2068,"enrollment":1938,"conditions":2069,"interventions":2070},"NCT01964859","Feasibility Study for Fibroblast Autologous Skin Grafts",[89],"2027-12-02","2028-11-01","2015-01-07",[718],[2071,2072],"autologous skin fibroblasts","Filler Product",{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[],{"intervention":2080,"totalTrials":2081,"cells":2082},"Omalizumab",9,{"EARLY_PHASE1":2083,"PHASE1":2096,"PHASE2":2098,"PHASE3":2155,"PHASE4":2157,"NA":2179},{"trials":2084,"activeCount":100},[2085],{"nctId":2086,"briefTitle":2087,"status":106,"phases":2088,"primaryCompletion":2089,"completion":2089,"start":2090,"enrollment":2091,"conditions":2092,"interventions":2095},"NCT04583501","Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis",[87],"2024-07-12","2020-12-15",21,[2093,2094],"Chronic Rhinosinusitis With Nasal Polyps","Nasal Polyps",[2080],{"trials":2097,"activeCount":100},[],{"trials":2099,"activeCount":280,"soonestReadout":2116},[2100,2112,2123,2131,2144],{"nctId":2101,"briefTitle":2102,"status":106,"phases":2103,"primaryCompletion":2104,"completion":2104,"start":2105,"enrollment":2106,"conditions":2107,"interventions":2110},"NCT00949078","Omalizumab in the Treatment of Peanut Allergy",[89],"2011-08","2009-07",51,[2108,2109],"Food Allergy","Peanut Allergy",[2111],"omalizumab",{"nctId":2113,"briefTitle":2114,"status":118,"phases":2115,"primaryCompletion":2116,"completion":2117,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2122},"NCT06934200","Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels",[89],"2027-04-15","2027-10-15","2025-05-19",32,[2121],"Food Hypersensitivity",[2080],{"nctId":2124,"briefTitle":2125,"status":873,"phases":2126,"primaryCompletion":2127,"completion":2127,"start":2128,"enrollment":22,"conditions":2129,"interventions":2130},"NCT00162773","Effect of Anti-IgE in Non-Allergic Asthma",[89],"2009-09","2005-04",[21],[2111],{"nctId":2132,"briefTitle":2133,"status":118,"phases":2134,"primaryCompletion":2135,"completion":2136,"start":2137,"enrollment":2138,"conditions":2139,"interventions":2142},"NCT07059091","Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD",[89],"2031-01","2031-05","2026-02-12",334,[2140,2141],"Chronic Obstructive Pulmonary Disease (COPD)","Allergies",[2080,2143],"Sodium Chloride (NaCl) 0.9 %",{"nctId":2145,"briefTitle":2146,"status":106,"phases":2147,"primaryCompletion":2148,"completion":2149,"start":2150,"enrollment":2151,"conditions":2152,"interventions":2154},"NCT01003301","The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge",[89],"2012-12","2013-09","2009-10",19,[2153],"Cat Allergy",[2080],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[2159,2168],{"nctId":2160,"briefTitle":2161,"status":106,"phases":2162,"primaryCompletion":2163,"completion":2163,"start":2164,"enrollment":1582,"conditions":2165,"interventions":2167},"NCT03111628","Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)",[91],"2020-05-01","2017-10-06",[2166],"Urticaria Chronic",[2080],{"nctId":2169,"briefTitle":2170,"status":106,"phases":2171,"primaryCompletion":2172,"completion":2173,"start":2174,"enrollment":2175,"conditions":2176,"interventions":2178},"NCT02023151","Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils",[91],"2016-06","2016-08","2013-02",17,[2177],"Allergic Asthma",[2080],{"trials":2180,"activeCount":100},[2181],{"nctId":2182,"briefTitle":2183,"status":106,"phases":2184,"primaryCompletion":2185,"completion":2185,"start":2186,"enrollment":1582,"conditions":2187,"interventions":2189},"NCT00604786","The Effect of Omalizumab on Responses to Cat Allergen Challenge",[92],"2009-01","2007-07",[2188],"Allergic Rhinitis",[2111],{"intervention":2191,"totalTrials":235,"cells":2192},"Atorvastatin Oral",{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2207,"PHASE4":2209,"NA":2230},{"trials":2194,"activeCount":100},[],{"trials":2196,"activeCount":100},[],{"trials":2198,"activeCount":126,"soonestReadout":2203},[2199],{"nctId":2200,"briefTitle":2201,"status":118,"phases":2202,"primaryCompletion":2203,"completion":213,"start":2204,"enrollment":1593,"conditions":2205,"interventions":2206},"NCT04765137","Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)",[89],"2026-07-31","2021-05-21",[1597],[2191],{"trials":2208,"activeCount":100},[],{"trials":2210,"activeCount":100},[2211,2221],{"nctId":2212,"briefTitle":2213,"status":106,"phases":2214,"completion":2215,"start":2216,"enrollment":1470,"conditions":2217,"interventions":2219},"NCT00120887","Lupus Atherosclerosis Prevention Study",[91],"2005-12","2002-04",[2218],"Systemic Lupus Erythematosus",[2220],"Atorvastatin",{"nctId":2222,"briefTitle":2223,"status":873,"phases":2224,"primaryCompletion":2225,"completion":1762,"start":2226,"enrollment":30,"conditions":2227,"interventions":2228},"NCT00181181","The Effect of Statin Use on Vascular Function in Hypertensive Subjects",[91],"2006-06","2003-05",[15],[2229],"atorvastatin",{"trials":2231,"activeCount":100},[],{"intervention":2233,"totalTrials":280,"cells":2234},"naltrexone",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2252,"PHASE4":2254,"NA":2265},{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":126,"soonestReadout":1805},[2241],{"nctId":2242,"briefTitle":2243,"status":754,"phases":2244,"primaryCompletion":1805,"completion":2245,"start":2246,"enrollment":2247,"conditions":2248,"interventions":2249},"NCT07249554","Combination Therapy for Alcohol Use Disorder",[89],"2028-09","2026-07",45,[1790],[2250,2251],"Glucagon-Like Peptide-1 Agonist","Naltrexone",{"trials":2253,"activeCount":100},[],{"trials":2255,"activeCount":100},[2256],{"nctId":2257,"briefTitle":2258,"status":106,"phases":2259,"completion":2260,"enrollment":2261,"conditions":2262,"interventions":2264},"NCT00000438","Naltrexone Treatment for Alcoholism",[91],"2003-03",192,[2263],"Alcoholism",[2233],{"trials":2266,"activeCount":100},[],{"intervention":2268,"totalTrials":614,"cells":2269},"Methadone",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2292,"PHASE3":2302,"PHASE4":2315,"NA":2317},{"trials":2271,"activeCount":100},[],{"trials":2273,"activeCount":100},[2274,2283],{"nctId":2275,"briefTitle":2276,"status":106,"phases":2277,"primaryCompletion":1645,"completion":1555,"start":2148,"enrollment":126,"conditions":2278,"interventions":2281},"NCT01723527","Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin",[88],[2279,24,2280],"Cocaine-Related Disorders","Heroin Dependence",[2268,2282],"Buprenorphine",{"nctId":2284,"briefTitle":2285,"status":106,"phases":2286,"primaryCompletion":1760,"completion":1760,"start":825,"enrollment":2287,"conditions":2288,"interventions":2291},"NCT01560221","Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution",[88],38,[2289,2290],"Substance-related Disorders","HIV Risk Behavior",[2268,2282],{"trials":2293,"activeCount":126,"soonestReadout":581},[2294],{"nctId":2295,"briefTitle":2296,"status":118,"phases":2297,"primaryCompletion":581,"completion":581,"start":2298,"enrollment":184,"conditions":2299,"interventions":2301},"NCT06536517","The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription.",[89],"2025-03-07",[2300],"Fibroid Uterus",[2268],{"trials":2303,"activeCount":100},[2304],{"nctId":2305,"briefTitle":2306,"status":106,"phases":2307,"primaryCompletion":1646,"completion":696,"start":2308,"enrollment":2309,"conditions":2310,"interventions":2314},"NCT00271219","RCT Comparing Methadone and Buprenorphine in Pregnant Women",[90],"2005-07",175,[2311,2312,2313],"Opioid Related Disorders","Pregnancy","Opioid Dependence",[2268,2282],{"trials":2316,"activeCount":100},[],{"trials":2318,"activeCount":100},[],{"intervention":2320,"totalTrials":280,"cells":2321},"niacin",{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2332,"PHASE4":2346,"NA":2348},{"trials":2323,"activeCount":100},[],{"trials":2325,"activeCount":100},[],{"trials":2327,"activeCount":126,"soonestReadout":581},[2328],{"nctId":1821,"briefTitle":1822,"status":118,"phases":2329,"primaryCompletion":581,"completion":1677,"start":1824,"enrollment":1825,"conditions":2330,"interventions":2331},[89],[1827],[71,1829],{"trials":2333,"activeCount":100},[2334],{"nctId":2335,"briefTitle":2336,"status":106,"phases":2337,"primaryCompletion":2338,"completion":2338,"start":2339,"enrollment":2340,"conditions":2341,"interventions":2344},"NCT00127218","High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly",[90],"2008-12","2003-09",145,[2342,2343],"Atherosclerosis","Cardiovascular Disease",[2345,2320],"any statin",{"trials":2347,"activeCount":100},[],{"trials":2349,"activeCount":100},[],{"intervention":2351,"totalTrials":280,"cells":2352},"Vortioxetine",{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2374,"PHASE4":2386,"NA":2388},{"trials":2354,"activeCount":100},[],{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":126,"soonestReadout":2363},[2359],{"nctId":2360,"briefTitle":2361,"status":118,"phases":2362,"primaryCompletion":2363,"completion":2364,"start":2365,"enrollment":311,"conditions":2366,"interventions":2373},"NCT06604520","Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia",[89],"2029-05-31","2029-09-01","2025-03-20",[2367,2368,2369,2370,2371,2372],"Fronto-temporal Dementia","Fronto-temporal Lobar Dementia","Frontotemporal Degeneration","Frontotemporal Dementia (FTD)","Frontotemporal Dementia, Behavioral Variant","Frontotemporal Dementia",[2351],{"trials":2375,"activeCount":100},[2376],{"nctId":2377,"briefTitle":2378,"status":149,"phases":2379,"primaryCompletion":2380,"completion":2380,"start":2381,"enrollment":100,"conditions":2382,"interventions":2385},"NCT02845349","Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)",[90],"2018-10","2016-10",[2383,2384],"TBI","Major Depression",[2351],{"trials":2387,"activeCount":100},[],{"trials":2389,"activeCount":100},[],{"intervention":200,"totalTrials":235,"cells":2391},{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2420,"PHASE4":2422,"NA":2424},{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":126,"soonestReadout":2402},[2398,2407,2411],{"nctId":2399,"briefTitle":2400,"status":118,"phases":2401,"primaryCompletion":2402,"completion":2402,"start":2403,"enrollment":347,"conditions":2404,"interventions":2406},"NCT05145764","Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl",[89],"2026-08","2022-03-30",[200,2405,1428],"Placebo",[200],{"nctId":190,"briefTitle":191,"status":106,"phases":2408,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":2409,"interventions":2410},[89],[197,198],[200,143],{"nctId":2412,"briefTitle":2413,"status":106,"phases":2414,"primaryCompletion":2415,"completion":2415,"start":2416,"enrollment":1593,"conditions":2417,"interventions":2419},"NCT05546515","Suvorexant for Opioid\u002FStimulant Co-use",[89],"2024-11-30","2022-12-01",[1428,2418],"Stimulant Use Disorder",[200],{"trials":2421,"activeCount":100},[],{"trials":2423,"activeCount":100},[],{"trials":2425,"activeCount":100},[],{"intervention":2427,"totalTrials":280,"cells":2428},"N-Acetyl Cysteine",{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2441,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2430,"activeCount":100},[],{"trials":2432,"activeCount":100},[2433],{"nctId":2434,"briefTitle":2435,"status":106,"phases":2436,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":164,"conditions":2439,"interventions":2440},"NCT03063021","The FIGHT-RP1 Study",[88],"2019-02-11","2017-02-15",[1319],[2427],{"trials":2442,"activeCount":126,"soonestReadout":2447},[2443],{"nctId":2444,"briefTitle":2445,"status":754,"phases":2446,"primaryCompletion":2447,"completion":2447,"start":758,"enrollment":264,"conditions":2448,"interventions":2450},"NCT04381897","Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome",[89],"2027-05-01",[2449],"Cornelia de Lange Syndrome",[2451],"N-acetyl cysteine",{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[],{"trials":2457,"activeCount":100},[],{"intervention":2459,"totalTrials":126,"cells":2460},"Trazodone",{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2477,"PHASE4":2479,"NA":2481},{"trials":2462,"activeCount":100},[],{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":126,"soonestReadout":2471},[2467],{"nctId":2468,"briefTitle":2469,"status":118,"phases":2470,"primaryCompletion":2471,"completion":2472,"start":2473,"enrollment":184,"conditions":2474,"interventions":2476},"NCT05282550","Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone",[89],"2027-07-30","2028-06-30","2023-02-02",[2475,197],"AMCI - Amnestic Mild Cognitive Impairment",[2459],{"trials":2478,"activeCount":100},[],{"trials":2480,"activeCount":100},[],{"trials":2482,"activeCount":100},[],{"intervention":2484,"totalTrials":126,"cells":2485},"MW189",{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2490,"PHASE3":2502,"PHASE4":2504,"NA":2506},{"trials":2487,"activeCount":100},[],{"trials":2489,"activeCount":100},[],{"trials":2491,"activeCount":126,"soonestReadout":2496},[2492],{"nctId":2493,"briefTitle":2494,"status":1312,"phases":2495,"primaryCompletion":2496,"completion":2497,"start":2498,"enrollment":347,"conditions":2499,"interventions":2501},"NCT05020535","Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)",[89],"2026-11-30","2027-10-01","2022-10-10",[2500],"Intracerebral Hemorrhage",[2484],{"trials":2503,"activeCount":100},[],{"trials":2505,"activeCount":100},[],{"trials":2507,"activeCount":100},[],{"intervention":2509,"totalTrials":126,"cells":2510},"[11C]CPPC PET ligand",{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2524,"PHASE4":2526,"NA":2528},{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":126,"soonestReadout":392},[2517],{"nctId":2518,"briefTitle":2519,"status":754,"phases":2520,"primaryCompletion":392,"completion":1161,"start":2402,"enrollment":1593,"conditions":2521,"interventions":2523},"NCT05602142","Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS",[88,89],[2522],"ALS",[2509],{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"intervention":2531,"totalTrials":126,"cells":2532},"Tetracycline 500 Mg",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":126,"soonestReadout":2246},[2539],{"nctId":2540,"briefTitle":2541,"status":492,"phases":2542,"primaryCompletion":2246,"completion":1700,"start":2543,"enrollment":715,"conditions":2544,"interventions":2545},"NCT05219929","Tetracycline Treatment Tolerability Trial",[89],"2022-11-02",[1727],[2531],{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[],{"trials":2551,"activeCount":100},[],{"intervention":2553,"totalTrials":126,"cells":2554},"Metformin hydrochloride extended-release",{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2556,"activeCount":100},[],{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":126,"soonestReadout":1591},[2561],{"nctId":2562,"briefTitle":2563,"status":118,"phases":2564,"primaryCompletion":1591,"completion":2565,"start":2566,"enrollment":184,"conditions":2567,"interventions":2570},"NCT06273072","Metformin IN Asthma for Overweight and Obese Individuals (MINA)",[89],"2028-12-31","2024-12-09",[21,2568,2569],"Asthma Chronic","Overweight and Obesity",[2553,2571],"Visually identical placebo Metformin hydrochloride extended-release",{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":100},[],{"trials":2577,"activeCount":100},[],{"intervention":2571,"totalTrials":126,"cells":2579},{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":100},[],{"trials":2585,"activeCount":126,"soonestReadout":1591},[2586],{"nctId":2562,"briefTitle":2563,"status":118,"phases":2587,"primaryCompletion":1591,"completion":2565,"start":2566,"enrollment":184,"conditions":2588,"interventions":2589},[89],[21,2568,2569],[2553,2571],{"trials":2591,"activeCount":100},[],{"trials":2593,"activeCount":100},[],{"trials":2595,"activeCount":100},[],{"intervention":1952,"totalTrials":126,"cells":2597},{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2608,"PHASE4":2610,"NA":2612},{"trials":2599,"activeCount":100},[],{"trials":2601,"activeCount":100},[],{"trials":2603,"activeCount":126,"soonestReadout":1947},[2604],{"nctId":1944,"briefTitle":1945,"status":118,"phases":2605,"primaryCompletion":1947,"completion":1948,"start":1949,"enrollment":1593,"conditions":2606,"interventions":2607},[89],[1897],[1844,1952,1953],{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[],{"trials":2613,"activeCount":100},[],{"intervention":1953,"totalTrials":126,"cells":2615},{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2626,"PHASE4":2628,"NA":2630},{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":100},[],{"trials":2621,"activeCount":126,"soonestReadout":1947},[2622],{"nctId":1944,"briefTitle":1945,"status":118,"phases":2623,"primaryCompletion":1947,"completion":1948,"start":1949,"enrollment":1593,"conditions":2624,"interventions":2625},[89],[1897],[1844,1952,1953],{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[],{"intervention":2633,"totalTrials":126,"cells":2634},"NLY01",{"EARLY_PHASE1":2635,"PHASE1":2637,"PHASE2":2639,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2636,"activeCount":100},[],{"trials":2638,"activeCount":100},[],{"trials":2640,"activeCount":126,"soonestReadout":2645},[2641],{"nctId":2642,"briefTitle":2643,"status":118,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":347,"conditions":2647,"interventions":2648},"NCT07497399","Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis",[89],"2030-01","2026-04-28",[313],[2633],{"trials":2650,"activeCount":100},[],{"trials":2652,"activeCount":100},[],{"trials":2654,"activeCount":100},[],{"intervention":2656,"totalTrials":126,"cells":2657},"Arexvy",{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2662,"PHASE3":2673,"PHASE4":2675,"NA":2677},{"trials":2659,"activeCount":100},[],{"trials":2661,"activeCount":100},[],{"trials":2663,"activeCount":126,"soonestReadout":345},[2664],{"nctId":2665,"briefTitle":2666,"status":118,"phases":2667,"primaryCompletion":345,"completion":2668,"start":2669,"enrollment":932,"conditions":2670,"interventions":2672},"NCT07050732","Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons",[89],"2028-04","2025-12-04",[2671],"Respiratory Syncytial Virus (RSV)",[2656,2656,2656],{"trials":2674,"activeCount":100},[],{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[],{"intervention":2680,"totalTrials":126,"cells":2681},"Daridorexant 50 mg",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2683,"activeCount":100},[],{"trials":2685,"activeCount":100},[],{"trials":2687,"activeCount":126,"soonestReadout":2692},[2688],{"nctId":2689,"briefTitle":2690,"status":754,"phases":2691,"primaryCompletion":2692,"completion":2693,"start":2694,"enrollment":1101,"conditions":2695,"interventions":2696},"NCT07532252","Daridorexant for Alcohol Use Disorder",[89],"2030-08-01","2031-02-01","2027-01-01",[1790],[2680],{"trials":2698,"activeCount":100},[],{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[],{"intervention":2704,"totalTrials":126,"cells":2705},"Tesamorelin 2 Milligrams",{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":126,"soonestReadout":1700},[2712],{"nctId":2713,"briefTitle":2714,"status":118,"phases":2715,"primaryCompletion":1700,"completion":1700,"start":2716,"enrollment":2717,"conditions":2718,"interventions":2720},"NCT03150511","Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury",[89],"2018-06-01",36,[2719],"Peripheral Nerve Injuries",[2704],{"trials":2722,"activeCount":100},[],{"trials":2724,"activeCount":100},[],{"trials":2726,"activeCount":100},[],{"intervention":2728,"totalTrials":126,"cells":2729},"Atorvastatin 10mg",{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2745,"PHASE4":2747,"NA":2749},{"trials":2731,"activeCount":100},[],{"trials":2733,"activeCount":100},[],{"trials":2735,"activeCount":126,"soonestReadout":392},[2736],{"nctId":2737,"briefTitle":2738,"status":492,"phases":2739,"primaryCompletion":392,"completion":1700,"start":2740,"enrollment":33,"conditions":2741,"interventions":2744},"NCT06369571","Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet",[88,89],"2024-10-04",[2742,2743],"Epilepsy","Dyslipidemia",[2728],{"trials":2746,"activeCount":100},[],{"trials":2748,"activeCount":100},[],{"trials":2750,"activeCount":100},[],{"intervention":2752,"totalTrials":126,"cells":2753},"hyaluronidase plus saline",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2770,"PHASE4":2772,"NA":2774},{"trials":2755,"activeCount":100},[],{"trials":2757,"activeCount":100},[],{"trials":2759,"activeCount":126,"soonestReadout":885},[2760],{"nctId":2761,"briefTitle":2762,"status":118,"phases":2763,"primaryCompletion":885,"completion":2764,"start":2765,"enrollment":2766,"conditions":2767,"interventions":2768},"NCT06718413","Myofascial Dysfunction in Post Stroke Shoulder Pain",[89],"2028-08-31","2025-03-28",68,[32],[2752,2769],"saline",{"trials":2771,"activeCount":100},[],{"trials":2773,"activeCount":100},[],{"trials":2775,"activeCount":100},[],{"intervention":2072,"totalTrials":126,"cells":2777},{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2788,"PHASE4":2790,"NA":2792},{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"trials":2783,"activeCount":126,"soonestReadout":2066},[2784],{"nctId":2063,"briefTitle":2064,"status":118,"phases":2785,"primaryCompletion":2066,"completion":2067,"start":2068,"enrollment":1938,"conditions":2786,"interventions":2787},[89],[718],[2071,2072],{"trials":2789,"activeCount":100},[],{"trials":2791,"activeCount":100},[],{"trials":2793,"activeCount":100},[],{"intervention":2795,"totalTrials":126,"cells":2796},"CORT108297",{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2812,"PHASE4":2814,"NA":2816},{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"trials":2802,"activeCount":126,"soonestReadout":271},[2803],{"nctId":2804,"briefTitle":2805,"status":118,"phases":2806,"primaryCompletion":271,"completion":2694,"start":2807,"enrollment":2808,"conditions":2809,"interventions":2811},"NCT04601038","Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)",[89],"2021-06-28",52,[1597,1596,2810],"Memory Impairment",[2795],{"trials":2813,"activeCount":100},[],{"trials":2815,"activeCount":100},[],{"trials":2817,"activeCount":100},[],{"intervention":2819,"totalTrials":126,"cells":2820},"Hyaluronidase",{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2825,"PHASE3":2835,"PHASE4":2837,"NA":2839},{"trials":2822,"activeCount":100},[],{"trials":2824,"activeCount":100},[],{"trials":2826,"activeCount":126,"soonestReadout":271},[2827],{"nctId":2828,"briefTitle":2829,"status":1312,"phases":2830,"primaryCompletion":271,"completion":271,"start":2831,"enrollment":698,"conditions":2832,"interventions":2834},"NCT03306615","Peripheral Modulation of Muscle Stiffness and Spasticity",[89],"2021-10-11",[2833],"Muscle Spasticity",[2819],{"trials":2836,"activeCount":100},[],{"trials":2838,"activeCount":100},[],{"trials":2840,"activeCount":100},[],{"intervention":1818,"totalTrials":126,"cells":2842},{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2847,"PHASE3":2853,"PHASE4":2855,"NA":2857},{"trials":2844,"activeCount":100},[],{"trials":2846,"activeCount":100},[],{"trials":2848,"activeCount":126,"soonestReadout":1735},[2849],{"nctId":1810,"briefTitle":1811,"status":754,"phases":2850,"primaryCompletion":1735,"completion":151,"start":494,"enrollment":1593,"conditions":2851,"interventions":2852},[88,89],[1814,1815,1816,112],[71,1818,1819],{"trials":2854,"activeCount":100},[],{"trials":2856,"activeCount":100},[],{"trials":2858,"activeCount":100},[],{"intervention":1819,"totalTrials":126,"cells":2860},{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2871,"PHASE4":2873,"NA":2875},{"trials":2862,"activeCount":100},[],{"trials":2864,"activeCount":100},[],{"trials":2866,"activeCount":126,"soonestReadout":1735},[2867],{"nctId":1810,"briefTitle":1811,"status":754,"phases":2868,"primaryCompletion":1735,"completion":151,"start":494,"enrollment":1593,"conditions":2869,"interventions":2870},[88,89],[1814,1815,1816,112],[71,1818,1819],{"trials":2872,"activeCount":100},[],{"trials":2874,"activeCount":100},[],{"trials":2876,"activeCount":100},[],{"intervention":2878,"totalTrials":126,"cells":2879},"Solriamfetol",{"EARLY_PHASE1":2880,"PHASE1":2882,"PHASE2":2884,"PHASE3":2896,"PHASE4":2898,"NA":2900},{"trials":2881,"activeCount":100},[],{"trials":2883,"activeCount":100},[],{"trials":2885,"activeCount":126,"soonestReadout":2890},[2886],{"nctId":2887,"briefTitle":2888,"status":118,"phases":2889,"primaryCompletion":2890,"completion":2891,"start":2892,"enrollment":2893,"conditions":2894,"interventions":2895},"NCT06170970","Solriamfetol for the Treatment of Multiple Sclerosis Fatigue",[89],"2026-12-01","2027-03-01","2024-06-01",46,[313,1988],[2878],{"trials":2897,"activeCount":100},[],{"trials":2899,"activeCount":100},[],{"trials":2901,"activeCount":100},[],{"intervention":2143,"totalTrials":126,"cells":2903},{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2914,"PHASE4":2916,"NA":2918},{"trials":2905,"activeCount":100},[],{"trials":2907,"activeCount":100},[],{"trials":2909,"activeCount":126,"soonestReadout":2135},[2910],{"nctId":2132,"briefTitle":2133,"status":118,"phases":2911,"primaryCompletion":2135,"completion":2136,"start":2137,"enrollment":2138,"conditions":2912,"interventions":2913},[89],[2140,2141],[2080,2143],{"trials":2915,"activeCount":100},[],{"trials":2917,"activeCount":100},[],{"trials":2919,"activeCount":100},[],{"intervention":2921,"totalTrials":126,"cells":2922},"Simvastatin 40mg",{"EARLY_PHASE1":2923,"PHASE1":2925,"PHASE2":2927,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2924,"activeCount":100},[],{"trials":2926,"activeCount":100},[],{"trials":2928,"activeCount":126,"soonestReadout":2203},[2929],{"nctId":2930,"briefTitle":2931,"status":118,"phases":2932,"primaryCompletion":2203,"completion":2203,"start":2933,"enrollment":715,"conditions":2934,"interventions":2939},"NCT03400826","Effects of Simvastatin on Uterine Leiomyoma Size",[89],"2018-08-20",[2300,2935,2936,2937,2938],"Fibroid Tumor","Leiomyoma","Fibromyoma","Leiomyoma, Uterine",[2921],{"trials":2941,"activeCount":100},[],{"trials":2943,"activeCount":100},[],{"trials":2945,"activeCount":100},[],{"intervention":2947,"totalTrials":126,"cells":2948},"N-Acetylglucosamine",{"EARLY_PHASE1":2949,"PHASE1":2951,"PHASE2":2953,"PHASE3":2963,"PHASE4":2965,"NA":2967},{"trials":2950,"activeCount":100},[],{"trials":2952,"activeCount":100},[],{"trials":2954,"activeCount":126,"soonestReadout":2959},[2955],{"nctId":2956,"briefTitle":2957,"status":754,"phases":2958,"primaryCompletion":2959,"completion":2565,"start":271,"enrollment":16,"conditions":2960,"interventions":2962},"NCT07225998","Oral N-acetylglucosamine in Crohn's Disease",[89],"2028-07-31",[2961],"Crohns Disease",[2947],{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[],{"intervention":2970,"totalTrials":126,"cells":2971},"Lithium orotate",{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2976,"PHASE3":2988,"PHASE4":2990,"NA":2992},{"trials":2973,"activeCount":100},[],{"trials":2975,"activeCount":100},[],{"trials":2977,"activeCount":126,"soonestReadout":2982},[2978],{"nctId":2979,"briefTitle":2980,"status":754,"phases":2981,"primaryCompletion":2982,"completion":2983,"start":1289,"enrollment":16,"conditions":2984,"interventions":2986},"NCT07459959","LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response",[88,89],"2029-06-01","2029-08-31",[2985],"Alzheimer s Disease",[2970,2987],"Matched Placebo",{"trials":2989,"activeCount":100},[],{"trials":2991,"activeCount":100},[],{"trials":2993,"activeCount":100},[],{"intervention":2987,"totalTrials":126,"cells":2995},{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2997,"activeCount":100},[],{"trials":2999,"activeCount":100},[],{"trials":3001,"activeCount":126,"soonestReadout":2982},[3002],{"nctId":2979,"briefTitle":2980,"status":754,"phases":3003,"primaryCompletion":2982,"completion":2983,"start":1289,"enrollment":16,"conditions":3004,"interventions":3005},[88,89],[2985],[2970,2987],{"trials":3007,"activeCount":100},[],{"trials":3009,"activeCount":100},[],{"trials":3011,"activeCount":100},[],{"intervention":3013,"totalTrials":126,"cells":3014},"Bone marrow cell-based therapy & single-drug immunosuppression.",{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3016,"activeCount":100},[],{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":126,"soonestReadout":3025},[3021],{"nctId":3022,"briefTitle":3023,"status":118,"phases":3024,"primaryCompletion":3025,"completion":3025,"start":3026,"enrollment":164,"conditions":3027,"interventions":3029},"NCT01459107","Human Upper Extremity Allotransplantation",[89],"2036-06-30","2011-07-21",[719,718,3028],"Hand Injuries",[3013],{"trials":3031,"activeCount":100},[],{"trials":3033,"activeCount":100},[],{"trials":3035,"activeCount":100},[],{"intervention":3037,"totalTrials":126,"cells":3038},"Escitalopram 10mg",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3056,"PHASE4":3058,"NA":3060},{"trials":3040,"activeCount":100},[],{"trials":3042,"activeCount":100},[],{"trials":3044,"activeCount":126,"soonestReadout":3049},[3045],{"nctId":3046,"briefTitle":3047,"status":118,"phases":3048,"primaryCompletion":3049,"completion":3050,"start":3051,"enrollment":3052,"conditions":3053,"interventions":3055},"NCT03843463","Escitalopram and Language Intervention for Subacute Aphasia",[89],"2026-09-18","2027-01-18","2021-07-18",88,[3054,32],"Aphasia",[3037],{"trials":3057,"activeCount":100},[],{"trials":3059,"activeCount":100},[],{"trials":3061,"activeCount":100},[],{"intervention":3063,"totalTrials":126,"cells":3064},"Tirzepatide",{"EARLY_PHASE1":3065,"PHASE1":3067,"PHASE2":3069,"PHASE3":3081,"PHASE4":3083,"NA":3085},{"trials":3066,"activeCount":100},[],{"trials":3068,"activeCount":100},[],{"trials":3070,"activeCount":126,"soonestReadout":3075},[3071],{"nctId":3072,"briefTitle":3073,"status":118,"phases":3074,"primaryCompletion":3075,"completion":3075,"start":1714,"enrollment":759,"conditions":3076,"interventions":3079},"NCT06847399","Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder",[89],"2027-12-01",[3077,3078],"Obesity and Overweight","Binge Eating Disorder",[3063,3080],"Lisdexamfetamine Dimesylate",{"trials":3082,"activeCount":100},[],{"trials":3084,"activeCount":100},[],{"trials":3086,"activeCount":100},[],{"intervention":3080,"totalTrials":126,"cells":3088},{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"trials":3094,"activeCount":126,"soonestReadout":3075},[3095],{"nctId":3072,"briefTitle":3073,"status":118,"phases":3096,"primaryCompletion":3075,"completion":3075,"start":1714,"enrollment":759,"conditions":3097,"interventions":3098},[89],[3077,3078],[3063,3080],{"trials":3100,"activeCount":100},[],{"trials":3102,"activeCount":100},[],{"trials":3104,"activeCount":100},[],{"intervention":3106,"totalTrials":126,"cells":3107},"Bone marrow cell-based therapy & 1-drug immunosuppression.",{"EARLY_PHASE1":3108,"PHASE1":3110,"PHASE2":3112,"PHASE3":3128,"PHASE4":3130,"NA":3132},{"trials":3109,"activeCount":100},[],{"trials":3111,"activeCount":100},[],{"trials":3113,"activeCount":126,"soonestReadout":2402},[3114],{"nctId":3115,"briefTitle":3116,"status":118,"phases":3117,"primaryCompletion":2402,"completion":3118,"start":3119,"enrollment":921,"conditions":3120,"interventions":3127},"NCT01889381","Human Craniomaxillofacial Allotransplantation",[89],"2031-08","2012-08",[3121,3122,3123,3124,3125,3126],"Facial Injuries","Traumatic Wounds and Injuries","Craniofacial Injuries","Craniofacial Defects","Facial Transplantation","Facial Deformity",[3106],{"trials":3129,"activeCount":100},[],{"trials":3131,"activeCount":100},[],{"trials":3133,"activeCount":100},[],{"intervention":3135,"totalTrials":126,"cells":3136},"Vancomycin",{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3141,"PHASE3":3152,"PHASE4":3154,"NA":3156},{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":126,"soonestReadout":3147},[3143],{"nctId":3144,"briefTitle":3145,"status":118,"phases":3146,"primaryCompletion":3147,"completion":272,"start":84,"enrollment":110,"conditions":3148,"interventions":3151},"NCT07605806","Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions",[88,89],"2027-05-30",[3149,3150,3135],"Healthy Volunteer","Hypersensitivity Reactions",[3135],{"trials":3153,"activeCount":100},[],{"trials":3155,"activeCount":100},[],{"trials":3157,"activeCount":100},[],{"intervention":3159,"totalTrials":126,"cells":3160},"Mirdametinib",{"EARLY_PHASE1":3161,"PHASE1":3163,"PHASE2":3165,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3162,"activeCount":100},[],{"trials":3164,"activeCount":100},[],{"trials":3166,"activeCount":126,"soonestReadout":3171},[3167],{"nctId":3168,"briefTitle":3169,"status":118,"phases":3170,"primaryCompletion":3171,"completion":3172,"start":3173,"enrollment":30,"conditions":3174,"interventions":3178},"NCT06159166","Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).",[88,89],"2027-11-15","2028-11-15","2024-02-12",[3175,3176,3177],"NF1","Cutaneous Neurofibroma","Monotherapy",[3159],{"trials":3180,"activeCount":100},[],{"trials":3182,"activeCount":100},[],{"trials":3184,"activeCount":100},[],{"intervention":2250,"totalTrials":126,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":126,"soonestReadout":1805},[3193],{"nctId":2242,"briefTitle":2243,"status":754,"phases":3194,"primaryCompletion":1805,"completion":2245,"start":2246,"enrollment":2247,"conditions":3195,"interventions":3196},[89],[1790],[2250,2251],{"trials":3198,"activeCount":100},[],{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[],{"intervention":3204,"totalTrials":293,"cells":3205},"Saline",{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3226,"PHASE4":3250,"NA":3262},{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"trials":3211,"activeCount":126,"soonestReadout":885},[3212,3222],{"nctId":3213,"briefTitle":3214,"status":873,"phases":3215,"primaryCompletion":696,"completion":3216,"start":2338,"enrollment":2151,"conditions":3217,"interventions":3220},"NCT00798590","The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients",[89],"2011-06",[3218,3219],"Critically Ill","Hypoglycemia",[3221,3204],"Glucagon-Like Peptide-1",{"nctId":2761,"briefTitle":2762,"status":118,"phases":3223,"primaryCompletion":885,"completion":2764,"start":2765,"enrollment":2766,"conditions":3224,"interventions":3225},[89],[32],[2752,2769],{"trials":3227,"activeCount":100},[3228,3237],{"nctId":3229,"briefTitle":3230,"status":873,"phases":3231,"primaryCompletion":3232,"completion":1760,"start":3232,"enrollment":1663,"conditions":3233,"interventions":3235},"NCT01360450","Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants",[89,90],"2011-07",[3234],"Neonatal Abstinence Syndrome",[3236,2769],"Clonidine HCL",{"nctId":3238,"briefTitle":3239,"status":873,"phases":3240,"primaryCompletion":3241,"completion":3242,"start":3243,"enrollment":1582,"conditions":3244,"interventions":3248},"NCT02161705","Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate Tissue Expander (TE) Reconstruction",[90],"2018-04","2019-02","2014-07",[3245,3246,3247],"Postoperative Pain","Postoperative Nausea and Vomiting","Quality of Life",[3249,3204],"Ropivacaine",{"trials":3251,"activeCount":100},[3252],{"nctId":3253,"briefTitle":3254,"status":149,"phases":3255,"primaryCompletion":3256,"completion":3257,"start":292,"enrollment":100,"conditions":3258,"interventions":3260},"NCT01494259","Bupivacaine Pain Pumps to Decrease Mastectomy Post-Operative Pain",[91],"2017-01","2017-09",[3259],"Pain",[3261,3204],"Bupivacaine",{"trials":3263,"activeCount":100},[3264],{"nctId":3265,"briefTitle":3266,"status":106,"phases":3267,"primaryCompletion":3268,"completion":3119,"start":2185,"enrollment":3269,"conditions":3270,"interventions":3272},"NCT00825344","Preoperative Etanercept Before Inguinal Hernia Surgery",[92],"2011-11",77,[3271,3245],"Inguinal Hernia",[3273,3204],"Etanercept",{"intervention":1981,"totalTrials":614,"cells":3275},{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3290,"PHASE4":3292,"NA":3305},{"trials":3277,"activeCount":100},[],{"trials":3279,"activeCount":100},[],{"trials":3281,"activeCount":126,"soonestReadout":84},[3282,3286],{"nctId":1973,"briefTitle":1974,"status":106,"phases":3283,"primaryCompletion":1976,"completion":1976,"start":1977,"enrollment":1582,"conditions":3284,"interventions":3285},[88,89],[313,1979],[85,1981],{"nctId":82,"briefTitle":83,"status":1312,"phases":3287,"primaryCompletion":84,"completion":1984,"start":1985,"enrollment":1986,"conditions":3288,"interventions":3289},[89],[1988],[85,1981],{"trials":3291,"activeCount":100},[],{"trials":3293,"activeCount":100},[3294],{"nctId":3295,"briefTitle":3296,"status":106,"phases":3297,"primaryCompletion":3298,"completion":3298,"start":3299,"enrollment":3300,"conditions":3301,"interventions":3303},"NCT02683707","The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)",[91],"2017-05-25","2016-03",212,[3302],"Coronary Artery Disease",[2006,3304,1981],"Lidocaine",{"trials":3306,"activeCount":100},[3307],{"nctId":3308,"briefTitle":3309,"status":106,"phases":3310,"primaryCompletion":2174,"completion":2174,"start":3311,"enrollment":3312,"conditions":3313,"interventions":3316},"NCT01472835","Effect of Sedation on Diagnostic Injections",[92],"2011-03",73,[3314,3315],"Sacroiliac Joint Pain","Sympathetically Maintained Pain",[1981,2006],{"intervention":3318,"totalTrials":235,"cells":3319},"Sildenafil",{"EARLY_PHASE1":3320,"PHASE1":3322,"PHASE2":3324,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":100},[],{"trials":3325,"activeCount":126,"soonestReadout":3330},[3326,3336],{"nctId":3327,"briefTitle":3328,"status":118,"phases":3329,"primaryCompletion":3330,"completion":3330,"start":3331,"enrollment":164,"conditions":3332,"interventions":3335},"NCT04797286","Sildenafil for Early Pulmonary Vascular Disease in Scleroderma",[89],"2026-09-01","2021-09-20",[3333,3334],"Scleroderma","Mildly Elevated Pulmonary Pressures",[3318],{"nctId":3337,"briefTitle":3338,"status":106,"phases":3339,"primaryCompletion":3340,"completion":3341,"start":3342,"enrollment":1773,"conditions":3343,"interventions":3346},"NCT00940901","Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia",[89],"2012-11","2013-12","2008-06",[3344,3345],"Sickle Cell Disease","Priapism",[3347],"sildenafil",{"trials":3349,"activeCount":100},[],{"trials":3351,"activeCount":100},[],{"trials":3353,"activeCount":100},[3354],{"nctId":3355,"briefTitle":3356,"status":106,"phases":3357,"primaryCompletion":930,"completion":901,"start":3358,"enrollment":184,"conditions":3359,"interventions":3361},"NCT00511498","Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Laparoscopic Radical Prostatectomy",[92],"2006-03",[3360],"Prostate Cancer",[3318],{"intervention":3363,"totalTrials":235,"cells":3364},"Nasal Microbiota Transplant",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3397,"PHASE3":3399,"PHASE4":3401,"NA":3403},{"trials":3366,"activeCount":100},[],{"trials":3368,"activeCount":235,"soonestReadout":50},[3369,3382,3391],{"nctId":3370,"briefTitle":3371,"status":118,"phases":3372,"primaryCompletion":3373,"completion":1947,"start":3374,"enrollment":2309,"conditions":3375,"interventions":3381},"NCT06805994","Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment",[88],"2027-09-01","2025-08-27",[3376,3377,3378,3379,3380],"Staphylococcal Aureus Infection","Microbial Colonization","Pediatric Infection","S. Aureus Colonization","Microbial Transplant",[3363],{"nctId":3383,"briefTitle":3384,"status":118,"phases":3385,"primaryCompletion":1289,"completion":213,"start":3386,"enrollment":2309,"conditions":3387,"interventions":3390},"NCT06283355","Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome",[88],"2024-09-03",[3388,3377,3389],"Staphylococcus Aureus","Neonatal Infection",[3363],{"nctId":48,"briefTitle":49,"status":1312,"phases":3392,"primaryCompletion":50,"completion":2890,"start":3393,"enrollment":3394,"conditions":3395,"interventions":3396},[88],"2023-10-25",34,[3388,3377,3389],[51],{"trials":3398,"activeCount":100},[],{"trials":3400,"activeCount":100},[],{"trials":3402,"activeCount":100},[],{"trials":3404,"activeCount":100},[],{"intervention":3406,"totalTrials":96,"cells":3407},"THC",{"EARLY_PHASE1":3408,"PHASE1":3410,"PHASE2":3457,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3409,"activeCount":100},[],{"trials":3411,"activeCount":280,"soonestReadout":2402},[3412,3420,3430,3440,3451],{"nctId":3413,"briefTitle":3414,"status":754,"phases":3415,"primaryCompletion":3416,"completion":3416,"start":2246,"enrollment":2119,"conditions":3417,"interventions":3418},"NCT05432284","Behavioral Pharmacology of THC and Beta-Myrcene",[88],"2027-11",[1886],[3406,3419],"Beta-Myrcene",{"nctId":3421,"briefTitle":3422,"status":106,"phases":3423,"primaryCompletion":3424,"completion":3424,"start":3425,"enrollment":394,"conditions":3426,"interventions":3428},"NCT04283019","The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions",[88],"2024-06-17","2021-08-15",[3427],"Cannabis, Drug Effects",[3429,3406],"CBD",{"nctId":3431,"briefTitle":3432,"status":106,"phases":3433,"primaryCompletion":3434,"completion":3434,"start":3435,"enrollment":3436,"conditions":3437,"interventions":3439},"NCT04741477","The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products",[88],"2022-09-16","2021-07-14",47,[1844,3438],"Drug Effect",[3429,3406],{"nctId":3441,"briefTitle":3442,"status":106,"phases":3443,"primaryCompletion":3444,"completion":3444,"start":3445,"enrollment":3446,"conditions":3447,"interventions":3449},"NCT04130633","Behavioral Pharmacology of THC and Alpha-pinene",[88],"2024-03-08","2020-11-05",33,[3406,3448],"Alpha-pinene",[3406,3450],"Alpha-Pinene",{"nctId":3452,"briefTitle":3453,"status":754,"phases":3454,"primaryCompletion":2402,"completion":2032,"start":494,"enrollment":1593,"conditions":3455,"interventions":3456},"NCT07603518","The Pharmacokinetics of a Hemp-Based Topical Product",[88],[1844],[3429,3406],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[],{"trials":3464,"activeCount":100},[],{"intervention":3466,"totalTrials":280,"cells":3467},"THC 0mg",{"EARLY_PHASE1":3468,"PHASE1":3470,"PHASE2":3498,"PHASE3":3500,"PHASE4":3502,"NA":3504},{"trials":3469,"activeCount":100},[],{"trials":3471,"activeCount":280,"soonestReadout":3476},[3472,3487],{"nctId":3473,"briefTitle":3474,"status":118,"phases":3475,"primaryCompletion":3476,"completion":3477,"start":3478,"enrollment":184,"conditions":3479,"interventions":3482},"NCT06609109","Effect of Cannabis on E-Cigarette Use Behavior",[88],"2029-04-01","2029-10-01","2025-03-19",[1886,3480,3481],"Tobacco Use","Electronic Cigarette Use",[3483,3484,3466,3485,3486],"THC High Dose","THC Low Dose","E-Cigarette Full Nicotine","E-Cigarette Placebo Nicotine",{"nctId":3488,"briefTitle":3489,"status":118,"phases":3490,"primaryCompletion":3476,"completion":3477,"start":3491,"enrollment":184,"conditions":3492,"interventions":3493},"NCT06609083","Effect of Cannabis on Cigarette Use Behavior",[88],"2025-01-22",[1886,3480,877],[3494,3495,3466,3496,3497],"THC 30mg","THC 5mg","Cigarette Full Nicotine","Cigarette Reduced Nicotine",{"trials":3499,"activeCount":100},[],{"trials":3501,"activeCount":100},[],{"trials":3503,"activeCount":100},[],{"trials":3505,"activeCount":100},[],{"intervention":3507,"totalTrials":280,"cells":3508},"Epidiolex",{"EARLY_PHASE1":3509,"PHASE1":3511,"PHASE2":3523,"PHASE3":3535,"PHASE4":3537,"NA":3539},{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":126,"soonestReadout":2364},[3513],{"nctId":3514,"briefTitle":3515,"status":118,"phases":3516,"primaryCompletion":2364,"completion":2364,"start":3517,"enrollment":215,"conditions":3518,"interventions":3522},"NCT07001930","Effects of Cannabidiol on Stress and Nicotine Withdrawal",[88],"2025-08-25",[3429,3519,3520,3521],"Stress","Nicotine Dependence","Tobacco Smoking",[3507],{"trials":3524,"activeCount":100},[3525],{"nctId":3526,"briefTitle":3527,"status":106,"phases":3528,"primaryCompletion":3529,"completion":3529,"start":3530,"enrollment":235,"conditions":3531,"interventions":3534},"NCT04238754","Oral Cannabidiol for Opioid Withdrawal",[88,89],"2022-06-30","2020-11-01",[3532,3533,1428],"Opioid Withdrawal","Opioid Craving",[3507],{"trials":3536,"activeCount":100},[],{"trials":3538,"activeCount":100},[],{"trials":3540,"activeCount":100},[],{"intervention":3429,"totalTrials":235,"cells":3542},{"EARLY_PHASE1":3543,"PHASE1":3545,"PHASE2":3559,"PHASE3":3561,"PHASE4":3563,"NA":3565},{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":126,"soonestReadout":2402},[3547,3551,3555],{"nctId":3421,"briefTitle":3422,"status":106,"phases":3548,"primaryCompletion":3424,"completion":3424,"start":3425,"enrollment":394,"conditions":3549,"interventions":3550},[88],[3427],[3429,3406],{"nctId":3431,"briefTitle":3432,"status":106,"phases":3552,"primaryCompletion":3434,"completion":3434,"start":3435,"enrollment":3436,"conditions":3553,"interventions":3554},[88],[1844,3438],[3429,3406],{"nctId":3452,"briefTitle":3453,"status":754,"phases":3556,"primaryCompletion":2402,"completion":2032,"start":494,"enrollment":1593,"conditions":3557,"interventions":3558},[88],[1844],[3429,3406],{"trials":3560,"activeCount":100},[],{"trials":3562,"activeCount":100},[],{"trials":3564,"activeCount":100},[],{"trials":3566,"activeCount":100},[],{"intervention":56,"totalTrials":235,"cells":3568},{"EARLY_PHASE1":3569,"PHASE1":3583,"PHASE2":3604,"PHASE3":3606,"PHASE4":3608,"NA":3610},{"trials":3570,"activeCount":100},[3571],{"nctId":3572,"briefTitle":3573,"status":106,"phases":3574,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":1593,"conditions":3577,"interventions":3579},"NCT05478863","The Pharmacodynamics of Cannabinoid-Caffeine Combinations",[87],"2024-10-02","2023-01-20",[3578],"Behavioral Pharmacology of Cannabinoids",[56,3580,3581,3582],"Oral THC","Oral CBD","Oral Caffeine",{"trials":3584,"activeCount":126,"soonestReadout":55},[3585,3598],{"nctId":3586,"briefTitle":3587,"status":106,"phases":3588,"primaryCompletion":3589,"completion":3575,"start":3590,"enrollment":1854,"conditions":3591,"interventions":3592},"NCT05287256","Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC",[88],"2024-08-08","2022-05-23",[1878],[3593,3594,56,3595,3596,3597],"Oral Delta-8-THC Cannabis","Oral Delta-9-THC Cannabis","Vaporized Delta-8-THC Cannabis","Vaporized Delta-9-THC Cannabis","Vaporized Placebo",{"nctId":53,"briefTitle":54,"status":118,"phases":3599,"primaryCompletion":55,"completion":55,"start":3600,"enrollment":164,"conditions":3601,"interventions":3602},[88],"2022-08-09",[1878],[56,3603],"Oral CBG Cannabis",{"trials":3605,"activeCount":100},[],{"trials":3607,"activeCount":100},[],{"trials":3609,"activeCount":100},[],{"trials":3611,"activeCount":100},[],{"intervention":3613,"totalTrials":280,"cells":3614},"Delta-9-THC",{"EARLY_PHASE1":3615,"PHASE1":3617,"PHASE2":3639,"PHASE3":3641,"PHASE4":3643,"NA":3645},{"trials":3616,"activeCount":100},[],{"trials":3618,"activeCount":126,"soonestReadout":1604},[3619,3627],{"nctId":3620,"briefTitle":3621,"status":106,"phases":3622,"primaryCompletion":3623,"completion":3623,"start":645,"enrollment":164,"conditions":3624,"interventions":3625},"NCT06218550","Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance",[88],"2025-09-08",[1844],[3613,3626],"Delta-8-THC",{"nctId":3628,"briefTitle":3629,"status":118,"phases":3630,"primaryCompletion":1604,"completion":3631,"start":3632,"enrollment":3633,"conditions":3634,"interventions":3637},"NCT06378957","Behavioral Pharmacology of Orally Administered THC and D-limonene",[88],"2027-12-31","2025-02-14",65,[3635,3406,3636],"Subjective Drug Effects","D-limonene",[3638,3613],"D-Limonene",{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[],{"trials":3644,"activeCount":100},[],{"trials":3646,"activeCount":100},[],{"intervention":1704,"totalTrials":280,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3668,"PHASE3":3670,"PHASE4":3672,"NA":3674},{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":126,"soonestReadout":1699},[3653,3664],{"nctId":3654,"briefTitle":3655,"status":106,"phases":3656,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":96,"conditions":3659,"interventions":3663},"NCT04226352","Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder",[88],"2021-12-07","2020-03-15",[3660,3661,889,3662],"MDD","Treatment Resistant Depression","Smoking",[1704],{"nctId":1696,"briefTitle":1697,"status":118,"phases":3665,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":311,"conditions":3666,"interventions":3667},[88],[1584],[71,85,1704,1705,1706,1707],{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[],{"trials":3673,"activeCount":100},[],{"trials":3675,"activeCount":100},[],{"intervention":1908,"totalTrials":280,"cells":3677},{"EARLY_PHASE1":3678,"PHASE1":3680,"PHASE2":3690,"PHASE3":3692,"PHASE4":3694,"NA":3696},{"trials":3679,"activeCount":100},[],{"trials":3681,"activeCount":126,"soonestReadout":1903},[3682,3686],{"nctId":1900,"briefTitle":1901,"status":118,"phases":3683,"primaryCompletion":1903,"completion":1700,"start":1904,"enrollment":215,"conditions":3684,"interventions":3685},[88],[1897,1906],[1844,1908],{"nctId":1919,"briefTitle":1920,"status":106,"phases":3687,"primaryCompletion":193,"completion":193,"start":1922,"enrollment":715,"conditions":3688,"interventions":3689},[88],[1897,1906],[1844,1908],{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[],{"trials":3695,"activeCount":100},[],{"trials":3697,"activeCount":100},[],{"intervention":3419,"totalTrials":126,"cells":3699},{"EARLY_PHASE1":3700,"PHASE1":3702,"PHASE2":3708,"PHASE3":3710,"PHASE4":3712,"NA":3714},{"trials":3701,"activeCount":100},[],{"trials":3703,"activeCount":126,"soonestReadout":3416},[3704],{"nctId":3413,"briefTitle":3414,"status":754,"phases":3705,"primaryCompletion":3416,"completion":3416,"start":2246,"enrollment":2119,"conditions":3706,"interventions":3707},[88],[1886],[3406,3419],{"trials":3709,"activeCount":100},[],{"trials":3711,"activeCount":100},[],{"trials":3713,"activeCount":100},[],{"trials":3715,"activeCount":100},[],{"intervention":3717,"totalTrials":126,"cells":3718},"MLT+EPO",{"EARLY_PHASE1":3719,"PHASE1":3721,"PHASE2":3730,"PHASE3":3732,"PHASE4":3734,"NA":3736},{"trials":3720,"activeCount":100},[],{"trials":3722,"activeCount":126,"soonestReadout":1162},[3723],{"nctId":3724,"briefTitle":3725,"status":118,"phases":3726,"primaryCompletion":1162,"completion":1162,"start":253,"enrollment":715,"conditions":3727,"interventions":3729},"NCT05617833","Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage",[88],[3728],"Intraventricular Hemorrhage of Prematurity",[3717],{"trials":3731,"activeCount":100},[],{"trials":3733,"activeCount":100},[],{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[],{"intervention":3739,"totalTrials":126,"cells":3740},"LSD",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3754,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3742,"activeCount":100},[],{"trials":3744,"activeCount":126,"soonestReadout":1604},[3745],{"nctId":3746,"briefTitle":3747,"status":754,"phases":3748,"primaryCompletion":1604,"completion":3075,"start":1796,"enrollment":264,"conditions":3749,"interventions":3752},"NCT07503002","Shortened LSD Intervention for Major Depressive Disorder",[88],[3750,3751,2384],"Major Depression Moderate","Major Depression Severe",[3739,3753],"Risperidone",{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[],{"intervention":3753,"totalTrials":126,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3772,"PHASE3":3774,"PHASE4":3776,"NA":3778},{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":126,"soonestReadout":1604},[3768],{"nctId":3746,"briefTitle":3747,"status":754,"phases":3769,"primaryCompletion":1604,"completion":3075,"start":1796,"enrollment":264,"conditions":3770,"interventions":3771},[88],[3750,3751,2384],[3739,3753],{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[],{"trials":3777,"activeCount":100},[],{"trials":3779,"activeCount":100},[],{"intervention":3781,"totalTrials":126,"cells":3782},"Imlygic",{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3798,"PHASE3":3800,"PHASE4":3802,"NA":3804},{"trials":3784,"activeCount":100},[],{"trials":3786,"activeCount":126,"soonestReadout":581},[3787],{"nctId":3788,"briefTitle":3789,"status":118,"phases":3790,"primaryCompletion":581,"completion":3631,"start":3791,"enrollment":264,"conditions":3792,"interventions":3797},"NCT07102394","Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1",[88],"2026-02-01",[3175,3793,3176,3794,3795,3796],"Neurofibromatosis","Neurofibroma","Von Recklinghausen Disease","Neurofibromas",[3781],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"trials":3803,"activeCount":100},[],{"trials":3805,"activeCount":100},[],{"intervention":3603,"totalTrials":126,"cells":3807},{"EARLY_PHASE1":3808,"PHASE1":3810,"PHASE2":3816,"PHASE3":3818,"PHASE4":3820,"NA":3822},{"trials":3809,"activeCount":100},[],{"trials":3811,"activeCount":126,"soonestReadout":55},[3812],{"nctId":53,"briefTitle":54,"status":118,"phases":3813,"primaryCompletion":55,"completion":55,"start":3600,"enrollment":164,"conditions":3814,"interventions":3815},[88],[1878],[56,3603],{"trials":3817,"activeCount":100},[],{"trials":3819,"activeCount":100},[],{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[],{"intervention":46,"totalTrials":126,"cells":3825},{"EARLY_PHASE1":3826,"PHASE1":3828,"PHASE2":3843,"PHASE3":3845,"PHASE4":3847,"NA":3849},{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":126,"soonestReadout":45},[3830],{"nctId":43,"briefTitle":44,"status":1312,"phases":3831,"primaryCompletion":45,"completion":3832,"start":3833,"enrollment":1895,"conditions":3834,"interventions":3842},[88],"2030-02-28","2018-12-21",[3835,3836,3837,3838,3839,3840,3841],"Anhydramnios","Potter Syndrome","Lung Hypoplasia","Multicystic Dysplastic Kidney","Multicystic Renal Dysplasia, Bilateral","Lower Urinary Tract Obstructive Syndrome","Fetal Renal Anomaly",[46],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[],{"trials":3848,"activeCount":100},[],{"trials":3850,"activeCount":100},[],{"intervention":3638,"totalTrials":126,"cells":3852},{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3854,"activeCount":100},[],{"trials":3856,"activeCount":126,"soonestReadout":1604},[3857],{"nctId":3628,"briefTitle":3629,"status":118,"phases":3858,"primaryCompletion":1604,"completion":3631,"start":3632,"enrollment":3633,"conditions":3859,"interventions":3860},[88],[3635,3406,3636],[3638,3613],{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[],{"intervention":3870,"totalTrials":126,"cells":3871},"psilocybin trihydrate",{"EARLY_PHASE1":3872,"PHASE1":3874,"PHASE2":3884,"PHASE3":3886,"PHASE4":3888,"NA":3890},{"trials":3873,"activeCount":100},[],{"trials":3875,"activeCount":126,"soonestReadout":2246},[3876],{"nctId":3877,"briefTitle":3878,"status":118,"phases":3879,"primaryCompletion":2246,"completion":1161,"start":3880,"enrollment":1593,"conditions":3881,"interventions":3883},"NCT06450210","Safety for Home Administration of Microdose Psilocybin Use",[88],"2024-12-06",[3882],"Psychedelic Experiences",[3870],{"trials":3885,"activeCount":100},[],{"trials":3887,"activeCount":100},[],{"trials":3889,"activeCount":100},[],{"trials":3891,"activeCount":100},[],{"intervention":3893,"totalTrials":126,"cells":3894},"Nicotine Pouches",{"EARLY_PHASE1":3895,"PHASE1":3897,"PHASE2":3909,"PHASE3":3911,"PHASE4":3913,"NA":3915},{"trials":3896,"activeCount":100},[],{"trials":3898,"activeCount":126,"soonestReadout":518},[3899],{"nctId":3900,"briefTitle":3901,"status":118,"phases":3902,"primaryCompletion":518,"completion":518,"start":3903,"enrollment":347,"conditions":3904,"interventions":3908},"NCT07128329","Acute Effects of Oral Nicotine Pouches",[88],"2025-11-21",[3905,3906,3907],"Nicotine Pouch Self-Administration","Nicotine Pharmacokinetic Study","Nicotine Pharmacodynamic Study",[3893],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":100},[],{"trials":3916,"activeCount":100},[],{"intervention":3918,"totalTrials":126,"cells":3919},"tenofovir alafenamide [TAF] 50 mg\u002Femtricitabine [FTC] 400mg",{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3932,"PHASE3":3934,"PHASE4":3936,"NA":3938},{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":126,"soonestReadout":2694},[3924],{"nctId":3925,"briefTitle":3926,"status":118,"phases":3927,"primaryCompletion":2694,"completion":1947,"start":3928,"enrollment":30,"conditions":3929,"interventions":3931},"NCT07349758","Evaluation of Single Dosing With Two F\u002FTAF Tablets Among Healthy Volunteers",[88],"2026-01-06",[3149,3930],"HIV Prevention",[3918],{"trials":3933,"activeCount":100},[],{"trials":3935,"activeCount":100},[],{"trials":3937,"activeCount":100},[],{"trials":3939,"activeCount":100},[],{"intervention":3941,"totalTrials":126,"cells":3942},"Nitroglycerin Ointment 2%",{"EARLY_PHASE1":3943,"PHASE1":3945,"PHASE2":3962,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":126,"soonestReadout":1162},[3947],{"nctId":3948,"briefTitle":3949,"status":754,"phases":3950,"primaryCompletion":1162,"completion":1700,"start":345,"enrollment":921,"conditions":3951,"interventions":3961},"NCT07004764","Enhancing Wound Perfusion in High-Risk Lower Extremity Orthopaedic Surgery: A Study on Nitropaste Using Intraoperative SPY Imaging.",[88],[3952,3953,3954,3955,3956,3957,3958,3959,3960],"Achilles Tendon Repairs\u002FReconstructions","Pilon Fracture of Tibia","Tibial Plateau Fracture","Ankle Fracture (Bimalleolar Equivalent, Bimalleolar, or Trimalleolar)","Calcaneus Fractures","Talus Fracture","Wound Infection Deep","Wound Infection Post-Traumatic","Wound Dehiscence, Surgical",[3941],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"trials":3969,"activeCount":100},[],{"intervention":3971,"totalTrials":126,"cells":3972},"300 mg Cannabidiol",{"EARLY_PHASE1":3973,"PHASE1":3975,"PHASE2":3986,"PHASE3":3988,"PHASE4":3990,"NA":3992},{"trials":3974,"activeCount":100},[],{"trials":3976,"activeCount":126,"soonestReadout":2890},[3977],{"nctId":3978,"briefTitle":3979,"status":118,"phases":3980,"primaryCompletion":2890,"completion":3981,"start":3982,"enrollment":311,"conditions":3983,"interventions":3984},"NCT05445804","Oral Cannabidiol for Tobacco Cessation",[88],"2027-02-01","2022-11-01",[3480,3521,255,1827,1044],[3971,3985],"600 mg Cannabidiol",{"trials":3987,"activeCount":100},[],{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[],{"trials":3993,"activeCount":100},[],{"intervention":3985,"totalTrials":126,"cells":3995},{"EARLY_PHASE1":3996,"PHASE1":3998,"PHASE2":4004,"PHASE3":4006,"PHASE4":4008,"NA":4010},{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":126,"soonestReadout":2890},[4000],{"nctId":3978,"briefTitle":3979,"status":118,"phases":4001,"primaryCompletion":2890,"completion":3981,"start":3982,"enrollment":311,"conditions":4002,"interventions":4003},[88],[3480,3521,255,1827,1044],[3971,3985],{"trials":4005,"activeCount":100},[],{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":100},[],{"intervention":3483,"totalTrials":126,"cells":4013},{"EARLY_PHASE1":4014,"PHASE1":4016,"PHASE2":4022,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4015,"activeCount":100},[],{"trials":4017,"activeCount":126,"soonestReadout":3476},[4018],{"nctId":3473,"briefTitle":3474,"status":118,"phases":4019,"primaryCompletion":3476,"completion":3477,"start":3478,"enrollment":184,"conditions":4020,"interventions":4021},[88],[1886,3480,3481],[3483,3484,3466,3485,3486],{"trials":4023,"activeCount":100},[],{"trials":4025,"activeCount":100},[],{"trials":4027,"activeCount":100},[],{"trials":4029,"activeCount":100},[],{"intervention":3484,"totalTrials":126,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4040,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4033,"activeCount":100},[],{"trials":4035,"activeCount":126,"soonestReadout":3476},[4036],{"nctId":3473,"briefTitle":3474,"status":118,"phases":4037,"primaryCompletion":3476,"completion":3477,"start":3478,"enrollment":184,"conditions":4038,"interventions":4039},[88],[1886,3480,3481],[3483,3484,3466,3485,3486],{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[],{"trials":4047,"activeCount":100},[],{"intervention":3485,"totalTrials":126,"cells":4049},{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4058,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":126,"soonestReadout":3476},[4054],{"nctId":3473,"briefTitle":3474,"status":118,"phases":4055,"primaryCompletion":3476,"completion":3477,"start":3478,"enrollment":184,"conditions":4056,"interventions":4057},[88],[1886,3480,3481],[3483,3484,3466,3485,3486],{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":100},[],{"trials":4065,"activeCount":100},[],{"intervention":3486,"totalTrials":126,"cells":4067},{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4076,"PHASE3":4078,"PHASE4":4080,"NA":4082},{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":126,"soonestReadout":3476},[4072],{"nctId":3473,"briefTitle":3474,"status":118,"phases":4073,"primaryCompletion":3476,"completion":3477,"start":3478,"enrollment":184,"conditions":4074,"interventions":4075},[88],[1886,3480,3481],[3483,3484,3466,3485,3486],{"trials":4077,"activeCount":100},[],{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"intervention":3494,"totalTrials":126,"cells":4085},{"EARLY_PHASE1":4086,"PHASE1":4088,"PHASE2":4094,"PHASE3":4096,"PHASE4":4098,"NA":4100},{"trials":4087,"activeCount":100},[],{"trials":4089,"activeCount":126,"soonestReadout":3476},[4090],{"nctId":3488,"briefTitle":3489,"status":118,"phases":4091,"primaryCompletion":3476,"completion":3477,"start":3491,"enrollment":184,"conditions":4092,"interventions":4093},[88],[1886,3480,877],[3494,3495,3466,3496,3497],{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"intervention":3495,"totalTrials":126,"cells":4103},{"EARLY_PHASE1":4104,"PHASE1":4106,"PHASE2":4112,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4105,"activeCount":100},[],{"trials":4107,"activeCount":126,"soonestReadout":3476},[4108],{"nctId":3488,"briefTitle":3489,"status":118,"phases":4109,"primaryCompletion":3476,"completion":3477,"start":3491,"enrollment":184,"conditions":4110,"interventions":4111},[88],[1886,3480,877],[3494,3495,3466,3496,3497],{"trials":4113,"activeCount":100},[],{"trials":4115,"activeCount":100},[],{"trials":4117,"activeCount":100},[],{"trials":4119,"activeCount":100},[],{"intervention":3496,"totalTrials":126,"cells":4121},{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4130,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":126,"soonestReadout":3476},[4126],{"nctId":3488,"briefTitle":3489,"status":118,"phases":4127,"primaryCompletion":3476,"completion":3477,"start":3491,"enrollment":184,"conditions":4128,"interventions":4129},[88],[1886,3480,877],[3494,3495,3466,3496,3497],{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"trials":4137,"activeCount":100},[],{"intervention":3497,"totalTrials":126,"cells":4139},{"EARLY_PHASE1":4140,"PHASE1":4142,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":126,"soonestReadout":3476},[4144],{"nctId":3488,"briefTitle":3489,"status":118,"phases":4145,"primaryCompletion":3476,"completion":3477,"start":3491,"enrollment":184,"conditions":4146,"interventions":4147},[88],[1886,3480,877],[3494,3495,3466,3496,3497],{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[],{"trials":4155,"activeCount":100},[],{"intervention":1705,"totalTrials":126,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4166,"PHASE3":4168,"PHASE4":4170,"NA":4172},{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":126,"soonestReadout":1699},[4162],{"nctId":1696,"briefTitle":1697,"status":118,"phases":4163,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":311,"conditions":4164,"interventions":4165},[88],[1584],[71,85,1704,1705,1706,1707],{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"trials":4171,"activeCount":100},[],{"trials":4173,"activeCount":100},[],{"intervention":1706,"totalTrials":126,"cells":4175},{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":126,"soonestReadout":1699},[4180],{"nctId":1696,"briefTitle":1697,"status":118,"phases":4181,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":311,"conditions":4182,"interventions":4183},[88],[1584],[71,85,1704,1705,1706,1707],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[],{"trials":4191,"activeCount":100},[],{"intervention":1707,"totalTrials":126,"cells":4193},{"EARLY_PHASE1":4194,"PHASE1":4196,"PHASE2":4202,"PHASE3":4204,"PHASE4":4206,"NA":4208},{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":126,"soonestReadout":1699},[4198],{"nctId":1696,"briefTitle":1697,"status":118,"phases":4199,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":311,"conditions":4200,"interventions":4201},[88],[1584],[71,85,1704,1705,1706,1707],{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[],{"trials":4209,"activeCount":100},[],{"intervention":1718,"totalTrials":126,"cells":4211},{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4220,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4213,"activeCount":100},[],{"trials":4215,"activeCount":126,"soonestReadout":1712},[4216],{"nctId":1709,"briefTitle":1710,"status":118,"phases":4217,"primaryCompletion":1712,"completion":1713,"start":1714,"enrollment":16,"conditions":4218,"interventions":4219},[88],[1716],[71,71,1718,1718],{"trials":4221,"activeCount":100},[],{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"intervention":4229,"totalTrials":126,"cells":4230},"NAC effervescent",{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4242,"PHASE3":4244,"PHASE4":4246,"NA":4248},{"trials":4232,"activeCount":100},[],{"trials":4234,"activeCount":126,"soonestReadout":2402},[4235],{"nctId":4236,"briefTitle":4237,"status":1312,"phases":4238,"primaryCompletion":2402,"completion":1699,"start":4239,"enrollment":164,"conditions":4240,"interventions":4241},"NCT03999021","FIGHT-RP 1 Extension Study",[88],"2019-06-24",[1319],[4229],{"trials":4243,"activeCount":100},[],{"trials":4245,"activeCount":100},[],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"intervention":4251,"totalTrials":126,"cells":4252},"Psilocybin 25 mgs",{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4265,"PHASE3":4267,"PHASE4":4269,"NA":4271},{"trials":4254,"activeCount":100},[],{"trials":4256,"activeCount":126,"soonestReadout":2402},[4257],{"nctId":4258,"briefTitle":4259,"status":1312,"phases":4260,"primaryCompletion":2402,"completion":2402,"start":4261,"enrollment":921,"conditions":4262,"interventions":4264},"NCT06835699","Psilocybin Brain Stimulation and Imaging Pilot Study",[88],"2025-04-18",[4263],"Healthy Volunteers",[4251],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[],{"trials":4272,"activeCount":100},[],{"intervention":830,"totalTrials":235,"cells":4274},{"EARLY_PHASE1":4275,"PHASE1":4286,"PHASE2":4288,"PHASE3":4294,"PHASE4":4296,"NA":4305},{"trials":4276,"activeCount":126,"soonestReadout":1162},[4277],{"nctId":4278,"briefTitle":4279,"status":1312,"phases":4280,"primaryCompletion":1162,"completion":1162,"start":4281,"enrollment":1101,"conditions":4282,"interventions":4284},"NCT04108897","Analysis of the Microbiome in Rosacea",[87],"2019-09-17",[4283],"Rosacea",[830,4285],"Ivermectin Topical",{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":100},[4290],{"nctId":821,"briefTitle":822,"status":106,"phases":4291,"primaryCompletion":824,"completion":824,"start":825,"enrollment":22,"conditions":4292,"interventions":4293},[89],[396],[828,770,829,830,831,832],{"trials":4295,"activeCount":100},[],{"trials":4297,"activeCount":100},[4298],{"nctId":4299,"briefTitle":4300,"status":149,"phases":4301,"primaryCompletion":3311,"completion":3311,"start":4302,"enrollment":100,"conditions":4303,"interventions":4304},"NCT01014260","Doxycycline Outcomes in Lupus Erythematosus",[91],"2010-09",[2343],[830],{"trials":4306,"activeCount":100},[],{"intervention":41,"totalTrials":280,"cells":4308},{"EARLY_PHASE1":4309,"PHASE1":4318,"PHASE2":4320,"PHASE3":4331,"PHASE4":4333,"NA":4335},{"trials":4310,"activeCount":126,"soonestReadout":40},[4311],{"nctId":38,"briefTitle":39,"status":1312,"phases":4312,"primaryCompletion":40,"completion":4313,"start":4314,"enrollment":1663,"conditions":4315,"interventions":4317},[87],"2026-10","2019-10-09",[4316],"Skin Aging",[41],{"trials":4319,"activeCount":100},[],{"trials":4321,"activeCount":100},[4322],{"nctId":4323,"briefTitle":4324,"status":873,"phases":4325,"primaryCompletion":4326,"completion":4326,"start":4327,"enrollment":2081,"conditions":4328,"interventions":4330},"NCT03126539","Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure",[89],"2019-01-18","2017-09-15",[4329],"Aging",[41],{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":100},[],{"intervention":61,"totalTrials":126,"cells":4338},{"EARLY_PHASE1":4339,"PHASE1":4348,"PHASE2":4350,"PHASE3":4352,"PHASE4":4354,"NA":4356},{"trials":4340,"activeCount":126,"soonestReadout":60},[4341],{"nctId":58,"briefTitle":59,"status":118,"phases":4342,"primaryCompletion":60,"completion":494,"start":4343,"enrollment":4344,"conditions":4345,"interventions":4347},[87],"2023-09-05",8,[2093,4346],"Chronic Rhinosinusitis (Diagnosis)",[61],{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"trials":4353,"activeCount":100},[],{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[],{"intervention":1586,"totalTrials":126,"cells":4359},{"EARLY_PHASE1":4360,"PHASE1":4366,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4361,"activeCount":126,"soonestReadout":1580},[4362],{"nctId":1577,"briefTitle":1578,"status":754,"phases":4363,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":4364,"interventions":4365},[87],[1584],[1586,71],{"trials":4367,"activeCount":100},[],{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"intervention":4285,"totalTrials":126,"cells":4377},{"EARLY_PHASE1":4378,"PHASE1":4384,"PHASE2":4386,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4379,"activeCount":126,"soonestReadout":1162},[4380],{"nctId":4278,"briefTitle":4279,"status":1312,"phases":4381,"primaryCompletion":1162,"completion":1162,"start":4281,"enrollment":1101,"conditions":4382,"interventions":4383},[87],[4283],[830,4285],{"trials":4385,"activeCount":100},[],{"trials":4387,"activeCount":100},[],{"trials":4389,"activeCount":100},[],{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"intervention":4395,"totalTrials":126,"cells":4396},"Bimatoprost Ophthalmic",{"EARLY_PHASE1":4397,"PHASE1":4408,"PHASE2":4410,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4398,"activeCount":126,"soonestReadout":605},[4399],{"nctId":4400,"briefTitle":4401,"status":118,"phases":4402,"primaryCompletion":605,"completion":4403,"start":4404,"enrollment":235,"conditions":4405,"interventions":4407},"NCT03708627","Bimatoprost as a Treatment for Graves' Orbitopathy",[87],"2031-07-01","2017-11-01",[4406],"Graves Ophthalmopathy",[4395],{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":100},[],{"intervention":4419,"totalTrials":126,"cells":4420},"Latanoprost",{"EARLY_PHASE1":4421,"PHASE1":4431,"PHASE2":4433,"PHASE3":4435,"PHASE4":4437,"NA":4439},{"trials":4422,"activeCount":126,"soonestReadout":4427},[4423],{"nctId":4424,"briefTitle":4425,"status":754,"phases":4426,"primaryCompletion":4427,"completion":4428,"start":2246,"enrollment":164,"conditions":4429,"interventions":4430},"NCT07425535","Optic Nerve Head Strain in Non-glaucoma Subjects",[87],"2028-03-01","2028-03-31",[331],[4419],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[],{"trials":4438,"activeCount":100},[],{"trials":4440,"activeCount":100},[],{"intervention":4442,"totalTrials":126,"cells":4443},"Transdermal Nicotine Patch",{"EARLY_PHASE1":4444,"PHASE1":4455,"PHASE2":4457,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4445,"activeCount":126,"soonestReadout":2472},[4446],{"nctId":4447,"briefTitle":4448,"status":118,"phases":4449,"primaryCompletion":2472,"completion":2472,"start":4450,"enrollment":1101,"conditions":4451,"interventions":4454},"NCT06066996","Evaluation of the Electronic Cigarette Withdrawal Syndrome",[87],"2023-11-28",[4452,4453],"E-cigarette Use","Withdrawal",[4442],{"trials":4456,"activeCount":100},[],{"trials":4458,"activeCount":100},[],{"trials":4460,"activeCount":100},[],{"trials":4462,"activeCount":100},[],{"trials":4464,"activeCount":100},[],{"intervention":4466,"totalTrials":280,"cells":4467},"Corrie Virtual Atrial Fibrillation Management Program",{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4474,"PHASE4":4476,"NA":4478},{"trials":4469,"activeCount":100},[],{"trials":4471,"activeCount":100},[],{"trials":4473,"activeCount":100},[],{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":126,"soonestReadout":1735},[4480,4490],{"nctId":4481,"briefTitle":4482,"status":106,"phases":4483,"primaryCompletion":4484,"completion":4484,"start":4485,"enrollment":4486,"conditions":4487,"interventions":4489},"NCT05400837","Patient Centered Mobile Health Technology Enabled Atrial Fibrillation Management",[92],"2024-05-23","2023-06-26",61,[1497,4488],"Behavior",[4466],{"nctId":4491,"briefTitle":4492,"status":118,"phases":4493,"primaryCompletion":1735,"completion":1735,"start":4494,"enrollment":4495,"conditions":4496,"interventions":4497},"NCT06500988","Mobile Health Technology-Enabled AFib Management",[92],"2025-06-03",248,[1497,4488],[4466],{"intervention":4499,"totalTrials":126,"cells":4500},"Influenza",{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4507,"PHASE4":4509,"NA":4511},{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[],{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[],{"trials":4512,"activeCount":126,"soonestReadout":2496},[4513],{"nctId":4514,"briefTitle":4515,"status":118,"phases":4516,"primaryCompletion":2496,"completion":4517,"start":4518,"enrollment":4519,"conditions":4520,"interventions":4524},"NCT02200276","Influenza Immunization in Adults Over Age 75",[92],"2027-11-30","2014-03",1025,[4499,4521,4522,4523],"Immunization","Older Adults","Over Age 75",[4499],{"intervention":4526,"totalTrials":126,"cells":4527},"Ofatumumab",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4532,"PHASE3":4534,"PHASE4":4536,"NA":4538},{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[],{"trials":4533,"activeCount":100},[],{"trials":4535,"activeCount":100},[],{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":126,"soonestReadout":1625},[4540],{"nctId":4541,"briefTitle":4542,"status":492,"phases":4543,"primaryCompletion":1625,"completion":1625,"start":4544,"enrollment":394,"conditions":4545,"interventions":4549},"NCT06167642","Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab",[],"2023-05-22",[313,4546,4547,4548],"Tomography, Optical Coherence","Retinal Degeneration","Visual Acuity",[4526],{"intervention":4551,"totalTrials":126,"cells":4552},"OxyCODONE 5 mg Oral",{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4557,"PHASE3":4559,"PHASE4":4561,"NA":4563},{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[],{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":126,"soonestReadout":213},[4565],{"nctId":4566,"briefTitle":4567,"status":1312,"phases":4568,"primaryCompletion":213,"completion":213,"start":4569,"enrollment":347,"conditions":4570,"interventions":4573},"NCT05548582","Reduced Opioid Prescription After Laparoscopic Hysterectomy",[92],"2023-01-12",[4571,4572,349,3259],"Pain, Postoperative","Opioid Misuse",[4551,4574,4575],"Acetaminophen 500 mg Tab","Ibuprofen 600 mg",{"intervention":4574,"totalTrials":126,"cells":4577},{"EARLY_PHASE1":4578,"PHASE1":4580,"PHASE2":4582,"PHASE3":4584,"PHASE4":4586,"NA":4588},{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[],{"trials":4583,"activeCount":100},[],{"trials":4585,"activeCount":100},[],{"trials":4587,"activeCount":100},[],{"trials":4589,"activeCount":126,"soonestReadout":213},[4590],{"nctId":4566,"briefTitle":4567,"status":1312,"phases":4591,"primaryCompletion":213,"completion":213,"start":4569,"enrollment":347,"conditions":4592,"interventions":4593},[92],[4571,4572,349,3259],[4551,4574,4575],{"intervention":4575,"totalTrials":126,"cells":4595},{"EARLY_PHASE1":4596,"PHASE1":4598,"PHASE2":4600,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4597,"activeCount":100},[],{"trials":4599,"activeCount":100},[],{"trials":4601,"activeCount":100},[],{"trials":4603,"activeCount":100},[],{"trials":4605,"activeCount":100},[],{"trials":4607,"activeCount":126,"soonestReadout":213},[4608],{"nctId":4566,"briefTitle":4567,"status":1312,"phases":4609,"primaryCompletion":213,"completion":213,"start":4569,"enrollment":347,"conditions":4610,"interventions":4611},[92],[4571,4572,349,3259],[4551,4574,4575],{"intervention":4613,"totalTrials":126,"cells":4614},"Surgeon-Initiated Bone Health Referral Pathway",{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4619,"PHASE3":4621,"PHASE4":4623,"NA":4625},{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":126,"soonestReadout":4631},[4627],{"nctId":4628,"briefTitle":4629,"status":118,"phases":4630,"primaryCompletion":4631,"completion":1805,"start":4632,"enrollment":4633,"conditions":4634,"interventions":4638},"NCT05845021","Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty",[92],"2027-10","2023-09-27",2000,[4635,4636,4637],"Osteoporosis","Arthroplasty Complications","Fragility Fracture",[4613],{"intervention":4640,"totalTrials":126,"cells":4641},"Early Dinner tracer",{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4648,"PHASE4":4650,"NA":4652},{"trials":4643,"activeCount":100},[],{"trials":4645,"activeCount":100},[],{"trials":4647,"activeCount":100},[],{"trials":4649,"activeCount":100},[],{"trials":4651,"activeCount":100},[],{"trials":4653,"activeCount":126,"soonestReadout":4428},[4654],{"nctId":4655,"briefTitle":4656,"status":118,"phases":4657,"primaryCompletion":4428,"completion":4428,"start":4658,"enrollment":2119,"conditions":4659,"interventions":4661},"NCT05745441","Dinner Time for Obesity and Prediabetes",[92],"2023-07-05",[4660,18,112],"PreDiabetes",[4640,4662],"Late Dinner tracer",{"intervention":4662,"totalTrials":126,"cells":4664},{"EARLY_PHASE1":4665,"PHASE1":4667,"PHASE2":4669,"PHASE3":4671,"PHASE4":4673,"NA":4675},{"trials":4666,"activeCount":100},[],{"trials":4668,"activeCount":100},[],{"trials":4670,"activeCount":100},[],{"trials":4672,"activeCount":100},[],{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":126,"soonestReadout":4428},[4677],{"nctId":4655,"briefTitle":4656,"status":118,"phases":4678,"primaryCompletion":4428,"completion":4428,"start":4658,"enrollment":2119,"conditions":4679,"interventions":4680},[92],[4660,18,112],[4640,4662],{"intervention":4682,"totalTrials":126,"cells":4683},"Intravenous Antibiotics",{"EARLY_PHASE1":4684,"PHASE1":4686,"PHASE2":4688,"PHASE3":4690,"PHASE4":4692,"NA":4694},{"trials":4685,"activeCount":100},[],{"trials":4687,"activeCount":100},[],{"trials":4689,"activeCount":100},[],{"trials":4691,"activeCount":100},[],{"trials":4693,"activeCount":100},[],{"trials":4695,"activeCount":126,"soonestReadout":4700},[4696],{"nctId":4697,"briefTitle":4698,"status":118,"phases":4699,"primaryCompletion":4700,"completion":272,"start":4701,"enrollment":4702,"conditions":4703,"interventions":4705},"NCT06080698","Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial",[92],"2027-05-31","2024-02-22",1030,[4704],"Gram-negative Bacteremia",[4682,4706],"Oral Antibiotics",{"intervention":4706,"totalTrials":126,"cells":4708},{"EARLY_PHASE1":4709,"PHASE1":4711,"PHASE2":4713,"PHASE3":4715,"PHASE4":4717,"NA":4719},{"trials":4710,"activeCount":100},[],{"trials":4712,"activeCount":100},[],{"trials":4714,"activeCount":100},[],{"trials":4716,"activeCount":100},[],{"trials":4718,"activeCount":100},[],{"trials":4720,"activeCount":126,"soonestReadout":4700},[4721],{"nctId":4697,"briefTitle":4698,"status":118,"phases":4722,"primaryCompletion":4700,"completion":272,"start":4701,"enrollment":4702,"conditions":4723,"interventions":4724},[92],[4704],[4682,4706],{"intervention":4726,"totalTrials":126,"cells":4727},"mRNA COVID-19 vaccine",{"EARLY_PHASE1":4728,"PHASE1":4730,"PHASE2":4732,"PHASE3":4734,"PHASE4":4736,"NA":4738},{"trials":4729,"activeCount":100},[],{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[],{"trials":4739,"activeCount":126,"soonestReadout":4744},[4740],{"nctId":4741,"briefTitle":4742,"status":118,"phases":4743,"primaryCompletion":4744,"completion":4745,"start":4746,"enrollment":4747,"conditions":4748,"interventions":4751},"NCT05197621","The Impact of COVID-19 on Maternal and Neonatal Outcomes",[],"2027-05-05","2028-05-05","2020-04-13",300,[4749,4750],"COVID-19","Pregnancy; Infection",[4726],{"intervention":4753,"totalTrials":126,"cells":4754},"Active tDCS on the DLPFC + Cognitive Intervention",{"EARLY_PHASE1":4755,"PHASE1":4757,"PHASE2":4759,"PHASE3":4761,"PHASE4":4763,"NA":4765},{"trials":4756,"activeCount":100},[],{"trials":4758,"activeCount":100},[],{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[],{"trials":4766,"activeCount":126,"soonestReadout":4771},[4767],{"nctId":4768,"briefTitle":4769,"status":754,"phases":4770,"primaryCompletion":4771,"completion":4771,"start":1581,"enrollment":1593,"conditions":4772,"interventions":4774},"NCT06989970","Treating Traumatic Brain Injury With Transcranial Direct Current Stimulation",[92],"2029-10-15",[4773],"Traumatic Brain Injury",[4753,4775],"Sham tDCS on the DLPFC + Cognitive Intervention",{"intervention":4775,"totalTrials":126,"cells":4777},{"EARLY_PHASE1":4778,"PHASE1":4780,"PHASE2":4782,"PHASE3":4784,"PHASE4":4786,"NA":4788},{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[],{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":126,"soonestReadout":4771},[4790],{"nctId":4768,"briefTitle":4769,"status":754,"phases":4791,"primaryCompletion":4771,"completion":4771,"start":1581,"enrollment":1593,"conditions":4792,"interventions":4793},[92],[4773],[4753,4775],{"intervention":4795,"totalTrials":96,"cells":4796},"Azithromycin",{"EARLY_PHASE1":4797,"PHASE1":4799,"PHASE2":4801,"PHASE3":4822,"PHASE4":4824,"NA":4859},{"trials":4798,"activeCount":100},[],{"trials":4800,"activeCount":100},[],{"trials":4802,"activeCount":100},[4803,4813],{"nctId":4804,"briefTitle":4805,"status":873,"phases":4806,"primaryCompletion":4807,"completion":4807,"start":4808,"enrollment":1582,"conditions":4809,"interventions":4811},"NCT00181272","Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease",[89],"2006-07","2005-09",[21,4810],"Chronic Obstructive Pulmonary Disease",[4812],"azithromycin",{"nctId":4814,"briefTitle":4815,"status":106,"phases":4816,"primaryCompletion":4817,"completion":4817,"start":4818,"enrollment":264,"conditions":4819,"interventions":4821},"NCT04287049","A Study of Standard Drugs for Mycobacterium Avium Complex",[89],"2025-03-21","2020-02-24",[4820],"Mycobacterium Avium Complex",[4795],{"trials":4823,"activeCount":100},[],{"trials":4825,"activeCount":100},[4826,4838,4850],{"nctId":4827,"briefTitle":4828,"status":106,"phases":4829,"primaryCompletion":4830,"completion":4830,"start":4831,"enrollment":4832,"conditions":4833,"interventions":4836},"NCT04069312","Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)",[91],"2026-03-01","2020-02-11",1032,[4834,4835],"Chronic Obstructive Pulmonary Disease Severe","Chronic Bronchitis",[4837,4795],"Roflumilast",{"nctId":4839,"briefTitle":4840,"status":106,"phases":4841,"primaryCompletion":4842,"completion":4843,"start":4844,"enrollment":4845,"conditions":4846,"interventions":4848},"NCT00347776","Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia",[91],"2003-12","2006-12","2001-08",1452,[4847],"Trichiasis",[4812,4849],"topical tetracycline",{"nctId":4851,"briefTitle":4852,"status":106,"phases":4853,"primaryCompletion":812,"completion":714,"start":4854,"enrollment":4855,"conditions":4856,"interventions":4858},"NCT00792922","Partnership for Rapid Elimination of Trachoma",[91],"2008-05",128,[4857],"Trachoma",[4795,4795],{"trials":4860,"activeCount":100},[],{"intervention":4862,"totalTrials":96,"cells":4863},"Normal saline",{"EARLY_PHASE1":4864,"PHASE1":4866,"PHASE2":4868,"PHASE3":4893,"PHASE4":4917,"NA":4930},{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[4870,4883],{"nctId":4871,"briefTitle":4872,"status":873,"phases":4873,"primaryCompletion":4874,"completion":4875,"start":4876,"enrollment":614,"conditions":4877,"interventions":4880},"NCT02802592","EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)",[88,89],"2016-06-15","2017-02-27","2015-05",[4878,4879],"Cardiac Surgery-CABG","Cardiac Valve Replacement",[4881,4882],"Epogen","Normal Saline",{"nctId":4884,"briefTitle":4885,"status":106,"phases":4886,"primaryCompletion":4854,"completion":4854,"start":4887,"enrollment":1582,"conditions":4888,"interventions":4890},"NCT00583466","Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection",[89],"2007-05",[4889],"Large Polyps in the Gastrointestinal Tract",[4891,4862,4892],"Autologous blood","HPMC",{"trials":4894,"activeCount":100},[4895,4907],{"nctId":4896,"briefTitle":4897,"status":106,"phases":4898,"primaryCompletion":3311,"completion":3311,"start":4899,"enrollment":4900,"conditions":4901,"interventions":4903},"NCT00733096","A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy",[89,90],"2008-08",84,[4902],"Lumbosacral Radiculopathy",[4904,4905,4906],"etanercept","methylprednisolone","normal saline",{"nctId":4908,"briefTitle":4909,"status":149,"phases":4910,"primaryCompletion":1041,"completion":4911,"start":4912,"enrollment":100,"conditions":4913,"interventions":4915},"NCT03260972","Intraabdominal Chloroprocaine During Cesarean Delivery for Pain Control",[90],"2023-06","2021-06",[4914,3259],"Cesarean Section Complications",[4916,4862],"Chloroprocaine Hcl 2% Inj",{"trials":4918,"activeCount":100},[4919],{"nctId":4920,"briefTitle":4921,"status":873,"phases":4922,"primaryCompletion":4923,"completion":4923,"start":183,"enrollment":4924,"conditions":4925,"interventions":4928},"NCT03247413","Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation",[91],"2022-10-14",63,[4926,4927],"Neuritis","Radiofrequency Ablation",[4929,4862],"Dexamethasone 4 mg\u002Fml",{"trials":4931,"activeCount":100},[],{"intervention":4933,"totalTrials":614,"cells":4934},"Aspirin",{"EARLY_PHASE1":4935,"PHASE1":4937,"PHASE2":4939,"PHASE3":4941,"PHASE4":4955,"NA":4981},{"trials":4936,"activeCount":100},[],{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[],{"trials":4942,"activeCount":100},[4943],{"nctId":4944,"briefTitle":4945,"status":149,"phases":4946,"primaryCompletion":4947,"completion":4947,"start":4948,"enrollment":100,"conditions":4949,"interventions":4954},"NCT04557475","Transplacental Aspirin Therapy for Early Onset Fetal Growth Restriction",[90],"2023-06-11","2022-06-11",[4950,4951,4952,4953],"Fetal Growth Restriction","Fetal Growth Retardation","Intrauterine Growth Restriction","Intrauterine Growth Retardation",[4933],{"trials":4956,"activeCount":100},[4957,4966,4974],{"nctId":4958,"briefTitle":4959,"status":106,"phases":4960,"primaryCompletion":714,"completion":714,"start":825,"enrollment":2151,"conditions":4961,"interventions":4964},"NCT01815008","Pharmacogenomics of Antiplatelet Response - I",[91],[4962,4963,3302],"Platelet Aggregation","Platelet Transcriptome",[4965,4933],"Clopidogrel",{"nctId":4967,"briefTitle":4968,"status":106,"phases":4969,"primaryCompletion":1555,"completion":1555,"start":4970,"enrollment":3446,"conditions":4971,"interventions":4973},"NCT01894555","Pharmacogenomics of Antiplatelet Response - II (PARes-II)",[91],"2013-01",[4972],"Atherothrombosis",[4933],{"nctId":4975,"briefTitle":4976,"status":106,"phases":4977,"primaryCompletion":4978,"completion":4876,"start":714,"enrollment":3394,"conditions":4979,"interventions":4980},"NCT02234427","Pharmacogenomics of Antiplatelet Response",[91],"2015-04",[2342],[4933],{"trials":4982,"activeCount":100},[],{"intervention":4984,"totalTrials":235,"cells":4985},"Sertraline",{"EARLY_PHASE1":4986,"PHASE1":4988,"PHASE2":4990,"PHASE3":4992,"PHASE4":5017,"NA":5028},{"trials":4987,"activeCount":100},[],{"trials":4989,"activeCount":100},[],{"trials":4991,"activeCount":100},[],{"trials":4993,"activeCount":100},[4994,5007],{"nctId":4995,"briefTitle":4996,"status":106,"phases":4997,"primaryCompletion":4998,"completion":4999,"start":5000,"enrollment":5001,"conditions":5002,"interventions":5006},"NCT00052078","Child and Adolescent Anxiety Disorders (CAMS)",[90],"2007-10","2008-03","2003-01",488,[5003,5004,5005],"Anxiety Disorders","Social Phobia","Generalized Anxiety Disorder",[4984],{"nctId":5008,"briefTitle":5009,"status":106,"phases":5010,"primaryCompletion":5011,"completion":2105,"start":5012,"enrollment":5013,"conditions":5014,"interventions":5016},"NCT00086138","Depression in Alzheimer's Disease-2",[89,90],"2008-07","2004-07",131,[5015,27],"Alzheimer's Disease",[4984],{"trials":5018,"activeCount":100},[5019],{"nctId":5020,"briefTitle":5021,"status":106,"phases":5022,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":4900,"conditions":5025,"interventions":5027},"NCT02777372","Stress & Premenstrual Symptoms Study",[91],"2021-12-01","2016-04-01",[5026,3519,1816],"PMDD",[4984],{"trials":5029,"activeCount":100},[],{"intervention":3261,"totalTrials":280,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5043,"PHASE2":5045,"PHASE3":5047,"PHASE4":5049,"NA":5055},{"trials":5033,"activeCount":100},[5034],{"nctId":5035,"briefTitle":5036,"status":106,"phases":5037,"primaryCompletion":5038,"completion":5038,"start":5039,"enrollment":5040,"conditions":5041,"interventions":5042},"NCT04157075","Intra-operative Uterosacral Ligament Bupivacaine Injection During Minimally Invasive Hysterectomy",[87],"2022-10-15","2021-03-15",180,[4571,349],[3261],{"trials":5044,"activeCount":100},[],{"trials":5046,"activeCount":100},[],{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[5051],{"nctId":3253,"briefTitle":3254,"status":149,"phases":5052,"primaryCompletion":3256,"completion":3257,"start":292,"enrollment":100,"conditions":5053,"interventions":5054},[91],[3259],[3261,3204],{"trials":5056,"activeCount":100},[],{"intervention":4837,"totalTrials":280,"cells":5058},{"EARLY_PHASE1":5059,"PHASE1":5061,"PHASE2":5063,"PHASE3":5065,"PHASE4":5067,"NA":5083},{"trials":5060,"activeCount":100},[],{"trials":5062,"activeCount":100},[],{"trials":5064,"activeCount":100},[],{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[5069,5073],{"nctId":4827,"briefTitle":4828,"status":106,"phases":5070,"primaryCompletion":4830,"completion":4830,"start":4831,"enrollment":4832,"conditions":5071,"interventions":5072},[91],[4834,4835],[4837,4795],{"nctId":5074,"briefTitle":5075,"status":106,"phases":5076,"primaryCompletion":5077,"completion":5077,"start":5078,"enrollment":1663,"conditions":5079,"interventions":5082},"NCT03073798","The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis",[91],"2015-05-14","2013-03-18",[5080,4835,5081],"COPD","Emphysema",[4837],{"trials":5084,"activeCount":100},[],{"intervention":5086,"totalTrials":280,"cells":5087},"Ribavirin",{"EARLY_PHASE1":5088,"PHASE1":5090,"PHASE2":5102,"PHASE3":5104,"PHASE4":5106,"NA":5120},{"trials":5089,"activeCount":100},[],{"trials":5091,"activeCount":100},[5092],{"nctId":5093,"briefTitle":5094,"status":106,"phases":5095,"primaryCompletion":5096,"completion":2148,"start":5097,"enrollment":25,"conditions":5098,"interventions":5100},"NCT01052701","Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment",[88],"2012-09","2009-12",[5099,24],"Hepatitis C",[5086,5101],"Ribavirin plus Abacavir",{"trials":5103,"activeCount":100},[],{"trials":5105,"activeCount":100},[],{"trials":5107,"activeCount":100},[5108],{"nctId":5109,"briefTitle":5110,"status":106,"phases":5111,"primaryCompletion":5112,"completion":5113,"start":5114,"enrollment":264,"conditions":5115,"interventions":5117},"NCT02781649","Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients",[91],"2017-05-03","2018-01-01","2016-07-20",[5116,5099],"End-Stage Renal Disease",[5118,5086,5119],"Zepatier","Sofosbuvir",{"trials":5121,"activeCount":100},[],{"intervention":5123,"totalTrials":280,"cells":5124},"Nimodipine",{"EARLY_PHASE1":5125,"PHASE1":5137,"PHASE2":5139,"PHASE3":5141,"PHASE4":5143,"NA":5154},{"trials":5126,"activeCount":100},[5127],{"nctId":5128,"briefTitle":5129,"status":106,"phases":5130,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":1582,"conditions":5133,"interventions":5136},"NCT03671525","Cognitive Effects of Nimodipine in Patients With Schizophrenia",[87],"2023-05-12","2018-10-05",[5134,5135],"Schizophrenia","Schizo Affective Disorder",[5123],{"trials":5138,"activeCount":100},[],{"trials":5140,"activeCount":100},[],{"trials":5142,"activeCount":100},[],{"trials":5144,"activeCount":100},[5145],{"nctId":5146,"briefTitle":5147,"status":149,"phases":5148,"primaryCompletion":5149,"completion":5149,"start":1772,"enrollment":100,"conditions":5150,"interventions":5152},"NCT03150524","RCVS: The Rational Approach to Diagnosis and Treatment",[91],"2019-05-31",[5151],"Reversible Cerebral Vasoconstriction Syndrome",[5123,5153],"Verapamil ER",{"trials":5155,"activeCount":100},[],{"intervention":5157,"totalTrials":280,"cells":5158},"Riluzole",{"EARLY_PHASE1":5159,"PHASE1":5161,"PHASE2":5163,"PHASE3":5175,"PHASE4":5177,"NA":5188},{"trials":5160,"activeCount":100},[],{"trials":5162,"activeCount":100},[],{"trials":5164,"activeCount":100},[5165],{"nctId":5166,"briefTitle":5167,"status":106,"phases":5168,"primaryCompletion":5169,"completion":5169,"start":5170,"enrollment":5171,"conditions":5172,"interventions":5174},"NCT00376220","A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression",[89],"2010-05","2004-05",94,[5173],"Bipolar Disorder",[5157],{"trials":5176,"activeCount":100},[],{"trials":5178,"activeCount":100},[5179],{"nctId":5180,"briefTitle":5181,"status":106,"phases":5182,"primaryCompletion":2149,"completion":2149,"start":5183,"enrollment":226,"conditions":5184,"interventions":5186},"NCT01018056","Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission",[91],"2009-11",[5185],"Tourette Syndrome",[5187,5157],"D-serine",{"trials":5189,"activeCount":100},[],{"intervention":141,"totalTrials":280,"cells":5191},{"EARLY_PHASE1":5192,"PHASE1":5194,"PHASE2":5196,"PHASE3":5198,"PHASE4":5204,"NA":5213},{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[],{"trials":5197,"activeCount":100},[],{"trials":5199,"activeCount":100},[5200],{"nctId":132,"briefTitle":133,"status":106,"phases":5201,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":5202,"interventions":5203},[90],[139],[141,142,95,143],{"trials":5205,"activeCount":100},[5206],{"nctId":5207,"briefTitle":5208,"status":149,"phases":5209,"primaryCompletion":5210,"completion":5210,"start":4808,"enrollment":100,"conditions":5211,"interventions":5212},"NCT00127114","Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)",[91],"2007-07-26",[2026],[141],{"trials":5214,"activeCount":100},[],{"intervention":5216,"totalTrials":280,"cells":5217},"Losartan",{"EARLY_PHASE1":5218,"PHASE1":5220,"PHASE2":5222,"PHASE3":5233,"PHASE4":5235,"NA":5244},{"trials":5219,"activeCount":100},[],{"trials":5221,"activeCount":100},[],{"trials":5223,"activeCount":100},[5224],{"nctId":5225,"briefTitle":5226,"status":106,"phases":5227,"primaryCompletion":2381,"completion":2381,"start":5228,"enrollment":5229,"conditions":5230,"interventions":5232},"NCT01989793","A Study of Muscle Strength Maintenance in Older Adults",[89],"2013-07",37,[5231],"Sarcopenia",[5216],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[5237],{"nctId":5238,"briefTitle":5239,"status":106,"phases":5240,"primaryCompletion":1555,"completion":2173,"start":5011,"enrollment":5241,"conditions":5242,"interventions":5243},"NCT00720226","Efficacy of Losartan in Preventing Progression of COPD",[91],106,[5080,5081,4835,3662],[5216],{"trials":5245,"activeCount":100},[],{"intervention":5247,"totalTrials":126,"cells":5248},"Standard Treatment",{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5255,"PHASE4":5257,"NA":5269},{"trials":5250,"activeCount":100},[],{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[],{"trials":5258,"activeCount":100},[5259],{"nctId":5260,"briefTitle":5261,"status":873,"phases":5262,"primaryCompletion":5263,"completion":5263,"start":5264,"enrollment":280,"conditions":5265,"interventions":5267},"NCT02029846","Glycemia in Diabetic Elders Trial",[91],"2017-02","2013-04",[5266],"Type 2 Diabetes Mellitus",[5247,5268],"Incretin-Based Treatment",{"trials":5270,"activeCount":100},[],{"intervention":5268,"totalTrials":126,"cells":5272},{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5279,"PHASE4":5281,"NA":5287},{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[],{"trials":5278,"activeCount":100},[],{"trials":5280,"activeCount":100},[],{"trials":5282,"activeCount":100},[5283],{"nctId":5260,"briefTitle":5261,"status":873,"phases":5284,"primaryCompletion":5263,"completion":5263,"start":5264,"enrollment":280,"conditions":5285,"interventions":5286},[91],[5266],[5247,5268],{"trials":5288,"activeCount":100},[],{"intervention":4965,"totalTrials":126,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5299,"NA":5305},{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[],{"trials":5300,"activeCount":100},[5301],{"nctId":4958,"briefTitle":4959,"status":106,"phases":5302,"primaryCompletion":714,"completion":714,"start":825,"enrollment":2151,"conditions":5303,"interventions":5304},[91],[4962,4963,3302],[4965,4933],{"trials":5306,"activeCount":100},[],{"intervention":5308,"totalTrials":126,"cells":5309},"Chlorhexidine gluconate soap",{"EARLY_PHASE1":5310,"PHASE1":5312,"PHASE2":5314,"PHASE3":5316,"PHASE4":5318,"NA":5329},{"trials":5311,"activeCount":100},[],{"trials":5313,"activeCount":100},[],{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[5320],{"nctId":5321,"briefTitle":5322,"status":106,"phases":5323,"primaryCompletion":5324,"completion":5324,"start":1686,"enrollment":3269,"conditions":5325,"interventions":5326},"NCT02029872","Stop Community MRSA Colonization Among Patients",[91],"2017-03",[857],[5308,5327,5328],"Chlorhexidine gluconate oral rinse","Mupirocin calcium 2 % ointment",{"trials":5330,"activeCount":100},[],{"intervention":5327,"totalTrials":126,"cells":5332},{"EARLY_PHASE1":5333,"PHASE1":5335,"PHASE2":5337,"PHASE3":5339,"PHASE4":5341,"NA":5347},{"trials":5334,"activeCount":100},[],{"trials":5336,"activeCount":100},[],{"trials":5338,"activeCount":100},[],{"trials":5340,"activeCount":100},[],{"trials":5342,"activeCount":100},[5343],{"nctId":5321,"briefTitle":5322,"status":106,"phases":5344,"primaryCompletion":5324,"completion":5324,"start":1686,"enrollment":3269,"conditions":5345,"interventions":5346},[91],[857],[5308,5327,5328],{"trials":5348,"activeCount":100},[],{"intervention":5328,"totalTrials":126,"cells":5350},{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5355,"PHASE3":5357,"PHASE4":5359,"NA":5365},{"trials":5352,"activeCount":100},[],{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[5361],{"nctId":5321,"briefTitle":5322,"status":106,"phases":5362,"primaryCompletion":5324,"completion":5324,"start":1686,"enrollment":3269,"conditions":5363,"interventions":5364},[91],[857],[5308,5327,5328],{"trials":5366,"activeCount":100},[],{"intervention":5368,"totalTrials":126,"cells":5369},"Aripiprazole or Perphenazine",{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5378,"NA":5390},{"trials":5371,"activeCount":100},[],{"trials":5373,"activeCount":100},[],{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":100},[],{"trials":5379,"activeCount":100},[5380],{"nctId":5381,"briefTitle":5382,"status":106,"phases":5383,"primaryCompletion":4518,"completion":4518,"start":2185,"enrollment":5384,"conditions":5385,"interventions":5387},"NCT00806234","Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics",[91],127,[5386],"Psychotic Disorders",[5368,5388,5389],"Metformin","Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine\u002Ffluoxetine",{"trials":5391,"activeCount":100},[],{"intervention":5389,"totalTrials":126,"cells":5393},{"EARLY_PHASE1":5394,"PHASE1":5396,"PHASE2":5398,"PHASE3":5400,"PHASE4":5402,"NA":5408},{"trials":5395,"activeCount":100},[],{"trials":5397,"activeCount":100},[],{"trials":5399,"activeCount":100},[],{"trials":5401,"activeCount":100},[],{"trials":5403,"activeCount":100},[5404],{"nctId":5381,"briefTitle":5382,"status":106,"phases":5405,"primaryCompletion":4518,"completion":4518,"start":2185,"enrollment":5384,"conditions":5406,"interventions":5407},[91],[5386],[5368,5388,5389],{"trials":5409,"activeCount":100},[],{"intervention":5411,"totalTrials":126,"cells":5412},"ILUVIEN®",{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5417,"PHASE3":5419,"PHASE4":5421,"NA":5432},{"trials":5414,"activeCount":100},[],{"trials":5416,"activeCount":100},[],{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[],{"trials":5422,"activeCount":100},[5423],{"nctId":5424,"briefTitle":5425,"status":149,"phases":5426,"primaryCompletion":5427,"completion":5427,"start":5428,"enrollment":100,"conditions":5429,"interventions":5431},"NCT02902744","Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study",[91],"2017-08-18","2017-03-01",[5430],"Diabetic Macular Edema",[5411],{"trials":5433,"activeCount":100},[],{"intervention":5435,"totalTrials":126,"cells":5436},"Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir [SOF\u002FVEL\u002FVOX]",{"EARLY_PHASE1":5437,"PHASE1":5439,"PHASE2":5441,"PHASE3":5443,"PHASE4":5445,"NA":5458},{"trials":5438,"activeCount":100},[],{"trials":5440,"activeCount":100},[],{"trials":5442,"activeCount":100},[],{"trials":5444,"activeCount":100},[],{"trials":5446,"activeCount":100},[5447],{"nctId":5448,"briefTitle":5449,"status":106,"phases":5450,"primaryCompletion":5451,"completion":5452,"start":3256,"enrollment":921,"conditions":5453,"interventions":5456},"NCT02938013","deLIVER: Direct Acting Antiviral Effects on the Liver",[91],"2019-09-30","2020-09-30",[5454,5455,24],"HCV Coinfection","Liver Disease",[5435,5457],"Sofosbuvir\u002FVelpatasvir",{"trials":5459,"activeCount":100},[],{"intervention":5457,"totalTrials":126,"cells":5461},{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5468,"PHASE4":5470,"NA":5476},{"trials":5463,"activeCount":100},[],{"trials":5465,"activeCount":100},[],{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[5472],{"nctId":5448,"briefTitle":5449,"status":106,"phases":5473,"primaryCompletion":5451,"completion":5452,"start":3256,"enrollment":921,"conditions":5474,"interventions":5475},[91],[5454,5455,24],[5435,5457],{"trials":5477,"activeCount":100},[],{"intervention":5479,"totalTrials":126,"cells":5480},"Dexamethasone pellet",{"EARLY_PHASE1":5481,"PHASE1":5483,"PHASE2":5485,"PHASE3":5487,"PHASE4":5489,"NA":5500},{"trials":5482,"activeCount":100},[],{"trials":5484,"activeCount":100},[],{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[5491],{"nctId":5492,"briefTitle":5493,"status":106,"phases":5494,"primaryCompletion":5495,"completion":5495,"start":1686,"enrollment":1593,"conditions":5496,"interventions":5499},"NCT02049476","Study of the Effectiveness of Ozurdex for the Control of Uveitis",[91],"2018-06-30",[5497,5498],"Uveitis, Intermediate","Uveitis, Posterior",[5479],{"trials":5501,"activeCount":100},[],{"intervention":5503,"totalTrials":126,"cells":5504},"Oseltamivir",{"EARLY_PHASE1":5505,"PHASE1":5507,"PHASE2":5509,"PHASE3":5511,"PHASE4":5513,"NA":5525},{"trials":5506,"activeCount":100},[],{"trials":5508,"activeCount":100},[],{"trials":5510,"activeCount":100},[],{"trials":5512,"activeCount":100},[],{"trials":5514,"activeCount":100},[5515],{"nctId":5516,"briefTitle":5517,"status":106,"phases":5518,"primaryCompletion":5519,"completion":5520,"start":5521,"enrollment":5040,"conditions":5522,"interventions":5523},"NCT02609399","ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir",[91],"2017-05-26","2018-05-31","2015-11-01",[4499],[5503,5524],"Peramivir",{"trials":5526,"activeCount":100},[],{"intervention":5524,"totalTrials":126,"cells":5528},{"EARLY_PHASE1":5529,"PHASE1":5531,"PHASE2":5533,"PHASE3":5535,"PHASE4":5537,"NA":5543},{"trials":5530,"activeCount":100},[],{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":100},[],{"trials":5536,"activeCount":100},[],{"trials":5538,"activeCount":100},[5539],{"nctId":5516,"briefTitle":5517,"status":106,"phases":5540,"primaryCompletion":5519,"completion":5520,"start":5521,"enrollment":5040,"conditions":5541,"interventions":5542},[91],[4499],[5503,5524],{"trials":5544,"activeCount":100},[],{"intervention":5546,"totalTrials":126,"cells":5547},"Zolpidem Tartrate",{"EARLY_PHASE1":5548,"PHASE1":5550,"PHASE2":5552,"PHASE3":5554,"PHASE4":5556,"NA":5565},{"trials":5549,"activeCount":100},[],{"trials":5551,"activeCount":100},[],{"trials":5553,"activeCount":100},[],{"trials":5555,"activeCount":100},[],{"trials":5557,"activeCount":100},[5558],{"nctId":5559,"briefTitle":5560,"status":106,"phases":5561,"primaryCompletion":5562,"completion":5562,"start":4404,"enrollment":96,"conditions":5563,"interventions":5564},"NCT03307005","Improving Sleep Quality in Heart Failure",[91],"2019-01-25",[197,497],[5546],{"trials":5566,"activeCount":100},[],{"intervention":5568,"totalTrials":126,"cells":5569},"Fluticasone\u002FSalmeterol Diskus",{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5574,"PHASE3":5576,"PHASE4":5578,"NA":5590},{"trials":5571,"activeCount":100},[],{"trials":5573,"activeCount":100},[],{"trials":5575,"activeCount":100},[],{"trials":5577,"activeCount":100},[],{"trials":5579,"activeCount":100},[5580],{"nctId":5581,"briefTitle":5582,"status":106,"phases":5583,"primaryCompletion":5584,"completion":875,"start":5585,"enrollment":5586,"conditions":5587,"interventions":5588},"NCT01437995","Long-acting Beta Agonist Step Down Study",[91],"2015-09","2012-03",459,[21],[5568,5568,5589],"Fluticasone Diskus",{"trials":5591,"activeCount":100},[],{"intervention":5589,"totalTrials":126,"cells":5593},{"EARLY_PHASE1":5594,"PHASE1":5596,"PHASE2":5598,"PHASE3":5600,"PHASE4":5602,"NA":5608},{"trials":5595,"activeCount":100},[],{"trials":5597,"activeCount":100},[],{"trials":5599,"activeCount":100},[],{"trials":5601,"activeCount":100},[],{"trials":5603,"activeCount":100},[5604],{"nctId":5581,"briefTitle":5582,"status":106,"phases":5605,"primaryCompletion":5584,"completion":875,"start":5585,"enrollment":5586,"conditions":5606,"interventions":5607},[91],[21],[5568,5568,5589],{"trials":5609,"activeCount":100},[],{"intervention":5611,"totalTrials":126,"cells":5612},"Penicillin Major Determinant (PrePen) Skin Testing",{"EARLY_PHASE1":5613,"PHASE1":5615,"PHASE2":5617,"PHASE3":5619,"PHASE4":5621,"NA":5634},{"trials":5614,"activeCount":100},[],{"trials":5616,"activeCount":100},[],{"trials":5618,"activeCount":100},[],{"trials":5620,"activeCount":100},[],{"trials":5622,"activeCount":100},[5623],{"nctId":5624,"briefTitle":5625,"status":106,"phases":5626,"primaryCompletion":5627,"completion":5627,"start":5628,"enrollment":5629,"conditions":5630,"interventions":5632},"NCT04620746","Penicillin Allergy Testing in STD Clinics",[91],"2022-12-31","2021-06-01",284,[5631],"Penicillin Allergy",[5611,5633],"Direct Oral challenge",{"trials":5635,"activeCount":100},[],{"intervention":5633,"totalTrials":126,"cells":5637},{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5642,"PHASE3":5644,"PHASE4":5646,"NA":5652},{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[],{"trials":5647,"activeCount":100},[5648],{"nctId":5624,"briefTitle":5625,"status":106,"phases":5649,"primaryCompletion":5627,"completion":5627,"start":5628,"enrollment":5629,"conditions":5650,"interventions":5651},[91],[5631],[5611,5633],{"trials":5653,"activeCount":100},[],{"intervention":5655,"totalTrials":126,"cells":5656},"fluticasone furoate",{"EARLY_PHASE1":5657,"PHASE1":5659,"PHASE2":5661,"PHASE3":5663,"PHASE4":5665,"NA":5675},{"trials":5658,"activeCount":100},[],{"trials":5660,"activeCount":100},[],{"trials":5662,"activeCount":100},[],{"trials":5664,"activeCount":100},[],{"trials":5666,"activeCount":100},[5667],{"nctId":5668,"briefTitle":5669,"status":873,"phases":5670,"primaryCompletion":5671,"completion":5671,"start":5183,"enrollment":1744,"conditions":5672,"interventions":5674},"NCT01013701","Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease",[91],"2010-07-29",[5673],"Patients With Nasal Polyps",[5655],{"trials":5676,"activeCount":100},[],{"intervention":5678,"totalTrials":126,"cells":5679},"tadalafil and ambrisentan upfront combination therapy",{"EARLY_PHASE1":5680,"PHASE1":5682,"PHASE2":5684,"PHASE3":5686,"PHASE4":5688,"NA":5703},{"trials":5681,"activeCount":100},[],{"trials":5683,"activeCount":100},[],{"trials":5685,"activeCount":100},[],{"trials":5687,"activeCount":100},[],{"trials":5689,"activeCount":100},[5690],{"nctId":5691,"briefTitle":5692,"status":106,"phases":5693,"primaryCompletion":5694,"completion":5694,"start":5695,"enrollment":110,"conditions":5696,"interventions":5702},"NCT01042158","A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis",[91],"2014-11","2010-01",[5697,5698,5699,5700,5701],"Pulmonary Arterial Hypertension","Systemic Sclerosis","Scleroderma Spectrum of Diseases","Connective Tissue Disease","Pulmonary Hypertension",[5678],{"trials":5704,"activeCount":100},[],{"intervention":4849,"totalTrials":126,"cells":5706},{"EARLY_PHASE1":5707,"PHASE1":5709,"PHASE2":5711,"PHASE3":5713,"PHASE4":5715,"NA":5721},{"trials":5708,"activeCount":100},[],{"trials":5710,"activeCount":100},[],{"trials":5712,"activeCount":100},[],{"trials":5714,"activeCount":100},[],{"trials":5716,"activeCount":100},[5717],{"nctId":4839,"briefTitle":4840,"status":106,"phases":5718,"primaryCompletion":4842,"completion":4843,"start":4844,"enrollment":4845,"conditions":5719,"interventions":5720},[91],[4847],[4812,4849],{"trials":5722,"activeCount":100},[],{"intervention":5724,"totalTrials":126,"cells":5725},"Prospective TDM Arm",{"EARLY_PHASE1":5726,"PHASE1":5728,"PHASE2":5730,"PHASE3":5732,"PHASE4":5734,"NA":5744},{"trials":5727,"activeCount":100},[],{"trials":5729,"activeCount":100},[],{"trials":5731,"activeCount":100},[],{"trials":5733,"activeCount":100},[],{"trials":5735,"activeCount":100},[5736],{"nctId":5737,"briefTitle":5738,"status":106,"phases":5739,"primaryCompletion":1760,"completion":1760,"start":5740,"enrollment":22,"conditions":5741,"interventions":5743},"NCT01416025","A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing",[91],"2012-01",[5742],"Fungal Infection",[5724],{"trials":5745,"activeCount":100},[],{"intervention":5747,"totalTrials":126,"cells":5748},"Subcutaneous Heparin",{"EARLY_PHASE1":5749,"PHASE1":5751,"PHASE2":5753,"PHASE3":5755,"PHASE4":5757,"NA":5771},{"trials":5750,"activeCount":100},[],{"trials":5752,"activeCount":100},[],{"trials":5754,"activeCount":100},[],{"trials":5756,"activeCount":100},[],{"trials":5758,"activeCount":100},[5759],{"nctId":5760,"briefTitle":5761,"status":873,"phases":5762,"primaryCompletion":5763,"completion":5763,"start":1772,"enrollment":5764,"conditions":5765,"interventions":5770},"NCT03006562","PREvention of VENous ThromboEmbolism Following Radical Prostatectomy",[91],"2019-11-01",501,[3360,5766,5767,5768,5769],"Venous Thromboembolism","Lymphocele After Surgical Procedure","Deep Venous Thrombosis","Pulmonary Embolism",[5747],{"trials":5772,"activeCount":100},[],{"intervention":5774,"totalTrials":126,"cells":5775},"Levetiracetam",{"EARLY_PHASE1":5776,"PHASE1":5778,"PHASE2":5780,"PHASE3":5782,"PHASE4":5784,"NA":5794},{"trials":5777,"activeCount":100},[],{"trials":5779,"activeCount":100},[],{"trials":5781,"activeCount":100},[],{"trials":5783,"activeCount":100},[],{"trials":5785,"activeCount":100},[5786],{"nctId":5787,"briefTitle":5788,"status":106,"phases":5789,"completion":5790,"start":5791,"enrollment":293,"conditions":5792,"interventions":5793},"NCT00181116","Levetiracetam for Benign Rolandic Epilepsy",[91],"2006-09","2005-03",[2742],[5774],{"trials":5795,"activeCount":100},[],{"intervention":5153,"totalTrials":126,"cells":5797},{"EARLY_PHASE1":5798,"PHASE1":5800,"PHASE2":5802,"PHASE3":5804,"PHASE4":5806,"NA":5812},{"trials":5799,"activeCount":100},[],{"trials":5801,"activeCount":100},[],{"trials":5803,"activeCount":100},[],{"trials":5805,"activeCount":100},[],{"trials":5807,"activeCount":100},[5808],{"nctId":5146,"briefTitle":5147,"status":149,"phases":5809,"primaryCompletion":5149,"completion":5149,"start":1772,"enrollment":100,"conditions":5810,"interventions":5811},[91],[5151],[5123,5153],{"trials":5813,"activeCount":100},[],{"intervention":5815,"totalTrials":126,"cells":5816},"Oxycodone and Lorazepam",{"EARLY_PHASE1":5817,"PHASE1":5819,"PHASE2":5821,"PHASE3":5823,"PHASE4":5825,"NA":5836},{"trials":5818,"activeCount":100},[],{"trials":5820,"activeCount":100},[],{"trials":5822,"activeCount":100},[],{"trials":5824,"activeCount":100},[],{"trials":5826,"activeCount":100},[5827],{"nctId":5828,"briefTitle":5829,"status":106,"phases":5830,"primaryCompletion":5831,"completion":5831,"start":5832,"enrollment":1561,"conditions":5833,"interventions":5835},"NCT03202550","Oral Sedation During Cervical Dilator Placement",[91],"2019-05-28","2017-06-28",[5834],"Oral Sedation and Cervical Dilator Pain",[5815],{"trials":5837,"activeCount":100},[],{"intervention":5839,"totalTrials":126,"cells":5840},"Sertraline [Zoloft]",{"EARLY_PHASE1":5841,"PHASE1":5843,"PHASE2":5845,"PHASE3":5847,"PHASE4":5849,"NA":5860},{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[],{"trials":5848,"activeCount":100},[],{"trials":5850,"activeCount":100},[5851],{"nctId":5852,"briefTitle":5853,"status":106,"phases":5854,"primaryCompletion":5855,"completion":5856,"start":5857,"conditions":5858,"interventions":5859},"NCT00009191","The Depression in Alzheimer's Disease Study (DIADS)",[91],"2006-11","2007-11","2005-11",[1596,27],[5839],{"trials":5861,"activeCount":100},[],{"intervention":5863,"totalTrials":126,"cells":5864},"Crisaborole",{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5869,"PHASE3":5871,"PHASE4":5873,"NA":5887},{"trials":5866,"activeCount":100},[],{"trials":5868,"activeCount":100},[],{"trials":5870,"activeCount":100},[],{"trials":5872,"activeCount":100},[],{"trials":5874,"activeCount":100},[5875],{"nctId":5876,"briefTitle":5877,"status":106,"phases":5878,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":30,"conditions":5881,"interventions":5883},"NCT03832010","Steroid-reducing Effects of Crisaborole",[91],"2024-02-16","2019-12-17",[522,5882],"Eczema",[5863,5884,5885,5886],"Hydrocortisone Ointment","Triamcinolone ointment","Aquaphor",{"trials":5888,"activeCount":100},[],{"intervention":5884,"totalTrials":126,"cells":5890},{"EARLY_PHASE1":5891,"PHASE1":5893,"PHASE2":5895,"PHASE3":5897,"PHASE4":5899,"NA":5905},{"trials":5892,"activeCount":100},[],{"trials":5894,"activeCount":100},[],{"trials":5896,"activeCount":100},[],{"trials":5898,"activeCount":100},[],{"trials":5900,"activeCount":100},[5901],{"nctId":5876,"briefTitle":5877,"status":106,"phases":5902,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":30,"conditions":5903,"interventions":5904},[91],[522,5882],[5863,5884,5885,5886],{"trials":5906,"activeCount":100},[],{"intervention":5885,"totalTrials":126,"cells":5908},{"EARLY_PHASE1":5909,"PHASE1":5911,"PHASE2":5913,"PHASE3":5915,"PHASE4":5917,"NA":5923},{"trials":5910,"activeCount":100},[],{"trials":5912,"activeCount":100},[],{"trials":5914,"activeCount":100},[],{"trials":5916,"activeCount":100},[],{"trials":5918,"activeCount":100},[5919],{"nctId":5876,"briefTitle":5877,"status":106,"phases":5920,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":30,"conditions":5921,"interventions":5922},[91],[522,5882],[5863,5884,5885,5886],{"trials":5924,"activeCount":100},[],{"intervention":5886,"totalTrials":126,"cells":5926},{"EARLY_PHASE1":5927,"PHASE1":5929,"PHASE2":5931,"PHASE3":5933,"PHASE4":5935,"NA":5941},{"trials":5928,"activeCount":100},[],{"trials":5930,"activeCount":100},[],{"trials":5932,"activeCount":100},[],{"trials":5934,"activeCount":100},[],{"trials":5936,"activeCount":100},[5937],{"nctId":5876,"briefTitle":5877,"status":106,"phases":5938,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":30,"conditions":5939,"interventions":5940},[91],[522,5882],[5863,5884,5885,5886],{"trials":5942,"activeCount":100},[],{"intervention":5944,"totalTrials":126,"cells":5945},"Sodium Citrate 4% Inj Syringe 3Ml",{"EARLY_PHASE1":5946,"PHASE1":5948,"PHASE2":5950,"PHASE3":5952,"PHASE4":5954,"NA":5964},{"trials":5947,"activeCount":100},[],{"trials":5949,"activeCount":100},[],{"trials":5951,"activeCount":100},[],{"trials":5953,"activeCount":100},[],{"trials":5955,"activeCount":100},[5956],{"nctId":5957,"briefTitle":5958,"status":873,"phases":5959,"primaryCompletion":4450,"completion":4450,"start":5960,"enrollment":126,"conditions":5961,"interventions":5963},"NCT04756427","Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition",[91],"2022-03-28",[5962],"CLABSI - Central Line Associated Bloodstream Infection",[5944],{"trials":5965,"activeCount":100},[],{"intervention":5967,"totalTrials":126,"cells":5968},"Rifapentine 600 mg and INH 300 mg",{"EARLY_PHASE1":5969,"PHASE1":5971,"PHASE2":5973,"PHASE3":5975,"PHASE4":5977,"NA":5989},{"trials":5970,"activeCount":100},[],{"trials":5972,"activeCount":100},[],{"trials":5974,"activeCount":100},[],{"trials":5976,"activeCount":100},[],{"trials":5978,"activeCount":100},[5979],{"nctId":5980,"briefTitle":5981,"status":106,"phases":5982,"primaryCompletion":5983,"completion":5983,"start":5984,"enrollment":5985,"conditions":5986,"interventions":5987},"NCT04703075","Ultra Curto (Ultra Short) TB Prevention Therapy",[91],"2024-06-10","2022-03-24",531,[35],[5967,5988],"Rifapentine 900 mg and INH 900 mg",{"trials":5990,"activeCount":100},[],{"intervention":5988,"totalTrials":126,"cells":5992},{"EARLY_PHASE1":5993,"PHASE1":5995,"PHASE2":5997,"PHASE3":5999,"PHASE4":6001,"NA":6007},{"trials":5994,"activeCount":100},[],{"trials":5996,"activeCount":100},[],{"trials":5998,"activeCount":100},[],{"trials":6000,"activeCount":100},[],{"trials":6002,"activeCount":100},[6003],{"nctId":5980,"briefTitle":5981,"status":106,"phases":6004,"primaryCompletion":5983,"completion":5983,"start":5984,"enrollment":5985,"conditions":6005,"interventions":6006},[91],[35],[5967,5988],{"trials":6008,"activeCount":100},[],{"intervention":6010,"totalTrials":126,"cells":6011},"nebulized albuterol",{"EARLY_PHASE1":6012,"PHASE1":6014,"PHASE2":6016,"PHASE3":6018,"PHASE4":6020,"NA":6031},{"trials":6013,"activeCount":100},[],{"trials":6015,"activeCount":100},[],{"trials":6017,"activeCount":100},[],{"trials":6019,"activeCount":100},[],{"trials":6021,"activeCount":100},[6022],{"nctId":6023,"briefTitle":6024,"status":106,"phases":6025,"completion":4808,"start":5170,"enrollment":264,"conditions":6026,"interventions":6028},"NCT00325767","Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol",[91],[6027],"Mucociliary Clearance",[6010,6029,6030],"nebulized levalbuterol","nebulized placebo",{"trials":6032,"activeCount":100},[],{"intervention":6029,"totalTrials":126,"cells":6034},{"EARLY_PHASE1":6035,"PHASE1":6037,"PHASE2":6039,"PHASE3":6041,"PHASE4":6043,"NA":6049},{"trials":6036,"activeCount":100},[],{"trials":6038,"activeCount":100},[],{"trials":6040,"activeCount":100},[],{"trials":6042,"activeCount":100},[],{"trials":6044,"activeCount":100},[6045],{"nctId":6023,"briefTitle":6024,"status":106,"phases":6046,"completion":4808,"start":5170,"enrollment":264,"conditions":6047,"interventions":6048},[91],[6027],[6010,6029,6030],{"trials":6050,"activeCount":100},[],{"intervention":6030,"totalTrials":126,"cells":6052},{"EARLY_PHASE1":6053,"PHASE1":6055,"PHASE2":6057,"PHASE3":6059,"PHASE4":6061,"NA":6067},{"trials":6054,"activeCount":100},[],{"trials":6056,"activeCount":100},[],{"trials":6058,"activeCount":100},[],{"trials":6060,"activeCount":100},[],{"trials":6062,"activeCount":100},[6063],{"nctId":6023,"briefTitle":6024,"status":106,"phases":6064,"completion":4808,"start":5170,"enrollment":264,"conditions":6065,"interventions":6066},[91],[6027],[6010,6029,6030],{"trials":6068,"activeCount":100},[],{"intervention":6070,"totalTrials":126,"cells":6071},"Levothyroxine",{"EARLY_PHASE1":6072,"PHASE1":6074,"PHASE2":6076,"PHASE3":6078,"PHASE4":6080,"NA":6089},{"trials":6073,"activeCount":100},[],{"trials":6075,"activeCount":100},[],{"trials":6077,"activeCount":100},[],{"trials":6079,"activeCount":100},[],{"trials":6081,"activeCount":100},[6082],{"nctId":6083,"briefTitle":6084,"status":149,"phases":6085,"primaryCompletion":3216,"completion":3216,"start":6086,"enrollment":100,"conditions":6087,"interventions":6088},"NCT01276782","Levothyroxine in Pregnant SLE Patients",[91],"2011-01",[2218],[6070],{"trials":6090,"activeCount":100},[],{"intervention":6092,"totalTrials":126,"cells":6093},"Antiretroviral therapy",{"EARLY_PHASE1":6094,"PHASE1":6096,"PHASE2":6098,"PHASE3":6100,"PHASE4":6102,"NA":6113},{"trials":6095,"activeCount":100},[],{"trials":6097,"activeCount":100},[],{"trials":6099,"activeCount":100},[],{"trials":6101,"activeCount":100},[],{"trials":6103,"activeCount":100},[6104],{"nctId":6105,"briefTitle":6106,"status":106,"phases":6107,"primaryCompletion":4978,"completion":4978,"start":6086,"enrollment":1593,"conditions":6108,"interventions":6110},"NCT01285050","Interferon Alfa Sensitivity in HIV\u002FHCV Persons Before and After HIV Meds",[91],[6109,5099],"HIV Infection",[6092,6111,6112],"raltegravir","Emtricitabine and tenofovir disoproxil fumarate",{"trials":6114,"activeCount":100},[],{"intervention":6111,"totalTrials":126,"cells":6116},{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6123,"PHASE4":6125,"NA":6131},{"trials":6118,"activeCount":100},[],{"trials":6120,"activeCount":100},[],{"trials":6122,"activeCount":100},[],{"trials":6124,"activeCount":100},[],{"trials":6126,"activeCount":100},[6127],{"nctId":6105,"briefTitle":6106,"status":106,"phases":6128,"primaryCompletion":4978,"completion":4978,"start":6086,"enrollment":1593,"conditions":6129,"interventions":6130},[91],[6109,5099],[6092,6111,6112],{"trials":6132,"activeCount":100},[],{"intervention":6112,"totalTrials":126,"cells":6134},{"EARLY_PHASE1":6135,"PHASE1":6137,"PHASE2":6139,"PHASE3":6141,"PHASE4":6143,"NA":6149},{"trials":6136,"activeCount":100},[],{"trials":6138,"activeCount":100},[],{"trials":6140,"activeCount":100},[],{"trials":6142,"activeCount":100},[],{"trials":6144,"activeCount":100},[6145],{"nctId":6105,"briefTitle":6106,"status":106,"phases":6146,"primaryCompletion":4978,"completion":4978,"start":6086,"enrollment":1593,"conditions":6147,"interventions":6148},[91],[6109,5099],[6092,6111,6112],{"trials":6150,"activeCount":100},[],{"intervention":230,"totalTrials":126,"cells":6152},{"EARLY_PHASE1":6153,"PHASE1":6155,"PHASE2":6157,"PHASE3":6159,"PHASE4":6161,"NA":6167},{"trials":6154,"activeCount":100},[],{"trials":6156,"activeCount":100},[],{"trials":6158,"activeCount":100},[],{"trials":6160,"activeCount":100},[],{"trials":6162,"activeCount":100},[6163],{"nctId":221,"briefTitle":222,"status":106,"phases":6164,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":6165,"interventions":6166},[91],[228],[230,143],{"trials":6168,"activeCount":100},[],{"intervention":6170,"totalTrials":126,"cells":6171},"Lansoprazole",{"EARLY_PHASE1":6172,"PHASE1":6174,"PHASE2":6176,"PHASE3":6178,"PHASE4":6180,"NA":6191},{"trials":6173,"activeCount":100},[],{"trials":6175,"activeCount":100},[],{"trials":6177,"activeCount":100},[],{"trials":6179,"activeCount":100},[],{"trials":6181,"activeCount":100},[6182],{"nctId":6183,"briefTitle":6184,"status":106,"phases":6185,"primaryCompletion":6186,"completion":2104,"start":6187,"enrollment":6188,"conditions":6189,"interventions":6190},"NCT00442013","Lansoprazole to Treat Children With Asthma",[91],"2011-04","2007-03",306,[21],[6170],{"trials":6192,"activeCount":100},[],{"intervention":6194,"totalTrials":126,"cells":6195},"Ciprofloxacin hydrochloride",{"EARLY_PHASE1":6196,"PHASE1":6198,"PHASE2":6200,"PHASE3":6202,"PHASE4":6204,"NA":6214},{"trials":6197,"activeCount":100},[],{"trials":6199,"activeCount":100},[],{"trials":6201,"activeCount":100},[],{"trials":6203,"activeCount":100},[],{"trials":6205,"activeCount":100},[6206],{"nctId":6207,"briefTitle":6208,"status":873,"phases":6209,"primaryCompletion":3216,"completion":3216,"start":6210,"enrollment":19,"conditions":6211,"interventions":6213},"NCT00596453","Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability",[91],"2008-01",[6212],"Prostate Infections",[6194],{"trials":6215,"activeCount":100},[],{"intervention":6217,"totalTrials":126,"cells":6218},"ethinyl estradiol-levonorgestrel",{"EARLY_PHASE1":6219,"PHASE1":6221,"PHASE2":6223,"PHASE3":6225,"PHASE4":6227,"NA":6238},{"trials":6220,"activeCount":100},[],{"trials":6222,"activeCount":100},[],{"trials":6224,"activeCount":100},[],{"trials":6226,"activeCount":100},[],{"trials":6228,"activeCount":100},[6229],{"nctId":6230,"briefTitle":6231,"status":149,"phases":6232,"primaryCompletion":6233,"completion":6233,"start":5264,"enrollment":100,"conditions":6234,"interventions":6237},"NCT01941134","Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery",[91],"2017-12-06",[6235,6236],"Bariatric Surgery Candidate","Contraception",[6217],{"trials":6239,"activeCount":100},[],{"intervention":6241,"totalTrials":126,"cells":6242},"intradermal naloxone",{"EARLY_PHASE1":6243,"PHASE1":6245,"PHASE2":6247,"PHASE3":6249,"PHASE4":6251,"NA":6261},{"trials":6244,"activeCount":100},[],{"trials":6246,"activeCount":100},[],{"trials":6248,"activeCount":100},[],{"trials":6250,"activeCount":100},[],{"trials":6252,"activeCount":100},[6253],{"nctId":6254,"briefTitle":6255,"status":149,"phases":6256,"primaryCompletion":1781,"completion":1781,"start":6257,"enrollment":100,"conditions":6258,"interventions":6260},"NCT05876572","Blood Naloxone Levels Following Intradermal Injection in Humans",[91],"2024-08",[6259],"Opioid Overdose",[6241],{"trials":6262,"activeCount":100},[],{"intervention":6264,"totalTrials":126,"cells":6265},"CHG 2% w\u002Fv and IPA 70% v\u002Fv",{"EARLY_PHASE1":6266,"PHASE1":6268,"PHASE2":6270,"PHASE3":6272,"PHASE4":6274,"NA":6284},{"trials":6267,"activeCount":100},[],{"trials":6269,"activeCount":100},[],{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[],{"trials":6275,"activeCount":100},[6276],{"nctId":6277,"briefTitle":6278,"status":106,"phases":6279,"primaryCompletion":1646,"completion":1646,"start":4899,"enrollment":1593,"conditions":6280,"interventions":6282},"NCT00739583","Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions",[91],[6281],"Arthroplasty, Replacement, Hip",[6264,6283],"Iodophor 0.7% and IPA 74% w\u002Fw",{"trials":6285,"activeCount":100},[],{"intervention":6283,"totalTrials":126,"cells":6287},{"EARLY_PHASE1":6288,"PHASE1":6290,"PHASE2":6292,"PHASE3":6294,"PHASE4":6296,"NA":6302},{"trials":6289,"activeCount":100},[],{"trials":6291,"activeCount":100},[],{"trials":6293,"activeCount":100},[],{"trials":6295,"activeCount":100},[],{"trials":6297,"activeCount":100},[6298],{"nctId":6277,"briefTitle":6278,"status":106,"phases":6299,"primaryCompletion":1646,"completion":1646,"start":4899,"enrollment":1593,"conditions":6300,"interventions":6301},[91],[6281],[6264,6283],{"trials":6303,"activeCount":100},[],{"intervention":6305,"totalTrials":126,"cells":6306},"rotigotine transdermal patch",{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6311,"PHASE3":6313,"PHASE4":6315,"NA":6325},{"trials":6308,"activeCount":100},[],{"trials":6310,"activeCount":100},[],{"trials":6312,"activeCount":100},[],{"trials":6314,"activeCount":100},[],{"trials":6316,"activeCount":100},[6317],{"nctId":6318,"briefTitle":6319,"status":873,"phases":6320,"primaryCompletion":6321,"completion":6321,"start":2173,"enrollment":614,"conditions":6322,"interventions":6324},"NCT02365870","Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment",[91],"2019-07",[5003,6323],"Parkinson Disease",[6305],{"trials":6326,"activeCount":100},[],{"intervention":6328,"totalTrials":126,"cells":6329},"Nicotine patch - transdermal",{"EARLY_PHASE1":6330,"PHASE1":6332,"PHASE2":6334,"PHASE3":6336,"PHASE4":6338,"NA":6349},{"trials":6331,"activeCount":100},[],{"trials":6333,"activeCount":100},[],{"trials":6335,"activeCount":100},[],{"trials":6337,"activeCount":100},[],{"trials":6339,"activeCount":100},[6340],{"nctId":6341,"briefTitle":6342,"status":106,"phases":6343,"primaryCompletion":6344,"completion":6345,"start":6346,"enrollment":5384,"conditions":6347,"interventions":6348},"NCT01664741","Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging",[91],"2018-05","2018-12","2012-04",[3520],[6328],{"trials":6350,"activeCount":100},[],{"intervention":6352,"totalTrials":126,"cells":6353},"Glecaprevir\u002Fpibrentasvir",{"EARLY_PHASE1":6354,"PHASE1":6356,"PHASE2":6358,"PHASE3":6360,"PHASE4":6362,"NA":6372},{"trials":6355,"activeCount":100},[],{"trials":6357,"activeCount":100},[],{"trials":6359,"activeCount":100},[],{"trials":6361,"activeCount":100},[],{"trials":6363,"activeCount":100},[6364],{"nctId":6365,"briefTitle":6366,"status":106,"phases":6367,"primaryCompletion":4450,"completion":6368,"start":194,"enrollment":264,"conditions":6369,"interventions":6371},"NCT04575896","Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors",[91],"2023-12-01",[6370,5099],"End Stage Renal Disease",[6352],{"trials":6373,"activeCount":100},[],{"intervention":6375,"totalTrials":126,"cells":6376},"Efavirenz",{"EARLY_PHASE1":6377,"PHASE1":6379,"PHASE2":6381,"PHASE3":6383,"PHASE4":6385,"NA":6396},{"trials":6378,"activeCount":100},[],{"trials":6380,"activeCount":100},[],{"trials":6382,"activeCount":100},[],{"trials":6384,"activeCount":100},[],{"trials":6386,"activeCount":100},[6387],{"nctId":6388,"briefTitle":6389,"status":873,"phases":6390,"primaryCompletion":6391,"completion":6391,"start":6392,"enrollment":126,"conditions":6393,"interventions":6395},"NCT01980342","Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz",[91],"2018-04-04","2014-10",[6394],"Drug Interaction",[6375],{"trials":6397,"activeCount":100},[],{"intervention":6399,"totalTrials":126,"cells":6400},"Testosterone Gel",{"EARLY_PHASE1":6401,"PHASE1":6403,"PHASE2":6405,"PHASE3":6407,"PHASE4":6409,"NA":6419},{"trials":6402,"activeCount":100},[],{"trials":6404,"activeCount":100},[],{"trials":6406,"activeCount":100},[],{"trials":6408,"activeCount":100},[],{"trials":6410,"activeCount":100},[6411],{"nctId":6412,"briefTitle":6413,"status":149,"phases":6414,"primaryCompletion":1655,"completion":1655,"start":3119,"enrollment":100,"conditions":6415,"interventions":6418},"NCT01689896","Testosterone and Pain Sensitivity",[91],[6416,6417,3259],"Low Testosterone","Hypogonadism",[6399],{"trials":6420,"activeCount":100},[],{"intervention":4929,"totalTrials":126,"cells":6422},{"EARLY_PHASE1":6423,"PHASE1":6425,"PHASE2":6427,"PHASE3":6429,"PHASE4":6431,"NA":6437},{"trials":6424,"activeCount":100},[],{"trials":6426,"activeCount":100},[],{"trials":6428,"activeCount":100},[],{"trials":6430,"activeCount":100},[],{"trials":6432,"activeCount":100},[6433],{"nctId":4920,"briefTitle":4921,"status":873,"phases":6434,"primaryCompletion":4923,"completion":4923,"start":183,"enrollment":4924,"conditions":6435,"interventions":6436},[91],[4926,4927],[4929,4862],{"trials":6438,"activeCount":100},[],{"intervention":6440,"totalTrials":126,"cells":6441},"INH preventive therapy",{"EARLY_PHASE1":6442,"PHASE1":6444,"PHASE2":6446,"PHASE3":6448,"PHASE4":6450,"NA":6461},{"trials":6443,"activeCount":100},[],{"trials":6445,"activeCount":100},[],{"trials":6447,"activeCount":100},[],{"trials":6449,"activeCount":100},[],{"trials":6451,"activeCount":100},[6452],{"nctId":6453,"briefTitle":6454,"status":106,"phases":6455,"primaryCompletion":6456,"completion":6456,"start":225,"enrollment":6457,"conditions":6458,"interventions":6459},"NCT00107887","TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)",[91],"2010-12",17415,[35,29],[6440,6460],"TST",{"trials":6462,"activeCount":100},[],{"intervention":6460,"totalTrials":126,"cells":6464},{"EARLY_PHASE1":6465,"PHASE1":6467,"PHASE2":6469,"PHASE3":6471,"PHASE4":6473,"NA":6479},{"trials":6466,"activeCount":100},[],{"trials":6468,"activeCount":100},[],{"trials":6470,"activeCount":100},[],{"trials":6472,"activeCount":100},[],{"trials":6474,"activeCount":100},[6475],{"nctId":6453,"briefTitle":6454,"status":106,"phases":6476,"primaryCompletion":6456,"completion":6456,"start":225,"enrollment":6457,"conditions":6477,"interventions":6478},[91],[35,29],[6440,6460],{"trials":6480,"activeCount":100},[],{"intervention":5187,"totalTrials":126,"cells":6482},{"EARLY_PHASE1":6483,"PHASE1":6485,"PHASE2":6487,"PHASE3":6489,"PHASE4":6491,"NA":6497},{"trials":6484,"activeCount":100},[],{"trials":6486,"activeCount":100},[],{"trials":6488,"activeCount":100},[],{"trials":6490,"activeCount":100},[],{"trials":6492,"activeCount":100},[6493],{"nctId":5180,"briefTitle":5181,"status":106,"phases":6494,"primaryCompletion":2149,"completion":2149,"start":5183,"enrollment":226,"conditions":6495,"interventions":6496},[91],[5185],[5187,5157],{"trials":6498,"activeCount":100},[],{"intervention":6500,"totalTrials":126,"cells":6501},"Gardasil9",{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6508,"PHASE4":6510,"NA":6523},{"trials":6503,"activeCount":100},[],{"trials":6505,"activeCount":100},[],{"trials":6507,"activeCount":100},[],{"trials":6509,"activeCount":100},[],{"trials":6511,"activeCount":100},[6512],{"nctId":6513,"briefTitle":6514,"status":106,"phases":6515,"primaryCompletion":1725,"completion":6516,"start":6517,"enrollment":6518,"conditions":6519,"interventions":6522},"NCT04274153","HPV Vaccination Study in Postpartum Women",[91],"2023-02-01","2020-08-03",225,[6520,4521,6521],"HPV","Human Papilloma Virus",[6500],{"trials":6524,"activeCount":100},[],{"intervention":6526,"totalTrials":126,"cells":6527},"Treximet",{"EARLY_PHASE1":6528,"PHASE1":6530,"PHASE2":6532,"PHASE3":6534,"PHASE4":6536,"NA":6545},{"trials":6529,"activeCount":100},[],{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[],{"trials":6535,"activeCount":100},[],{"trials":6537,"activeCount":100},[6538],{"nctId":6539,"briefTitle":6540,"status":106,"phases":6541,"primaryCompletion":812,"completion":812,"start":2127,"enrollment":2717,"conditions":6542,"interventions":6544},"NCT01138150","Ictal and Interictal Inflammatory Markers in Migraine",[91],[6543],"Migraine",[6526],{"trials":6546,"activeCount":100},[],{"intervention":6548,"totalTrials":126,"cells":6549},"Cosyntropin",{"EARLY_PHASE1":6550,"PHASE1":6552,"PHASE2":6554,"PHASE3":6556,"PHASE4":6558,"NA":6568},{"trials":6551,"activeCount":100},[],{"trials":6553,"activeCount":100},[],{"trials":6555,"activeCount":100},[],{"trials":6557,"activeCount":100},[],{"trials":6559,"activeCount":100},[6560],{"nctId":6561,"briefTitle":6562,"status":149,"phases":6563,"primaryCompletion":5452,"completion":6564,"start":6321,"enrollment":100,"conditions":6565,"interventions":6567},"NCT03752190","Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers",[91],"2020-12-31",[6566],"Adrenal Insufficiency",[6548],{"trials":6569,"activeCount":100},[],{"intervention":6571,"totalTrials":126,"cells":6572},"Carvedilol",{"EARLY_PHASE1":6573,"PHASE1":6575,"PHASE2":6577,"PHASE3":6579,"PHASE4":6581,"NA":6589},{"trials":6574,"activeCount":100},[],{"trials":6576,"activeCount":100},[],{"trials":6578,"activeCount":100},[],{"trials":6580,"activeCount":100},[],{"trials":6582,"activeCount":100},[6583],{"nctId":6584,"briefTitle":6585,"status":106,"phases":6586,"primaryCompletion":1761,"completion":3256,"start":3216,"enrollment":22,"conditions":6587,"interventions":6588},"NCT01354444","Trial of Carvedilol in Alzheimer's Disease",[91],[5015],[6571],{"trials":6590,"activeCount":100},[],{"intervention":6592,"totalTrials":126,"cells":6593},"Furosemide",{"EARLY_PHASE1":6594,"PHASE1":6596,"PHASE2":6598,"PHASE3":6600,"PHASE4":6602,"NA":6613},{"trials":6595,"activeCount":100},[],{"trials":6597,"activeCount":100},[],{"trials":6599,"activeCount":100},[],{"trials":6601,"activeCount":100},[],{"trials":6603,"activeCount":100},[6604],{"nctId":6605,"briefTitle":6606,"status":106,"phases":6607,"primaryCompletion":6608,"completion":6344,"start":1929,"enrollment":215,"conditions":6609,"interventions":6611},"NCT01901809","Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction",[91],"2017-06",[6610],"Heart Failure, Diastolic",[6592,6612],"Dopamine",{"trials":6614,"activeCount":100},[],{"intervention":6612,"totalTrials":126,"cells":6616},{"EARLY_PHASE1":6617,"PHASE1":6619,"PHASE2":6621,"PHASE3":6623,"PHASE4":6625,"NA":6631},{"trials":6618,"activeCount":100},[],{"trials":6620,"activeCount":100},[],{"trials":6622,"activeCount":100},[],{"trials":6624,"activeCount":100},[],{"trials":6626,"activeCount":100},[6627],{"nctId":6605,"briefTitle":6606,"status":106,"phases":6628,"primaryCompletion":6608,"completion":6344,"start":1929,"enrollment":215,"conditions":6629,"interventions":6630},[91],[6610],[6592,6612],{"trials":6632,"activeCount":100},[],{"intervention":6634,"totalTrials":126,"cells":6635},"300mg glecaprevir\u002Fpibrentasivir 120mg",{"EARLY_PHASE1":6636,"PHASE1":6638,"PHASE2":6640,"PHASE3":6642,"PHASE4":6644,"NA":6654},{"trials":6637,"activeCount":100},[],{"trials":6639,"activeCount":100},[],{"trials":6641,"activeCount":100},[],{"trials":6643,"activeCount":100},[],{"trials":6645,"activeCount":100},[6646],{"nctId":6647,"briefTitle":6648,"status":106,"phases":6649,"primaryCompletion":6650,"completion":3331,"start":6651,"enrollment":329,"conditions":6652,"interventions":6653},"NCT03627299","Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors",[91],"2019-12-19","2018-09-25",[6370,5099],[6634],{"trials":6655,"activeCount":100},[],{"intervention":6657,"totalTrials":126,"cells":6658},"Chlorthalidone",{"EARLY_PHASE1":6659,"PHASE1":6661,"PHASE2":6663,"PHASE3":6665,"PHASE4":6667,"NA":6677},{"trials":6660,"activeCount":100},[],{"trials":6662,"activeCount":100},[],{"trials":6664,"activeCount":100},[],{"trials":6666,"activeCount":100},[],{"trials":6668,"activeCount":100},[6669],{"nctId":6670,"briefTitle":6671,"status":149,"phases":6672,"primaryCompletion":6608,"completion":6673,"start":2173,"enrollment":100,"conditions":6674,"interventions":6675},"NCT01748123","EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network",[91],"2018-06",[15],[6657,6676],"Hydrochlorothiazide",{"trials":6678,"activeCount":100},[],{"intervention":6676,"totalTrials":126,"cells":6680},{"EARLY_PHASE1":6681,"PHASE1":6683,"PHASE2":6685,"PHASE3":6687,"PHASE4":6689,"NA":6695},{"trials":6682,"activeCount":100},[],{"trials":6684,"activeCount":100},[],{"trials":6686,"activeCount":100},[],{"trials":6688,"activeCount":100},[],{"trials":6690,"activeCount":100},[6691],{"nctId":6670,"briefTitle":6671,"status":149,"phases":6692,"primaryCompletion":6608,"completion":6673,"start":2173,"enrollment":100,"conditions":6693,"interventions":6694},[91],[15],[6657,6676],{"trials":6696,"activeCount":100},[],{"intervention":6698,"totalTrials":126,"cells":6699},"Aspirin 81 mg",{"EARLY_PHASE1":6700,"PHASE1":6702,"PHASE2":6704,"PHASE3":6706,"PHASE4":6708,"NA":6718},{"trials":6701,"activeCount":100},[],{"trials":6703,"activeCount":100},[],{"trials":6705,"activeCount":100},[],{"trials":6707,"activeCount":100},[],{"trials":6709,"activeCount":100},[6710],{"nctId":6711,"briefTitle":6712,"status":873,"phases":6713,"primaryCompletion":6714,"completion":6714,"start":2148,"enrollment":184,"conditions":6715,"interventions":6717},"NCT01875185","Hormones Inflammation and Thrombosis",[91],"2013-11",[186,6716],"Thrombosis",[6698],{"trials":6719,"activeCount":100},[],{"intervention":6721,"totalTrials":126,"cells":6722},"Vaginal estradiol",{"EARLY_PHASE1":6723,"PHASE1":6725,"PHASE2":6727,"PHASE3":6729,"PHASE4":6731,"NA":6745},{"trials":6724,"activeCount":100},[],{"trials":6726,"activeCount":100},[],{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[],{"trials":6732,"activeCount":100},[6733],{"nctId":6734,"briefTitle":6735,"status":106,"phases":6736,"primaryCompletion":6737,"completion":6738,"start":6739,"enrollment":1561,"conditions":6740,"interventions":6744},"NCT05551949","Preventing Recurrent UTI With Vaginal Estrogen",[91],"2025-06-30","2025-08-31","2022-01-01",[6741,6742,6743],"Recurrent Urinary Tract Infection","Urinary Tract Infections","Cystitis Recurrent",[6721],{"trials":6746,"activeCount":100},[],{"intervention":6748,"totalTrials":126,"cells":6749},"Mometasone",{"EARLY_PHASE1":6750,"PHASE1":6752,"PHASE2":6754,"PHASE3":6756,"PHASE4":6758,"NA":6768},{"trials":6751,"activeCount":100},[],{"trials":6753,"activeCount":100},[],{"trials":6755,"activeCount":100},[],{"trials":6757,"activeCount":100},[],{"trials":6759,"activeCount":100},[6760],{"nctId":6761,"briefTitle":6762,"status":873,"phases":6763,"primaryCompletion":6764,"completion":6764,"start":1762,"enrollment":3446,"conditions":6765,"interventions":6766},"NCT00461812","A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma",[91],"2010-01-19",[21],[6748,6767],"Advair",{"trials":6769,"activeCount":100},[],{"intervention":6767,"totalTrials":126,"cells":6771},{"EARLY_PHASE1":6772,"PHASE1":6774,"PHASE2":6776,"PHASE3":6778,"PHASE4":6780,"NA":6786},{"trials":6773,"activeCount":100},[],{"trials":6775,"activeCount":100},[],{"trials":6777,"activeCount":100},[],{"trials":6779,"activeCount":100},[],{"trials":6781,"activeCount":100},[6782],{"nctId":6761,"briefTitle":6762,"status":873,"phases":6783,"primaryCompletion":6764,"completion":6764,"start":1762,"enrollment":3446,"conditions":6784,"interventions":6785},[91],[21],[6748,6767],{"trials":6787,"activeCount":100},[],{"intervention":6789,"totalTrials":126,"cells":6790},"Sustained Release Dexamethasone, 0.4 mg",{"EARLY_PHASE1":6791,"PHASE1":6793,"PHASE2":6795,"PHASE3":6797,"PHASE4":6799,"NA":6810},{"trials":6792,"activeCount":100},[],{"trials":6794,"activeCount":100},[],{"trials":6796,"activeCount":100},[],{"trials":6798,"activeCount":100},[],{"trials":6800,"activeCount":100},[6801],{"nctId":6802,"briefTitle":6803,"status":873,"phases":6804,"primaryCompletion":6805,"completion":6805,"start":6806,"enrollment":3269,"conditions":6807,"interventions":6809},"NCT04498468","Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye",[91],"2023-03-03","2021-03-16",[6808],"Dry Eye",[6789],{"trials":6811,"activeCount":100},[],{"intervention":6813,"totalTrials":126,"cells":6814},"Ketorolac",{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6819,"PHASE3":6821,"PHASE4":6823,"NA":6834},{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[],{"trials":6820,"activeCount":100},[],{"trials":6822,"activeCount":100},[],{"trials":6824,"activeCount":100},[6825],{"nctId":6826,"briefTitle":6827,"status":106,"phases":6828,"primaryCompletion":1760,"completion":1760,"start":2174,"enrollment":6829,"conditions":6830,"interventions":6832},"NCT01807234","Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine",[91],72,[6831],"Migraines",[6813,6833],"Sumatriptan",{"trials":6835,"activeCount":100},[],{"intervention":6833,"totalTrials":126,"cells":6837},{"EARLY_PHASE1":6838,"PHASE1":6840,"PHASE2":6842,"PHASE3":6844,"PHASE4":6846,"NA":6852},{"trials":6839,"activeCount":100},[],{"trials":6841,"activeCount":100},[],{"trials":6843,"activeCount":100},[],{"trials":6845,"activeCount":100},[],{"trials":6847,"activeCount":100},[6848],{"nctId":6826,"briefTitle":6827,"status":106,"phases":6849,"primaryCompletion":1760,"completion":1760,"start":2174,"enrollment":6829,"conditions":6850,"interventions":6851},[91],[6831],[6813,6833],{"trials":6853,"activeCount":100},[],{"intervention":6855,"totalTrials":126,"cells":6856},"Antiplatelet Agents",{"EARLY_PHASE1":6857,"PHASE1":6859,"PHASE2":6861,"PHASE3":6863,"PHASE4":6865,"NA":6882},{"trials":6858,"activeCount":100},[],{"trials":6860,"activeCount":100},[],{"trials":6862,"activeCount":100},[],{"trials":6864,"activeCount":100},[],{"trials":6866,"activeCount":100},[6867],{"nctId":6868,"briefTitle":6869,"status":106,"phases":6870,"primaryCompletion":5169,"completion":5169,"start":6871,"enrollment":6872,"conditions":6873,"interventions":6879},"NCT00241904","Reducing Total Cardiovascular Risk in an Urban Community",[91],"2006-05",525,[6874,6875,6876,6877,2342,6878,15],"Cardiovascular Diseases","Heart Diseases","Coronary Disease","Diabetes Mellitus","Cerebral Arteriosclerosis",[6855,6880,6881],"Beta Blocker","ACE Inhibitors",{"trials":6883,"activeCount":100},[],{"intervention":6880,"totalTrials":126,"cells":6885},{"EARLY_PHASE1":6886,"PHASE1":6888,"PHASE2":6890,"PHASE3":6892,"PHASE4":6894,"NA":6900},{"trials":6887,"activeCount":100},[],{"trials":6889,"activeCount":100},[],{"trials":6891,"activeCount":100},[],{"trials":6893,"activeCount":100},[],{"trials":6895,"activeCount":100},[6896],{"nctId":6868,"briefTitle":6869,"status":106,"phases":6897,"primaryCompletion":5169,"completion":5169,"start":6871,"enrollment":6872,"conditions":6898,"interventions":6899},[91],[6874,6875,6876,6877,2342,6878,15],[6855,6880,6881],{"trials":6901,"activeCount":100},[],{"intervention":6881,"totalTrials":126,"cells":6903},{"EARLY_PHASE1":6904,"PHASE1":6906,"PHASE2":6908,"PHASE3":6910,"PHASE4":6912,"NA":6918},{"trials":6905,"activeCount":100},[],{"trials":6907,"activeCount":100},[],{"trials":6909,"activeCount":100},[],{"trials":6911,"activeCount":100},[],{"trials":6913,"activeCount":100},[6914],{"nctId":6868,"briefTitle":6869,"status":106,"phases":6915,"primaryCompletion":5169,"completion":5169,"start":6871,"enrollment":6872,"conditions":6916,"interventions":6917},[91],[6874,6875,6876,6877,2342,6878,15],[6855,6880,6881],{"trials":6919,"activeCount":100},[],{"intervention":6921,"totalTrials":126,"cells":6922},"Moxifloxacin 0.5% ophthalmic solution",{"EARLY_PHASE1":6923,"PHASE1":6925,"PHASE2":6927,"PHASE3":6929,"PHASE4":6931,"NA":6941},{"trials":6924,"activeCount":100},[],{"trials":6926,"activeCount":100},[],{"trials":6928,"activeCount":100},[],{"trials":6930,"activeCount":100},[],{"trials":6932,"activeCount":100},[6933],{"nctId":6934,"briefTitle":6935,"status":106,"phases":6936,"primaryCompletion":2150,"completion":5183,"start":2127,"enrollment":311,"conditions":6937,"interventions":6939},"NCT00924729","Study of Ocular Penetration of Topically Administered Fluoroquinolones",[91],[6938],"Cataract Extraction",[6921,6940],"Besifloxacin 0.6% ophthalmic suspension",{"trials":6942,"activeCount":100},[],{"intervention":6940,"totalTrials":126,"cells":6944},{"EARLY_PHASE1":6945,"PHASE1":6947,"PHASE2":6949,"PHASE3":6951,"PHASE4":6953,"NA":6959},{"trials":6946,"activeCount":100},[],{"trials":6948,"activeCount":100},[],{"trials":6950,"activeCount":100},[],{"trials":6952,"activeCount":100},[],{"trials":6954,"activeCount":100},[6955],{"nctId":6934,"briefTitle":6935,"status":106,"phases":6956,"primaryCompletion":2150,"completion":5183,"start":2127,"enrollment":311,"conditions":6957,"interventions":6958},[91],[6938],[6921,6940],{"trials":6960,"activeCount":100},[],{"intervention":5118,"totalTrials":126,"cells":6962},{"EARLY_PHASE1":6963,"PHASE1":6965,"PHASE2":6967,"PHASE3":6969,"PHASE4":6971,"NA":6977},{"trials":6964,"activeCount":100},[],{"trials":6966,"activeCount":100},[],{"trials":6968,"activeCount":100},[],{"trials":6970,"activeCount":100},[],{"trials":6972,"activeCount":100},[6973],{"nctId":5109,"briefTitle":5110,"status":106,"phases":6974,"primaryCompletion":5112,"completion":5113,"start":5114,"enrollment":264,"conditions":6975,"interventions":6976},[91],[5116,5099],[5118,5086,5119],{"trials":6978,"activeCount":100},[],{"intervention":5119,"totalTrials":126,"cells":6980},{"EARLY_PHASE1":6981,"PHASE1":6983,"PHASE2":6985,"PHASE3":6987,"PHASE4":6989,"NA":6995},{"trials":6982,"activeCount":100},[],{"trials":6984,"activeCount":100},[],{"trials":6986,"activeCount":100},[],{"trials":6988,"activeCount":100},[],{"trials":6990,"activeCount":100},[6991],{"nctId":5109,"briefTitle":5110,"status":106,"phases":6992,"primaryCompletion":5112,"completion":5113,"start":5114,"enrollment":264,"conditions":6993,"interventions":6994},[91],[5116,5099],[5118,5086,5119],{"trials":6996,"activeCount":100},[],{"intervention":6998,"totalTrials":126,"cells":6999},"Genvoya Oral dose",{"EARLY_PHASE1":7000,"PHASE1":7002,"PHASE2":7004,"PHASE3":7006,"PHASE4":7008,"NA":7019},{"trials":7001,"activeCount":100},[],{"trials":7003,"activeCount":100},[],{"trials":7005,"activeCount":100},[],{"trials":7007,"activeCount":100},[],{"trials":7009,"activeCount":100},[7010],{"nctId":7011,"briefTitle":7012,"status":106,"phases":7013,"primaryCompletion":7014,"completion":7014,"start":7015,"enrollment":1663,"conditions":7016,"interventions":7017},"NCT03717129","Analysis of Crushed and Whole Tablet Genvoya",[91],"2021-11-01","2019-04-15",[4263],[6998,7018],"Genvoya Crushed Dose",{"trials":7020,"activeCount":100},[],{"intervention":7018,"totalTrials":126,"cells":7022},{"EARLY_PHASE1":7023,"PHASE1":7025,"PHASE2":7027,"PHASE3":7029,"PHASE4":7031,"NA":7037},{"trials":7024,"activeCount":100},[],{"trials":7026,"activeCount":100},[],{"trials":7028,"activeCount":100},[],{"trials":7030,"activeCount":100},[],{"trials":7032,"activeCount":100},[7033],{"nctId":7011,"briefTitle":7012,"status":106,"phases":7034,"primaryCompletion":7014,"completion":7014,"start":7015,"enrollment":1663,"conditions":7035,"interventions":7036},[91],[4263],[6998,7018],{"trials":7038,"activeCount":100},[],{"intervention":7040,"totalTrials":126,"cells":7041},"Alemtuzumab",{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7046,"PHASE3":7048,"PHASE4":7050,"NA":7059},{"trials":7043,"activeCount":100},[],{"trials":7045,"activeCount":100},[],{"trials":7047,"activeCount":100},[],{"trials":7049,"activeCount":100},[],{"trials":7051,"activeCount":100},[7052],{"nctId":7053,"briefTitle":7054,"status":149,"phases":7055,"primaryCompletion":2173,"completion":2173,"start":3340,"enrollment":100,"conditions":7056,"interventions":7058},"NCT01757574","Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)",[91],[7057],"Chronic Inflammatory Demyelinating Neuropathy",[7040],{"trials":7060,"activeCount":100},[],{"intervention":7062,"totalTrials":126,"cells":7063},"Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]",{"EARLY_PHASE1":7064,"PHASE1":7066,"PHASE2":7068,"PHASE3":7070,"PHASE4":7072,"NA":7083},{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":100},[],{"trials":7069,"activeCount":100},[],{"trials":7071,"activeCount":100},[],{"trials":7073,"activeCount":100},[7074],{"nctId":7075,"briefTitle":7076,"status":149,"phases":7077,"primaryCompletion":7078,"completion":7078,"start":7079,"enrollment":100,"conditions":7080,"interventions":7082},"NCT03061045","Contrast Enhanced Ultrasound Evaluation of Brain Perfusion in Neonatal Post-Hemorrhagic Hydrocephalus",[91],"2018-01-22","2017-04-01",[7081],"Neonatal Post-Hemorrhagic Hydrocephalus",[7062],{"trials":7084,"activeCount":100},[],{"intervention":2282,"totalTrials":2081,"cells":7086},{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7118,"PHASE3":7147,"PHASE4":7160,"NA":7162},{"trials":7088,"activeCount":100},[],{"trials":7090,"activeCount":100},[7091,7100,7110,7114],{"nctId":7092,"briefTitle":7093,"status":106,"phases":7094,"primaryCompletion":290,"completion":290,"start":1929,"enrollment":7095,"conditions":7096,"interventions":7098},"NCT01642030","Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance",[88],132,[2313,3259,7097],"Addiction",[7099,2282],"Hydromorphone",{"nctId":7101,"briefTitle":7102,"status":106,"phases":7103,"primaryCompletion":6608,"completion":6608,"start":7104,"enrollment":7105,"conditions":7106,"interventions":7109},"NCT02372591","Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain",[88],"2015-08",14,[7107,7108],"Opioid-Related Disorders","Chronic Pain",[2282,7099],{"nctId":2275,"briefTitle":2276,"status":106,"phases":7111,"primaryCompletion":1645,"completion":1555,"start":2148,"enrollment":126,"conditions":7112,"interventions":7113},[88],[2279,24,2280],[2268,2282],{"nctId":2284,"briefTitle":2285,"status":106,"phases":7115,"primaryCompletion":1760,"completion":1760,"start":825,"enrollment":2287,"conditions":7116,"interventions":7117},[88],[2289,2290],[2268,2282],{"trials":7119,"activeCount":100},[7120,7128,7138],{"nctId":7121,"briefTitle":7122,"status":106,"phases":7123,"primaryCompletion":2105,"completion":2105,"start":697,"enrollment":1663,"conditions":7124,"interventions":7126},"NCT00460239","Buprenorphine's Dose Response Curve",[89],[7125],"Opioid-related Disorders",[2282,7127],"Morphine",{"nctId":7129,"briefTitle":7130,"status":106,"phases":7131,"primaryCompletion":5585,"completion":5585,"start":7132,"enrollment":1663,"conditions":7133,"interventions":7135},"NCT01136356","A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals",[88,89],"2010-07",[7134,2313],"Opioid Abuse",[7136,7137],"buprenorphine","morphine",{"nctId":7139,"briefTitle":7140,"status":106,"phases":7141,"primaryCompletion":7142,"completion":7143,"start":7144,"enrollment":3436,"conditions":7145,"interventions":7146},"NCT03492099","Assessing the Safety of Buprenorphine in People With Sickle Cell Disease",[89],"2019-09-23","2022-02-28","2018-08-01",[3344],[7136],{"trials":7148,"activeCount":100},[7149,7153],{"nctId":2305,"briefTitle":2306,"status":106,"phases":7150,"primaryCompletion":1646,"completion":696,"start":2308,"enrollment":2309,"conditions":7151,"interventions":7152},[90],[2311,2312,2313],[2268,2282],{"nctId":7154,"briefTitle":7155,"status":106,"phases":7156,"primaryCompletion":2172,"completion":2172,"start":7157,"enrollment":5384,"conditions":7158,"interventions":7159},"NCT01561079","Fetal and Infant Effects of Maternal Buprenorphine Treatment",[89,90],"2012-02",[3234],[2282],{"trials":7161,"activeCount":100},[],{"trials":7163,"activeCount":100},[],{"intervention":7165,"totalTrials":280,"cells":7166},"Thalidomide",{"EARLY_PHASE1":7167,"PHASE1":7169,"PHASE2":7171,"PHASE3":7181,"PHASE4":7193,"NA":7195},{"trials":7168,"activeCount":100},[],{"trials":7170,"activeCount":100},[],{"trials":7172,"activeCount":100},[7173],{"nctId":7174,"briefTitle":7175,"status":106,"phases":7176,"completion":2186,"start":7177,"enrollment":2151,"conditions":7178,"interventions":7180},"NCT00162760","Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide",[89],"2003-10",[7179],"Idiopathic Pulmonary Fibrosis (IPF)",[7165],{"trials":7182,"activeCount":100},[7183],{"nctId":7184,"briefTitle":7185,"status":106,"phases":7186,"primaryCompletion":7187,"completion":7187,"start":7188,"enrollment":110,"conditions":7189,"interventions":7192},"NCT00600028","Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide",[90],"2011-09","2007-12",[7190,7191],"Idiopathic Pulmonary Fibrosis","Cough",[7165],{"trials":7194,"activeCount":100},[],{"trials":7196,"activeCount":100},[],{"intervention":7198,"totalTrials":280,"cells":7199},"Dexamethasone Implant",{"EARLY_PHASE1":7200,"PHASE1":7202,"PHASE2":7204,"PHASE3":7215,"PHASE4":7225,"NA":7227},{"trials":7201,"activeCount":100},[],{"trials":7203,"activeCount":100},[],{"trials":7205,"activeCount":100},[7206],{"nctId":7207,"briefTitle":7208,"status":106,"phases":7209,"primaryCompletion":7210,"completion":7210,"start":7211,"enrollment":1593,"conditions":7212,"interventions":7213},"NCT01951066","Diabetic Macular Edema Treated With Ozurdex (DMEO)",[89],"2015-12","2013-10",[5430],[7198,7214],"Anti-VEGF",{"trials":7216,"activeCount":100},[7217],{"nctId":7218,"briefTitle":7219,"status":106,"phases":7220,"primaryCompletion":1760,"completion":1760,"start":2174,"enrollment":16,"conditions":7221,"interventions":7223},"NCT01790685","Ozurdex for Retinal Vein Occlusion Study (ORVO Study)",[89,90],[7222],"Retinal Vein Occlusion",[7224],"dexamethasone implant",{"trials":7226,"activeCount":100},[],{"trials":7228,"activeCount":100},[],{"intervention":7230,"totalTrials":126,"cells":7231},"rt-PA",{"EARLY_PHASE1":7232,"PHASE1":7234,"PHASE2":7236,"PHASE3":7238,"PHASE4":7249,"NA":7251},{"trials":7233,"activeCount":100},[],{"trials":7235,"activeCount":100},[],{"trials":7237,"activeCount":100},[],{"trials":7239,"activeCount":100},[7240],{"nctId":7241,"briefTitle":7242,"status":106,"phases":7243,"primaryCompletion":7244,"completion":7244,"start":7245,"enrollment":7246,"conditions":7247,"interventions":7248},"NCT01827046","Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III",[90],"2018-09","2013-12-30",499,[2500],[7230],{"trials":7250,"activeCount":100},[],{"trials":7252,"activeCount":100},[],{"intervention":3236,"totalTrials":126,"cells":7254},{"EARLY_PHASE1":7255,"PHASE1":7257,"PHASE2":7259,"PHASE3":7261,"PHASE4":7267,"NA":7269},{"trials":7256,"activeCount":100},[],{"trials":7258,"activeCount":100},[],{"trials":7260,"activeCount":100},[],{"trials":7262,"activeCount":100},[7263],{"nctId":3229,"briefTitle":3230,"status":873,"phases":7264,"primaryCompletion":3232,"completion":1760,"start":3232,"enrollment":1663,"conditions":7265,"interventions":7266},[89,90],[3234],[3236,2769],{"trials":7268,"activeCount":100},[],{"trials":7270,"activeCount":100},[],{"intervention":7272,"totalTrials":126,"cells":7273},"Zolpidem extended-release",{"EARLY_PHASE1":7274,"PHASE1":7276,"PHASE2":7278,"PHASE3":7280,"PHASE4":7290,"NA":7292},{"trials":7275,"activeCount":100},[],{"trials":7277,"activeCount":100},[],{"trials":7279,"activeCount":100},[],{"trials":7281,"activeCount":100},[7282],{"nctId":7283,"briefTitle":7284,"status":106,"phases":7285,"primaryCompletion":7286,"completion":7286,"start":5096,"enrollment":5384,"conditions":7287,"interventions":7289},"NCT01685073","The Role of Sleep in the Treatment of Cannabis Use Disorders",[89,90],"2018-07",[7288],"Drug Addiction",[7272],{"trials":7291,"activeCount":100},[],{"trials":7293,"activeCount":100},[],{"intervention":2345,"totalTrials":126,"cells":7295},{"EARLY_PHASE1":7296,"PHASE1":7298,"PHASE2":7300,"PHASE3":7302,"PHASE4":7308,"NA":7310},{"trials":7297,"activeCount":100},[],{"trials":7299,"activeCount":100},[],{"trials":7301,"activeCount":100},[],{"trials":7303,"activeCount":100},[7304],{"nctId":2335,"briefTitle":2336,"status":106,"phases":7305,"primaryCompletion":2338,"completion":2338,"start":2339,"enrollment":2340,"conditions":7306,"interventions":7307},[90],[2342,2343],[2345,2320],{"trials":7309,"activeCount":100},[],{"trials":7311,"activeCount":100},[],{"intervention":7313,"totalTrials":126,"cells":7314},"PredA + Kelac",{"EARLY_PHASE1":7315,"PHASE1":7317,"PHASE2":7319,"PHASE3":7321,"PHASE4":7332,"NA":7334},{"trials":7316,"activeCount":100},[],{"trials":7318,"activeCount":100},[],{"trials":7320,"activeCount":100},[],{"trials":7322,"activeCount":100},[7323],{"nctId":7324,"briefTitle":7325,"status":106,"phases":7326,"primaryCompletion":7327,"completion":7327,"start":3119,"enrollment":7328,"conditions":7329,"interventions":7331},"NCT01769352","Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)",[89,90],"2016-04",42,[7330],"Post-surgical Cystoid Macular Edema (PSCME)",[7313],{"trials":7333,"activeCount":100},[],{"trials":7335,"activeCount":100},[],{"intervention":7337,"totalTrials":126,"cells":7338},"Vitamin D3",{"EARLY_PHASE1":7339,"PHASE1":7341,"PHASE2":7343,"PHASE3":7345,"PHASE4":7356,"NA":7358},{"trials":7340,"activeCount":100},[],{"trials":7342,"activeCount":100},[],{"trials":7344,"activeCount":100},[],{"trials":7346,"activeCount":100},[7347],{"nctId":7348,"briefTitle":7349,"status":106,"phases":7350,"primaryCompletion":7351,"completion":7351,"start":5585,"enrollment":7352,"conditions":7353,"interventions":7355},"NCT01490502","Vitamin D Supplementation in Multiple Sclerosis",[90],"2021-05-15",172,[7354],"Relapsing Remitting Multiple Sclerosis",[7337],{"trials":7357,"activeCount":100},[],{"trials":7359,"activeCount":100},[],{"intervention":7361,"totalTrials":126,"cells":7362},"2% Chlorhexidine gluconate cloth",{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7367,"PHASE3":7369,"PHASE4":7381,"NA":7383},{"trials":7364,"activeCount":100},[],{"trials":7366,"activeCount":100},[],{"trials":7368,"activeCount":100},[],{"trials":7370,"activeCount":100},[7371],{"nctId":7372,"briefTitle":7373,"status":106,"phases":7374,"primaryCompletion":6456,"completion":7375,"start":7376,"enrollment":7377,"conditions":7378,"interventions":7380},"NCT00549393","Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit",[89,90],"2012-06","2008-02",5659,[7379],"Nosocomial Infections",[7361],{"trials":7382,"activeCount":100},[],{"trials":7384,"activeCount":100},[],{"intervention":7386,"totalTrials":126,"cells":7387},"Periocular injection of triamcinolone acetonide 40mg",{"EARLY_PHASE1":7388,"PHASE1":7390,"PHASE2":7392,"PHASE3":7394,"PHASE4":7405,"NA":7407},{"trials":7389,"activeCount":100},[],{"trials":7391,"activeCount":100},[],{"trials":7393,"activeCount":100},[],{"trials":7395,"activeCount":100},[7396],{"nctId":7397,"briefTitle":7398,"status":106,"phases":7399,"completion":5857,"start":7400,"enrollment":184,"conditions":7401,"interventions":7404},"NCT00305630","Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)",[89,90],"2002-07",[7402,7403],"Choroidal Neovascularization","Age-Related Macular Degeneration",[7386],{"trials":7406,"activeCount":100},[],{"trials":7408,"activeCount":100},[],{"intervention":7410,"totalTrials":126,"cells":7411},"Exparel 133 miligrams per 10 milliliter",{"EARLY_PHASE1":7412,"PHASE1":7414,"PHASE2":7416,"PHASE3":7418,"PHASE4":7435,"NA":7437},{"trials":7413,"activeCount":100},[],{"trials":7415,"activeCount":100},[],{"trials":7417,"activeCount":100},[],{"trials":7419,"activeCount":100},[7420],{"nctId":7421,"briefTitle":7422,"status":873,"phases":7423,"primaryCompletion":7424,"completion":7424,"start":7425,"enrollment":902,"conditions":7426,"interventions":7433},"NCT04826484","Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel",[90],"2023-04-26","2021-10-01",[7427,7428,7429,7430,7431,7432],"Urologic Diseases","Hypospadias","Undescended Testes","Chordee","Hydrocele","Orchiectomy",[7410,7434],"Bupivacaine Hydrochloride",{"trials":7436,"activeCount":100},[],{"trials":7438,"activeCount":100},[],{"intervention":7434,"totalTrials":126,"cells":7440},{"EARLY_PHASE1":7441,"PHASE1":7443,"PHASE2":7445,"PHASE3":7447,"PHASE4":7453,"NA":7455},{"trials":7442,"activeCount":100},[],{"trials":7444,"activeCount":100},[],{"trials":7446,"activeCount":100},[],{"trials":7448,"activeCount":100},[7449],{"nctId":7421,"briefTitle":7422,"status":873,"phases":7450,"primaryCompletion":7424,"completion":7424,"start":7425,"enrollment":902,"conditions":7451,"interventions":7452},[90],[7427,7428,7429,7430,7431,7432],[7410,7434],{"trials":7454,"activeCount":100},[],{"trials":7456,"activeCount":100},[],{"intervention":3249,"totalTrials":126,"cells":7458},{"EARLY_PHASE1":7459,"PHASE1":7461,"PHASE2":7463,"PHASE3":7465,"PHASE4":7471,"NA":7473},{"trials":7460,"activeCount":100},[],{"trials":7462,"activeCount":100},[],{"trials":7464,"activeCount":100},[],{"trials":7466,"activeCount":100},[7467],{"nctId":3238,"briefTitle":3239,"status":873,"phases":7468,"primaryCompletion":3241,"completion":3242,"start":3243,"enrollment":1582,"conditions":7469,"interventions":7470},[90],[3245,3246,3247],[3249,3204],{"trials":7472,"activeCount":100},[],{"trials":7474,"activeCount":100},[],{"intervention":7476,"totalTrials":126,"cells":7477},"IV Cyclophosphamide",{"EARLY_PHASE1":7478,"PHASE1":7480,"PHASE2":7482,"PHASE3":7484,"PHASE4":7493,"NA":7495},{"trials":7479,"activeCount":100},[],{"trials":7481,"activeCount":100},[],{"trials":7483,"activeCount":100},[],{"trials":7485,"activeCount":100},[7486],{"nctId":7487,"briefTitle":7488,"status":106,"phases":7489,"primaryCompletion":5011,"completion":5169,"start":7490,"enrollment":293,"conditions":7491,"interventions":7492},"NCT00501995","High Dose Cyclophosphamide for Treatment of Scleroderma",[90],"2001-02",[3333],[7476],{"trials":7494,"activeCount":100},[],{"trials":7496,"activeCount":100},[],{"intervention":7498,"totalTrials":126,"cells":7499},"Lofexidine",{"EARLY_PHASE1":7500,"PHASE1":7502,"PHASE2":7504,"PHASE3":7506,"PHASE4":7517,"NA":7519},{"trials":7501,"activeCount":100},[],{"trials":7503,"activeCount":100},[],{"trials":7505,"activeCount":100},[],{"trials":7507,"activeCount":100},[7508],{"nctId":7509,"briefTitle":7510,"status":106,"phases":7511,"primaryCompletion":7512,"completion":65,"start":7513,"enrollment":2893,"conditions":7514,"interventions":7516},"NCT04325659","An Innovative Intervention for OUD Treatment",[89,90],"2025-04-20","2020-11-15",[7107,2313,7515,3532],"Opioid Addiction",[7498],{"trials":7518,"activeCount":100},[],{"trials":7520,"activeCount":100},[],{"intervention":7522,"totalTrials":126,"cells":7523},"Bupropion XL",{"EARLY_PHASE1":7524,"PHASE1":7526,"PHASE2":7528,"PHASE3":7530,"PHASE4":7543,"NA":7545},{"trials":7525,"activeCount":100},[],{"trials":7527,"activeCount":100},[],{"trials":7529,"activeCount":100},[],{"trials":7531,"activeCount":100},[7532],{"nctId":7533,"briefTitle":7534,"status":106,"phases":7535,"primaryCompletion":7536,"completion":7537,"start":3243,"enrollment":7538,"conditions":7539,"interventions":7542},"NCT02111798","Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence",[89,90],"2020-05","2021-01",83,[7540,7541],"Substance Abuse","Cocaine Dependence",[7522],{"trials":7544,"activeCount":100},[],{"trials":7546,"activeCount":100},[],{"intervention":7548,"totalTrials":126,"cells":7549},"Mirasol-treated Fresh Whole Blood",{"EARLY_PHASE1":7550,"PHASE1":7552,"PHASE2":7554,"PHASE3":7556,"PHASE4":7568,"NA":7570},{"trials":7551,"activeCount":100},[],{"trials":7553,"activeCount":100},[],{"trials":7555,"activeCount":100},[],{"trials":7557,"activeCount":100},[7558],{"nctId":7559,"briefTitle":7560,"status":106,"phases":7561,"primaryCompletion":7562,"completion":7562,"start":7563,"enrollment":4633,"conditions":7564,"interventions":7566},"NCT03737669","Mirasol Evaluation of Reduction in Infections Trial",[90],"2025-09-29","2019-11-13",[7565],"Transfusion-Transmitted Infectious Disease",[7548,7567],"Standard Fresh Whole Blood",{"trials":7569,"activeCount":100},[],{"trials":7571,"activeCount":100},[],{"intervention":7567,"totalTrials":126,"cells":7573},{"EARLY_PHASE1":7574,"PHASE1":7576,"PHASE2":7578,"PHASE3":7580,"PHASE4":7586,"NA":7588},{"trials":7575,"activeCount":100},[],{"trials":7577,"activeCount":100},[],{"trials":7579,"activeCount":100},[],{"trials":7581,"activeCount":100},[7582],{"nctId":7559,"briefTitle":7560,"status":106,"phases":7583,"primaryCompletion":7562,"completion":7562,"start":7563,"enrollment":4633,"conditions":7584,"interventions":7585},[90],[7565],[7548,7567],{"trials":7587,"activeCount":100},[],{"trials":7589,"activeCount":100},[],{"intervention":7591,"totalTrials":126,"cells":7592},"BIIB017",{"EARLY_PHASE1":7593,"PHASE1":7595,"PHASE2":7597,"PHASE3":7599,"PHASE4":7608,"NA":7610},{"trials":7594,"activeCount":100},[],{"trials":7596,"activeCount":100},[],{"trials":7598,"activeCount":100},[],{"trials":7600,"activeCount":100},[7601],{"nctId":7602,"briefTitle":7603,"status":149,"phases":7604,"primaryCompletion":1929,"completion":1929,"start":7605,"enrollment":100,"conditions":7606,"interventions":7607},"NCT01337427","Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis",[90],"2010-08",[7354],[7591],{"trials":7609,"activeCount":100},[],{"trials":7611,"activeCount":100},[],{"intervention":7613,"totalTrials":126,"cells":7614},"Emetine Hydrochloride",{"EARLY_PHASE1":7615,"PHASE1":7617,"PHASE2":7619,"PHASE3":7621,"PHASE4":7631,"NA":7633},{"trials":7616,"activeCount":100},[],{"trials":7618,"activeCount":100},[],{"trials":7620,"activeCount":100},[],{"trials":7622,"activeCount":100},[7623],{"nctId":7624,"briefTitle":7625,"status":873,"phases":7626,"primaryCompletion":7627,"completion":7627,"start":7628,"enrollment":614,"conditions":7629,"interventions":7630},"NCT05889793","Evaluating Emetine for Viral Outbreaks (EVOLVE)",[89,90],"2025-12-15","2024-05-15",[4749],[7613],{"trials":7632,"activeCount":100},[],{"trials":7634,"activeCount":100},[],{"intervention":4905,"totalTrials":126,"cells":7636},{"EARLY_PHASE1":7637,"PHASE1":7639,"PHASE2":7641,"PHASE3":7643,"PHASE4":7649,"NA":7651},{"trials":7638,"activeCount":100},[],{"trials":7640,"activeCount":100},[],{"trials":7642,"activeCount":100},[],{"trials":7644,"activeCount":100},[7645],{"nctId":4896,"briefTitle":4897,"status":106,"phases":7646,"primaryCompletion":3311,"completion":3311,"start":4899,"enrollment":4900,"conditions":7647,"interventions":7648},[89,90],[4902],[4904,4905,4906],{"trials":7650,"activeCount":100},[],{"trials":7652,"activeCount":100},[],{"intervention":7654,"totalTrials":126,"cells":7655},"Alteplase",{"EARLY_PHASE1":7656,"PHASE1":7658,"PHASE2":7660,"PHASE3":7662,"PHASE4":7673,"NA":7675},{"trials":7657,"activeCount":100},[],{"trials":7659,"activeCount":100},[],{"trials":7661,"activeCount":100},[],{"trials":7663,"activeCount":100},[7664],{"nctId":7665,"briefTitle":7666,"status":106,"phases":7667,"primaryCompletion":7668,"completion":292,"start":2105,"enrollment":7669,"conditions":7670,"interventions":7672},"NCT00784134","Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III",[90],"2015-07",500,[7671],"Intraventricular Hemorrhage",[7654],{"trials":7674,"activeCount":100},[],{"trials":7676,"activeCount":100},[],{"intervention":7678,"totalTrials":126,"cells":7679},"Low Frequency Right sided repetitive transcranial magnetic stimulation",{"EARLY_PHASE1":7680,"PHASE1":7682,"PHASE2":7684,"PHASE3":7686,"PHASE4":7696,"NA":7698},{"trials":7681,"activeCount":100},[],{"trials":7683,"activeCount":100},[],{"trials":7685,"activeCount":100},[],{"trials":7687,"activeCount":100},[7688],{"nctId":7689,"briefTitle":7690,"status":106,"phases":7691,"primaryCompletion":7692,"completion":7692,"start":1655,"enrollment":1895,"conditions":7693,"interventions":7695},"NCT02367521","Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)",[89,90],"2017-10-01",[7694],"TBI Depression",[7678],{"trials":7697,"activeCount":100},[],{"trials":7699,"activeCount":100},[],{"intervention":7701,"totalTrials":126,"cells":7702},"Mono-Therapy with Sildenafil",{"EARLY_PHASE1":7703,"PHASE1":7705,"PHASE2":7707,"PHASE3":7709,"PHASE4":7720,"NA":7722},{"trials":7704,"activeCount":100},[],{"trials":7706,"activeCount":100},[],{"trials":7708,"activeCount":100},[],{"trials":7710,"activeCount":100},[7711],{"nctId":7712,"briefTitle":7713,"status":106,"phases":7714,"primaryCompletion":60,"completion":60,"start":7715,"enrollment":1854,"conditions":7716,"interventions":7718},"NCT04039464","Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension",[90],"2022-08-01",[7717],"Pediatric Pulmonary Hypertension",[7701,7719],"Duo-Therapy with Sildenafil + Bosentan",{"trials":7721,"activeCount":100},[],{"trials":7723,"activeCount":100},[],{"intervention":7719,"totalTrials":126,"cells":7725},{"EARLY_PHASE1":7726,"PHASE1":7728,"PHASE2":7730,"PHASE3":7732,"PHASE4":7738,"NA":7740},{"trials":7727,"activeCount":100},[],{"trials":7729,"activeCount":100},[],{"trials":7731,"activeCount":100},[],{"trials":7733,"activeCount":100},[7734],{"nctId":7712,"briefTitle":7713,"status":106,"phases":7735,"primaryCompletion":60,"completion":60,"start":7715,"enrollment":1854,"conditions":7736,"interventions":7737},[90],[7717],[7701,7719],{"trials":7739,"activeCount":100},[],{"trials":7741,"activeCount":100},[],{"intervention":7743,"totalTrials":126,"cells":7744},"Duloxetine",{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7749,"PHASE3":7751,"PHASE4":7764,"NA":7766},{"trials":7746,"activeCount":100},[],{"trials":7748,"activeCount":100},[],{"trials":7750,"activeCount":100},[],{"trials":7752,"activeCount":100},[7753],{"nctId":7754,"briefTitle":7755,"status":106,"phases":7756,"primaryCompletion":7757,"completion":7757,"start":7758,"enrollment":7759,"conditions":7760,"interventions":7762},"NCT04504812","A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain",[90],"2025-04-08","2021-02-01",1937,[7761],"Knee Osteoarthritis",[7743,7763],"Intra-Articular",{"trials":7765,"activeCount":100},[],{"trials":7767,"activeCount":100},[],{"intervention":7763,"totalTrials":126,"cells":7769},{"EARLY_PHASE1":7770,"PHASE1":7772,"PHASE2":7774,"PHASE3":7776,"PHASE4":7782,"NA":7784},{"trials":7771,"activeCount":100},[],{"trials":7773,"activeCount":100},[],{"trials":7775,"activeCount":100},[],{"trials":7777,"activeCount":100},[7778],{"nctId":7754,"briefTitle":7755,"status":106,"phases":7779,"primaryCompletion":7757,"completion":7757,"start":7758,"enrollment":7759,"conditions":7780,"interventions":7781},[90],[7761],[7743,7763],{"trials":7783,"activeCount":100},[],{"trials":7785,"activeCount":100},[],{"intervention":702,"totalTrials":126,"cells":7787},{"EARLY_PHASE1":7788,"PHASE1":7790,"PHASE2":7792,"PHASE3":7794,"PHASE4":7800,"NA":7802},{"trials":7789,"activeCount":100},[],{"trials":7791,"activeCount":100},[],{"trials":7793,"activeCount":100},[],{"trials":7795,"activeCount":100},[7796],{"nctId":693,"briefTitle":694,"status":106,"phases":7797,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":7798,"interventions":7799},[90],[700],[702,703,704,661,705,706,707],{"trials":7801,"activeCount":100},[],{"trials":7803,"activeCount":100},[],{"intervention":703,"totalTrials":126,"cells":7805},{"EARLY_PHASE1":7806,"PHASE1":7808,"PHASE2":7810,"PHASE3":7812,"PHASE4":7818,"NA":7820},{"trials":7807,"activeCount":100},[],{"trials":7809,"activeCount":100},[],{"trials":7811,"activeCount":100},[],{"trials":7813,"activeCount":100},[7814],{"nctId":693,"briefTitle":694,"status":106,"phases":7815,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":7816,"interventions":7817},[90],[700],[702,703,704,661,705,706,707],{"trials":7819,"activeCount":100},[],{"trials":7821,"activeCount":100},[],{"intervention":704,"totalTrials":126,"cells":7823},{"EARLY_PHASE1":7824,"PHASE1":7826,"PHASE2":7828,"PHASE3":7830,"PHASE4":7836,"NA":7838},{"trials":7825,"activeCount":100},[],{"trials":7827,"activeCount":100},[],{"trials":7829,"activeCount":100},[],{"trials":7831,"activeCount":100},[7832],{"nctId":693,"briefTitle":694,"status":106,"phases":7833,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":7834,"interventions":7835},[90],[700],[702,703,704,661,705,706,707],{"trials":7837,"activeCount":100},[],{"trials":7839,"activeCount":100},[],{"intervention":706,"totalTrials":126,"cells":7841},{"EARLY_PHASE1":7842,"PHASE1":7844,"PHASE2":7846,"PHASE3":7848,"PHASE4":7854,"NA":7856},{"trials":7843,"activeCount":100},[],{"trials":7845,"activeCount":100},[],{"trials":7847,"activeCount":100},[],{"trials":7849,"activeCount":100},[7850],{"nctId":693,"briefTitle":694,"status":106,"phases":7851,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":7852,"interventions":7853},[90],[700],[702,703,704,661,705,706,707],{"trials":7855,"activeCount":100},[],{"trials":7857,"activeCount":100},[],{"intervention":707,"totalTrials":126,"cells":7859},{"EARLY_PHASE1":7860,"PHASE1":7862,"PHASE2":7864,"PHASE3":7866,"PHASE4":7872,"NA":7874},{"trials":7861,"activeCount":100},[],{"trials":7863,"activeCount":100},[],{"trials":7865,"activeCount":100},[],{"trials":7867,"activeCount":100},[7868],{"nctId":693,"briefTitle":694,"status":106,"phases":7869,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":7870,"interventions":7871},[90],[700],[702,703,704,661,705,706,707],{"trials":7873,"activeCount":100},[],{"trials":7875,"activeCount":100},[],{"intervention":7877,"totalTrials":126,"cells":7878},"Furosemide Injection Solution",{"EARLY_PHASE1":7879,"PHASE1":7881,"PHASE2":7883,"PHASE3":7885,"PHASE4":7896,"NA":7898},{"trials":7880,"activeCount":100},[],{"trials":7882,"activeCount":100},[],{"trials":7884,"activeCount":100},[],{"trials":7886,"activeCount":100},[7887],{"nctId":7888,"briefTitle":7889,"status":106,"phases":7890,"primaryCompletion":6608,"completion":290,"start":7891,"enrollment":16,"conditions":7892,"interventions":7894},"NCT02579057","Sub-Q Versus IV Furosemide in Acute Heart Failure",[89,90],"2016-02",[7893],"Congestive Heart Failure",[7877,7895],"Furosemide Injection Solution, USP",{"trials":7897,"activeCount":100},[],{"trials":7899,"activeCount":100},[],{"intervention":7895,"totalTrials":126,"cells":7901},{"EARLY_PHASE1":7902,"PHASE1":7904,"PHASE2":7906,"PHASE3":7908,"PHASE4":7914,"NA":7916},{"trials":7903,"activeCount":100},[],{"trials":7905,"activeCount":100},[],{"trials":7907,"activeCount":100},[],{"trials":7909,"activeCount":100},[7910],{"nctId":7888,"briefTitle":7889,"status":106,"phases":7911,"primaryCompletion":6608,"completion":290,"start":7891,"enrollment":16,"conditions":7912,"interventions":7913},[89,90],[7893],[7877,7895],{"trials":7915,"activeCount":100},[],{"trials":7917,"activeCount":100},[],{"intervention":7919,"totalTrials":126,"cells":7920},"PCA fentanyl",{"EARLY_PHASE1":7921,"PHASE1":7923,"PHASE2":7925,"PHASE3":7927,"PHASE4":7938,"NA":7940},{"trials":7922,"activeCount":100},[],{"trials":7924,"activeCount":100},[],{"trials":7926,"activeCount":100},[],{"trials":7928,"activeCount":100},[7929],{"nctId":7930,"briefTitle":7931,"status":106,"phases":7932,"primaryCompletion":7132,"completion":7132,"start":3358,"enrollment":7933,"conditions":7934,"interventions":7936},"NCT00286221","IVPCA in the Management of Pain Following Major Intracranial Surgery",[89,90],159,[7935],"Intracranial Surgery",[7919,7937],"PRN fentanyl",{"trials":7939,"activeCount":100},[],{"trials":7941,"activeCount":100},[],{"intervention":7937,"totalTrials":126,"cells":7943},{"EARLY_PHASE1":7944,"PHASE1":7946,"PHASE2":7948,"PHASE3":7950,"PHASE4":7956,"NA":7958},{"trials":7945,"activeCount":100},[],{"trials":7947,"activeCount":100},[],{"trials":7949,"activeCount":100},[],{"trials":7951,"activeCount":100},[7952],{"nctId":7930,"briefTitle":7931,"status":106,"phases":7953,"primaryCompletion":7132,"completion":7132,"start":3358,"enrollment":7933,"conditions":7954,"interventions":7955},[89,90],[7935],[7919,7937],{"trials":7957,"activeCount":100},[],{"trials":7959,"activeCount":100},[],{"intervention":7961,"totalTrials":126,"cells":7962},"Zenapax",{"EARLY_PHASE1":7963,"PHASE1":7965,"PHASE2":7967,"PHASE3":7969,"PHASE4":7980,"NA":7982},{"trials":7964,"activeCount":100},[],{"trials":7966,"activeCount":100},[],{"trials":7968,"activeCount":100},[],{"trials":7970,"activeCount":100},[7971],{"nctId":7972,"briefTitle":7973,"status":106,"phases":7974,"primaryCompletion":7975,"completion":7975,"start":7976,"enrollment":715,"conditions":7977,"interventions":7979},"NCT00181142","The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation",[89,90],"2004-12","1999-10",[7978],"Patients Active and Listed for Lung Transplantation",[7961],{"trials":7981,"activeCount":100},[],{"trials":7983,"activeCount":100},[],{"intervention":142,"totalTrials":126,"cells":7985},{"EARLY_PHASE1":7986,"PHASE1":7988,"PHASE2":7990,"PHASE3":7992,"PHASE4":7998,"NA":8000},{"trials":7987,"activeCount":100},[],{"trials":7989,"activeCount":100},[],{"trials":7991,"activeCount":100},[],{"trials":7993,"activeCount":100},[7994],{"nctId":132,"briefTitle":133,"status":106,"phases":7995,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":7996,"interventions":7997},[90],[139],[141,142,95,143],{"trials":7999,"activeCount":100},[],{"trials":8001,"activeCount":100},[],{"intervention":4916,"totalTrials":126,"cells":8003},{"EARLY_PHASE1":8004,"PHASE1":8006,"PHASE2":8008,"PHASE3":8010,"PHASE4":8016,"NA":8018},{"trials":8005,"activeCount":100},[],{"trials":8007,"activeCount":100},[],{"trials":8009,"activeCount":100},[],{"trials":8011,"activeCount":100},[8012],{"nctId":4908,"briefTitle":4909,"status":149,"phases":8013,"primaryCompletion":1041,"completion":4911,"start":4912,"enrollment":100,"conditions":8014,"interventions":8015},[90],[4914,3259],[4916,4862],{"trials":8017,"activeCount":100},[],{"trials":8019,"activeCount":100},[],{"intervention":8021,"totalTrials":126,"cells":8022},"Low dose fentanyl PCA",{"EARLY_PHASE1":8023,"PHASE1":8025,"PHASE2":8027,"PHASE3":8029,"PHASE4":8041,"NA":8043},{"trials":8024,"activeCount":100},[],{"trials":8026,"activeCount":100},[],{"trials":8028,"activeCount":100},[],{"trials":8030,"activeCount":100},[8031],{"nctId":8032,"briefTitle":8033,"status":873,"phases":8034,"primaryCompletion":8035,"completion":8035,"start":8036,"enrollment":126,"conditions":8037,"interventions":8039},"NCT01851720","Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage",[89,90],"2014-09-15","2012-07",[8038],"Headaches Associated With Subarachnoid Hemorrhage (SAH)",[8021,8040],"Standard IV fentanyl bolus",{"trials":8042,"activeCount":100},[],{"trials":8044,"activeCount":100},[],{"intervention":8040,"totalTrials":126,"cells":8046},{"EARLY_PHASE1":8047,"PHASE1":8049,"PHASE2":8051,"PHASE3":8053,"PHASE4":8059,"NA":8061},{"trials":8048,"activeCount":100},[],{"trials":8050,"activeCount":100},[],{"trials":8052,"activeCount":100},[],{"trials":8054,"activeCount":100},[8055],{"nctId":8032,"briefTitle":8033,"status":873,"phases":8056,"primaryCompletion":8035,"completion":8035,"start":8036,"enrollment":126,"conditions":8057,"interventions":8058},[89,90],[8038],[8021,8040],{"trials":8060,"activeCount":100},[],{"trials":8062,"activeCount":100},[],{"intervention":8064,"totalTrials":126,"cells":8065},"ketorolac and lidocaine",{"EARLY_PHASE1":8066,"PHASE1":8068,"PHASE2":8070,"PHASE3":8072,"PHASE4":8084,"NA":8086},{"trials":8067,"activeCount":100},[],{"trials":8069,"activeCount":100},[],{"trials":8071,"activeCount":100},[],{"trials":8073,"activeCount":100},[8074],{"nctId":8075,"briefTitle":8076,"status":106,"phases":8077,"primaryCompletion":8078,"completion":8079,"start":6210,"enrollment":311,"conditions":8080,"interventions":8082},"NCT00617097","Paracervical Block in First Trimester Surgical Abortions",[89,90],"2009-05","2009-06",[3259,8081],"Surgical Abortion",[8083,8064],"lidocaine",{"trials":8085,"activeCount":100},[],{"trials":8087,"activeCount":100},[],{"intervention":8089,"totalTrials":126,"cells":8090},"Fasudil",{"EARLY_PHASE1":8091,"PHASE1":8093,"PHASE2":8095,"PHASE3":8097,"PHASE4":8106,"NA":8108},{"trials":8092,"activeCount":100},[],{"trials":8094,"activeCount":100},[],{"trials":8096,"activeCount":100},[],{"trials":8098,"activeCount":100},[8099],{"nctId":8100,"briefTitle":8101,"status":106,"phases":8102,"primaryCompletion":5585,"completion":5585,"start":1762,"enrollment":2175,"conditions":8103,"interventions":8105},"NCT00498615","A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon",[90],[8104,3333],"Raynaud",[8089],{"trials":8107,"activeCount":100},[],{"trials":8109,"activeCount":100},[],{"intervention":8111,"totalTrials":126,"cells":8112},"Onabotulinumtoxin A",{"EARLY_PHASE1":8113,"PHASE1":8115,"PHASE2":8117,"PHASE3":8119,"PHASE4":8129,"NA":8131},{"trials":8114,"activeCount":100},[],{"trials":8116,"activeCount":100},[],{"trials":8118,"activeCount":100},[],{"trials":8120,"activeCount":100},[8121],{"nctId":8122,"briefTitle":8123,"status":106,"phases":8124,"primaryCompletion":5584,"completion":5584,"start":328,"enrollment":16,"conditions":8125,"interventions":8127},"NCT02165111","Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome",[90],[3333,8126],"Raynaud's Syndrome",[8111,8128],"sterile saline solution",{"trials":8130,"activeCount":100},[],{"trials":8132,"activeCount":100},[],{"intervention":8128,"totalTrials":126,"cells":8134},{"EARLY_PHASE1":8135,"PHASE1":8137,"PHASE2":8139,"PHASE3":8141,"PHASE4":8147,"NA":8149},{"trials":8136,"activeCount":100},[],{"trials":8138,"activeCount":100},[],{"trials":8140,"activeCount":100},[],{"trials":8142,"activeCount":100},[8143],{"nctId":8122,"briefTitle":8123,"status":106,"phases":8144,"primaryCompletion":5584,"completion":5584,"start":328,"enrollment":16,"conditions":8145,"interventions":8146},[90],[3333,8126],[8111,8128],{"trials":8148,"activeCount":100},[],{"trials":8150,"activeCount":100},[],{"intervention":8152,"totalTrials":96,"cells":8153},"Ranibizumab",{"EARLY_PHASE1":8154,"PHASE1":8156,"PHASE2":8181,"PHASE3":8200,"PHASE4":8202,"NA":8204},{"trials":8155,"activeCount":100},[],{"trials":8157,"activeCount":100},[8158,8165,8172],{"nctId":8159,"briefTitle":8160,"status":106,"phases":8161,"primaryCompletion":930,"completion":2338,"start":5790,"enrollment":264,"conditions":8162,"interventions":8164},"NCT00378196","Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial",[88],[8163],"Telangiectasia",[8152,8152],{"nctId":8166,"briefTitle":8167,"status":106,"phases":8168,"primaryCompletion":3342,"completion":8078,"start":8169,"enrollment":1744,"conditions":8170,"interventions":8171},"NCT00363168","Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial",[88],"2006-08",[7402],[8152,8152],{"nctId":8173,"briefTitle":8174,"status":149,"phases":8175,"primaryCompletion":8176,"completion":814,"start":8177,"enrollment":100,"conditions":8178,"interventions":8179},"NCT00676559","Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study",[88],"2009-04","2008-04",[5430],[8180,8152],"Efalizumab",{"trials":8182,"activeCount":100},[8183,8193],{"nctId":8184,"briefTitle":8185,"status":106,"phases":8186,"primaryCompletion":5585,"completion":8187,"start":8188,"enrollment":8189,"conditions":8190,"interventions":8191},"NCT01077401","Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study",[89],"2013-03","2010-02",152,[5430],[8152,8192],"ranibizumab",{"nctId":8194,"briefTitle":8195,"status":106,"phases":8196,"primaryCompletion":7605,"completion":2104,"start":4843,"enrollment":8197,"conditions":8198,"interventions":8199},"NCT00407381","The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study",[89],126,[5430],[8152],{"trials":8201,"activeCount":100},[],{"trials":8203,"activeCount":100},[],{"trials":8205,"activeCount":100},[],{"intervention":8207,"totalTrials":235,"cells":8208},"Within-Subject test of blinded study medication",{"EARLY_PHASE1":8209,"PHASE1":8211,"PHASE2":8213,"PHASE3":8245,"PHASE4":8247,"NA":8249},{"trials":8210,"activeCount":100},[],{"trials":8212,"activeCount":100},[],{"trials":8214,"activeCount":100},[8215,8225,8234],{"nctId":8216,"briefTitle":8217,"status":106,"phases":8218,"primaryCompletion":8219,"completion":8219,"start":8220,"enrollment":8221,"conditions":8222,"interventions":8224},"NCT03680287","Effects of Sleep Disruption on Drug Response",[89],"2025-04-29","2019-10-07",109,[8223,112],"Low Back Pain, Recurrent",[8207],{"nctId":8226,"briefTitle":8227,"status":106,"phases":8228,"primaryCompletion":6738,"completion":6738,"start":8229,"enrollment":8230,"conditions":8231,"interventions":8233},"NCT04299490","Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug",[89],"2020-11-11",148,[8232,112],"Sleep Disorder",[8207],{"nctId":8235,"briefTitle":8236,"status":106,"phases":8237,"primaryCompletion":7536,"completion":8238,"start":4978,"enrollment":184,"conditions":8239,"interventions":8243},"NCT02360371","A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans",[89],"2021-05",[8240,8241,8242],"Opioid Sensitivity","Individual Difference","Abuse Opioids",[8244],"Within-subject test of blinded study medication",{"trials":8246,"activeCount":100},[],{"trials":8248,"activeCount":100},[],{"trials":8250,"activeCount":100},[],{"intervention":188,"totalTrials":235,"cells":8252},{"EARLY_PHASE1":8253,"PHASE1":8255,"PHASE2":8257,"PHASE3":8280,"PHASE4":8282,"NA":8284},{"trials":8254,"activeCount":100},[],{"trials":8256,"activeCount":100},[],{"trials":8258,"activeCount":100},[8259,8263,8272],{"nctId":179,"briefTitle":180,"status":106,"phases":8260,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":8261,"interventions":8262},[89],[186],[188,143],{"nctId":8264,"briefTitle":8265,"status":106,"phases":8266,"primaryCompletion":8267,"completion":8267,"start":8268,"enrollment":2151,"conditions":8269,"interventions":8271},"NCT03500302","Effect of Evolocumab on Coronary Endothelial Function",[89],"2019-11-30","2018-05-04",[8270,3302],"Human Immunodeficiency Virus",[188],{"nctId":8273,"briefTitle":8274,"status":106,"phases":8275,"primaryCompletion":182,"completion":8276,"start":8277,"enrollment":715,"conditions":8278,"interventions":8279},"NCT03515304","Evolocumab in Acute Coronary Syndrome",[89],"2025-03-25","2018-05-20",[186],[188],{"trials":8281,"activeCount":100},[],{"trials":8283,"activeCount":100},[],{"trials":8285,"activeCount":100},[],{"intervention":8287,"totalTrials":235,"cells":8288},"Control",{"EARLY_PHASE1":8289,"PHASE1":8291,"PHASE2":8303,"PHASE3":8321,"PHASE4":8323,"NA":8325},{"trials":8290,"activeCount":100},[],{"trials":8292,"activeCount":100},[8293],{"nctId":8294,"briefTitle":8295,"status":873,"phases":8296,"primaryCompletion":8297,"completion":8298,"start":8299,"enrollment":235,"conditions":8300,"interventions":8301},"NCT03069911","Trial of OnabotulinumtoxinA for Depression in Parkinson Disease",[88],"2019-05-30","2019-06-01","2018-11-01",[6323,27],[8302,8287],"OnabotulinumtoxinA",{"trials":8304,"activeCount":100},[8305,8314],{"nctId":8306,"briefTitle":8307,"status":873,"phases":8308,"primaryCompletion":8309,"completion":8309,"start":4807,"enrollment":126,"conditions":8310,"interventions":8312},"NCT00358423","The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema",[88,89],"2007-02",[8311],"Cystoid Macular Edema",[8313,8287],"Pegaptanib Sodium",{"nctId":8315,"briefTitle":8316,"status":873,"phases":8317,"primaryCompletion":1762,"completion":4887,"start":2225,"enrollment":614,"conditions":8318,"interventions":8319},"NCT00346983","Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics",[88,89],[8311],[8320,8287],"Pegaptanib sodium",{"trials":8322,"activeCount":100},[],{"trials":8324,"activeCount":100},[],{"trials":8326,"activeCount":100},[],{"intervention":8328,"totalTrials":280,"cells":8329},"Dronabinol 120mg\u002Fday",{"EARLY_PHASE1":8330,"PHASE1":8332,"PHASE2":8334,"PHASE3":8355,"PHASE4":8357,"NA":8359},{"trials":8331,"activeCount":100},[],{"trials":8333,"activeCount":100},[],{"trials":8335,"activeCount":100},[8336,8345],{"nctId":8337,"briefTitle":8338,"status":106,"phases":8339,"primaryCompletion":5096,"completion":5096,"start":8340,"enrollment":110,"conditions":8341,"interventions":8343},"NCT01394185","Effects of Dronabinol (Oral THC) on Cannabis Use",[88,89],"2011-02",[8342],"Marijuana Smoking",[8328,8344],"Dronabinol 240mg\u002Fday",{"nctId":8346,"briefTitle":8347,"status":106,"phases":8348,"primaryCompletion":8349,"completion":8349,"start":8176,"enrollment":30,"conditions":8350,"interventions":8352},"NCT00893074","The Effect of Prescription Medications in Marijuana Users",[88,89],"2011-10",[8351],"Marijuana Abuse",[8353,8354,8328],"Dronabinol 30mg\u002Fday","Dronabinol 60mg\u002Fday",{"trials":8356,"activeCount":100},[],{"trials":8358,"activeCount":100},[],{"trials":8360,"activeCount":100},[],{"intervention":8362,"totalTrials":280,"cells":8363},"Zonisamide",{"EARLY_PHASE1":8364,"PHASE1":8366,"PHASE2":8368,"PHASE3":8385,"PHASE4":8387,"NA":8389},{"trials":8365,"activeCount":100},[],{"trials":8367,"activeCount":100},[],{"trials":8369,"activeCount":100},[8370,8377],{"nctId":8371,"briefTitle":8372,"status":106,"phases":8373,"primaryCompletion":5585,"completion":1929,"start":696,"enrollment":2151,"conditions":8374,"interventions":8375},"NCT01137890","Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse",[88,89],[7541],[8362,8376],"Cocaine Hydrochloride",{"nctId":8378,"briefTitle":8379,"status":106,"phases":8380,"primaryCompletion":1645,"completion":1645,"start":5096,"enrollment":8381,"conditions":8382,"interventions":8383},"NCT01685996","Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation",[88,89],74,[3520],[8384],"zonisamide",{"trials":8386,"activeCount":100},[],{"trials":8388,"activeCount":100},[],{"trials":8390,"activeCount":100},[],{"intervention":8392,"totalTrials":280,"cells":8393},"Propranolol",{"EARLY_PHASE1":8394,"PHASE1":8396,"PHASE2":8398,"PHASE3":8418,"PHASE4":8420,"NA":8422},{"trials":8395,"activeCount":100},[],{"trials":8397,"activeCount":100},[],{"trials":8399,"activeCount":100},[8400,8409],{"nctId":8401,"briefTitle":8402,"status":149,"phases":8403,"primaryCompletion":8404,"completion":8404,"start":3232,"enrollment":100,"conditions":8405,"interventions":8407},"NCT01343329","Controlling Hyperadrenergic Activity in Neurologic Injury",[88,89],"2014-02-14",[4773,8406],"Dysautonomia",[8408,8392],"Esmolol",{"nctId":8410,"briefTitle":8411,"status":106,"phases":8412,"primaryCompletion":8413,"completion":8413,"start":2438,"enrollment":30,"conditions":8414,"interventions":8416},"NCT03049306","Propranolol for Sleep Apnea Therapy",[89],"2024-05-01",[8415],"Obstructive Sleep Apnea",[8417],"Propranolol Oral",{"trials":8419,"activeCount":100},[],{"trials":8421,"activeCount":100},[],{"trials":8423,"activeCount":100},[],{"intervention":8425,"totalTrials":280,"cells":8426},"Clonidine",{"EARLY_PHASE1":8427,"PHASE1":8429,"PHASE2":8431,"PHASE3":8452,"PHASE4":8454,"NA":8456},{"trials":8428,"activeCount":100},[],{"trials":8430,"activeCount":100},[],{"trials":8432,"activeCount":100},[8433,8442],{"nctId":8434,"briefTitle":8435,"status":106,"phases":8436,"primaryCompletion":8437,"completion":8437,"start":8438,"enrollment":1773,"conditions":8439,"interventions":8441},"NCT01862250","Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia",[88,89],"2015-04-14","2013-10-03",[8440],"Encephalopathy, Hypoxic-Ischemic",[8425],{"nctId":8443,"briefTitle":8444,"status":106,"phases":8445,"primaryCompletion":8446,"completion":8446,"start":8447,"enrollment":5241,"conditions":8448,"interventions":8449},"NCT01188421","Medications Development for Drug Abuse Disorders",[88,89],"2015-06","2010-10",[2311,2313,7515],[8450,8425,8451],"Buprenorphine\u002Fnaloxone","Tramadol ER",{"trials":8453,"activeCount":100},[],{"trials":8455,"activeCount":100},[],{"trials":8457,"activeCount":100},[],{"intervention":8459,"totalTrials":280,"cells":8460},"Rituximab",{"EARLY_PHASE1":8461,"PHASE1":8463,"PHASE2":8474,"PHASE3":8484,"PHASE4":8486,"NA":8488},{"trials":8462,"activeCount":100},[],{"trials":8464,"activeCount":100},[8465],{"nctId":8466,"briefTitle":8467,"status":106,"phases":8468,"primaryCompletion":8469,"completion":8469,"start":5694,"enrollment":4344,"conditions":8470,"interventions":8473},"NCT02253264","A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients",[88],"2017-08",[8471,8472],"Primary Progressive Multiple Sclerosis","Secondary Progressive Multiple Sclerosis",[8459],{"trials":8475,"activeCount":100},[8476],{"nctId":8477,"briefTitle":8478,"status":873,"phases":8479,"primaryCompletion":4887,"completion":4887,"start":8480,"enrollment":921,"conditions":8481,"interventions":8483},"NCT00216762","Safety Study of Rituximab (Rituxan®) in Chronic Urticaria",[88,89],"2006-01",[8482],"Urticaria",[8459],{"trials":8485,"activeCount":100},[],{"trials":8487,"activeCount":100},[],{"trials":8489,"activeCount":100},[],{"intervention":8491,"totalTrials":280,"cells":8492},"Colchicine",{"EARLY_PHASE1":8493,"PHASE1":8495,"PHASE2":8497,"PHASE3":8516,"PHASE4":8518,"NA":8520},{"trials":8494,"activeCount":100},[],{"trials":8496,"activeCount":100},[],{"trials":8498,"activeCount":100},[8499,8508],{"nctId":8500,"briefTitle":8501,"status":106,"phases":8502,"primaryCompletion":636,"completion":8503,"start":328,"enrollment":8504,"conditions":8505,"interventions":8506},"NCT02366091","Inflammation and Coronary Endothelial Function",[89],"2020-09-01",111,[3302],[8507,8491],"Methotrexate",{"nctId":8509,"briefTitle":8510,"status":106,"phases":8511,"primaryCompletion":636,"completion":8503,"start":8512,"enrollment":8513,"conditions":8514,"interventions":8515},"NCT02624180","Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV",[89],"2015-11",81,[3302,8270],[8491],{"trials":8517,"activeCount":100},[],{"trials":8519,"activeCount":100},[],{"trials":8521,"activeCount":100},[],{"intervention":8523,"totalTrials":280,"cells":8524},"American ginseng",{"EARLY_PHASE1":8525,"PHASE1":8527,"PHASE2":8537,"PHASE3":8548,"PHASE4":8550,"NA":8552},{"trials":8526,"activeCount":100},[],{"trials":8528,"activeCount":100},[8529],{"nctId":8530,"briefTitle":8531,"status":106,"phases":8532,"primaryCompletion":8533,"completion":8533,"start":8534,"enrollment":921,"conditions":8535,"interventions":8536},"NCT01136928","Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers",[88],"2011-03-14","2010-09-28",[4263],[8523],{"trials":8538,"activeCount":100},[8539],{"nctId":8540,"briefTitle":8541,"status":106,"phases":8542,"primaryCompletion":8543,"completion":8543,"start":2174,"enrollment":8544,"conditions":8545,"interventions":8547},"NCT01500096","American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial",[89],"2016-09",96,[8546],"HIV\u002FAIDS-associated Fatigue",[8523],{"trials":8549,"activeCount":100},[],{"trials":8551,"activeCount":100},[],{"trials":8553,"activeCount":100},[],{"intervention":8555,"totalTrials":280,"cells":8556},"Cholecalciferol",{"EARLY_PHASE1":8557,"PHASE1":8559,"PHASE2":8569,"PHASE3":8579,"PHASE4":8581,"NA":8583},{"trials":8558,"activeCount":100},[],{"trials":8560,"activeCount":100},[8561],{"nctId":8562,"briefTitle":8563,"status":106,"phases":8564,"primaryCompletion":4970,"completion":4970,"start":8565,"enrollment":16,"conditions":8566,"interventions":8568},"NCT01024777","Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis",[88],"2010-03",[313,8567],"Vitamin D Deficiency",[8555,8555],{"trials":8570,"activeCount":100},[8571],{"nctId":8572,"briefTitle":8573,"status":106,"phases":8574,"primaryCompletion":4978,"completion":4978,"start":8575,"enrollment":3394,"conditions":8576,"interventions":8578},"NCT01532349","Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease",[89],"2012-05",[8577],"Anemia of Chronic Kidney Disease",[8555],{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"trials":8584,"activeCount":100},[],{"intervention":8586,"totalTrials":280,"cells":8587},"Acellular Adipose Tissue",{"EARLY_PHASE1":8588,"PHASE1":8590,"PHASE2":8599,"PHASE3":8611,"PHASE4":8613,"NA":8615},{"trials":8589,"activeCount":100},[],{"trials":8591,"activeCount":100},[8592],{"nctId":8593,"briefTitle":8594,"status":106,"phases":8595,"primaryCompletion":8596,"completion":8596,"start":7327,"enrollment":4344,"conditions":8597,"interventions":8598},"NCT02817984","Safety Study of Acellular Adipose Tissue for Soft Tissue Reconstruction",[88],"2017-04-06",[4263],[8586],{"trials":8600,"activeCount":100},[8601],{"nctId":8602,"briefTitle":8603,"status":106,"phases":8604,"primaryCompletion":8605,"completion":8605,"start":8606,"enrollment":921,"conditions":8607,"interventions":8610},"NCT03544632","Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction",[89],"2026-02-28","2018-06-21",[8608,8609],"Soft Tissue Injuries","Trauma",[8586],{"trials":8612,"activeCount":100},[],{"trials":8614,"activeCount":100},[],{"trials":8616,"activeCount":100},[],{"intervention":8618,"totalTrials":280,"cells":8619},"Within-subject test of blinded study medications",{"EARLY_PHASE1":8620,"PHASE1":8622,"PHASE2":8624,"PHASE3":8640,"PHASE4":8642,"NA":8644},{"trials":8621,"activeCount":100},[],{"trials":8623,"activeCount":100},[],{"trials":8625,"activeCount":100},[8626,8634],{"nctId":8627,"briefTitle":8628,"status":106,"phases":8629,"primaryCompletion":8630,"completion":8630,"start":1761,"enrollment":22,"conditions":8631,"interventions":8633},"NCT02901275","Enhancing Medication-based Analgesia in Humans",[89],"2020-03-23",[3259,1844,8632],"Opioid Use, Unspecified",[8618],{"nctId":8635,"briefTitle":8636,"status":106,"phases":8637,"primaryCompletion":3982,"completion":3982,"start":1874,"enrollment":19,"conditions":8638,"interventions":8639},"NCT04036968","Enhancing Medication-based Analgesia in Humans- STUDY 2",[89],[3259,1844,349],[8618],{"trials":8641,"activeCount":100},[],{"trials":8643,"activeCount":100},[],{"trials":8645,"activeCount":100},[],{"intervention":8647,"totalTrials":280,"cells":8648},"Salvinorin A",{"EARLY_PHASE1":8649,"PHASE1":8651,"PHASE2":8660,"PHASE3":8670,"PHASE4":8672,"NA":8674},{"trials":8650,"activeCount":100},[],{"trials":8652,"activeCount":100},[8653],{"nctId":8654,"briefTitle":8655,"status":106,"phases":8656,"primaryCompletion":6714,"start":8657,"enrollment":7105,"conditions":8658,"interventions":8659},"NCT00996411","Human Psychopharmacology of Salvinorin A",[88],"2008-11",[112],[8647],{"trials":8661,"activeCount":100},[8662],{"nctId":8663,"briefTitle":8664,"status":106,"phases":8665,"primaryCompletion":8666,"completion":8666,"start":8667,"enrollment":1773,"conditions":8668,"interventions":8669},"NCT03418714","Effects of Salvinorin A on Brain Function",[88,89],"2020-03-02","2017-12-14",[3438],[8647],{"trials":8671,"activeCount":100},[],{"trials":8673,"activeCount":100},[],{"trials":8675,"activeCount":100},[],{"intervention":8677,"totalTrials":280,"cells":8678},"Ramelteon",{"EARLY_PHASE1":8679,"PHASE1":8681,"PHASE2":8693,"PHASE3":8709,"PHASE4":8711,"NA":8713},{"trials":8680,"activeCount":100},[],{"trials":8682,"activeCount":100},[8683],{"nctId":8684,"briefTitle":8685,"status":106,"phases":8686,"primaryCompletion":8447,"completion":8447,"start":901,"enrollment":2717,"conditions":8687,"interventions":8689},"NCT00893269","The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep",[88],[8688],"Marijuana Dependence",[8690,8691,8692],"eszopiclone","ramelteon","zolpidem",{"trials":8694,"activeCount":100},[8695],{"nctId":8696,"briefTitle":8697,"status":106,"phases":8698,"primaryCompletion":8699,"completion":8699,"start":8700,"enrollment":1938,"conditions":8701,"interventions":8706},"NCT02324153","Ramelteon in the Prevention of Post-operative Delirium",[89],"2019-06-26","2017-03-24",[8702,8703,8704,8705],"Delirium","Delirium, Dementia, Amnestic, Cognitive Disorders","Delayed Emergence From Anesthesia","Cognitive Disorders",[8677,8707,8708],"Microcrystalline Cellulose","Riboflavin 100 mg",{"trials":8710,"activeCount":100},[],{"trials":8712,"activeCount":100},[],{"trials":8714,"activeCount":100},[],{"intervention":8716,"totalTrials":280,"cells":8717},"abatacept",{"EARLY_PHASE1":8718,"PHASE1":8730,"PHASE2":8732,"PHASE3":8740,"PHASE4":8742,"NA":8744},{"trials":8719,"activeCount":100},[8720],{"nctId":8721,"briefTitle":8722,"status":873,"phases":8723,"primaryCompletion":8724,"completion":8724,"start":8725,"enrollment":293,"conditions":8726,"interventions":8728},"NCT03059888","Trial of Orencia in Patients With Myasthenia Gravis",[87],"2019-07-15","2017-04-12",[8727],"Myasthenia Gravis",[8729],"Abatacept",{"trials":8731,"activeCount":100},[],{"trials":8733,"activeCount":100},[8734],{"nctId":8735,"briefTitle":8736,"status":106,"phases":8737,"primaryCompletion":8187,"completion":8187,"start":8078,"enrollment":614,"conditions":8738,"interventions":8739},"NCT00886795","Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy",[88,89],[8482],[8716],{"trials":8741,"activeCount":100},[],{"trials":8743,"activeCount":100},[],{"trials":8745,"activeCount":100},[],{"intervention":8747,"totalTrials":280,"cells":8748},"Eculizumab",{"EARLY_PHASE1":8749,"PHASE1":8751,"PHASE2":8766,"PHASE3":8776,"PHASE4":8778,"NA":8780},{"trials":8750,"activeCount":100},[],{"trials":8752,"activeCount":100},[8753],{"nctId":8754,"briefTitle":8755,"status":106,"phases":8756,"primaryCompletion":1914,"completion":8757,"start":8758,"enrollment":235,"conditions":8759,"interventions":8765},"NCT04103489","The Use of Eculizumab in HELLP Syndrome",[88],"2023-09-04","2021-02-23",[8760,8761,8762,8763,8764],"HELLP Syndrome (HELLP), Third Trimester","Complement Abnormality","Morbidity;Newborn","Maternal Injury","Preeclampsia Severe",[8747],{"trials":8767,"activeCount":100},[8768],{"nctId":8769,"briefTitle":8770,"status":106,"phases":8771,"primaryCompletion":8772,"completion":8772,"start":5183,"enrollment":126,"conditions":8773,"interventions":8775},"NCT01029587","Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome",[89],"2010-05-06",[8774,6370],"Antiphospholipid Antibody Syndrome",[8747],{"trials":8777,"activeCount":100},[],{"trials":8779,"activeCount":100},[],{"trials":8781,"activeCount":100},[],{"intervention":8313,"totalTrials":280,"cells":8783},{"EARLY_PHASE1":8784,"PHASE1":8786,"PHASE2":8788,"PHASE3":8798,"PHASE4":8800,"NA":8802},{"trials":8785,"activeCount":100},[],{"trials":8787,"activeCount":100},[],{"trials":8789,"activeCount":100},[8790,8794],{"nctId":8306,"briefTitle":8307,"status":873,"phases":8791,"primaryCompletion":8309,"completion":8309,"start":4807,"enrollment":126,"conditions":8792,"interventions":8793},[88,89],[8311],[8313,8287],{"nctId":8315,"briefTitle":8316,"status":873,"phases":8795,"primaryCompletion":1762,"completion":4887,"start":2225,"enrollment":614,"conditions":8796,"interventions":8797},[88,89],[8311],[8320,8287],{"trials":8799,"activeCount":100},[],{"trials":8801,"activeCount":100},[],{"trials":8803,"activeCount":100},[],{"intervention":8805,"totalTrials":280,"cells":8806},"d-cycloserine",{"EARLY_PHASE1":8807,"PHASE1":8818,"PHASE2":8820,"PHASE3":8830,"PHASE4":8832,"NA":8834},{"trials":8808,"activeCount":100},[8809],{"nctId":8810,"briefTitle":8811,"status":149,"phases":8812,"primaryCompletion":8813,"completion":8814,"start":8815,"enrollment":100,"conditions":8816,"interventions":8817},"NCT04357951","D-cycloserine Augmented Treatment for Youth With Tic Disorders",[87],"2024-03","2024-09","2023-04-15",[5185],[8805],{"trials":8819,"activeCount":100},[],{"trials":8821,"activeCount":100},[8822],{"nctId":8823,"briefTitle":8824,"status":106,"phases":8825,"primaryCompletion":8187,"completion":8187,"start":7187,"enrollment":2808,"conditions":8826,"interventions":8828},"NCT01526538","Improving Learning-based Treatment of Cocaine Dependence With Medication",[89],[8827],"COCAINE-RELATED DISORDERS",[8805,8829],"sugar pill",{"trials":8831,"activeCount":100},[],{"trials":8833,"activeCount":100},[],{"trials":8835,"activeCount":100},[],{"intervention":8837,"totalTrials":126,"cells":8838},"Nortriptyline Oral",{"EARLY_PHASE1":8839,"PHASE1":8841,"PHASE2":8843,"PHASE3":8855,"PHASE4":8857,"NA":8859},{"trials":8840,"activeCount":100},[],{"trials":8842,"activeCount":100},[],{"trials":8844,"activeCount":100},[8845],{"nctId":8846,"briefTitle":8847,"status":106,"phases":8848,"primaryCompletion":3342,"completion":5011,"start":8849,"enrollment":8850,"conditions":8851,"interventions":8853},"NCT00066937","Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)",[89],"2002-11",140,[8852],"Temporomandibular Joint Disorders",[8837,8854],"Benztropine Oral Product",{"trials":8856,"activeCount":100},[],{"trials":8858,"activeCount":100},[],{"trials":8860,"activeCount":100},[],{"intervention":8854,"totalTrials":126,"cells":8862},{"EARLY_PHASE1":8863,"PHASE1":8865,"PHASE2":8867,"PHASE3":8873,"PHASE4":8875,"NA":8877},{"trials":8864,"activeCount":100},[],{"trials":8866,"activeCount":100},[],{"trials":8868,"activeCount":100},[8869],{"nctId":8846,"briefTitle":8847,"status":106,"phases":8870,"primaryCompletion":3342,"completion":5011,"start":8849,"enrollment":8850,"conditions":8871,"interventions":8872},[89],[8852],[8837,8854],{"trials":8874,"activeCount":100},[],{"trials":8876,"activeCount":100},[],{"trials":8878,"activeCount":100},[],{"intervention":8344,"totalTrials":126,"cells":8880},{"EARLY_PHASE1":8881,"PHASE1":8883,"PHASE2":8885,"PHASE3":8891,"PHASE4":8893,"NA":8895},{"trials":8882,"activeCount":100},[],{"trials":8884,"activeCount":100},[],{"trials":8886,"activeCount":100},[8887],{"nctId":8337,"briefTitle":8338,"status":106,"phases":8888,"primaryCompletion":5096,"completion":5096,"start":8340,"enrollment":110,"conditions":8889,"interventions":8890},[88,89],[8342],[8328,8344],{"trials":8892,"activeCount":100},[],{"trials":8894,"activeCount":100},[],{"trials":8896,"activeCount":100},[],{"intervention":8898,"totalTrials":126,"cells":8899},"Fluconazole",{"EARLY_PHASE1":8900,"PHASE1":8902,"PHASE2":8904,"PHASE3":8916,"PHASE4":8918,"NA":8920},{"trials":8901,"activeCount":100},[],{"trials":8903,"activeCount":100},[],{"trials":8905,"activeCount":100},[8906],{"nctId":8907,"briefTitle":8908,"status":106,"phases":8909,"primaryCompletion":3299,"completion":3299,"start":8910,"enrollment":2247,"conditions":8911,"interventions":8913},"NCT01354314","Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder",[88,89],"2010-11",[8912],"HIV Associated Neurocognitive Disorder",[8898,8914,8915],"Paroxetine","Paroxetine and Fluconazole",{"trials":8917,"activeCount":100},[],{"trials":8919,"activeCount":100},[],{"trials":8921,"activeCount":100},[],{"intervention":8914,"totalTrials":126,"cells":8923},{"EARLY_PHASE1":8924,"PHASE1":8926,"PHASE2":8928,"PHASE3":8934,"PHASE4":8936,"NA":8938},{"trials":8925,"activeCount":100},[],{"trials":8927,"activeCount":100},[],{"trials":8929,"activeCount":100},[8930],{"nctId":8907,"briefTitle":8908,"status":106,"phases":8931,"primaryCompletion":3299,"completion":3299,"start":8910,"enrollment":2247,"conditions":8932,"interventions":8933},[88,89],[8912],[8898,8914,8915],{"trials":8935,"activeCount":100},[],{"trials":8937,"activeCount":100},[],{"trials":8939,"activeCount":100},[],{"intervention":8915,"totalTrials":126,"cells":8941},{"EARLY_PHASE1":8942,"PHASE1":8944,"PHASE2":8946,"PHASE3":8952,"PHASE4":8954,"NA":8956},{"trials":8943,"activeCount":100},[],{"trials":8945,"activeCount":100},[],{"trials":8947,"activeCount":100},[8948],{"nctId":8907,"briefTitle":8908,"status":106,"phases":8949,"primaryCompletion":3299,"completion":3299,"start":8910,"enrollment":2247,"conditions":8950,"interventions":8951},[88,89],[8912],[8898,8914,8915],{"trials":8953,"activeCount":100},[],{"trials":8955,"activeCount":100},[],{"trials":8957,"activeCount":100},[],{"intervention":8376,"totalTrials":126,"cells":8959},{"EARLY_PHASE1":8960,"PHASE1":8962,"PHASE2":8964,"PHASE3":8970,"PHASE4":8972,"NA":8974},{"trials":8961,"activeCount":100},[],{"trials":8963,"activeCount":100},[],{"trials":8965,"activeCount":100},[8966],{"nctId":8371,"briefTitle":8372,"status":106,"phases":8967,"primaryCompletion":5585,"completion":1929,"start":696,"enrollment":2151,"conditions":8968,"interventions":8969},[88,89],[7541],[8362,8376],{"trials":8971,"activeCount":100},[],{"trials":8973,"activeCount":100},[],{"trials":8975,"activeCount":100},[],{"intervention":8408,"totalTrials":126,"cells":8977},{"EARLY_PHASE1":8978,"PHASE1":8980,"PHASE2":8982,"PHASE3":8988,"PHASE4":8990,"NA":8992},{"trials":8979,"activeCount":100},[],{"trials":8981,"activeCount":100},[],{"trials":8983,"activeCount":100},[8984],{"nctId":8401,"briefTitle":8402,"status":149,"phases":8985,"primaryCompletion":8404,"completion":8404,"start":3232,"enrollment":100,"conditions":8986,"interventions":8987},[88,89],[4773,8406],[8408,8392],{"trials":8989,"activeCount":100},[],{"trials":8991,"activeCount":100},[],{"trials":8993,"activeCount":100},[],{"intervention":8995,"totalTrials":126,"cells":8996},"Melatonin",{"EARLY_PHASE1":8997,"PHASE1":8999,"PHASE2":9001,"PHASE3":9010,"PHASE4":9012,"NA":9014},{"trials":8998,"activeCount":100},[],{"trials":9000,"activeCount":100},[],{"trials":9002,"activeCount":100},[9003],{"nctId":9004,"briefTitle":9005,"status":149,"phases":9006,"primaryCompletion":9007,"completion":9007,"start":813,"enrollment":100,"conditions":9008,"interventions":9009},"NCT02099331","Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin",[89],"2015-07-06",[1497],[8995],{"trials":9011,"activeCount":100},[],{"trials":9013,"activeCount":100},[],{"trials":9015,"activeCount":100},[],{"intervention":9017,"totalTrials":126,"cells":9018},"Roflumilast 500 Mcg Oral",{"EARLY_PHASE1":9019,"PHASE1":9021,"PHASE2":9023,"PHASE3":9033,"PHASE4":9035,"NA":9037},{"trials":9020,"activeCount":100},[],{"trials":9022,"activeCount":100},[],{"trials":9024,"activeCount":100},[9025],{"nctId":9026,"briefTitle":9027,"status":106,"phases":9028,"primaryCompletion":9029,"completion":9029,"start":9030,"enrollment":2287,"conditions":9031,"interventions":9032},"NCT03532490","Trial of Roflumilast in Asthma Management (TRIM)",[89],"2021-07-30","2018-08-03",[21,18],[9017],{"trials":9034,"activeCount":100},[],{"trials":9036,"activeCount":100},[],{"trials":9038,"activeCount":100},[],{"intervention":9040,"totalTrials":126,"cells":9041},"minocycline",{"EARLY_PHASE1":9042,"PHASE1":9044,"PHASE2":9046,"PHASE3":9056,"PHASE4":9058,"NA":9060},{"trials":9043,"activeCount":100},[],{"trials":9045,"activeCount":100},[],{"trials":9047,"activeCount":100},[9048],{"nctId":9049,"briefTitle":9050,"status":873,"phases":9051,"primaryCompletion":5097,"completion":5097,"start":8177,"enrollment":3312,"conditions":9052,"interventions":9054},"NCT00855062","Minocycline for HIV+ Cognitive Impairment in Uganda",[88,89],[9053,29],"HIV-associated Cognitive Impairment",[9040,9055],"minocycline placebo",{"trials":9057,"activeCount":100},[],{"trials":9059,"activeCount":100},[],{"trials":9061,"activeCount":100},[],{"intervention":9055,"totalTrials":126,"cells":9063},{"EARLY_PHASE1":9064,"PHASE1":9066,"PHASE2":9068,"PHASE3":9074,"PHASE4":9076,"NA":9078},{"trials":9065,"activeCount":100},[],{"trials":9067,"activeCount":100},[],{"trials":9069,"activeCount":100},[9070],{"nctId":9049,"briefTitle":9050,"status":873,"phases":9071,"primaryCompletion":5097,"completion":5097,"start":8177,"enrollment":3312,"conditions":9072,"interventions":9073},[88,89],[9053,29],[9040,9055],{"trials":9075,"activeCount":100},[],{"trials":9077,"activeCount":100},[],{"trials":9079,"activeCount":100},[],{"intervention":9081,"totalTrials":126,"cells":9082},"Velcade",{"EARLY_PHASE1":9083,"PHASE1":9085,"PHASE2":9087,"PHASE3":9096,"PHASE4":9098,"NA":9100},{"trials":9084,"activeCount":100},[],{"trials":9086,"activeCount":100},[],{"trials":9088,"activeCount":100},[9089],{"nctId":9090,"briefTitle":9091,"status":149,"phases":9092,"enrollment":100,"conditions":9093,"interventions":9095},"NCT00367718","Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma",[89],[9094],"Nasopharyngeal Carcinoma",[9081],{"trials":9097,"activeCount":100},[],{"trials":9099,"activeCount":100},[],{"trials":9101,"activeCount":100},[],{"intervention":9103,"totalTrials":126,"cells":9104},"GHRH",{"EARLY_PHASE1":9105,"PHASE1":9107,"PHASE2":9109,"PHASE3":9120,"PHASE4":9122,"NA":9124},{"trials":9106,"activeCount":100},[],{"trials":9108,"activeCount":100},[],{"trials":9110,"activeCount":100},[9111],{"nctId":9112,"briefTitle":9113,"status":873,"phases":9114,"primaryCompletion":9115,"completion":9115,"start":9116,"enrollment":96,"conditions":9117,"interventions":9119},"NCT00807365","Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly",[89],"2010-04-29","2007-12-17",[9118],"Elderly",[9103],{"trials":9121,"activeCount":100},[],{"trials":9123,"activeCount":100},[],{"trials":9125,"activeCount":100},[],{"intervention":9127,"totalTrials":126,"cells":9128},"Lorcaserin",{"EARLY_PHASE1":9129,"PHASE1":9131,"PHASE2":9133,"PHASE3":9144,"PHASE4":9146,"NA":9148},{"trials":9130,"activeCount":100},[],{"trials":9132,"activeCount":100},[],{"trials":9134,"activeCount":100},[9135],{"nctId":9136,"briefTitle":9137,"status":873,"phases":9138,"primaryCompletion":9139,"completion":9139,"start":7210,"enrollment":96,"conditions":9140,"interventions":9143},"NCT02523690","Evaluating Muscle Weakness Improvement With Lorcaserin in ICU",[88,89],"2017-12",[9141,9142],"Muscle Weakness","Sepsis",[9127],{"trials":9145,"activeCount":100},[],{"trials":9147,"activeCount":100},[],{"trials":9149,"activeCount":100},[],{"intervention":9151,"totalTrials":126,"cells":9152},"Buprenorphine Naloxone",{"EARLY_PHASE1":9153,"PHASE1":9155,"PHASE2":9157,"PHASE3":9169,"PHASE4":9171,"NA":9173},{"trials":9154,"activeCount":100},[],{"trials":9156,"activeCount":100},[],{"trials":9158,"activeCount":100},[9159],{"nctId":9160,"briefTitle":9161,"status":106,"phases":9162,"primaryCompletion":9163,"completion":9164,"start":2716,"enrollment":7328,"conditions":9165,"interventions":9168},"NCT03291847","Maternal Buprenorphine-naloxone Treatment and the Infant",[89],"2022-12-27","2023-12-15",[9166,9167],"Maternal Opioid Use Disorder","Opioid Exposed Infant",[9151],{"trials":9170,"activeCount":100},[],{"trials":9172,"activeCount":100},[],{"trials":9174,"activeCount":100},[],{"intervention":9176,"totalTrials":126,"cells":9177},"Peanut Dissolving Film",{"EARLY_PHASE1":9178,"PHASE1":9180,"PHASE2":9182,"PHASE3":9191,"PHASE4":9193,"NA":9195},{"trials":9179,"activeCount":100},[],{"trials":9181,"activeCount":100},[],{"trials":9183,"activeCount":100},[9184],{"nctId":9185,"briefTitle":9186,"status":873,"phases":9187,"primaryCompletion":9188,"completion":9188,"start":3340,"enrollment":96,"conditions":9189,"interventions":9190},"NCT01897077","The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy",[88,89],"2013-02-03",[2109],[9176],{"trials":9192,"activeCount":100},[],{"trials":9194,"activeCount":100},[],{"trials":9196,"activeCount":100},[],{"intervention":9198,"totalTrials":126,"cells":9199},"Blinded study medication",{"EARLY_PHASE1":9200,"PHASE1":9202,"PHASE2":9204,"PHASE3":9214,"PHASE4":9216,"NA":9218},{"trials":9201,"activeCount":100},[],{"trials":9203,"activeCount":100},[],{"trials":9205,"activeCount":100},[9206],{"nctId":9207,"briefTitle":9208,"status":106,"phases":9209,"primaryCompletion":9210,"completion":886,"start":4404,"enrollment":9211,"conditions":9212,"interventions":9213},"NCT03098563","Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis",[89],"2023-11-17",58,[7761],[9198],{"trials":9215,"activeCount":100},[],{"trials":9217,"activeCount":100},[],{"trials":9219,"activeCount":100},[],{"intervention":9221,"totalTrials":126,"cells":9222},"Peanut powder",{"EARLY_PHASE1":9223,"PHASE1":9225,"PHASE2":9227,"PHASE3":9238,"PHASE4":9240,"NA":9242},{"trials":9224,"activeCount":100},[],{"trials":9226,"activeCount":100},[],{"trials":9228,"activeCount":100},[9229],{"nctId":9230,"briefTitle":9231,"status":106,"phases":9232,"primaryCompletion":5740,"completion":4970,"start":8565,"enrollment":2091,"conditions":9233,"interventions":9236},"NCT01084174","A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual\u002FOral Immunotherapy for the Treatment of Peanut Allergy",[88,89],[9234,2121,9235],"Peanut Hypersensitivity","Immediate Hypersensitivity",[9221,9237],"Peanut extract",{"trials":9239,"activeCount":100},[],{"trials":9241,"activeCount":100},[],{"trials":9243,"activeCount":100},[],{"intervention":9237,"totalTrials":126,"cells":9245},{"EARLY_PHASE1":9246,"PHASE1":9248,"PHASE2":9250,"PHASE3":9256,"PHASE4":9258,"NA":9260},{"trials":9247,"activeCount":100},[],{"trials":9249,"activeCount":100},[],{"trials":9251,"activeCount":100},[9252],{"nctId":9230,"briefTitle":9231,"status":106,"phases":9253,"primaryCompletion":5740,"completion":4970,"start":8565,"enrollment":2091,"conditions":9254,"interventions":9255},[88,89],[9234,2121,9235],[9221,9237],{"trials":9257,"activeCount":100},[],{"trials":9259,"activeCount":100},[],{"trials":9261,"activeCount":100},[],{"intervention":9263,"totalTrials":126,"cells":9264},"Caffeine",{"EARLY_PHASE1":9265,"PHASE1":9267,"PHASE2":9269,"PHASE3":9278,"PHASE4":9280,"NA":9282},{"trials":9266,"activeCount":100},[],{"trials":9268,"activeCount":100},[],{"trials":9270,"activeCount":100},[9271],{"nctId":9272,"briefTitle":9273,"status":149,"phases":9274,"primaryCompletion":9139,"completion":6345,"start":6392,"enrollment":100,"conditions":9275,"interventions":9277},"NCT02594358","Caffeine in Amblyopia Study",[88,89],[9276],"Amblyopia",[9263],{"trials":9279,"activeCount":100},[],{"trials":9281,"activeCount":100},[],{"trials":9283,"activeCount":100},[],{"intervention":9285,"totalTrials":126,"cells":9286},"Acalabrutinib",{"EARLY_PHASE1":9287,"PHASE1":9289,"PHASE2":9291,"PHASE3":9302,"PHASE4":9304,"NA":9306},{"trials":9288,"activeCount":100},[],{"trials":9290,"activeCount":100},[],{"trials":9292,"activeCount":100},[9293],{"nctId":9294,"briefTitle":9295,"status":106,"phases":9296,"primaryCompletion":9297,"completion":5627,"start":9298,"enrollment":264,"conditions":9299,"interventions":9301},"NCT05038904","Preventing Anaphylaxis With Acalabrutinib",[89],"2022-12-08","2021-12-16",[2108,9300],"Food Allergy Peanut",[9285],{"trials":9303,"activeCount":100},[],{"trials":9305,"activeCount":100},[],{"trials":9307,"activeCount":100},[],{"intervention":9309,"totalTrials":126,"cells":9310},"6R-BH4",{"EARLY_PHASE1":9311,"PHASE1":9313,"PHASE2":9315,"PHASE3":9325,"PHASE4":9327,"NA":9329},{"trials":9312,"activeCount":100},[],{"trials":9314,"activeCount":100},[],{"trials":9316,"activeCount":100},[9317],{"nctId":9318,"briefTitle":9319,"status":873,"phases":9320,"primaryCompletion":8078,"completion":8078,"start":2338,"enrollment":235,"conditions":9321,"interventions":9324},"NCT00802893","Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction",[89],[9322,9323],"Isolated Systolic Hypertension","Endothelial Dysfunction",[9309],{"trials":9326,"activeCount":100},[],{"trials":9328,"activeCount":100},[],{"trials":9330,"activeCount":100},[],{"intervention":9332,"totalTrials":126,"cells":9333},"Cyclophosphamide\u002FGlatiramer acetate",{"EARLY_PHASE1":9334,"PHASE1":9336,"PHASE2":9338,"PHASE3":9346,"PHASE4":9348,"NA":9350},{"trials":9335,"activeCount":100},[],{"trials":9337,"activeCount":100},[],{"trials":9339,"activeCount":100},[9340],{"nctId":9341,"briefTitle":9342,"status":149,"phases":9343,"primaryCompletion":8910,"completion":8910,"start":8910,"enrollment":100,"conditions":9344,"interventions":9345},"NCT00939549","High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis",[89],[7354],[9332],{"trials":9347,"activeCount":100},[],{"trials":9349,"activeCount":100},[],{"trials":9351,"activeCount":100},[],{"intervention":3221,"totalTrials":126,"cells":9353},{"EARLY_PHASE1":9354,"PHASE1":9356,"PHASE2":9358,"PHASE3":9364,"PHASE4":9366,"NA":9368},{"trials":9355,"activeCount":100},[],{"trials":9357,"activeCount":100},[],{"trials":9359,"activeCount":100},[9360],{"nctId":3213,"briefTitle":3214,"status":873,"phases":9361,"primaryCompletion":696,"completion":3216,"start":2338,"enrollment":2151,"conditions":9362,"interventions":9363},[89],[3218,3219],[3221,3204],{"trials":9365,"activeCount":100},[],{"trials":9367,"activeCount":100},[],{"trials":9369,"activeCount":100},[],{"intervention":8507,"totalTrials":126,"cells":9371},{"EARLY_PHASE1":9372,"PHASE1":9374,"PHASE2":9376,"PHASE3":9382,"PHASE4":9384,"NA":9386},{"trials":9373,"activeCount":100},[],{"trials":9375,"activeCount":100},[],{"trials":9377,"activeCount":100},[9378],{"nctId":8500,"briefTitle":8501,"status":106,"phases":9379,"primaryCompletion":636,"completion":8503,"start":328,"enrollment":8504,"conditions":9380,"interventions":9381},[89],[3302],[8507,8491],{"trials":9383,"activeCount":100},[],{"trials":9385,"activeCount":100},[],{"trials":9387,"activeCount":100},[],{"intervention":9389,"totalTrials":126,"cells":9390},"Insulin, intranasal",{"EARLY_PHASE1":9391,"PHASE1":9393,"PHASE2":9395,"PHASE3":9408,"PHASE4":9410,"NA":9412},{"trials":9392,"activeCount":100},[],{"trials":9394,"activeCount":100},[],{"trials":9396,"activeCount":100},[9397],{"nctId":9398,"briefTitle":9399,"status":873,"phases":9400,"primaryCompletion":9401,"completion":9402,"start":9403,"enrollment":2091,"conditions":9404,"interventions":9407},"NCT03081117","Intranasal Insulin for the Treatment of HAND",[88,89],"2020-05-20","2020-10-16","2017-08-01",[9405,9406],"HIV Dementia","HIV-Associated Cognitive Motor Complex",[9389],{"trials":9409,"activeCount":100},[],{"trials":9411,"activeCount":100},[],{"trials":9413,"activeCount":100},[],{"intervention":9415,"totalTrials":126,"cells":9416},"Peanut powder or peanut butter",{"EARLY_PHASE1":9417,"PHASE1":9419,"PHASE2":9421,"PHASE3":9429,"PHASE4":9431,"NA":9433},{"trials":9418,"activeCount":100},[],{"trials":9420,"activeCount":100},[],{"trials":9422,"activeCount":100},[9423],{"nctId":9424,"briefTitle":9425,"status":149,"phases":9426,"primaryCompletion":1797,"completion":2067,"start":7014,"enrollment":100,"conditions":9427,"interventions":9428},"NCT04761835","STEP-IT-UP - Peanut Allergy Study for Infants",[89],[2109,2108],[9415],{"trials":9430,"activeCount":100},[],{"trials":9432,"activeCount":100},[],{"trials":9434,"activeCount":100},[],{"intervention":9436,"totalTrials":126,"cells":9437},"epidural injection of etanercept",{"EARLY_PHASE1":9438,"PHASE1":9440,"PHASE2":9442,"PHASE3":9451,"PHASE4":9453,"NA":9455},{"trials":9439,"activeCount":100},[],{"trials":9441,"activeCount":100},[],{"trials":9443,"activeCount":100},[9444],{"nctId":9445,"briefTitle":9446,"status":106,"phases":9447,"primaryCompletion":7188,"completion":7188,"start":6871,"enrollment":30,"conditions":9448,"interventions":9450},"NCT00364572","Efficacy of Epidural Etanercept in the Treatment of Sciatica",[88,89],[9449],"Sciatica",[9436],{"trials":9452,"activeCount":100},[],{"trials":9454,"activeCount":100},[],{"trials":9456,"activeCount":100},[],{"intervention":9458,"totalTrials":126,"cells":9459},"employment-based reinforcement",{"EARLY_PHASE1":9460,"PHASE1":9462,"PHASE2":9464,"PHASE3":9474,"PHASE4":9476,"NA":9478},{"trials":9461,"activeCount":100},[],{"trials":9463,"activeCount":100},[],{"trials":9465,"activeCount":100},[9466],{"nctId":9467,"briefTitle":9468,"status":106,"phases":9469,"primaryCompletion":8078,"completion":9470,"start":6871,"enrollment":1572,"conditions":9471,"interventions":9473},"NCT00684788","Employment-Based Depot Naltrexone Clinical Trial",[89],"2009-05-03",[9472],"Opiate Dependence",[9458],{"trials":9475,"activeCount":100},[],{"trials":9477,"activeCount":100},[],{"trials":9479,"activeCount":100},[],{"intervention":9481,"totalTrials":126,"cells":9482},"Zinc Acetate 50 Mg Oral",{"EARLY_PHASE1":9483,"PHASE1":9485,"PHASE2":9487,"PHASE3":9497,"PHASE4":9499,"NA":9501},{"trials":9484,"activeCount":100},[],{"trials":9486,"activeCount":100},[],{"trials":9488,"activeCount":100},[9489],{"nctId":9490,"briefTitle":9491,"status":106,"phases":9492,"primaryCompletion":9493,"completion":9493,"start":9494,"enrollment":3394,"conditions":9495,"interventions":9496},"NCT03135522","Pilot of Zinc Acetate to Improve Chronic Cough",[89],"2019-12-11","2018-02-14",[7191],[9481],{"trials":9498,"activeCount":100},[],{"trials":9500,"activeCount":100},[],{"trials":9502,"activeCount":100},[],{"intervention":9504,"totalTrials":126,"cells":9505},"SARS-CoV-2 convalescent plasma",{"EARLY_PHASE1":9506,"PHASE1":9508,"PHASE2":9510,"PHASE3":9524,"PHASE4":9526,"NA":9528},{"trials":9507,"activeCount":100},[],{"trials":9509,"activeCount":100},[],{"trials":9511,"activeCount":100},[9512],{"nctId":9513,"briefTitle":9514,"status":106,"phases":9515,"primaryCompletion":9516,"completion":9517,"start":9518,"enrollment":9519,"conditions":9520,"interventions":9522},"NCT04373460","Convalescent Plasma to Limit SARS-CoV-2 Associated Complications",[89],"2022-01-14","2022-12-14","2020-06-03",1225,[9521],"SARS-CoV 2",[9504,9523],"Plasma from a volunteer donor",{"trials":9525,"activeCount":100},[],{"trials":9527,"activeCount":100},[],{"trials":9529,"activeCount":100},[],{"intervention":9523,"totalTrials":126,"cells":9531},{"EARLY_PHASE1":9532,"PHASE1":9534,"PHASE2":9536,"PHASE3":9542,"PHASE4":9544,"NA":9546},{"trials":9533,"activeCount":100},[],{"trials":9535,"activeCount":100},[],{"trials":9537,"activeCount":100},[9538],{"nctId":9513,"briefTitle":9514,"status":106,"phases":9539,"primaryCompletion":9516,"completion":9517,"start":9518,"enrollment":9519,"conditions":9540,"interventions":9541},[89],[9521],[9504,9523],{"trials":9543,"activeCount":100},[],{"trials":9545,"activeCount":100},[],{"trials":9547,"activeCount":100},[],{"intervention":9549,"totalTrials":126,"cells":9550},"Pravastatin",{"EARLY_PHASE1":9551,"PHASE1":9553,"PHASE2":9555,"PHASE3":9566,"PHASE4":9568,"NA":9570},{"trials":9552,"activeCount":100},[],{"trials":9554,"activeCount":100},[],{"trials":9556,"activeCount":100},[9557],{"nctId":9558,"briefTitle":9559,"status":106,"phases":9560,"primaryCompletion":9561,"completion":9561,"start":9562,"enrollment":9563,"conditions":9564,"interventions":9565},"NCT03456102","Statin Adjunctive Therapy for TB",[89],"2022-08-31","2020-03-09",16,[35],[9549],{"trials":9567,"activeCount":100},[],{"trials":9569,"activeCount":100},[],{"trials":9571,"activeCount":100},[],{"intervention":9573,"totalTrials":126,"cells":9574},"Anti- SARS-CoV-2 Plasma",{"EARLY_PHASE1":9575,"PHASE1":9577,"PHASE2":9579,"PHASE3":9593,"PHASE4":9595,"NA":9597},{"trials":9576,"activeCount":100},[],{"trials":9578,"activeCount":100},[],{"trials":9580,"activeCount":100},[9581],{"nctId":9582,"briefTitle":9583,"status":106,"phases":9584,"primaryCompletion":9585,"completion":9586,"start":9587,"enrollment":5040,"conditions":9588,"interventions":9591},"NCT04323800","Convalescent Plasma to Stem Coronavirus (CSSC-001)",[89],"2021-04-22","2021-06-22","2020-06-10",[9589,9590],"Coronavirus","Convalescence",[9573,9592],"SARS-CoV-2 non-immune Plasma",{"trials":9594,"activeCount":100},[],{"trials":9596,"activeCount":100},[],{"trials":9598,"activeCount":100},[],{"intervention":9592,"totalTrials":126,"cells":9600},{"EARLY_PHASE1":9601,"PHASE1":9603,"PHASE2":9605,"PHASE3":9611,"PHASE4":9613,"NA":9615},{"trials":9602,"activeCount":100},[],{"trials":9604,"activeCount":100},[],{"trials":9606,"activeCount":100},[9607],{"nctId":9582,"briefTitle":9583,"status":106,"phases":9608,"primaryCompletion":9585,"completion":9586,"start":9587,"enrollment":5040,"conditions":9609,"interventions":9610},[89],[9589,9590],[9573,9592],{"trials":9612,"activeCount":100},[],{"trials":9614,"activeCount":100},[],{"trials":9616,"activeCount":100},[],{"intervention":9618,"totalTrials":126,"cells":9619},"Peanut Flour",{"EARLY_PHASE1":9620,"PHASE1":9622,"PHASE2":9624,"PHASE3":9635,"PHASE4":9637,"NA":9639},{"trials":9621,"activeCount":100},[],{"trials":9623,"activeCount":100},[],{"trials":9625,"activeCount":100},[9626],{"nctId":9627,"briefTitle":9628,"status":106,"phases":9629,"primaryCompletion":9630,"completion":9630,"start":9631,"enrollment":1744,"conditions":9632,"interventions":9634},"NCT03345160","Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study",[89],"2020-10-07","2018-04-27",[9633],"Treatment Efficacy",[9618],{"trials":9636,"activeCount":100},[],{"trials":9638,"activeCount":100},[],{"trials":9640,"activeCount":100},[],{"intervention":9642,"totalTrials":126,"cells":9643},"Benralizumab",{"EARLY_PHASE1":9644,"PHASE1":9646,"PHASE2":9648,"PHASE3":9658,"PHASE4":9660,"NA":9662},{"trials":9645,"activeCount":100},[],{"trials":9647,"activeCount":100},[],{"trials":9649,"activeCount":100},[9650],{"nctId":9651,"briefTitle":9652,"status":106,"phases":9653,"primaryCompletion":9654,"completion":1874,"start":1772,"enrollment":3446,"conditions":9655,"interventions":9657},"NCT03450083","Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis",[89],"2020-01-01",[4346,2094,9656],"Eosinophilia",[9642],{"trials":9659,"activeCount":100},[],{"trials":9661,"activeCount":100},[],{"trials":9663,"activeCount":100},[],{"intervention":9665,"totalTrials":126,"cells":9666},"Fentanyl\u002FDexmedetomidine",{"EARLY_PHASE1":9667,"PHASE1":9669,"PHASE2":9671,"PHASE3":9682,"PHASE4":9684,"NA":9686},{"trials":9668,"activeCount":100},[],{"trials":9670,"activeCount":100},[],{"trials":9672,"activeCount":100},[9673],{"nctId":9674,"briefTitle":9675,"status":106,"phases":9676,"primaryCompletion":7188,"completion":7188,"start":9677,"enrollment":1572,"conditions":9678,"interventions":9680},"NCT00390871","Acute Neurological ICU Sedation Trial (ANIST)",[89],"2005-05",[9679],"Sedation",[9665,9681,2006],"Fentanyl\u002FPropofol",{"trials":9683,"activeCount":100},[],{"trials":9685,"activeCount":100},[],{"trials":9687,"activeCount":100},[],{"intervention":9681,"totalTrials":126,"cells":9689},{"EARLY_PHASE1":9690,"PHASE1":9692,"PHASE2":9694,"PHASE3":9700,"PHASE4":9702,"NA":9704},{"trials":9691,"activeCount":100},[],{"trials":9693,"activeCount":100},[],{"trials":9695,"activeCount":100},[9696],{"nctId":9674,"briefTitle":9675,"status":106,"phases":9697,"primaryCompletion":7188,"completion":7188,"start":9677,"enrollment":1572,"conditions":9698,"interventions":9699},[89],[9679],[9665,9681,2006],{"trials":9701,"activeCount":100},[],{"trials":9703,"activeCount":100},[],{"trials":9705,"activeCount":100},[],{"intervention":9707,"totalTrials":126,"cells":9708},"Sodium Nitrite",{"EARLY_PHASE1":9709,"PHASE1":9711,"PHASE2":9713,"PHASE3":9722,"PHASE4":9724,"NA":9726},{"trials":9710,"activeCount":100},[],{"trials":9712,"activeCount":100},[],{"trials":9714,"activeCount":100},[9715],{"nctId":9716,"briefTitle":9717,"status":106,"phases":9718,"primaryCompletion":2172,"completion":2172,"start":2105,"enrollment":164,"conditions":9719,"interventions":9721},"NCT00924118","Sodium Nitrite in Acute Myocardial Infarction",[89],[9720],"Acute Myocardial Infarction",[9707],{"trials":9723,"activeCount":100},[],{"trials":9725,"activeCount":100},[],{"trials":9727,"activeCount":100},[],{"intervention":9729,"totalTrials":126,"cells":9730},"topiramate",{"EARLY_PHASE1":9731,"PHASE1":9733,"PHASE2":9735,"PHASE3":9744,"PHASE4":9746,"NA":9748},{"trials":9732,"activeCount":100},[],{"trials":9734,"activeCount":100},[],{"trials":9736,"activeCount":100},[9737],{"nctId":9738,"briefTitle":9739,"status":106,"phases":9740,"primaryCompletion":3216,"completion":7187,"start":8309,"enrollment":9741,"conditions":9742,"interventions":9743},"NCT00685178","Clinical Trial of Topiramate for Cocaine Addiction",[89],250,[7541],[9729],{"trials":9745,"activeCount":100},[],{"trials":9747,"activeCount":100},[],{"trials":9749,"activeCount":100},[],{"intervention":9751,"totalTrials":126,"cells":9752},"Prazosin",{"EARLY_PHASE1":9753,"PHASE1":9755,"PHASE2":9757,"PHASE3":9767,"PHASE4":9769,"NA":9771},{"trials":9754,"activeCount":100},[],{"trials":9756,"activeCount":100},[],{"trials":9758,"activeCount":100},[9759],{"nctId":9760,"briefTitle":9761,"status":873,"phases":9762,"primaryCompletion":9763,"completion":9763,"start":9764,"enrollment":96,"conditions":9765,"interventions":9766},"NCT04365257","Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)",[89],"2022-03-31","2020-05-13",[4749],[9751],{"trials":9768,"activeCount":100},[],{"trials":9770,"activeCount":100},[],{"trials":9772,"activeCount":100},[],{"intervention":9774,"totalTrials":126,"cells":9775},"Valacyclovir",{"EARLY_PHASE1":9776,"PHASE1":9778,"PHASE2":9780,"PHASE3":9788,"PHASE4":9790,"NA":9792},{"trials":9777,"activeCount":100},[],{"trials":9779,"activeCount":100},[],{"trials":9781,"activeCount":100},[9782],{"nctId":9783,"briefTitle":9784,"status":106,"phases":9785,"primaryCompletion":3119,"completion":825,"start":6187,"enrollment":715,"conditions":9786,"interventions":9787},"NCT00428298","Research Study of Bipolar Mood Symptoms and Cognitive Problems",[89],[5173],[9774],{"trials":9789,"activeCount":100},[],{"trials":9791,"activeCount":100},[],{"trials":9793,"activeCount":100},[],{"intervention":4881,"totalTrials":126,"cells":9795},{"EARLY_PHASE1":9796,"PHASE1":9798,"PHASE2":9800,"PHASE3":9806,"PHASE4":9808,"NA":9810},{"trials":9797,"activeCount":100},[],{"trials":9799,"activeCount":100},[],{"trials":9801,"activeCount":100},[9802],{"nctId":4871,"briefTitle":4872,"status":873,"phases":9803,"primaryCompletion":4874,"completion":4875,"start":4876,"enrollment":614,"conditions":9804,"interventions":9805},[88,89],[4878,4879],[4881,4882],{"trials":9807,"activeCount":100},[],{"trials":9809,"activeCount":100},[],{"trials":9811,"activeCount":100},[],{"intervention":9813,"totalTrials":126,"cells":9814},"Insulin",{"EARLY_PHASE1":9815,"PHASE1":9817,"PHASE2":9819,"PHASE3":9831,"PHASE4":9833,"NA":9835},{"trials":9816,"activeCount":100},[],{"trials":9818,"activeCount":100},[],{"trials":9820,"activeCount":100},[9821],{"nctId":9822,"briefTitle":9823,"status":106,"phases":9824,"primaryCompletion":9825,"completion":9825,"start":9826,"enrollment":759,"conditions":9827,"interventions":9830},"NCT02988401","Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis",[88,89],"2021-12-17","2017-12-01",[638,9828,9829],"Multiple Sclerosis, Secondary Progressive","Multiple Sclerosis, Primary Progressive",[9813],{"trials":9832,"activeCount":100},[],{"trials":9834,"activeCount":100},[],{"trials":9836,"activeCount":100},[],{"intervention":9838,"totalTrials":126,"cells":9839},"Pancreatic Polypeptide",{"EARLY_PHASE1":9840,"PHASE1":9842,"PHASE2":9844,"PHASE3":9853,"PHASE4":9855,"NA":9857},{"trials":9841,"activeCount":100},[],{"trials":9843,"activeCount":100},[],{"trials":9845,"activeCount":100},[9846],{"nctId":9847,"briefTitle":9848,"status":873,"phases":9849,"primaryCompletion":696,"completion":696,"start":4998,"enrollment":4344,"conditions":9850,"interventions":9852},"NCT00791076","The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients",[89],[9851],"Diabetes Mellitus, Type 1",[9838],{"trials":9854,"activeCount":100},[],{"trials":9856,"activeCount":100},[],{"trials":9858,"activeCount":100},[],{"intervention":9860,"totalTrials":126,"cells":9861},"IVIg and rituximab",{"EARLY_PHASE1":9862,"PHASE1":9864,"PHASE2":9866,"PHASE3":9875,"PHASE4":9877,"NA":9879},{"trials":9863,"activeCount":100},[],{"trials":9865,"activeCount":100},[],{"trials":9867,"activeCount":100},[9868],{"nctId":9869,"briefTitle":9870,"status":873,"phases":9871,"primaryCompletion":3232,"completion":3232,"start":2127,"enrollment":1593,"conditions":9872,"interventions":9874},"NCT00986947","Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates",[89],[9873],"Kidney Failure",[9860],{"trials":9876,"activeCount":100},[],{"trials":9878,"activeCount":100},[],{"trials":9880,"activeCount":100},[],{"intervention":9882,"totalTrials":126,"cells":9883},"Combretastatin A-4 phosphate",{"EARLY_PHASE1":9884,"PHASE1":9886,"PHASE2":9888,"PHASE3":9901,"PHASE4":9903,"NA":9905},{"trials":9885,"activeCount":100},[],{"trials":9887,"activeCount":100},[],{"trials":9889,"activeCount":100},[9890],{"nctId":9891,"briefTitle":9892,"status":106,"phases":9893,"primaryCompletion":225,"completion":225,"start":2226,"enrollment":4344,"conditions":9894,"interventions":9899},"NCT01570790","Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration",[88,89],[9895,9896,9897,9898,7402],"Combretastatin A4 Phosphate","Age-related Macular Degeneration","AMD","CNV",[9882,9900,9900],"Combretastatin A-4 Phosphate",{"trials":9902,"activeCount":100},[],{"trials":9904,"activeCount":100},[],{"trials":9906,"activeCount":100},[],{"intervention":9908,"totalTrials":126,"cells":9909},"Low Dose Suvorexant",{"EARLY_PHASE1":9910,"PHASE1":9912,"PHASE2":9914,"PHASE3":9925,"PHASE4":9927,"NA":9929},{"trials":9911,"activeCount":100},[],{"trials":9913,"activeCount":100},[],{"trials":9915,"activeCount":100},[9916],{"nctId":9917,"briefTitle":9918,"status":106,"phases":9919,"primaryCompletion":9920,"completion":9920,"start":9921,"enrollment":215,"conditions":9922,"interventions":9923},"NCT03789214","Medical Management of Sleep Disturbance During Opioid Tapering",[89],"2021-06-10","2019-07-01",[2313,3532,197],[9908,9924],"High Dose Suvorexant",{"trials":9926,"activeCount":100},[],{"trials":9928,"activeCount":100},[],{"trials":9930,"activeCount":100},[],{"intervention":9924,"totalTrials":126,"cells":9932},{"EARLY_PHASE1":9933,"PHASE1":9935,"PHASE2":9937,"PHASE3":9943,"PHASE4":9945,"NA":9947},{"trials":9934,"activeCount":100},[],{"trials":9936,"activeCount":100},[],{"trials":9938,"activeCount":100},[9939],{"nctId":9917,"briefTitle":9918,"status":106,"phases":9940,"primaryCompletion":9920,"completion":9920,"start":9921,"enrollment":215,"conditions":9941,"interventions":9942},[89],[2313,3532,197],[9908,9924],{"trials":9944,"activeCount":100},[],{"trials":9946,"activeCount":100},[],{"trials":9948,"activeCount":100},[],{"intervention":9950,"totalTrials":126,"cells":9951},"Levetiracetam 62.5mg",{"EARLY_PHASE1":9952,"PHASE1":9954,"PHASE2":9956,"PHASE3":9967,"PHASE4":9969,"NA":9971},{"trials":9953,"activeCount":100},[],{"trials":9955,"activeCount":100},[],{"trials":9957,"activeCount":100},[9958],{"nctId":9959,"briefTitle":9960,"status":106,"phases":9961,"primaryCompletion":8036,"completion":8036,"start":5097,"enrollment":8544,"conditions":9962,"interventions":9964},"NCT01044758","Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)",[89],[9963],"Mild Cognitive Impairment (MCI)",[9950,9965,9966],"Levetiracetam 125mg","Levetiracetam 250mg",{"trials":9968,"activeCount":100},[],{"trials":9970,"activeCount":100},[],{"trials":9972,"activeCount":100},[],{"intervention":9965,"totalTrials":126,"cells":9974},{"EARLY_PHASE1":9975,"PHASE1":9977,"PHASE2":9979,"PHASE3":9985,"PHASE4":9987,"NA":9989},{"trials":9976,"activeCount":100},[],{"trials":9978,"activeCount":100},[],{"trials":9980,"activeCount":100},[9981],{"nctId":9959,"briefTitle":9960,"status":106,"phases":9982,"primaryCompletion":8036,"completion":8036,"start":5097,"enrollment":8544,"conditions":9983,"interventions":9984},[89],[9963],[9950,9965,9966],{"trials":9986,"activeCount":100},[],{"trials":9988,"activeCount":100},[],{"trials":9990,"activeCount":100},[],{"intervention":9966,"totalTrials":126,"cells":9992},{"EARLY_PHASE1":9993,"PHASE1":9995,"PHASE2":9997,"PHASE3":10003,"PHASE4":10005,"NA":10007},{"trials":9994,"activeCount":100},[],{"trials":9996,"activeCount":100},[],{"trials":9998,"activeCount":100},[9999],{"nctId":9959,"briefTitle":9960,"status":106,"phases":10000,"primaryCompletion":8036,"completion":8036,"start":5097,"enrollment":8544,"conditions":10001,"interventions":10002},[89],[9963],[9950,9965,9966],{"trials":10004,"activeCount":100},[],{"trials":10006,"activeCount":100},[],{"trials":10008,"activeCount":100},[],{"intervention":8707,"totalTrials":126,"cells":10010},{"EARLY_PHASE1":10011,"PHASE1":10013,"PHASE2":10015,"PHASE3":10021,"PHASE4":10023,"NA":10025},{"trials":10012,"activeCount":100},[],{"trials":10014,"activeCount":100},[],{"trials":10016,"activeCount":100},[10017],{"nctId":8696,"briefTitle":8697,"status":106,"phases":10018,"primaryCompletion":8699,"completion":8699,"start":8700,"enrollment":1938,"conditions":10019,"interventions":10020},[89],[8702,8703,8704,8705],[8677,8707,8708],{"trials":10022,"activeCount":100},[],{"trials":10024,"activeCount":100},[],{"trials":10026,"activeCount":100},[],{"intervention":8708,"totalTrials":126,"cells":10028},{"EARLY_PHASE1":10029,"PHASE1":10031,"PHASE2":10033,"PHASE3":10039,"PHASE4":10041,"NA":10043},{"trials":10030,"activeCount":100},[],{"trials":10032,"activeCount":100},[],{"trials":10034,"activeCount":100},[10035],{"nctId":8696,"briefTitle":8697,"status":106,"phases":10036,"primaryCompletion":8699,"completion":8699,"start":8700,"enrollment":1938,"conditions":10037,"interventions":10038},[89],[8702,8703,8704,8705],[8677,8707,8708],{"trials":10040,"activeCount":100},[],{"trials":10042,"activeCount":100},[],{"trials":10044,"activeCount":100},[],{"intervention":10046,"totalTrials":126,"cells":10047},"LAAM. buprenorphine and methadone",{"EARLY_PHASE1":10048,"PHASE1":10050,"PHASE2":10052,"PHASE3":10063,"PHASE4":10065,"NA":10067},{"trials":10049,"activeCount":100},[],{"trials":10051,"activeCount":100},[],{"trials":10053,"activeCount":100},[10054],{"nctId":10055,"briefTitle":10056,"status":106,"phases":10057,"completion":10058,"start":10059,"enrollment":10060,"conditions":10061,"interventions":10062},"NCT00344812","Opioid Maintenance Medications Comparison Study",[89],"1998-06","1996-01",220,[2313],[10046],{"trials":10064,"activeCount":100},[],{"trials":10066,"activeCount":100},[],{"trials":10068,"activeCount":100},[],{"intervention":10070,"totalTrials":126,"cells":10071},"High-dose Cyclophosphamide",{"EARLY_PHASE1":10072,"PHASE1":10074,"PHASE2":10076,"PHASE3":10087,"PHASE4":10089,"NA":10091},{"trials":10073,"activeCount":100},[],{"trials":10075,"activeCount":100},[],{"trials":10077,"activeCount":100},[10078],{"nctId":10079,"briefTitle":10080,"status":149,"phases":10081,"primaryCompletion":10082,"completion":10082,"start":1655,"enrollment":100,"conditions":10083,"interventions":10086},"NCT01836289","High-dose Cyclophosphamide for Severe Refractory Crohn Disease",[88,89],"2018-03",[10084,10085],"Crohn's Disease","Crohn Disease",[10070],{"trials":10088,"activeCount":100},[],{"trials":10090,"activeCount":100},[],{"trials":10092,"activeCount":100},[],{"intervention":10094,"totalTrials":126,"cells":10095},"Mifepristone",{"EARLY_PHASE1":10096,"PHASE1":10098,"PHASE2":10100,"PHASE3":10110,"PHASE4":10112,"NA":10114},{"trials":10097,"activeCount":100},[],{"trials":10099,"activeCount":100},[],{"trials":10101,"activeCount":100},[10102],{"nctId":10103,"briefTitle":10104,"status":106,"phases":10105,"primaryCompletion":10106,"completion":10106,"start":10107,"enrollment":3633,"conditions":10108,"interventions":10109},"NCT02989662","INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers",[88,89],"2024-01-31","2017-09-26",[1790],[10094],{"trials":10111,"activeCount":100},[],{"trials":10113,"activeCount":100},[],{"trials":10115,"activeCount":100},[],{"intervention":10117,"totalTrials":126,"cells":10118},"Fluocinolone Acetonide\u002FMedidur",{"EARLY_PHASE1":10119,"PHASE1":10121,"PHASE2":10123,"PHASE3":10132,"PHASE4":10134,"NA":10136},{"trials":10120,"activeCount":100},[],{"trials":10122,"activeCount":100},[],{"trials":10124,"activeCount":100},[10125],{"nctId":10126,"briefTitle":10127,"status":106,"phases":10128,"primaryCompletion":3268,"completion":3268,"start":6210,"enrollment":293,"conditions":10129,"interventions":10131},"NCT00605423","The MAP Study: Fluocinolone Acetonide (FA)\u002FMedidur (TM) for Age Related Macular Degeneration (AMD) Pilot",[89],[10130],"Age Related Macular Degeneration",[10117,10117],{"trials":10133,"activeCount":100},[],{"trials":10135,"activeCount":100},[],{"trials":10137,"activeCount":100},[],{"intervention":10139,"totalTrials":126,"cells":10140},"GLP-1 (7-36) amide",{"EARLY_PHASE1":10141,"PHASE1":10143,"PHASE2":10145,"PHASE3":10154,"PHASE4":10156,"NA":10158},{"trials":10142,"activeCount":100},[],{"trials":10144,"activeCount":100},[],{"trials":10146,"activeCount":100},[10147],{"nctId":10148,"briefTitle":10149,"status":873,"phases":10150,"primaryCompletion":1646,"completion":5096,"start":224,"enrollment":1663,"conditions":10151,"interventions":10153},"NCT00966654","Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery",[89],[10152],"CABG",[10139],{"trials":10155,"activeCount":100},[],{"trials":10157,"activeCount":100},[],{"trials":10159,"activeCount":100},[],{"intervention":10161,"totalTrials":126,"cells":10162},"Vericiguat",{"EARLY_PHASE1":10163,"PHASE1":10165,"PHASE2":10167,"PHASE3":10179,"PHASE4":10181,"NA":10183},{"trials":10164,"activeCount":100},[],{"trials":10166,"activeCount":100},[],{"trials":10168,"activeCount":100},[10169],{"nctId":10170,"briefTitle":10171,"status":106,"phases":10172,"primaryCompletion":10173,"completion":10173,"start":10174,"enrollment":2247,"conditions":10175,"interventions":10178},"NCT05711719","Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction",[89],"2025-11-18","2023-06-16",[10176,10177],"Metabolic Syndrome","Coronary Microvascular Dysfunction",[10161],{"trials":10180,"activeCount":100},[],{"trials":10182,"activeCount":100},[],{"trials":10184,"activeCount":100},[],{"intervention":10186,"totalTrials":126,"cells":10187},"Januvia",{"EARLY_PHASE1":10188,"PHASE1":10190,"PHASE2":10192,"PHASE3":10202,"PHASE4":10204,"NA":10206},{"trials":10189,"activeCount":100},[],{"trials":10191,"activeCount":100},[],{"trials":10193,"activeCount":100},[10194],{"nctId":10195,"briefTitle":10196,"status":873,"phases":10197,"primaryCompletion":8565,"completion":8565,"start":10198,"enrollment":1663,"conditions":10199,"interventions":10201},"NCT00947011","Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)",[89],"2009-03",[10200],"Glucose Homeostasis",[10186],{"trials":10203,"activeCount":100},[],{"trials":10205,"activeCount":100},[],{"trials":10207,"activeCount":100},[],{"intervention":10209,"totalTrials":126,"cells":10210},"Stravix lyopreserved placental tissue",{"EARLY_PHASE1":10211,"PHASE1":10213,"PHASE2":10215,"PHASE3":10225,"PHASE4":10227,"NA":10229},{"trials":10212,"activeCount":100},[],{"trials":10214,"activeCount":100},[],{"trials":10216,"activeCount":100},[10217],{"nctId":10218,"briefTitle":10219,"status":873,"phases":10220,"primaryCompletion":10221,"completion":10221,"start":10222,"enrollment":235,"conditions":10223,"interventions":10224},"NCT05366842","Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care",[89],"2025-04-25","2022-04-01",[3360],[10209],{"trials":10226,"activeCount":100},[],{"trials":10228,"activeCount":100},[],{"trials":10230,"activeCount":100},[],{"intervention":10232,"totalTrials":126,"cells":10233},"AIC",{"EARLY_PHASE1":10234,"PHASE1":10236,"PHASE2":10238,"PHASE3":10249,"PHASE4":10251,"NA":10253},{"trials":10235,"activeCount":100},[],{"trials":10237,"activeCount":100},[],{"trials":10239,"activeCount":100},[10240],{"nctId":10241,"briefTitle":10242,"status":106,"phases":10243,"primaryCompletion":10244,"completion":10244,"start":10245,"enrollment":110,"conditions":10246,"interventions":10248},"NCT00346086","DNA Vaccine for Ragweed Allergic Adults",[89],"2001-08-21","2001-05-18",[10247],"Seasonal Allergic Rhinitis",[10232],{"trials":10250,"activeCount":100},[],{"trials":10252,"activeCount":100},[],{"trials":10254,"activeCount":100},[],{"intervention":10256,"totalTrials":126,"cells":10257},"Milk Protein Extract Immunotherapy goal of 4mg\u002Fday",{"EARLY_PHASE1":10258,"PHASE1":10260,"PHASE2":10262,"PHASE3":10274,"PHASE4":10276,"NA":10278},{"trials":10259,"activeCount":100},[],{"trials":10261,"activeCount":100},[],{"trials":10263,"activeCount":100},[10264],{"nctId":10265,"briefTitle":10266,"status":106,"phases":10267,"primaryCompletion":696,"completion":7375,"start":4899,"enrollment":164,"conditions":10268,"interventions":10270},"NCT00732654","The Safety and Efficacy of Sublingual\u002FOral Immunotherapy for the Treatment of Milk Protein Allergy",[88,89],[10269],"Milk Allergy",[10256,10271,10272,10273],"Milk Protein Extract Immunotherapy goal of 7mg\u002Fday","Milk Powder Immunotherapy goal dose 2000 mg\u002Fday","Milk Powder Immunotherapy goal dose 1000mg\u002Fday",{"trials":10275,"activeCount":100},[],{"trials":10277,"activeCount":100},[],{"trials":10279,"activeCount":100},[],{"intervention":10271,"totalTrials":126,"cells":10281},{"EARLY_PHASE1":10282,"PHASE1":10284,"PHASE2":10286,"PHASE3":10292,"PHASE4":10294,"NA":10296},{"trials":10283,"activeCount":100},[],{"trials":10285,"activeCount":100},[],{"trials":10287,"activeCount":100},[10288],{"nctId":10265,"briefTitle":10266,"status":106,"phases":10289,"primaryCompletion":696,"completion":7375,"start":4899,"enrollment":164,"conditions":10290,"interventions":10291},[88,89],[10269],[10256,10271,10272,10273],{"trials":10293,"activeCount":100},[],{"trials":10295,"activeCount":100},[],{"trials":10297,"activeCount":100},[],{"intervention":10272,"totalTrials":126,"cells":10299},{"EARLY_PHASE1":10300,"PHASE1":10302,"PHASE2":10304,"PHASE3":10310,"PHASE4":10312,"NA":10314},{"trials":10301,"activeCount":100},[],{"trials":10303,"activeCount":100},[],{"trials":10305,"activeCount":100},[10306],{"nctId":10265,"briefTitle":10266,"status":106,"phases":10307,"primaryCompletion":696,"completion":7375,"start":4899,"enrollment":164,"conditions":10308,"interventions":10309},[88,89],[10269],[10256,10271,10272,10273],{"trials":10311,"activeCount":100},[],{"trials":10313,"activeCount":100},[],{"trials":10315,"activeCount":100},[],{"intervention":10273,"totalTrials":126,"cells":10317},{"EARLY_PHASE1":10318,"PHASE1":10320,"PHASE2":10322,"PHASE3":10328,"PHASE4":10330,"NA":10332},{"trials":10319,"activeCount":100},[],{"trials":10321,"activeCount":100},[],{"trials":10323,"activeCount":100},[10324],{"nctId":10265,"briefTitle":10266,"status":106,"phases":10325,"primaryCompletion":696,"completion":7375,"start":4899,"enrollment":164,"conditions":10326,"interventions":10327},[88,89],[10269],[10256,10271,10272,10273],{"trials":10329,"activeCount":100},[],{"trials":10331,"activeCount":100},[],{"trials":10333,"activeCount":100},[],{"intervention":10335,"totalTrials":126,"cells":10336},"Vivitrol",{"EARLY_PHASE1":10337,"PHASE1":10339,"PHASE2":10341,"PHASE3":10351,"PHASE4":10353,"NA":10355},{"trials":10338,"activeCount":100},[],{"trials":10340,"activeCount":100},[],{"trials":10342,"activeCount":100},[10343],{"nctId":10344,"briefTitle":10345,"status":106,"phases":10346,"primaryCompletion":10347,"completion":10348,"start":8575,"enrollment":4900,"conditions":10349,"interventions":10350},"NCT01556425","The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence",[89],"2016-12-12","2017-08-06",[2313],[10335],{"trials":10352,"activeCount":100},[],{"trials":10354,"activeCount":100},[],{"trials":10356,"activeCount":100},[],{"intervention":788,"totalTrials":126,"cells":10358},{"EARLY_PHASE1":10359,"PHASE1":10361,"PHASE2":10363,"PHASE3":10369,"PHASE4":10371,"NA":10373},{"trials":10360,"activeCount":100},[],{"trials":10362,"activeCount":100},[],{"trials":10364,"activeCount":100},[10365],{"nctId":779,"briefTitle":780,"status":106,"phases":10366,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":10367,"interventions":10368},[89],[786],[788,770,789,790,791,792],{"trials":10370,"activeCount":100},[],{"trials":10372,"activeCount":100},[],{"trials":10374,"activeCount":100},[],{"intervention":789,"totalTrials":126,"cells":10376},{"EARLY_PHASE1":10377,"PHASE1":10379,"PHASE2":10381,"PHASE3":10387,"PHASE4":10389,"NA":10391},{"trials":10378,"activeCount":100},[],{"trials":10380,"activeCount":100},[],{"trials":10382,"activeCount":100},[10383],{"nctId":779,"briefTitle":780,"status":106,"phases":10384,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":10385,"interventions":10386},[89],[786],[788,770,789,790,791,792],{"trials":10388,"activeCount":100},[],{"trials":10390,"activeCount":100},[],{"trials":10392,"activeCount":100},[],{"intervention":10394,"totalTrials":126,"cells":10395},"Bromfenac",{"EARLY_PHASE1":10396,"PHASE1":10398,"PHASE2":10400,"PHASE3":10409,"PHASE4":10411,"NA":10413},{"trials":10397,"activeCount":100},[],{"trials":10399,"activeCount":100},[],{"trials":10401,"activeCount":100},[10402],{"nctId":10403,"briefTitle":10404,"status":149,"phases":10405,"primaryCompletion":7132,"completion":4302,"start":4854,"enrollment":100,"conditions":10406,"interventions":10407},"NCT00438243","Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.",[89],[8311],[10394,10408],"Refresh Plus",{"trials":10410,"activeCount":100},[],{"trials":10412,"activeCount":100},[],{"trials":10414,"activeCount":100},[],{"intervention":10408,"totalTrials":126,"cells":10416},{"EARLY_PHASE1":10417,"PHASE1":10419,"PHASE2":10421,"PHASE3":10427,"PHASE4":10429,"NA":10431},{"trials":10418,"activeCount":100},[],{"trials":10420,"activeCount":100},[],{"trials":10422,"activeCount":100},[10423],{"nctId":10403,"briefTitle":10404,"status":149,"phases":10424,"primaryCompletion":7132,"completion":4302,"start":4854,"enrollment":100,"conditions":10425,"interventions":10426},[89],[8311],[10394,10408],{"trials":10428,"activeCount":100},[],{"trials":10430,"activeCount":100},[],{"trials":10432,"activeCount":100},[],{"intervention":10434,"totalTrials":126,"cells":10435},"Docosahexaenoic Acid",{"EARLY_PHASE1":10436,"PHASE1":10438,"PHASE2":10440,"PHASE3":10450,"PHASE4":10452,"NA":10454},{"trials":10437,"activeCount":100},[],{"trials":10439,"activeCount":100},[],{"trials":10441,"activeCount":100},[10442],{"nctId":10443,"briefTitle":10444,"status":149,"phases":10445,"primaryCompletion":645,"completion":10446,"start":10447,"enrollment":100,"conditions":10448,"interventions":10449},"NCT03402789","Docosahexaenoic Acid (DHA) Supplementation in Amblyopia",[88,89],"2024-12-30","2024-01-01",[9276],[10434],{"trials":10451,"activeCount":100},[],{"trials":10453,"activeCount":100},[],{"trials":10455,"activeCount":100},[],{"intervention":10457,"totalTrials":126,"cells":10458},"Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid",{"EARLY_PHASE1":10459,"PHASE1":10461,"PHASE2":10463,"PHASE3":10473,"PHASE4":10475,"NA":10477},{"trials":10460,"activeCount":100},[],{"trials":10462,"activeCount":100},[],{"trials":10464,"activeCount":100},[10465],{"nctId":10466,"briefTitle":10467,"status":873,"phases":10468,"primaryCompletion":5264,"completion":5264,"start":5183,"enrollment":10469,"conditions":10470,"interventions":10471},"NCT00728507","Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis",[89],121,[35],[10457,10472],"Isoniazid, Rifampin, Pyrazinamide, Ethambutol",{"trials":10474,"activeCount":100},[],{"trials":10476,"activeCount":100},[],{"trials":10478,"activeCount":100},[],{"intervention":10472,"totalTrials":126,"cells":10480},{"EARLY_PHASE1":10481,"PHASE1":10483,"PHASE2":10485,"PHASE3":10491,"PHASE4":10493,"NA":10495},{"trials":10482,"activeCount":100},[],{"trials":10484,"activeCount":100},[],{"trials":10486,"activeCount":100},[10487],{"nctId":10466,"briefTitle":10467,"status":873,"phases":10488,"primaryCompletion":5264,"completion":5264,"start":5183,"enrollment":10469,"conditions":10489,"interventions":10490},[89],[35],[10457,10472],{"trials":10492,"activeCount":100},[],{"trials":10494,"activeCount":100},[],{"trials":10496,"activeCount":100},[],{"intervention":10498,"totalTrials":126,"cells":10499},"tissue plasminogen activator, rt-PA",{"EARLY_PHASE1":10500,"PHASE1":10502,"PHASE2":10504,"PHASE3":10513,"PHASE4":10515,"NA":10517},{"trials":10501,"activeCount":100},[],{"trials":10503,"activeCount":100},[],{"trials":10505,"activeCount":100},[10506],{"nctId":10507,"briefTitle":10508,"status":106,"phases":10509,"primaryCompletion":4899,"completion":4899,"start":10510,"enrollment":2808,"conditions":10511,"interventions":10512},"NCT00650858","Clinical Trial on Treatment of Intraventricular Hemorrhage",[89],"2004-02",[7671],[10498],{"trials":10514,"activeCount":100},[],{"trials":10516,"activeCount":100},[],{"trials":10518,"activeCount":100},[],{"intervention":10520,"totalTrials":126,"cells":10521},"Hydroxyurea",{"EARLY_PHASE1":10522,"PHASE1":10524,"PHASE2":10526,"PHASE3":10536,"PHASE4":10538,"NA":10540},{"trials":10523,"activeCount":100},[],{"trials":10525,"activeCount":100},[],{"trials":10527,"activeCount":100},[10528],{"nctId":10529,"briefTitle":10530,"status":106,"phases":10531,"primaryCompletion":10532,"completion":10532,"start":10533,"enrollment":1854,"conditions":10534,"interventions":10535},"NCT01389024","Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease",[89],"2022-05-24","2012-08-16",[3344,32],[10520],{"trials":10537,"activeCount":100},[],{"trials":10539,"activeCount":100},[],{"trials":10541,"activeCount":100},[],{"intervention":10543,"totalTrials":126,"cells":10544},"Erythropoietin",{"EARLY_PHASE1":10545,"PHASE1":10547,"PHASE2":10549,"PHASE3":10559,"PHASE4":10561,"NA":10563},{"trials":10546,"activeCount":100},[],{"trials":10548,"activeCount":100},[],{"trials":10550,"activeCount":100},[10551],{"nctId":10552,"briefTitle":10553,"status":106,"phases":10554,"primaryCompletion":10555,"completion":10555,"start":1772,"enrollment":698,"conditions":10556,"interventions":10558},"NCT00737893","Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy",[89],"2019-12-31",[3360,10557],"Erectile Dysfunction",[10543],{"trials":10560,"activeCount":100},[],{"trials":10562,"activeCount":100},[],{"trials":10564,"activeCount":100},[],{"intervention":10566,"totalTrials":126,"cells":10567},"Sulforaphane 25",{"EARLY_PHASE1":10568,"PHASE1":10570,"PHASE2":10572,"PHASE3":10581,"PHASE4":10583,"NA":10585},{"trials":10569,"activeCount":100},[],{"trials":10571,"activeCount":100},[],{"trials":10573,"activeCount":100},[10574],{"nctId":10575,"briefTitle":10576,"status":106,"phases":10577,"primaryCompletion":5228,"completion":8446,"start":4302,"enrollment":10578,"conditions":10579,"interventions":10580},"NCT01335971","Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD",[89],89,[5080],[10566],{"trials":10582,"activeCount":100},[],{"trials":10584,"activeCount":100},[],{"trials":10586,"activeCount":100},[],{"intervention":10588,"totalTrials":126,"cells":10589},"Work Plus Naltrexone Contingency",{"EARLY_PHASE1":10590,"PHASE1":10592,"PHASE2":10594,"PHASE3":10603,"PHASE4":10605,"NA":10607},{"trials":10591,"activeCount":100},[],{"trials":10593,"activeCount":100},[],{"trials":10595,"activeCount":100},[10596],{"nctId":10597,"briefTitle":10598,"status":106,"phases":10599,"primaryCompletion":10600,"completion":10600,"start":4854,"enrollment":2287,"conditions":10601,"interventions":10602},"NCT00684775","Employment-Based Depot Naltrexone Clinical Trial II",[89],"2010-04-30",[9472],[10588],{"trials":10604,"activeCount":100},[],{"trials":10606,"activeCount":100},[],{"trials":10608,"activeCount":100},[],{"intervention":10610,"totalTrials":126,"cells":10611},"Tamoxifen Citrate",{"EARLY_PHASE1":10612,"PHASE1":10614,"PHASE2":10616,"PHASE3":10629,"PHASE4":10631,"NA":10633},{"trials":10613,"activeCount":100},[],{"trials":10615,"activeCount":100},[],{"trials":10617,"activeCount":100},[10618],{"nctId":10619,"briefTitle":10620,"status":106,"phases":10621,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":164,"conditions":10624,"interventions":10626},"NCT04129216","The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer",[89],"2022-11-10","2019-02-20",[10625],"Breast Cancer",[10610,10627,10628],"Letrozole","Exemestane",{"trials":10630,"activeCount":100},[],{"trials":10632,"activeCount":100},[],{"trials":10634,"activeCount":100},[],{"intervention":10627,"totalTrials":126,"cells":10636},{"EARLY_PHASE1":10637,"PHASE1":10639,"PHASE2":10641,"PHASE3":10647,"PHASE4":10649,"NA":10651},{"trials":10638,"activeCount":100},[],{"trials":10640,"activeCount":100},[],{"trials":10642,"activeCount":100},[10643],{"nctId":10619,"briefTitle":10620,"status":106,"phases":10644,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":164,"conditions":10645,"interventions":10646},[89],[10625],[10610,10627,10628],{"trials":10648,"activeCount":100},[],{"trials":10650,"activeCount":100},[],{"trials":10652,"activeCount":100},[],{"intervention":10628,"totalTrials":126,"cells":10654},{"EARLY_PHASE1":10655,"PHASE1":10657,"PHASE2":10659,"PHASE3":10665,"PHASE4":10667,"NA":10669},{"trials":10656,"activeCount":100},[],{"trials":10658,"activeCount":100},[],{"trials":10660,"activeCount":100},[10661],{"nctId":10619,"briefTitle":10620,"status":106,"phases":10662,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":164,"conditions":10663,"interventions":10664},[89],[10625],[10610,10627,10628],{"trials":10666,"activeCount":100},[],{"trials":10668,"activeCount":100},[],{"trials":10670,"activeCount":100},[],{"intervention":10672,"totalTrials":126,"cells":10673},"cow's milk powder",{"EARLY_PHASE1":10674,"PHASE1":10676,"PHASE2":10678,"PHASE3":10687,"PHASE4":10689,"NA":10691},{"trials":10675,"activeCount":100},[],{"trials":10677,"activeCount":100},[],{"trials":10679,"activeCount":100},[10680],{"nctId":10681,"briefTitle":10682,"status":106,"phases":10683,"primaryCompletion":3342,"completion":3342,"start":8169,"enrollment":1593,"conditions":10684,"interventions":10686},"NCT00465569","A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy",[88,89],[10685],"Milk Hypersensitivity",[10672],{"trials":10688,"activeCount":100},[],{"trials":10690,"activeCount":100},[],{"trials":10692,"activeCount":100},[],{"intervention":10694,"totalTrials":126,"cells":10695},"Baked non-fat cow's milk powder",{"EARLY_PHASE1":10696,"PHASE1":10698,"PHASE2":10700,"PHASE3":10713,"PHASE4":10715,"NA":10717},{"trials":10697,"activeCount":100},[],{"trials":10699,"activeCount":100},[],{"trials":10701,"activeCount":100},[10702],{"nctId":10703,"briefTitle":10704,"status":106,"phases":10705,"primaryCompletion":10706,"completion":10707,"start":10708,"enrollment":10709,"conditions":10710,"interventions":10712},"NCT03462030","Baked Milk Oral Immunotherapy for Cow's Milk Allergy",[89],"2021-01-25","2024-02-19","2018-03-15",41,[10711],"Cow's Milk Allergy",[10694],{"trials":10714,"activeCount":100},[],{"trials":10716,"activeCount":100},[],{"trials":10718,"activeCount":100},[],{"intervention":10720,"totalTrials":126,"cells":10721},"Allergen Immunotherapy Extract",{"EARLY_PHASE1":10722,"PHASE1":10724,"PHASE2":10726,"PHASE3":10736,"PHASE4":10738,"NA":10740},{"trials":10723,"activeCount":100},[],{"trials":10725,"activeCount":100},[],{"trials":10727,"activeCount":100},[10728],{"nctId":10729,"briefTitle":10730,"status":106,"phases":10731,"primaryCompletion":6673,"completion":8299,"start":10732,"enrollment":19,"conditions":10733,"interventions":10734},"NCT03360071","A Novel Biologic Therapy for Perennial Allergic Rhinitis",[89],"2016-12-19",[2188],[10720,10735],"Allergen Immunotherapy Control",{"trials":10737,"activeCount":100},[],{"trials":10739,"activeCount":100},[],{"trials":10741,"activeCount":100},[],{"intervention":10735,"totalTrials":126,"cells":10743},{"EARLY_PHASE1":10744,"PHASE1":10746,"PHASE2":10748,"PHASE3":10754,"PHASE4":10756,"NA":10758},{"trials":10745,"activeCount":100},[],{"trials":10747,"activeCount":100},[],{"trials":10749,"activeCount":100},[10750],{"nctId":10729,"briefTitle":10730,"status":106,"phases":10751,"primaryCompletion":6673,"completion":8299,"start":10732,"enrollment":19,"conditions":10752,"interventions":10753},[89],[2188],[10720,10735],{"trials":10755,"activeCount":100},[],{"trials":10757,"activeCount":100},[],{"trials":10759,"activeCount":100},[],{"intervention":10761,"totalTrials":126,"cells":10762},"Decitabine",{"EARLY_PHASE1":10763,"PHASE1":10765,"PHASE2":10767,"PHASE3":10777,"PHASE4":10779,"NA":10781},{"trials":10764,"activeCount":100},[],{"trials":10766,"activeCount":100},[],{"trials":10768,"activeCount":100},[10769],{"nctId":10770,"briefTitle":10771,"status":10772,"phases":10773,"primaryCompletion":2246,"completion":581,"start":10774,"enrollment":3446,"conditions":10775,"interventions":10776},"NCT04482621","Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial","SUSPENDED",[89],"2020-09-14",[4749],[10761],{"trials":10778,"activeCount":100},[],{"trials":10780,"activeCount":100},[],{"trials":10782,"activeCount":100},[],{"intervention":10784,"totalTrials":126,"cells":10785},"Flovent Diskus",{"EARLY_PHASE1":10786,"PHASE1":10788,"PHASE2":10790,"PHASE3":10802,"PHASE4":10804,"NA":10806},{"trials":10787,"activeCount":100},[],{"trials":10789,"activeCount":100},[],{"trials":10791,"activeCount":100},[10792],{"nctId":10793,"briefTitle":10794,"status":106,"phases":10795,"primaryCompletion":10796,"completion":10796,"start":10797,"enrollment":10798,"conditions":10799,"interventions":10800},"NCT02251379","Environmental Control as Add-on Therapy in Childhood Asthma",[89],"2018-11","2014-10-01",155,[21],[10784,10801],"Advair Diskus",{"trials":10803,"activeCount":100},[],{"trials":10805,"activeCount":100},[],{"trials":10807,"activeCount":100},[],{"intervention":10801,"totalTrials":126,"cells":10809},{"EARLY_PHASE1":10810,"PHASE1":10812,"PHASE2":10814,"PHASE3":10820,"PHASE4":10822,"NA":10824},{"trials":10811,"activeCount":100},[],{"trials":10813,"activeCount":100},[],{"trials":10815,"activeCount":100},[10816],{"nctId":10793,"briefTitle":10794,"status":106,"phases":10817,"primaryCompletion":10796,"completion":10796,"start":10797,"enrollment":10798,"conditions":10818,"interventions":10819},[89],[21],[10784,10801],{"trials":10821,"activeCount":100},[],{"trials":10823,"activeCount":100},[],{"trials":10825,"activeCount":100},[],{"intervention":10827,"totalTrials":126,"cells":10828},"nurse-administered intermittent IV bolus opioid therapy",{"EARLY_PHASE1":10829,"PHASE1":10831,"PHASE2":10833,"PHASE3":10843,"PHASE4":10845,"NA":10847},{"trials":10830,"activeCount":100},[],{"trials":10832,"activeCount":100},[],{"trials":10834,"activeCount":100},[10835],{"nctId":10836,"briefTitle":10837,"status":149,"phases":10838,"primaryCompletion":2127,"completion":10839,"start":930,"enrollment":100,"conditions":10840,"interventions":10842},"NCT00711698","Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)",[89],"2009-09-01",[3344,10841],"Vaso-occlusive Crisis",[10827],{"trials":10844,"activeCount":100},[],{"trials":10846,"activeCount":100},[],{"trials":10848,"activeCount":100},[],{"intervention":10850,"totalTrials":126,"cells":10851},"Crizanlizumab",{"EARLY_PHASE1":10852,"PHASE1":10854,"PHASE2":10856,"PHASE3":10868,"PHASE4":10870,"NA":10872},{"trials":10853,"activeCount":100},[],{"trials":10855,"activeCount":100},[],{"trials":10857,"activeCount":100},[10858],{"nctId":10859,"briefTitle":10860,"status":106,"phases":10861,"primaryCompletion":10862,"completion":10863,"start":10864,"enrollment":10865,"conditions":10866,"interventions":10867},"NCT04435184","Crizanlizumab for Treating COVID-19 Vasculopathy",[89],"2020-11-28","2021-01-04","2020-07-09",54,[4749],[10850],{"trials":10869,"activeCount":100},[],{"trials":10871,"activeCount":100},[],{"trials":10873,"activeCount":100},[],{"intervention":10875,"totalTrials":126,"cells":10876},"iCo-007 350 mcg",{"EARLY_PHASE1":10877,"PHASE1":10879,"PHASE2":10881,"PHASE3":10893,"PHASE4":10895,"NA":10897},{"trials":10878,"activeCount":100},[],{"trials":10880,"activeCount":100},[],{"trials":10882,"activeCount":100},[10883],{"nctId":10884,"briefTitle":10885,"status":873,"phases":10886,"primaryCompletion":1644,"completion":6392,"start":7157,"enrollment":10887,"conditions":10888,"interventions":10889},"NCT01565148","A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)",[89],185,[5430],[10875,10890,10891,10892],"iCo-007 700 mcg","iCo-007 350 mcg and Laser","Ranibizumab and iCo-007 350 mcg",{"trials":10894,"activeCount":100},[],{"trials":10896,"activeCount":100},[],{"trials":10898,"activeCount":100},[],{"intervention":10890,"totalTrials":126,"cells":10900},{"EARLY_PHASE1":10901,"PHASE1":10903,"PHASE2":10905,"PHASE3":10911,"PHASE4":10913,"NA":10915},{"trials":10902,"activeCount":100},[],{"trials":10904,"activeCount":100},[],{"trials":10906,"activeCount":100},[10907],{"nctId":10884,"briefTitle":10885,"status":873,"phases":10908,"primaryCompletion":1644,"completion":6392,"start":7157,"enrollment":10887,"conditions":10909,"interventions":10910},[89],[5430],[10875,10890,10891,10892],{"trials":10912,"activeCount":100},[],{"trials":10914,"activeCount":100},[],{"trials":10916,"activeCount":100},[],{"intervention":10891,"totalTrials":126,"cells":10918},{"EARLY_PHASE1":10919,"PHASE1":10921,"PHASE2":10923,"PHASE3":10929,"PHASE4":10931,"NA":10933},{"trials":10920,"activeCount":100},[],{"trials":10922,"activeCount":100},[],{"trials":10924,"activeCount":100},[10925],{"nctId":10884,"briefTitle":10885,"status":873,"phases":10926,"primaryCompletion":1644,"completion":6392,"start":7157,"enrollment":10887,"conditions":10927,"interventions":10928},[89],[5430],[10875,10890,10891,10892],{"trials":10930,"activeCount":100},[],{"trials":10932,"activeCount":100},[],{"trials":10934,"activeCount":100},[],{"intervention":10892,"totalTrials":126,"cells":10936},{"EARLY_PHASE1":10937,"PHASE1":10939,"PHASE2":10941,"PHASE3":10947,"PHASE4":10949,"NA":10951},{"trials":10938,"activeCount":100},[],{"trials":10940,"activeCount":100},[],{"trials":10942,"activeCount":100},[10943],{"nctId":10884,"briefTitle":10885,"status":873,"phases":10944,"primaryCompletion":1644,"completion":6392,"start":7157,"enrollment":10887,"conditions":10945,"interventions":10946},[89],[5430],[10875,10890,10891,10892],{"trials":10948,"activeCount":100},[],{"trials":10950,"activeCount":100},[],{"trials":10952,"activeCount":100},[],{"intervention":10954,"totalTrials":126,"cells":10955},"ondansetron",{"EARLY_PHASE1":10956,"PHASE1":10958,"PHASE2":10960,"PHASE3":10972,"PHASE4":10974,"NA":10976},{"trials":10957,"activeCount":100},[],{"trials":10959,"activeCount":100},[],{"trials":10961,"activeCount":100},[10962],{"nctId":10963,"briefTitle":10964,"status":106,"phases":10965,"primaryCompletion":3256,"completion":3256,"start":6456,"enrollment":10966,"conditions":10967,"interventions":10970},"NCT01254877","Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons",[89],357,[10968,10969],"Alcohol Abuse","Alcohol Dependence",[10954,10971],"Ondansetron",{"trials":10973,"activeCount":100},[],{"trials":10975,"activeCount":100},[],{"trials":10977,"activeCount":100},[],{"intervention":803,"totalTrials":126,"cells":10979},{"EARLY_PHASE1":10980,"PHASE1":10982,"PHASE2":10984,"PHASE3":10990,"PHASE4":10992,"NA":10994},{"trials":10981,"activeCount":100},[],{"trials":10983,"activeCount":100},[],{"trials":10985,"activeCount":100},[10986],{"nctId":794,"briefTitle":795,"status":106,"phases":10987,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":10988,"interventions":10989},[89],[801],[770,803,804,805,806,807],{"trials":10991,"activeCount":100},[],{"trials":10993,"activeCount":100},[],{"trials":10995,"activeCount":100},[],{"intervention":804,"totalTrials":126,"cells":10997},{"EARLY_PHASE1":10998,"PHASE1":11000,"PHASE2":11002,"PHASE3":11008,"PHASE4":11010,"NA":11012},{"trials":10999,"activeCount":100},[],{"trials":11001,"activeCount":100},[],{"trials":11003,"activeCount":100},[11004],{"nctId":794,"briefTitle":795,"status":106,"phases":11005,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":11006,"interventions":11007},[89],[801],[770,803,804,805,806,807],{"trials":11009,"activeCount":100},[],{"trials":11011,"activeCount":100},[],{"trials":11013,"activeCount":100},[],{"intervention":805,"totalTrials":126,"cells":11015},{"EARLY_PHASE1":11016,"PHASE1":11018,"PHASE2":11020,"PHASE3":11026,"PHASE4":11028,"NA":11030},{"trials":11017,"activeCount":100},[],{"trials":11019,"activeCount":100},[],{"trials":11021,"activeCount":100},[11022],{"nctId":794,"briefTitle":795,"status":106,"phases":11023,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":11024,"interventions":11025},[89],[801],[770,803,804,805,806,807],{"trials":11027,"activeCount":100},[],{"trials":11029,"activeCount":100},[],{"trials":11031,"activeCount":100},[],{"intervention":806,"totalTrials":126,"cells":11033},{"EARLY_PHASE1":11034,"PHASE1":11036,"PHASE2":11038,"PHASE3":11044,"PHASE4":11046,"NA":11048},{"trials":11035,"activeCount":100},[],{"trials":11037,"activeCount":100},[],{"trials":11039,"activeCount":100},[11040],{"nctId":794,"briefTitle":795,"status":106,"phases":11041,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":11042,"interventions":11043},[89],[801],[770,803,804,805,806,807],{"trials":11045,"activeCount":100},[],{"trials":11047,"activeCount":100},[],{"trials":11049,"activeCount":100},[],{"intervention":807,"totalTrials":126,"cells":11051},{"EARLY_PHASE1":11052,"PHASE1":11054,"PHASE2":11056,"PHASE3":11062,"PHASE4":11064,"NA":11066},{"trials":11053,"activeCount":100},[],{"trials":11055,"activeCount":100},[],{"trials":11057,"activeCount":100},[11058],{"nctId":794,"briefTitle":795,"status":106,"phases":11059,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":11060,"interventions":11061},[89],[801],[770,803,804,805,806,807],{"trials":11063,"activeCount":100},[],{"trials":11065,"activeCount":100},[],{"trials":11067,"activeCount":100},[],{"intervention":11069,"totalTrials":126,"cells":11070},"tadalafil",{"EARLY_PHASE1":11071,"PHASE1":11073,"PHASE2":11075,"PHASE3":11084,"PHASE4":11086,"NA":11088},{"trials":11072,"activeCount":100},[],{"trials":11074,"activeCount":100},[],{"trials":11076,"activeCount":100},[11077],{"nctId":11078,"briefTitle":11079,"status":149,"phases":11080,"primaryCompletion":1646,"completion":1646,"start":5855,"enrollment":100,"conditions":11081,"interventions":11083},"NCT00538564","Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia",[89],[11082,3345],"Sickle Cell Anemia",[11069],{"trials":11085,"activeCount":100},[],{"trials":11087,"activeCount":100},[],{"trials":11089,"activeCount":100},[],{"intervention":11091,"totalTrials":126,"cells":11092},"Mirabegron",{"EARLY_PHASE1":11093,"PHASE1":11095,"PHASE2":11097,"PHASE3":11107,"PHASE4":11109,"NA":11111},{"trials":11094,"activeCount":100},[],{"trials":11096,"activeCount":100},[],{"trials":11098,"activeCount":100},[11099],{"nctId":11100,"briefTitle":11101,"status":106,"phases":11102,"primaryCompletion":9654,"completion":9654,"start":9403,"enrollment":1593,"conditions":11103,"interventions":11106},"NCT02916693","Mirabegron For Erectile Dysfunction",[88,89],[10557,11104,11105],"Overactive Bladder","Urinary Incontinence",[11091],{"trials":11108,"activeCount":100},[],{"trials":11110,"activeCount":100},[],{"trials":11112,"activeCount":100},[],{"intervention":11114,"totalTrials":126,"cells":11115},"3,5-Diiodothyropropionic acid (DITPA) therapy",{"EARLY_PHASE1":11116,"PHASE1":11118,"PHASE2":11120,"PHASE3":11130,"PHASE4":11132,"NA":11134},{"trials":11117,"activeCount":100},[],{"trials":11119,"activeCount":100},[],{"trials":11121,"activeCount":100},[11122],{"nctId":11123,"briefTitle":11124,"status":873,"phases":11125,"completion":1762,"start":11126,"enrollment":715,"conditions":11127,"interventions":11129},"NCT00311987","Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients",[88,89],"2006-04",[11128],"Hypercholesterolemia",[11114],{"trials":11131,"activeCount":100},[],{"trials":11133,"activeCount":100},[],{"trials":11135,"activeCount":100},[],{"intervention":11137,"totalTrials":126,"cells":11138},"High-dose: RIF, INH, PZA, EMB",{"EARLY_PHASE1":11139,"PHASE1":11141,"PHASE2":11143,"PHASE3":11155,"PHASE4":11157,"NA":11159},{"trials":11140,"activeCount":100},[],{"trials":11142,"activeCount":100},[],{"trials":11144,"activeCount":100},[11145],{"nctId":11146,"briefTitle":11147,"status":106,"phases":11148,"primaryCompletion":7513,"completion":7513,"start":11149,"enrollment":2287,"conditions":11150,"interventions":11152},"NCT02958709","Optimizing Treatment to Improve TBM Outcomes in Children",[88,89],"2017-02-22",[11151],"Tuberculosis, Meningeal",[11137,11153,11154],"High dose: RIF, INH, PZA, LEVO","Standard of care: RIF, INH, PZA, EMB",{"trials":11156,"activeCount":100},[],{"trials":11158,"activeCount":100},[],{"trials":11160,"activeCount":100},[],{"intervention":11153,"totalTrials":126,"cells":11162},{"EARLY_PHASE1":11163,"PHASE1":11165,"PHASE2":11167,"PHASE3":11173,"PHASE4":11175,"NA":11177},{"trials":11164,"activeCount":100},[],{"trials":11166,"activeCount":100},[],{"trials":11168,"activeCount":100},[11169],{"nctId":11146,"briefTitle":11147,"status":106,"phases":11170,"primaryCompletion":7513,"completion":7513,"start":11149,"enrollment":2287,"conditions":11171,"interventions":11172},[88,89],[11151],[11137,11153,11154],{"trials":11174,"activeCount":100},[],{"trials":11176,"activeCount":100},[],{"trials":11178,"activeCount":100},[],{"intervention":11154,"totalTrials":126,"cells":11180},{"EARLY_PHASE1":11181,"PHASE1":11183,"PHASE2":11185,"PHASE3":11191,"PHASE4":11193,"NA":11195},{"trials":11182,"activeCount":100},[],{"trials":11184,"activeCount":100},[],{"trials":11186,"activeCount":100},[11187],{"nctId":11146,"briefTitle":11147,"status":106,"phases":11188,"primaryCompletion":7513,"completion":7513,"start":11149,"enrollment":2287,"conditions":11189,"interventions":11190},[88,89],[11151],[11137,11153,11154],{"trials":11192,"activeCount":100},[],{"trials":11194,"activeCount":100},[],{"trials":11196,"activeCount":100},[],{"intervention":11198,"totalTrials":126,"cells":11199},"BCG TICE Vaccine",{"EARLY_PHASE1":11200,"PHASE1":11202,"PHASE2":11204,"PHASE3":11216,"PHASE4":11218,"NA":11220},{"trials":11201,"activeCount":100},[],{"trials":11203,"activeCount":100},[],{"trials":11205,"activeCount":100},[11206],{"nctId":11207,"briefTitle":11208,"status":106,"phases":11209,"primaryCompletion":11210,"completion":11210,"start":11211,"enrollment":164,"conditions":11212,"interventions":11215},"NCT04884308","Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections",[89],"2023-12-30","2021-04-28",[396,11213,11214],"Bronchiectasis Adult","Non-Tuberculous Mycobacteria",[11198],{"trials":11217,"activeCount":100},[],{"trials":11219,"activeCount":100},[],{"trials":11221,"activeCount":100},[],{"intervention":11223,"totalTrials":126,"cells":11224},"naloxone",{"EARLY_PHASE1":11225,"PHASE1":11227,"PHASE2":11229,"PHASE3":11239,"PHASE4":11241,"NA":11243},{"trials":11226,"activeCount":100},[],{"trials":11228,"activeCount":100},[],{"trials":11230,"activeCount":100},[11231],{"nctId":11232,"briefTitle":11233,"status":106,"phases":11234,"primaryCompletion":8079,"completion":8079,"start":5170,"enrollment":394,"conditions":11235,"interventions":11238},"NCT00330343","Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children\u002FAdolescents",[89],[3259,11236,11237],"Nausea","Pruritus",[11223],{"trials":11240,"activeCount":100},[],{"trials":11242,"activeCount":100},[],{"trials":11244,"activeCount":100},[],{"intervention":11246,"totalTrials":126,"cells":11247},"Tramadol",{"EARLY_PHASE1":11248,"PHASE1":11250,"PHASE2":11252,"PHASE3":11260,"PHASE4":11262,"NA":11264},{"trials":11249,"activeCount":100},[],{"trials":11251,"activeCount":100},[],{"trials":11253,"activeCount":100},[11254],{"nctId":11255,"briefTitle":11256,"status":106,"phases":11257,"primaryCompletion":4998,"completion":5856,"start":8480,"enrollment":2081,"conditions":11258,"interventions":11259},"NCT00301210","Assessment of Tramadol as a Treatment for Opioid Addiction",[88,89],[7107],[11246],{"trials":11261,"activeCount":100},[],{"trials":11263,"activeCount":100},[],{"trials":11265,"activeCount":100},[],{"intervention":11267,"totalTrials":126,"cells":11268},"ibogaine with magnesium treatment",{"EARLY_PHASE1":11269,"PHASE1":11271,"PHASE2":11273,"PHASE3":11287,"PHASE4":11289,"NA":11291},{"trials":11270,"activeCount":100},[],{"trials":11272,"activeCount":100},[],{"trials":11274,"activeCount":100},[11275],{"nctId":11276,"briefTitle":11277,"status":149,"phases":11278,"primaryCompletion":581,"completion":1700,"start":11279,"enrollment":100,"conditions":11280,"interventions":11285},"NCT06810765","Trifecta Research Study",[89],"2025-09",[11281,11282,11283,11284],"PTSD - Post Traumatic Stress Disorder","Cognitive Dysfunction","Brain Trauma","Brain Injuries",[11267,11286],"5-MeO-DMT",{"trials":11288,"activeCount":100},[],{"trials":11290,"activeCount":100},[],{"trials":11292,"activeCount":100},[],{"intervention":11286,"totalTrials":126,"cells":11294},{"EARLY_PHASE1":11295,"PHASE1":11297,"PHASE2":11299,"PHASE3":11305,"PHASE4":11307,"NA":11309},{"trials":11296,"activeCount":100},[],{"trials":11298,"activeCount":100},[],{"trials":11300,"activeCount":100},[11301],{"nctId":11276,"briefTitle":11277,"status":149,"phases":11302,"primaryCompletion":581,"completion":1700,"start":11279,"enrollment":100,"conditions":11303,"interventions":11304},[89],[11281,11282,11283,11284],[11267,11286],{"trials":11306,"activeCount":100},[],{"trials":11308,"activeCount":100},[],{"trials":11310,"activeCount":100},[],{"intervention":11312,"totalTrials":126,"cells":11313},"Celecoxib",{"EARLY_PHASE1":11314,"PHASE1":11316,"PHASE2":11318,"PHASE3":11330,"PHASE4":11332,"NA":11334},{"trials":11315,"activeCount":100},[],{"trials":11317,"activeCount":100},[],{"trials":11319,"activeCount":100},[11320],{"nctId":11321,"briefTitle":11322,"status":873,"phases":11323,"primaryCompletion":11324,"completion":11324,"start":11325,"enrollment":1744,"conditions":11326,"interventions":11328},"NCT02845336","Celecoxib for Thyroid Eye Disease",[89],"2019-06-30","2017-03-05",[11327],"Thyroid Eye Disease",[11312,11329],"artificial tears",{"trials":11331,"activeCount":100},[],{"trials":11333,"activeCount":100},[],{"trials":11335,"activeCount":100},[],{"intervention":11329,"totalTrials":126,"cells":11337},{"EARLY_PHASE1":11338,"PHASE1":11340,"PHASE2":11342,"PHASE3":11348,"PHASE4":11350,"NA":11352},{"trials":11339,"activeCount":100},[],{"trials":11341,"activeCount":100},[],{"trials":11343,"activeCount":100},[11344],{"nctId":11321,"briefTitle":11322,"status":873,"phases":11345,"primaryCompletion":11324,"completion":11324,"start":11325,"enrollment":1744,"conditions":11346,"interventions":11347},[89],[11327],[11312,11329],{"trials":11349,"activeCount":100},[],{"trials":11351,"activeCount":100},[],{"trials":11353,"activeCount":100},[],{"intervention":11355,"totalTrials":126,"cells":11356},"Tauroursodeoxycholic Acid",{"EARLY_PHASE1":11357,"PHASE1":11359,"PHASE2":11361,"PHASE3":11374,"PHASE4":11376,"NA":11378},{"trials":11358,"activeCount":100},[],{"trials":11360,"activeCount":100},[],{"trials":11362,"activeCount":100},[11363],{"nctId":11364,"briefTitle":11365,"status":106,"phases":11366,"primaryCompletion":11367,"completion":11368,"start":11369,"enrollment":11370,"conditions":11371,"interventions":11373},"NCT03423121","A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis",[88,89],"2022-04-28","2022-07-05","2018-06-19",59,[11372],"Progressive Multiple Sclerosis",[11355],{"trials":11375,"activeCount":100},[],{"trials":11377,"activeCount":100},[],{"trials":11379,"activeCount":100},[],{"intervention":11381,"totalTrials":126,"cells":11382},"Abrocitinib",{"EARLY_PHASE1":11383,"PHASE1":11385,"PHASE2":11387,"PHASE3":11401,"PHASE4":11403,"NA":11405},{"trials":11384,"activeCount":100},[],{"trials":11386,"activeCount":100},[],{"trials":11388,"activeCount":100},[11389],{"nctId":11390,"briefTitle":11391,"status":106,"phases":11392,"primaryCompletion":11393,"completion":11393,"start":11394,"enrollment":1593,"conditions":11395,"interventions":11400},"NCT05038982","Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin",[89],"2022-07-11","2021-09-09",[11396,11237,11397,11398,11399],"Prurigo Nodularis","Chronic Pruritus","Chronic Prurigo","Skin Diseases",[11381],{"trials":11402,"activeCount":100},[],{"trials":11404,"activeCount":100},[],{"trials":11406,"activeCount":100},[],{"intervention":11408,"totalTrials":126,"cells":11409},"Nicotinamide riboside",{"EARLY_PHASE1":11410,"PHASE1":11412,"PHASE2":11414,"PHASE3":11425,"PHASE4":11427,"NA":11429},{"trials":11411,"activeCount":100},[],{"trials":11413,"activeCount":100},[],{"trials":11415,"activeCount":100},[11416],{"nctId":11417,"briefTitle":11418,"status":106,"phases":11419,"primaryCompletion":11420,"completion":11421,"start":8503,"enrollment":2247,"conditions":11422,"interventions":11424},"NCT03912220","Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration",[89],"2023-05-01","2023-05-30",[11423],"Small Fiber Neuropathy",[11408],{"trials":11426,"activeCount":100},[],{"trials":11428,"activeCount":100},[],{"trials":11430,"activeCount":100},[],{"intervention":11432,"totalTrials":126,"cells":11433},"Escitalopram",{"EARLY_PHASE1":11434,"PHASE1":11436,"PHASE2":11438,"PHASE3":11447,"PHASE4":11449,"NA":11451},{"trials":11435,"activeCount":100},[],{"trials":11437,"activeCount":100},[],{"trials":11439,"activeCount":100},[11440],{"nctId":11441,"briefTitle":11442,"status":106,"phases":11443,"primaryCompletion":2148,"completion":8187,"start":814,"enrollment":9563,"conditions":11444,"interventions":11446},"NCT01368432","Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions",[89],[2383,2384,11445],"Other Psychiatric Disorders",[11432],{"trials":11448,"activeCount":100},[],{"trials":11450,"activeCount":100},[],{"trials":11452,"activeCount":100},[],{"intervention":11454,"totalTrials":126,"cells":11455},"Dalfampridine",{"EARLY_PHASE1":11456,"PHASE1":11458,"PHASE2":11460,"PHASE3":11472,"PHASE4":11474,"NA":11476},{"trials":11457,"activeCount":100},[],{"trials":11459,"activeCount":100},[],{"trials":11461,"activeCount":100},[11462],{"nctId":11463,"briefTitle":11464,"status":106,"phases":11465,"primaryCompletion":11466,"completion":11466,"start":1644,"enrollment":30,"conditions":11467,"interventions":11471},"NCT02166346","Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)",[89],"2017-01-08",[11468,295,11469,11470],"Transverse Myelitis","Idiopathic Transverse Myelitis","Myelitis NOS",[11454],{"trials":11473,"activeCount":100},[],{"trials":11475,"activeCount":100},[],{"trials":11477,"activeCount":100},[],{"intervention":11479,"totalTrials":126,"cells":11480},"CoQ10",{"EARLY_PHASE1":11481,"PHASE1":11483,"PHASE2":11485,"PHASE3":11494,"PHASE4":11496,"NA":11498},{"trials":11482,"activeCount":100},[],{"trials":11484,"activeCount":100},[],{"trials":11486,"activeCount":100},[11487],{"nctId":11488,"briefTitle":11489,"status":106,"phases":11490,"primaryCompletion":5585,"completion":5585,"start":8188,"enrollment":215,"conditions":11491,"interventions":11493},"NCT00920699","Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)",[89],[11492],"Huntington's Disease",[11479],{"trials":11495,"activeCount":100},[],{"trials":11497,"activeCount":100},[],{"trials":11499,"activeCount":100},[],{"intervention":11501,"totalTrials":126,"cells":11502},"Peginterferon lambda alfa-1a subcutaneous",{"EARLY_PHASE1":11503,"PHASE1":11505,"PHASE2":11507,"PHASE3":11518,"PHASE4":11520,"NA":11522},{"trials":11504,"activeCount":100},[],{"trials":11506,"activeCount":100},[],{"trials":11508,"activeCount":100},[11509],{"nctId":11510,"briefTitle":11511,"status":873,"phases":11512,"primaryCompletion":11513,"completion":11513,"start":11514,"enrollment":293,"conditions":11515,"interventions":11517},"NCT04344600","Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection",[89],"2021-09-24","2020-06-29",[11516],"Sars-CoV-2 Infection",[11501],{"trials":11519,"activeCount":100},[],{"trials":11521,"activeCount":100},[],{"trials":11523,"activeCount":100},[],{"intervention":818,"totalTrials":126,"cells":11525},{"EARLY_PHASE1":11526,"PHASE1":11528,"PHASE2":11530,"PHASE3":11536,"PHASE4":11538,"NA":11540},{"trials":11527,"activeCount":100},[],{"trials":11529,"activeCount":100},[],{"trials":11531,"activeCount":100},[11532],{"nctId":809,"briefTitle":810,"status":106,"phases":11533,"primaryCompletion":812,"completion":813,"start":814,"enrollment":815,"conditions":11534,"interventions":11535},[89],[35],[818,819,770],{"trials":11537,"activeCount":100},[],{"trials":11539,"activeCount":100},[],{"trials":11541,"activeCount":100},[],{"intervention":819,"totalTrials":126,"cells":11543},{"EARLY_PHASE1":11544,"PHASE1":11546,"PHASE2":11548,"PHASE3":11554,"PHASE4":11556,"NA":11558},{"trials":11545,"activeCount":100},[],{"trials":11547,"activeCount":100},[],{"trials":11549,"activeCount":100},[11550],{"nctId":809,"briefTitle":810,"status":106,"phases":11551,"primaryCompletion":812,"completion":813,"start":814,"enrollment":815,"conditions":11552,"interventions":11553},[89],[35],[818,819,770],{"trials":11555,"activeCount":100},[],{"trials":11557,"activeCount":100},[],{"trials":11559,"activeCount":100},[],{"intervention":11561,"totalTrials":126,"cells":11562},"Abaloparatide",{"EARLY_PHASE1":11563,"PHASE1":11565,"PHASE2":11567,"PHASE3":11578,"PHASE4":11580,"NA":11582},{"trials":11564,"activeCount":100},[],{"trials":11566,"activeCount":100},[],{"trials":11568,"activeCount":100},[11569],{"nctId":11570,"briefTitle":11571,"status":149,"phases":11572,"primaryCompletion":11573,"completion":1780,"start":11574,"enrollment":100,"conditions":11575,"interventions":11577},"NCT03708926","Effect of Abaloparatide on Lumbar Disc Degeneration",[89],"2023-08","2021-03",[11576],"Degeneration Disc Intervertebral",[11561],{"trials":11579,"activeCount":100},[],{"trials":11581,"activeCount":100},[],{"trials":11583,"activeCount":100},[],{"intervention":11585,"totalTrials":126,"cells":11586},"Dronabinol",{"EARLY_PHASE1":11587,"PHASE1":11589,"PHASE2":11591,"PHASE3":11599,"PHASE4":11601,"NA":11603},{"trials":11588,"activeCount":100},[],{"trials":11590,"activeCount":100},[],{"trials":11592,"activeCount":100},[11593],{"nctId":11594,"briefTitle":11595,"status":106,"phases":11596,"primaryCompletion":1654,"completion":1654,"start":5428,"enrollment":4900,"conditions":11597,"interventions":11598},"NCT02792257","Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease",[89],[5015],[11585],{"trials":11600,"activeCount":100},[],{"trials":11602,"activeCount":100},[],{"trials":11604,"activeCount":100},[],{"intervention":11606,"totalTrials":126,"cells":11607},"GLP-1",{"EARLY_PHASE1":11608,"PHASE1":11610,"PHASE2":11612,"PHASE3":11621,"PHASE4":11623,"NA":11625},{"trials":11609,"activeCount":100},[],{"trials":11611,"activeCount":100},[],{"trials":11613,"activeCount":100},[11614],{"nctId":11615,"briefTitle":11616,"status":873,"phases":11617,"primaryCompletion":8447,"completion":8447,"start":4887,"enrollment":2106,"conditions":11618,"interventions":11620},"NCT00686972","The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition",[89],[11619],"Bariatric Surgery",[11606],{"trials":11622,"activeCount":100},[],{"trials":11624,"activeCount":100},[],{"trials":11626,"activeCount":100},[],{"intervention":11628,"totalTrials":126,"cells":11629},"Xolair®",{"EARLY_PHASE1":11630,"PHASE1":11632,"PHASE2":11634,"PHASE3":11643,"PHASE4":11645,"NA":11647},{"trials":11631,"activeCount":100},[],{"trials":11633,"activeCount":100},[],{"trials":11635,"activeCount":100},[11636],{"nctId":11637,"briefTitle":11638,"status":106,"phases":11639,"primaryCompletion":930,"completion":930,"start":11640,"enrollment":1593,"conditions":11641,"interventions":11642},"NCT00130234","Effect of Anti-IgE in Chronic Urticaria",[89],"2004-11",[8482],[11628],{"trials":11644,"activeCount":100},[],{"trials":11646,"activeCount":100},[],{"trials":11648,"activeCount":100},[],{"intervention":11650,"totalTrials":126,"cells":11651},"Belimumab",{"EARLY_PHASE1":11652,"PHASE1":11654,"PHASE2":11656,"PHASE3":11667,"PHASE4":11669,"NA":11671},{"trials":11653,"activeCount":100},[],{"trials":11655,"activeCount":100},[],{"trials":11657,"activeCount":100},[11658],{"nctId":11659,"briefTitle":11660,"status":873,"phases":11661,"primaryCompletion":11662,"completion":11662,"start":7425,"enrollment":614,"conditions":11663,"interventions":11664},"NCT04767698","Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis",[89],"2022-05-10",[313],[11650,11665,11666],"Short-course Ocrelizumab","Continued Ocrelizumab",{"trials":11668,"activeCount":100},[],{"trials":11670,"activeCount":100},[],{"trials":11672,"activeCount":100},[],{"intervention":11665,"totalTrials":126,"cells":11674},{"EARLY_PHASE1":11675,"PHASE1":11677,"PHASE2":11679,"PHASE3":11685,"PHASE4":11687,"NA":11689},{"trials":11676,"activeCount":100},[],{"trials":11678,"activeCount":100},[],{"trials":11680,"activeCount":100},[11681],{"nctId":11659,"briefTitle":11660,"status":873,"phases":11682,"primaryCompletion":11662,"completion":11662,"start":7425,"enrollment":614,"conditions":11683,"interventions":11684},[89],[313],[11650,11665,11666],{"trials":11686,"activeCount":100},[],{"trials":11688,"activeCount":100},[],{"trials":11690,"activeCount":100},[],{"intervention":11666,"totalTrials":126,"cells":11692},{"EARLY_PHASE1":11693,"PHASE1":11695,"PHASE2":11697,"PHASE3":11703,"PHASE4":11705,"NA":11707},{"trials":11694,"activeCount":100},[],{"trials":11696,"activeCount":100},[],{"trials":11698,"activeCount":100},[11699],{"nctId":11659,"briefTitle":11660,"status":873,"phases":11700,"primaryCompletion":11662,"completion":11662,"start":7425,"enrollment":614,"conditions":11701,"interventions":11702},[89],[313],[11650,11665,11666],{"trials":11704,"activeCount":100},[],{"trials":11706,"activeCount":100},[],{"trials":11708,"activeCount":100},[],{"intervention":11710,"totalTrials":126,"cells":11711},"Euthyroid Group",{"EARLY_PHASE1":11712,"PHASE1":11714,"PHASE2":11716,"PHASE3":11726,"PHASE4":11728,"NA":11730},{"trials":11713,"activeCount":100},[],{"trials":11715,"activeCount":100},[],{"trials":11717,"activeCount":100},[11718],{"nctId":11719,"briefTitle":11720,"status":106,"phases":11721,"primaryCompletion":2339,"completion":2339,"start":11722,"enrollment":4924,"conditions":11723,"interventions":11725},"NCT00181168","Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer",[89],"2001-03",[11724],"Thyroid Cancer",[11710],{"trials":11727,"activeCount":100},[],{"trials":11729,"activeCount":100},[],{"trials":11731,"activeCount":100},[],{"intervention":11733,"totalTrials":126,"cells":11734},"Itraconazole 200 mg",{"EARLY_PHASE1":11735,"PHASE1":11737,"PHASE2":11739,"PHASE3":11748,"PHASE4":11750,"NA":11752},{"trials":11736,"activeCount":100},[],{"trials":11738,"activeCount":100},[],{"trials":11740,"activeCount":100},[11741],{"nctId":11742,"briefTitle":11743,"status":106,"phases":11744,"primaryCompletion":900,"completion":3341,"start":2105,"enrollment":2893,"conditions":11745,"interventions":11746},"NCT00887458","A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy",[89],[3360],[11733,11747],"Itraconazole 300mg",{"trials":11749,"activeCount":100},[],{"trials":11751,"activeCount":100},[],{"trials":11753,"activeCount":100},[],{"intervention":11747,"totalTrials":126,"cells":11755},{"EARLY_PHASE1":11756,"PHASE1":11758,"PHASE2":11760,"PHASE3":11766,"PHASE4":11768,"NA":11770},{"trials":11757,"activeCount":100},[],{"trials":11759,"activeCount":100},[],{"trials":11761,"activeCount":100},[11762],{"nctId":11742,"briefTitle":11743,"status":106,"phases":11763,"primaryCompletion":900,"completion":3341,"start":2105,"enrollment":2893,"conditions":11764,"interventions":11765},[89],[3360],[11733,11747],{"trials":11767,"activeCount":100},[],{"trials":11769,"activeCount":100},[],{"trials":11771,"activeCount":100},[],{"intervention":828,"totalTrials":126,"cells":11773},{"EARLY_PHASE1":11774,"PHASE1":11776,"PHASE2":11778,"PHASE3":11784,"PHASE4":11786,"NA":11788},{"trials":11775,"activeCount":100},[],{"trials":11777,"activeCount":100},[],{"trials":11779,"activeCount":100},[11780],{"nctId":821,"briefTitle":822,"status":106,"phases":11781,"primaryCompletion":824,"completion":824,"start":825,"enrollment":22,"conditions":11782,"interventions":11783},[89],[396],[828,770,829,830,831,832],{"trials":11785,"activeCount":100},[],{"trials":11787,"activeCount":100},[],{"trials":11789,"activeCount":100},[],{"intervention":829,"totalTrials":126,"cells":11791},{"EARLY_PHASE1":11792,"PHASE1":11794,"PHASE2":11796,"PHASE3":11802,"PHASE4":11804,"NA":11806},{"trials":11793,"activeCount":100},[],{"trials":11795,"activeCount":100},[],{"trials":11797,"activeCount":100},[11798],{"nctId":821,"briefTitle":822,"status":106,"phases":11799,"primaryCompletion":824,"completion":824,"start":825,"enrollment":22,"conditions":11800,"interventions":11801},[89],[396],[828,770,829,830,831,832],{"trials":11803,"activeCount":100},[],{"trials":11805,"activeCount":100},[],{"trials":11807,"activeCount":100},[],{"intervention":831,"totalTrials":126,"cells":11809},{"EARLY_PHASE1":11810,"PHASE1":11812,"PHASE2":11814,"PHASE3":11820,"PHASE4":11822,"NA":11824},{"trials":11811,"activeCount":100},[],{"trials":11813,"activeCount":100},[],{"trials":11815,"activeCount":100},[11816],{"nctId":821,"briefTitle":822,"status":106,"phases":11817,"primaryCompletion":824,"completion":824,"start":825,"enrollment":22,"conditions":11818,"interventions":11819},[89],[396],[828,770,829,830,831,832],{"trials":11821,"activeCount":100},[],{"trials":11823,"activeCount":100},[],{"trials":11825,"activeCount":100},[],{"intervention":832,"totalTrials":126,"cells":11827},{"EARLY_PHASE1":11828,"PHASE1":11830,"PHASE2":11832,"PHASE3":11838,"PHASE4":11840,"NA":11842},{"trials":11829,"activeCount":100},[],{"trials":11831,"activeCount":100},[],{"trials":11833,"activeCount":100},[11834],{"nctId":821,"briefTitle":822,"status":106,"phases":11835,"primaryCompletion":824,"completion":824,"start":825,"enrollment":22,"conditions":11836,"interventions":11837},[89],[396],[828,770,829,830,831,832],{"trials":11839,"activeCount":100},[],{"trials":11841,"activeCount":100},[],{"trials":11843,"activeCount":100},[],{"intervention":8829,"totalTrials":126,"cells":11845},{"EARLY_PHASE1":11846,"PHASE1":11848,"PHASE2":11850,"PHASE3":11856,"PHASE4":11858,"NA":11860},{"trials":11847,"activeCount":100},[],{"trials":11849,"activeCount":100},[],{"trials":11851,"activeCount":100},[11852],{"nctId":8823,"briefTitle":8824,"status":106,"phases":11853,"primaryCompletion":8187,"completion":8187,"start":7187,"enrollment":2808,"conditions":11854,"interventions":11855},[89],[8827],[8805,8829],{"trials":11857,"activeCount":100},[],{"trials":11859,"activeCount":100},[],{"trials":11861,"activeCount":100},[],{"intervention":11863,"totalTrials":126,"cells":11864},"0.12% saline",{"EARLY_PHASE1":11865,"PHASE1":11867,"PHASE2":11869,"PHASE3":11878,"PHASE4":11880,"NA":11882},{"trials":11866,"activeCount":100},[],{"trials":11868,"activeCount":100},[],{"trials":11870,"activeCount":100},[11871],{"nctId":11872,"briefTitle":11873,"status":106,"phases":11874,"primaryCompletion":8079,"completion":8079,"start":2186,"enrollment":2175,"conditions":11875,"interventions":11876},"NCT01293084","Hypertonic Saline and Mucociliary Clearance in Children",[89],[396],[11863,11877],"7% saline",{"trials":11879,"activeCount":100},[],{"trials":11881,"activeCount":100},[],{"trials":11883,"activeCount":100},[],{"intervention":11877,"totalTrials":126,"cells":11885},{"EARLY_PHASE1":11886,"PHASE1":11888,"PHASE2":11890,"PHASE3":11896,"PHASE4":11898,"NA":11900},{"trials":11887,"activeCount":100},[],{"trials":11889,"activeCount":100},[],{"trials":11891,"activeCount":100},[11892],{"nctId":11872,"briefTitle":11873,"status":106,"phases":11893,"primaryCompletion":8079,"completion":8079,"start":2186,"enrollment":2175,"conditions":11894,"interventions":11895},[89],[396],[11863,11877],{"trials":11897,"activeCount":100},[],{"trials":11899,"activeCount":100},[],{"trials":11901,"activeCount":100},[],{"intervention":11903,"totalTrials":126,"cells":11904},"Retinol",{"EARLY_PHASE1":11905,"PHASE1":11907,"PHASE2":11909,"PHASE3":11921,"PHASE4":11923,"NA":11925},{"trials":11906,"activeCount":100},[],{"trials":11908,"activeCount":100},[],{"trials":11910,"activeCount":100},[11911],{"nctId":11912,"briefTitle":11913,"status":106,"phases":11914,"primaryCompletion":11915,"completion":11915,"start":8910,"enrollment":30,"conditions":11916,"interventions":11919},"NCT01283464","Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles",[89],"2011-12",[11917,11918],"Photodamaged Skin","Wrinkles",[11903,11920],"Tretinoin",{"trials":11922,"activeCount":100},[],{"trials":11924,"activeCount":100},[],{"trials":11926,"activeCount":100},[],{"intervention":11928,"totalTrials":126,"cells":11929},"AZD1981",{"EARLY_PHASE1":11930,"PHASE1":11932,"PHASE2":11934,"PHASE3":11943,"PHASE4":11945,"NA":11947},{"trials":11931,"activeCount":100},[],{"trials":11933,"activeCount":100},[],{"trials":11935,"activeCount":100},[11936],{"nctId":11937,"briefTitle":11938,"status":106,"phases":11939,"primaryCompletion":292,"completion":292,"start":1686,"enrollment":2287,"conditions":11940,"interventions":11942},"NCT02031679","Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines",[89],[11941],"Chronic Idiopathic Urticaria",[11928],{"trials":11944,"activeCount":100},[],{"trials":11946,"activeCount":100},[],{"trials":11948,"activeCount":100},[],{"intervention":11950,"totalTrials":126,"cells":11951},"intravenous saline",{"EARLY_PHASE1":11952,"PHASE1":11954,"PHASE2":11956,"PHASE3":11969,"PHASE4":11971,"NA":11973},{"trials":11953,"activeCount":100},[],{"trials":11955,"activeCount":100},[],{"trials":11957,"activeCount":100},[11958],{"nctId":11959,"briefTitle":11960,"status":106,"phases":11961,"completion":2128,"start":11962,"enrollment":715,"conditions":11963,"interventions":11965},"NCT00227448","Induced Hypertension for Acute Ischemic Stroke",[89],"2003-06",[11964],"Acute Ischemic Stroke",[11950,11966,11967,11968],"intravenous phenylephrine","intravenous levophed","oral midodrine",{"trials":11970,"activeCount":100},[],{"trials":11972,"activeCount":100},[],{"trials":11974,"activeCount":100},[],{"intervention":11966,"totalTrials":126,"cells":11976},{"EARLY_PHASE1":11977,"PHASE1":11979,"PHASE2":11981,"PHASE3":11987,"PHASE4":11989,"NA":11991},{"trials":11978,"activeCount":100},[],{"trials":11980,"activeCount":100},[],{"trials":11982,"activeCount":100},[11983],{"nctId":11959,"briefTitle":11960,"status":106,"phases":11984,"completion":2128,"start":11962,"enrollment":715,"conditions":11985,"interventions":11986},[89],[11964],[11950,11966,11967,11968],{"trials":11988,"activeCount":100},[],{"trials":11990,"activeCount":100},[],{"trials":11992,"activeCount":100},[],{"intervention":11967,"totalTrials":126,"cells":11994},{"EARLY_PHASE1":11995,"PHASE1":11997,"PHASE2":11999,"PHASE3":12005,"PHASE4":12007,"NA":12009},{"trials":11996,"activeCount":100},[],{"trials":11998,"activeCount":100},[],{"trials":12000,"activeCount":100},[12001],{"nctId":11959,"briefTitle":11960,"status":106,"phases":12002,"completion":2128,"start":11962,"enrollment":715,"conditions":12003,"interventions":12004},[89],[11964],[11950,11966,11967,11968],{"trials":12006,"activeCount":100},[],{"trials":12008,"activeCount":100},[],{"trials":12010,"activeCount":100},[],{"intervention":11968,"totalTrials":126,"cells":12012},{"EARLY_PHASE1":12013,"PHASE1":12015,"PHASE2":12017,"PHASE3":12023,"PHASE4":12025,"NA":12027},{"trials":12014,"activeCount":100},[],{"trials":12016,"activeCount":100},[],{"trials":12018,"activeCount":100},[12019],{"nctId":11959,"briefTitle":11960,"status":106,"phases":12020,"completion":2128,"start":11962,"enrollment":715,"conditions":12021,"interventions":12022},[89],[11964],[11950,11966,11967,11968],{"trials":12024,"activeCount":100},[],{"trials":12026,"activeCount":100},[],{"trials":12028,"activeCount":100},[],{"intervention":8353,"totalTrials":126,"cells":12030},{"EARLY_PHASE1":12031,"PHASE1":12033,"PHASE2":12035,"PHASE3":12041,"PHASE4":12043,"NA":12045},{"trials":12032,"activeCount":100},[],{"trials":12034,"activeCount":100},[],{"trials":12036,"activeCount":100},[12037],{"nctId":8346,"briefTitle":8347,"status":106,"phases":12038,"primaryCompletion":8349,"completion":8349,"start":8176,"enrollment":30,"conditions":12039,"interventions":12040},[88,89],[8351],[8353,8354,8328],{"trials":12042,"activeCount":100},[],{"trials":12044,"activeCount":100},[],{"trials":12046,"activeCount":100},[],{"intervention":8354,"totalTrials":126,"cells":12048},{"EARLY_PHASE1":12049,"PHASE1":12051,"PHASE2":12053,"PHASE3":12059,"PHASE4":12061,"NA":12063},{"trials":12050,"activeCount":100},[],{"trials":12052,"activeCount":100},[],{"trials":12054,"activeCount":100},[12055],{"nctId":8346,"briefTitle":8347,"status":106,"phases":12056,"primaryCompletion":8349,"completion":8349,"start":8176,"enrollment":30,"conditions":12057,"interventions":12058},[88,89],[8351],[8353,8354,8328],{"trials":12060,"activeCount":100},[],{"trials":12062,"activeCount":100},[],{"trials":12064,"activeCount":100},[],{"intervention":12066,"totalTrials":126,"cells":12067},"dupilumab",{"EARLY_PHASE1":12068,"PHASE1":12070,"PHASE2":12072,"PHASE3":12083,"PHASE4":12085,"NA":12087},{"trials":12069,"activeCount":100},[],{"trials":12071,"activeCount":100},[],{"trials":12073,"activeCount":100},[12074],{"nctId":12075,"briefTitle":12076,"status":106,"phases":12077,"primaryCompletion":12078,"completion":12078,"start":12079,"enrollment":3446,"conditions":12080,"interventions":12082},"NCT04362501","Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)",[89],"2025-09-30","2020-10-15",[12081],"Chronic Sinusitis",[12066],{"trials":12084,"activeCount":100},[],{"trials":12086,"activeCount":100},[],{"trials":12088,"activeCount":100},[],{"intervention":12090,"totalTrials":126,"cells":12091},"curcumin",{"EARLY_PHASE1":12092,"PHASE1":12094,"PHASE2":12096,"PHASE3":12105,"PHASE4":12107,"NA":12109},{"trials":12093,"activeCount":100},[],{"trials":12095,"activeCount":100},[],{"trials":12097,"activeCount":100},[12098],{"nctId":12099,"briefTitle":12100,"status":149,"phases":12101,"primaryCompletion":3342,"start":5857,"enrollment":100,"conditions":12102,"interventions":12104},"NCT00248053","Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients",[89],[12103],"Familial Adenomatous Polyposis",[12090],{"trials":12106,"activeCount":100},[],{"trials":12108,"activeCount":100},[],{"trials":12110,"activeCount":100},[],{"intervention":12112,"totalTrials":126,"cells":12113},"Allopurinol",{"EARLY_PHASE1":12114,"PHASE1":12116,"PHASE2":12118,"PHASE3":12126,"PHASE4":12128,"NA":12130},{"trials":12115,"activeCount":100},[],{"trials":12117,"activeCount":100},[],{"trials":12119,"activeCount":100},[12120],{"nctId":12121,"briefTitle":12122,"status":106,"phases":12123,"primaryCompletion":6456,"completion":6456,"start":11640,"enrollment":1582,"conditions":12124,"interventions":12125},"NCT00181155","Intravenous Allopurinol in Heart Failure",[89],[7893],[12112],{"trials":12127,"activeCount":100},[],{"trials":12129,"activeCount":100},[],{"trials":12131,"activeCount":100},[],{"intervention":12133,"totalTrials":126,"cells":12134},"Pregabalin",{"EARLY_PHASE1":12135,"PHASE1":12137,"PHASE2":12139,"PHASE3":12148,"PHASE4":12150,"NA":12152},{"trials":12136,"activeCount":100},[],{"trials":12138,"activeCount":100},[],{"trials":12140,"activeCount":100},[12141],{"nctId":12142,"briefTitle":12143,"status":106,"phases":12144,"primaryCompletion":7286,"completion":7286,"start":5584,"enrollment":329,"conditions":12145,"interventions":12147},"NCT02607254","Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy",[89],[12146],"Idiopathic Small Fiber Neuropathy",[12133],{"trials":12149,"activeCount":100},[],{"trials":12151,"activeCount":100},[],{"trials":12153,"activeCount":100},[],{"intervention":12155,"totalTrials":126,"cells":12156},"tPA",{"EARLY_PHASE1":12157,"PHASE1":12159,"PHASE2":12161,"PHASE3":12169,"PHASE4":12171,"NA":12173},{"trials":12158,"activeCount":100},[],{"trials":12160,"activeCount":100},[],{"trials":12162,"activeCount":100},[12163],{"nctId":12164,"briefTitle":12165,"status":106,"phases":12166,"primaryCompletion":7210,"completion":7210,"start":4970,"enrollment":1593,"conditions":12167,"interventions":12168},"NCT01643902","Safety of Intravenous Thrombolytics in Stroke on Awakening",[89],[32],[12155],{"trials":12170,"activeCount":100},[],{"trials":12172,"activeCount":100},[],{"trials":12174,"activeCount":100},[],{"intervention":12176,"totalTrials":126,"cells":12177},"Recombinant Tissue Plasminogen Activator",{"EARLY_PHASE1":12178,"PHASE1":12180,"PHASE2":12182,"PHASE3":12193,"PHASE4":12195,"NA":12197},{"trials":12179,"activeCount":100},[],{"trials":12181,"activeCount":100},[],{"trials":12183,"activeCount":100},[12184],{"nctId":12185,"briefTitle":12186,"status":106,"phases":12187,"completion":12188,"start":12189,"enrollment":164,"conditions":12190,"interventions":12192},"NCT00029315","Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage",[89],"2004-09","2001-09",[12191],"Cerebral Hemorrhage",[12176],{"trials":12194,"activeCount":100},[],{"trials":12196,"activeCount":100},[],{"trials":12198,"activeCount":100},[],{"intervention":12200,"totalTrials":126,"cells":12201},"rhLactoferrin",{"EARLY_PHASE1":12202,"PHASE1":12204,"PHASE2":12206,"PHASE3":12218,"PHASE4":12220,"NA":12222},{"trials":12203,"activeCount":100},[],{"trials":12205,"activeCount":100},[],{"trials":12207,"activeCount":100},[12208],{"nctId":12209,"briefTitle":12210,"status":106,"phases":12211,"primaryCompletion":12212,"completion":12212,"start":12213,"enrollment":2717,"conditions":12214,"interventions":12217},"NCT02968992","Effects of rhLactoferrin on Chronic Inflammation in the Elderly",[89],"2019-02-25","2017-08-14",[12215,12216],"Inflammation","Cognitive Deterioration",[12200],{"trials":12219,"activeCount":100},[],{"trials":12221,"activeCount":100},[],{"trials":12223,"activeCount":100},[],{"intervention":8450,"totalTrials":126,"cells":12225},{"EARLY_PHASE1":12226,"PHASE1":12228,"PHASE2":12230,"PHASE3":12236,"PHASE4":12238,"NA":12240},{"trials":12227,"activeCount":100},[],{"trials":12229,"activeCount":100},[],{"trials":12231,"activeCount":100},[12232],{"nctId":8443,"briefTitle":8444,"status":106,"phases":12233,"primaryCompletion":8446,"completion":8446,"start":8447,"enrollment":5241,"conditions":12234,"interventions":12235},[88,89],[2311,2313,7515],[8450,8425,8451],{"trials":12237,"activeCount":100},[],{"trials":12239,"activeCount":100},[],{"trials":12241,"activeCount":100},[],{"intervention":8451,"totalTrials":126,"cells":12243},{"EARLY_PHASE1":12244,"PHASE1":12246,"PHASE2":12248,"PHASE3":12254,"PHASE4":12256,"NA":12258},{"trials":12245,"activeCount":100},[],{"trials":12247,"activeCount":100},[],{"trials":12249,"activeCount":100},[12250],{"nctId":8443,"briefTitle":8444,"status":106,"phases":12251,"primaryCompletion":8446,"completion":8446,"start":8447,"enrollment":5241,"conditions":12252,"interventions":12253},[88,89],[2311,2313,7515],[8450,8425,8451],{"trials":12255,"activeCount":100},[],{"trials":12257,"activeCount":100},[],{"trials":12259,"activeCount":100},[],{"intervention":12261,"totalTrials":126,"cells":12262},"Simvastatin 80 mg",{"EARLY_PHASE1":12263,"PHASE1":12265,"PHASE2":12267,"PHASE3":12275,"PHASE4":12277,"NA":12279},{"trials":12264,"activeCount":100},[],{"trials":12266,"activeCount":100},[],{"trials":12268,"activeCount":100},[12269],{"nctId":12270,"briefTitle":12271,"status":873,"phases":12272,"primaryCompletion":8079,"completion":8079,"start":901,"enrollment":126,"conditions":12273,"interventions":12274},"NCT00718328","Simvastatin For Intracerebral Hemorrhage Study",[89],[2500],[12261],{"trials":12276,"activeCount":100},[],{"trials":12278,"activeCount":100},[],{"trials":12280,"activeCount":100},[],{"intervention":4891,"totalTrials":126,"cells":12282},{"EARLY_PHASE1":12283,"PHASE1":12285,"PHASE2":12287,"PHASE3":12293,"PHASE4":12295,"NA":12297},{"trials":12284,"activeCount":100},[],{"trials":12286,"activeCount":100},[],{"trials":12288,"activeCount":100},[12289],{"nctId":4884,"briefTitle":4885,"status":106,"phases":12290,"primaryCompletion":4854,"completion":4854,"start":4887,"enrollment":1582,"conditions":12291,"interventions":12292},[89],[4889],[4891,4862,4892],{"trials":12294,"activeCount":100},[],{"trials":12296,"activeCount":100},[],{"trials":12298,"activeCount":100},[],{"intervention":4892,"totalTrials":126,"cells":12300},{"EARLY_PHASE1":12301,"PHASE1":12303,"PHASE2":12305,"PHASE3":12311,"PHASE4":12313,"NA":12315},{"trials":12302,"activeCount":100},[],{"trials":12304,"activeCount":100},[],{"trials":12306,"activeCount":100},[12307],{"nctId":4884,"briefTitle":4885,"status":106,"phases":12308,"primaryCompletion":4854,"completion":4854,"start":4887,"enrollment":1582,"conditions":12309,"interventions":12310},[89],[4889],[4891,4862,4892],{"trials":12312,"activeCount":100},[],{"trials":12314,"activeCount":100},[],{"trials":12316,"activeCount":100},[],{"intervention":12318,"totalTrials":280,"cells":12319},"Bevacizumab",{"EARLY_PHASE1":12320,"PHASE1":12322,"PHASE2":12339,"PHASE3":12341,"PHASE4":12343,"NA":12345},{"trials":12321,"activeCount":100},[],{"trials":12323,"activeCount":100},[12324,12332],{"nctId":12325,"briefTitle":12326,"status":106,"phases":12327,"primaryCompletion":1762,"completion":4854,"start":225,"enrollment":264,"conditions":12328,"interventions":12331},"NCT00407719","Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)",[88],[7402,12329,12330],"Degenerative Myopia","Pathological Myopia",[12318],{"nctId":12333,"briefTitle":12334,"status":106,"phases":12335,"primaryCompletion":12336,"completion":4876,"start":812,"enrollment":264,"conditions":12337,"interventions":12338},"NCT01777412","Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations",[88],"2015-02",[295,296],[12318],{"trials":12340,"activeCount":100},[],{"trials":12342,"activeCount":100},[],{"trials":12344,"activeCount":100},[],{"trials":12346,"activeCount":100},[],{"intervention":7099,"totalTrials":280,"cells":12348},{"EARLY_PHASE1":12349,"PHASE1":12351,"PHASE2":12361,"PHASE3":12363,"PHASE4":12365,"NA":12367},{"trials":12350,"activeCount":100},[],{"trials":12352,"activeCount":100},[12353,12357],{"nctId":7092,"briefTitle":7093,"status":106,"phases":12354,"primaryCompletion":290,"completion":290,"start":1929,"enrollment":7095,"conditions":12355,"interventions":12356},[88],[2313,3259,7097],[7099,2282],{"nctId":7101,"briefTitle":7102,"status":106,"phases":12358,"primaryCompletion":6608,"completion":6608,"start":7104,"enrollment":7105,"conditions":12359,"interventions":12360},[88],[7107,7108],[2282,7099],{"trials":12362,"activeCount":100},[],{"trials":12364,"activeCount":100},[],{"trials":12366,"activeCount":100},[],{"trials":12368,"activeCount":100},[],{"intervention":12370,"totalTrials":280,"cells":12371},"IV Diazoxide",{"EARLY_PHASE1":12372,"PHASE1":12374,"PHASE2":12394,"PHASE3":12396,"PHASE4":12398,"NA":12400},{"trials":12373,"activeCount":100},[],{"trials":12375,"activeCount":100},[12376,12385],{"nctId":12377,"briefTitle":12378,"status":106,"phases":12379,"primaryCompletion":12380,"completion":12380,"start":12381,"enrollment":164,"conditions":12382,"interventions":12384},"NCT06308107","Safety and Feasibility of Hyperkalemic Cardioplegia With Diazoxide in Cardiac Surgery (CPG-DZX) Trial",[88],"2025-05-09","2024-07-08",[12383],"Myocardial Stunning",[12370],{"nctId":12386,"briefTitle":12387,"status":149,"phases":12388,"primaryCompletion":12389,"completion":12390,"start":12391,"enrollment":100,"conditions":12392,"interventions":12393},"NCT04830982","Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass",[88],"2025-08-30","2025-10-30","2023-09-01",[12383],[12370],{"trials":12395,"activeCount":100},[],{"trials":12397,"activeCount":100},[],{"trials":12399,"activeCount":100},[],{"trials":12401,"activeCount":100},[],{"intervention":12403,"totalTrials":280,"cells":12404},"[11C]CPPC",{"EARLY_PHASE1":12405,"PHASE1":12417,"PHASE2":12427,"PHASE3":12429,"PHASE4":12431,"NA":12433},{"trials":12406,"activeCount":100},[12407],{"nctId":12408,"briefTitle":12409,"status":106,"phases":12410,"primaryCompletion":12411,"completion":12412,"start":12413,"enrollment":293,"conditions":12414,"interventions":12416},"NCT06223971","Long COVID-19 [11C]CPPC Study",[87],"2025-04-30","2026-03-31","2024-08-06",[12415],"COVID Long-Haul",[12403,12403],{"trials":12418,"activeCount":100},[12419],{"nctId":12420,"briefTitle":12421,"status":873,"phases":12422,"primaryCompletion":12423,"completion":12423,"start":12424,"enrollment":614,"conditions":12425,"interventions":12426},"NCT04749433","Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS",[88],"2023-03-30","2021-09-01",[1607],[12403],{"trials":12428,"activeCount":100},[],{"trials":12430,"activeCount":100},[],{"trials":12432,"activeCount":100},[],{"trials":12434,"activeCount":100},[],{"intervention":12436,"totalTrials":280,"cells":12437},"Tenofovir Douche",{"EARLY_PHASE1":12438,"PHASE1":12440,"PHASE2":12458,"PHASE3":12460,"PHASE4":12462,"NA":12464},{"trials":12439,"activeCount":100},[],{"trials":12441,"activeCount":100},[12442,12449],{"nctId":12443,"briefTitle":12444,"status":106,"phases":12445,"primaryCompletion":5627,"completion":5627,"start":5628,"enrollment":293,"conditions":12446,"interventions":12448},"NCT04195776","Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse",[88],[12447,3930],"HIV\u002FAIDS",[12436],{"nctId":12450,"briefTitle":12451,"status":106,"phases":12452,"primaryCompletion":12453,"completion":12453,"start":12454,"enrollment":2081,"conditions":12455,"interventions":12456},"NCT04016233","Tenofovir Rectal Douche to Prevent HIV Transmission",[88],"2021-04-27","2020-01-10",[12447,3930],[12457],"Tenofovir douche",{"trials":12459,"activeCount":100},[],{"trials":12461,"activeCount":100},[],{"trials":12463,"activeCount":100},[],{"trials":12465,"activeCount":100},[],{"intervention":12467,"totalTrials":126,"cells":12468},"Tofacitinib",{"EARLY_PHASE1":12469,"PHASE1":12471,"PHASE2":12480,"PHASE3":12482,"PHASE4":12484,"NA":12486},{"trials":12470,"activeCount":100},[],{"trials":12472,"activeCount":100},[12473],{"nctId":12474,"briefTitle":12475,"status":106,"phases":12476,"primaryCompletion":5452,"completion":5452,"start":3256,"enrollment":264,"conditions":12477,"interventions":12479},"NCT03002649","Study of Tofacitinib in Refractory Dermatomyositis",[88],[12478],"Dermatomyositis",[12467],{"trials":12481,"activeCount":100},[],{"trials":12483,"activeCount":100},[],{"trials":12485,"activeCount":100},[],{"trials":12487,"activeCount":100},[],{"intervention":3593,"totalTrials":126,"cells":12489},{"EARLY_PHASE1":12490,"PHASE1":12492,"PHASE2":12498,"PHASE3":12500,"PHASE4":12502,"NA":12504},{"trials":12491,"activeCount":100},[],{"trials":12493,"activeCount":100},[12494],{"nctId":3586,"briefTitle":3587,"status":106,"phases":12495,"primaryCompletion":3589,"completion":3575,"start":3590,"enrollment":1854,"conditions":12496,"interventions":12497},[88],[1878],[3593,3594,56,3595,3596,3597],{"trials":12499,"activeCount":100},[],{"trials":12501,"activeCount":100},[],{"trials":12503,"activeCount":100},[],{"trials":12505,"activeCount":100},[],{"intervention":3594,"totalTrials":126,"cells":12507},{"EARLY_PHASE1":12508,"PHASE1":12510,"PHASE2":12516,"PHASE3":12518,"PHASE4":12520,"NA":12522},{"trials":12509,"activeCount":100},[],{"trials":12511,"activeCount":100},[12512],{"nctId":3586,"briefTitle":3587,"status":106,"phases":12513,"primaryCompletion":3589,"completion":3575,"start":3590,"enrollment":1854,"conditions":12514,"interventions":12515},[88],[1878],[3593,3594,56,3595,3596,3597],{"trials":12517,"activeCount":100},[],{"trials":12519,"activeCount":100},[],{"trials":12521,"activeCount":100},[],{"trials":12523,"activeCount":100},[],{"intervention":3595,"totalTrials":126,"cells":12525},{"EARLY_PHASE1":12526,"PHASE1":12528,"PHASE2":12534,"PHASE3":12536,"PHASE4":12538,"NA":12540},{"trials":12527,"activeCount":100},[],{"trials":12529,"activeCount":100},[12530],{"nctId":3586,"briefTitle":3587,"status":106,"phases":12531,"primaryCompletion":3589,"completion":3575,"start":3590,"enrollment":1854,"conditions":12532,"interventions":12533},[88],[1878],[3593,3594,56,3595,3596,3597],{"trials":12535,"activeCount":100},[],{"trials":12537,"activeCount":100},[],{"trials":12539,"activeCount":100},[],{"trials":12541,"activeCount":100},[],{"intervention":3596,"totalTrials":126,"cells":12543},{"EARLY_PHASE1":12544,"PHASE1":12546,"PHASE2":12552,"PHASE3":12554,"PHASE4":12556,"NA":12558},{"trials":12545,"activeCount":100},[],{"trials":12547,"activeCount":100},[12548],{"nctId":3586,"briefTitle":3587,"status":106,"phases":12549,"primaryCompletion":3589,"completion":3575,"start":3590,"enrollment":1854,"conditions":12550,"interventions":12551},[88],[1878],[3593,3594,56,3595,3596,3597],{"trials":12553,"activeCount":100},[],{"trials":12555,"activeCount":100},[],{"trials":12557,"activeCount":100},[],{"trials":12559,"activeCount":100},[],{"intervention":3597,"totalTrials":126,"cells":12561},{"EARLY_PHASE1":12562,"PHASE1":12564,"PHASE2":12570,"PHASE3":12572,"PHASE4":12574,"NA":12576},{"trials":12563,"activeCount":100},[],{"trials":12565,"activeCount":100},[12566],{"nctId":3586,"briefTitle":3587,"status":106,"phases":12567,"primaryCompletion":3589,"completion":3575,"start":3590,"enrollment":1854,"conditions":12568,"interventions":12569},[88],[1878],[3593,3594,56,3595,3596,3597],{"trials":12571,"activeCount":100},[],{"trials":12573,"activeCount":100},[],{"trials":12575,"activeCount":100},[],{"trials":12577,"activeCount":100},[],{"intervention":12579,"totalTrials":126,"cells":12580},"valproic acid",{"EARLY_PHASE1":12581,"PHASE1":12583,"PHASE2":12592,"PHASE3":12594,"PHASE4":12596,"NA":12598},{"trials":12582,"activeCount":100},[],{"trials":12584,"activeCount":100},[12585],{"nctId":12586,"briefTitle":12587,"status":149,"phases":12588,"completion":5790,"start":12589,"enrollment":100,"conditions":12590,"interventions":12591},"NCT00181220","Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma",[88],"2004-04",[9094],[12579],{"trials":12593,"activeCount":100},[],{"trials":12595,"activeCount":100},[],{"trials":12597,"activeCount":100},[],{"trials":12599,"activeCount":100},[],{"intervention":12601,"totalTrials":126,"cells":12602},"Tenofovir",{"EARLY_PHASE1":12603,"PHASE1":12605,"PHASE2":12617,"PHASE3":12619,"PHASE4":12621,"NA":12623},{"trials":12604,"activeCount":100},[],{"trials":12606,"activeCount":100},[12607],{"nctId":12608,"briefTitle":12609,"status":106,"phases":12610,"primaryCompletion":12611,"completion":12611,"start":12612,"enrollment":12613,"conditions":12614,"interventions":12616},"NCT03719053","Single Dose Truvada Study",[88],"2020-06-30","2018-10-25",44,[12615,3930],"Medication Adherence",[12601],{"trials":12618,"activeCount":100},[],{"trials":12620,"activeCount":100},[],{"trials":12622,"activeCount":100},[],{"trials":12624,"activeCount":100},[],{"intervention":12626,"totalTrials":126,"cells":12627},"Oral or vaporized cannabidiol",{"EARLY_PHASE1":12628,"PHASE1":12630,"PHASE2":12641,"PHASE3":12643,"PHASE4":12645,"NA":12647},{"trials":12629,"activeCount":100},[],{"trials":12631,"activeCount":100},[12632],{"nctId":12633,"briefTitle":12634,"status":106,"phases":12635,"primaryCompletion":12636,"completion":12637,"start":2716,"enrollment":2151,"conditions":12638,"interventions":12640},"NCT03164512","The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol",[88],"2019-08-29","2020-01-22",[12639],"Cannabidiol Pharmacokinetics",[12626],{"trials":12642,"activeCount":100},[],{"trials":12644,"activeCount":100},[],{"trials":12646,"activeCount":100},[],{"trials":12648,"activeCount":100},[],{"intervention":12650,"totalTrials":126,"cells":12651},"grape seed polyphenolic extract, resveratrol",{"EARLY_PHASE1":12652,"PHASE1":12654,"PHASE2":12663,"PHASE3":12665,"PHASE4":12667,"NA":12669},{"trials":12653,"activeCount":100},[],{"trials":12655,"activeCount":100},[12656],{"nctId":12657,"briefTitle":12658,"status":106,"phases":12659,"primaryCompletion":12660,"completion":12660,"start":8446,"enrollment":7105,"conditions":12661,"interventions":12662},"NCT02502253","BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)",[88],"2022-06-01",[1597,5015],[12650],{"trials":12664,"activeCount":100},[],{"trials":12666,"activeCount":100},[],{"trials":12668,"activeCount":100},[],{"trials":12670,"activeCount":100},[],{"intervention":12672,"totalTrials":126,"cells":12673},"Estradiol",{"EARLY_PHASE1":12674,"PHASE1":12676,"PHASE2":12685,"PHASE3":12687,"PHASE4":12689,"NA":12691},{"trials":12675,"activeCount":100},[],{"trials":12677,"activeCount":100},[12678],{"nctId":12679,"briefTitle":12680,"status":149,"phases":12681,"primaryCompletion":12682,"completion":12682,"start":1761,"enrollment":100,"conditions":12683,"interventions":12684},"NCT02792153","Estradiol and Fear Extinction in Anorexia Nervosa (AN)",[88],"2018-08-22",[1618],[12672],{"trials":12686,"activeCount":100},[],{"trials":12688,"activeCount":100},[],{"trials":12690,"activeCount":100},[],{"trials":12692,"activeCount":100},[],{"intervention":12694,"totalTrials":126,"cells":12695},"intermittent IV CLON",{"EARLY_PHASE1":12696,"PHASE1":12698,"PHASE2":12708,"PHASE3":12710,"PHASE4":12712,"NA":12714},{"trials":12697,"activeCount":100},[],{"trials":12699,"activeCount":100},[12700],{"nctId":12701,"briefTitle":12702,"status":106,"phases":12703,"primaryCompletion":12704,"completion":12704,"start":5584,"enrollment":7105,"conditions":12705,"interventions":12707},"NCT02249039","Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study",[88],"2019-12",[12706],"Mechanical Ventilation Complication",[12694],{"trials":12709,"activeCount":100},[],{"trials":12711,"activeCount":100},[],{"trials":12713,"activeCount":100},[],{"trials":12715,"activeCount":100},[],{"intervention":12717,"totalTrials":126,"cells":12718},"Sargramostim",{"EARLY_PHASE1":12719,"PHASE1":12721,"PHASE2":12730,"PHASE3":12732,"PHASE4":12734,"NA":12736},{"trials":12720,"activeCount":100},[],{"trials":12722,"activeCount":100},[12723],{"nctId":12724,"briefTitle":12725,"status":106,"phases":12726,"primaryCompletion":714,"completion":714,"start":1687,"enrollment":280,"conditions":12727,"interventions":12729},"NCT01871467","Sargramostim for Myeloid Dendritic Cell Deficiency",[88],[12728],"Dendritic Cell Deficiency",[12717],{"trials":12731,"activeCount":100},[],{"trials":12733,"activeCount":100},[],{"trials":12735,"activeCount":100},[],{"trials":12737,"activeCount":100},[],{"intervention":12739,"totalTrials":126,"cells":12740},"Jojoba oil with broccoli sprout extract",{"EARLY_PHASE1":12741,"PHASE1":12743,"PHASE2":12754,"PHASE3":12756,"PHASE4":12758,"NA":12760},{"trials":12742,"activeCount":100},[],{"trials":12744,"activeCount":100},[12745],{"nctId":12746,"briefTitle":12747,"status":106,"phases":12748,"primaryCompletion":1761,"completion":1761,"start":5584,"enrollment":96,"conditions":12749,"interventions":12752},"NCT02592954","Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin",[88],[12750,12751],"Epidermolysis Bullosa Simplex","Pachyonychia Congenita",[12739,12753],"Jojoba oil",{"trials":12755,"activeCount":100},[],{"trials":12757,"activeCount":100},[],{"trials":12759,"activeCount":100},[],{"trials":12761,"activeCount":100},[],{"intervention":12753,"totalTrials":126,"cells":12763},{"EARLY_PHASE1":12764,"PHASE1":12766,"PHASE2":12772,"PHASE3":12774,"PHASE4":12776,"NA":12778},{"trials":12765,"activeCount":100},[],{"trials":12767,"activeCount":100},[12768],{"nctId":12746,"briefTitle":12747,"status":106,"phases":12769,"primaryCompletion":1761,"completion":1761,"start":5584,"enrollment":96,"conditions":12770,"interventions":12771},[88],[12750,12751],[12739,12753],{"trials":12773,"activeCount":100},[],{"trials":12775,"activeCount":100},[],{"trials":12777,"activeCount":100},[],{"trials":12779,"activeCount":100},[],{"intervention":12781,"totalTrials":126,"cells":12782},"Blinded drug dose conditions",{"EARLY_PHASE1":12783,"PHASE1":12785,"PHASE2":12794,"PHASE3":12796,"PHASE4":12798,"NA":12800},{"trials":12784,"activeCount":100},[],{"trials":12786,"activeCount":100},[12787],{"nctId":12788,"briefTitle":12789,"status":873,"phases":12790,"primaryCompletion":2473,"completion":2473,"start":12791,"enrollment":126,"conditions":12792,"interventions":12793},"NCT04315961","Effects of Dietary Conditions on Drug Response",[88],"2020-09-18",[112],[12781],{"trials":12795,"activeCount":100},[],{"trials":12797,"activeCount":100},[],{"trials":12799,"activeCount":100},[],{"trials":12801,"activeCount":100},[],{"intervention":12803,"totalTrials":126,"cells":12804},"CeraLyte 90",{"EARLY_PHASE1":12805,"PHASE1":12807,"PHASE2":12821,"PHASE3":12823,"PHASE4":12825,"NA":12827},{"trials":12806,"activeCount":100},[],{"trials":12808,"activeCount":100},[12809],{"nctId":12810,"briefTitle":12811,"status":873,"phases":12812,"primaryCompletion":1655,"completion":1655,"start":1687,"enrollment":235,"conditions":12813,"interventions":12820},"NCT02124265","Oral Rehydration Therapy in Burn Patients",[88],[12814,12815,12816,12817,12818,12819],"Burn Any Degree Involving 20-29 Percent of Body Surface","Burn Any Degree Involving 30-39 Percent of Body Surface","Burn Any Degree Involving 40-49 Percent of Body Surface","Burn Any Degree Involving 50-59 Percent of Body Surface","Burn Any Degree Involving 60-65 Percent of Body Surface","Fluid Resuscitation",[12803],{"trials":12822,"activeCount":100},[],{"trials":12824,"activeCount":100},[],{"trials":12826,"activeCount":100},[],{"trials":12828,"activeCount":100},[],{"intervention":12830,"totalTrials":126,"cells":12831},"2% buffered hypertonic saline administration",{"EARLY_PHASE1":12832,"PHASE1":12834,"PHASE2":12843,"PHASE3":12845,"PHASE4":12847,"NA":12849},{"trials":12833,"activeCount":100},[],{"trials":12835,"activeCount":100},[12836],{"nctId":12837,"briefTitle":12838,"status":106,"phases":12839,"primaryCompletion":11126,"completion":11126,"start":11962,"enrollment":1593,"conditions":12840,"interventions":12842},"NCT00181077","Hypertonic Saline Use in Preeclampsia",[88],[12841],"Preeclampsia",[12830],{"trials":12844,"activeCount":100},[],{"trials":12846,"activeCount":100},[],{"trials":12848,"activeCount":100},[],{"trials":12850,"activeCount":100},[],{"intervention":12852,"totalTrials":126,"cells":12853},"DuoGel",{"EARLY_PHASE1":12854,"PHASE1":12856,"PHASE2":12865,"PHASE3":12867,"PHASE4":12869,"NA":12871},{"trials":12855,"activeCount":100},[],{"trials":12857,"activeCount":100},[12858],{"nctId":12859,"briefTitle":12860,"status":106,"phases":12861,"primaryCompletion":8297,"completion":12862,"start":4404,"enrollment":264,"conditions":12863,"interventions":12864},"NCT03082690","ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study",[88],"2019-06-02",[3930],[12852],{"trials":12866,"activeCount":100},[],{"trials":12868,"activeCount":100},[],{"trials":12870,"activeCount":100},[],{"trials":12872,"activeCount":100},[],{"intervention":12874,"totalTrials":126,"cells":12875},"MDC",{"EARLY_PHASE1":12876,"PHASE1":12878,"PHASE2":12889,"PHASE3":12891,"PHASE4":12893,"NA":12895},{"trials":12877,"activeCount":100},[],{"trials":12879,"activeCount":100},[12880],{"nctId":12881,"briefTitle":12882,"status":873,"phases":12883,"primaryCompletion":12884,"completion":12884,"start":12885,"enrollment":280,"conditions":12886,"interventions":12888},"NCT01011777","Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence",[88],"2020-01-23","2017-02-01",[12887,11105],"Bladder Exstrophy",[12874],{"trials":12890,"activeCount":100},[],{"trials":12892,"activeCount":100},[],{"trials":12894,"activeCount":100},[],{"trials":12896,"activeCount":100},[],{"intervention":12898,"totalTrials":126,"cells":12899},"Timolol",{"EARLY_PHASE1":12900,"PHASE1":12902,"PHASE2":12911,"PHASE3":12913,"PHASE4":12915,"NA":12917},{"trials":12901,"activeCount":100},[],{"trials":12903,"activeCount":100},[12904],{"nctId":12905,"briefTitle":12906,"status":106,"phases":12907,"primaryCompletion":11574,"completion":11574,"start":3299,"enrollment":4344,"conditions":12908,"interventions":12910},"NCT02774590","Timolol for the Treatment of Acne and Rosacea",[88],[12909,4283],"Acne Vulgaris",[12898],{"trials":12912,"activeCount":100},[],{"trials":12914,"activeCount":100},[],{"trials":12916,"activeCount":100},[],{"trials":12918,"activeCount":100},[],{"intervention":12920,"totalTrials":126,"cells":12921},"Maraviroc",{"EARLY_PHASE1":12922,"PHASE1":12924,"PHASE2":12935,"PHASE3":12937,"PHASE4":12939,"NA":12941},{"trials":12923,"activeCount":100},[],{"trials":12925,"activeCount":100},[12926],{"nctId":12927,"briefTitle":12928,"status":106,"phases":12929,"primaryCompletion":4518,"completion":4518,"start":4970,"enrollment":30,"conditions":12930,"interventions":12934},"NCT01980329","Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites",[88],[12931,12932,12933],"Cytochrome P450 CYP3A5 Enzyme Polymorphism","Healthy Subjects","Pharmacokinetics of Maraviroc",[12920],{"trials":12936,"activeCount":100},[],{"trials":12938,"activeCount":100},[],{"trials":12940,"activeCount":100},[],{"trials":12942,"activeCount":100},[],{"intervention":12944,"totalTrials":126,"cells":12945},"Tenofovir Disoproxil Fumarate\u002FEmtricitabine",{"EARLY_PHASE1":12946,"PHASE1":12948,"PHASE2":12957,"PHASE3":12959,"PHASE4":12961,"NA":12963},{"trials":12947,"activeCount":100},[],{"trials":12949,"activeCount":100},[12950],{"nctId":12951,"briefTitle":12952,"status":106,"phases":12953,"primaryCompletion":5520,"completion":5520,"start":12954,"enrollment":9563,"conditions":12955,"interventions":12956},"NCT03060785","Finding the Right Tenofovir\u002FEmtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women",[88],"2016-03-08",[3930],[12944],{"trials":12958,"activeCount":100},[],{"trials":12960,"activeCount":100},[],{"trials":12962,"activeCount":100},[],{"trials":12964,"activeCount":100},[],{"intervention":12966,"totalTrials":126,"cells":12967},"Heparin Sodium",{"EARLY_PHASE1":12968,"PHASE1":12970,"PHASE2":12981,"PHASE3":12983,"PHASE4":12985,"NA":12987},{"trials":12969,"activeCount":100},[],{"trials":12971,"activeCount":100},[12972],{"nctId":12973,"briefTitle":12974,"status":149,"phases":12975,"primaryCompletion":4912,"completion":4912,"start":12976,"enrollment":100,"conditions":12977,"interventions":12979},"NCT03707418","Bivalirudin vs Heparin in ECMO Patients",[88],"2021-04",[12978],"Extracorporeal Membrane Oxygenation Complication",[12966,12980],"Bivalirudin Injection [Angiomax]",{"trials":12982,"activeCount":100},[],{"trials":12984,"activeCount":100},[],{"trials":12986,"activeCount":100},[],{"trials":12988,"activeCount":100},[],{"intervention":12980,"totalTrials":126,"cells":12990},{"EARLY_PHASE1":12991,"PHASE1":12993,"PHASE2":12999,"PHASE3":13001,"PHASE4":13003,"NA":13005},{"trials":12992,"activeCount":100},[],{"trials":12994,"activeCount":100},[12995],{"nctId":12973,"briefTitle":12974,"status":149,"phases":12996,"primaryCompletion":4912,"completion":4912,"start":12976,"enrollment":100,"conditions":12997,"interventions":12998},[88],[12978],[12966,12980],{"trials":13000,"activeCount":100},[],{"trials":13002,"activeCount":100},[],{"trials":13004,"activeCount":100},[],{"trials":13006,"activeCount":100},[],{"intervention":5101,"totalTrials":126,"cells":13008},{"EARLY_PHASE1":13009,"PHASE1":13011,"PHASE2":13017,"PHASE3":13019,"PHASE4":13021,"NA":13023},{"trials":13010,"activeCount":100},[],{"trials":13012,"activeCount":100},[13013],{"nctId":5093,"briefTitle":5094,"status":106,"phases":13014,"primaryCompletion":5096,"completion":2148,"start":5097,"enrollment":25,"conditions":13015,"interventions":13016},[88],[5099,24],[5086,5101],{"trials":13018,"activeCount":100},[],{"trials":13020,"activeCount":100},[],{"trials":13022,"activeCount":100},[],{"trials":13024,"activeCount":100},[],{"intervention":13026,"totalTrials":126,"cells":13027},"Hallucinogens and psychoactive substances",{"EARLY_PHASE1":13028,"PHASE1":13030,"PHASE2":13039,"PHASE3":13041,"PHASE4":13043,"NA":13045},{"trials":13029,"activeCount":100},[],{"trials":13031,"activeCount":100},[13032],{"nctId":13033,"briefTitle":13034,"status":106,"phases":13035,"primaryCompletion":3242,"completion":3242,"start":13036,"enrollment":1593,"conditions":13037,"interventions":13038},"NCT02033707","Effects of Hallucinogens and Other Drugs on Mood and Performance",[88],"2014-04",[112],[13026],{"trials":13040,"activeCount":100},[],{"trials":13042,"activeCount":100},[],{"trials":13044,"activeCount":100},[],{"trials":13046,"activeCount":100},[],{"intervention":13048,"totalTrials":126,"cells":13049},"Cervicovaginal secretions",{"EARLY_PHASE1":13050,"PHASE1":13052,"PHASE2":13063,"PHASE3":13065,"PHASE4":13067,"NA":13069},{"trials":13051,"activeCount":100},[],{"trials":13053,"activeCount":100},[13054],{"nctId":13055,"briefTitle":13056,"status":149,"phases":13057,"primaryCompletion":1782,"completion":1782,"start":13058,"enrollment":100,"conditions":13059,"interventions":13061},"NCT03769688","Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV)",[88],"2022-03",[13060],"Bacterial Vaginosis",[13048,13062],"Metronidazole gel",{"trials":13064,"activeCount":100},[],{"trials":13066,"activeCount":100},[],{"trials":13068,"activeCount":100},[],{"trials":13070,"activeCount":100},[],{"intervention":13062,"totalTrials":126,"cells":13072},{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13081,"PHASE3":13083,"PHASE4":13085,"NA":13087},{"trials":13074,"activeCount":100},[],{"trials":13076,"activeCount":100},[13077],{"nctId":13055,"briefTitle":13056,"status":149,"phases":13078,"primaryCompletion":1782,"completion":1782,"start":13058,"enrollment":100,"conditions":13079,"interventions":13080},[88],[13060],[13048,13062],{"trials":13082,"activeCount":100},[],{"trials":13084,"activeCount":100},[],{"trials":13086,"activeCount":100},[],{"trials":13088,"activeCount":100},[],{"intervention":3450,"totalTrials":126,"cells":13090},{"EARLY_PHASE1":13091,"PHASE1":13093,"PHASE2":13099,"PHASE3":13101,"PHASE4":13103,"NA":13105},{"trials":13092,"activeCount":100},[],{"trials":13094,"activeCount":100},[13095],{"nctId":3441,"briefTitle":3442,"status":106,"phases":13096,"primaryCompletion":3444,"completion":3444,"start":3445,"enrollment":3446,"conditions":13097,"interventions":13098},[88],[3406,3448],[3406,3450],{"trials":13100,"activeCount":100},[],{"trials":13102,"activeCount":100},[],{"trials":13104,"activeCount":100},[],{"trials":13106,"activeCount":100},[],{"intervention":13108,"totalTrials":126,"cells":13109},"oxytocin",{"EARLY_PHASE1":13110,"PHASE1":13112,"PHASE2":13122,"PHASE3":13124,"PHASE4":13126,"NA":13128},{"trials":13111,"activeCount":100},[],{"trials":13113,"activeCount":100},[13114],{"nctId":13115,"briefTitle":13116,"status":106,"phases":13117,"primaryCompletion":13118,"completion":13118,"start":1655,"enrollment":1561,"conditions":13119,"interventions":13121},"NCT02407340","Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder",[88],"2017-06-15",[2263,13120],"Alcohol Related Disorders",[13108],{"trials":13123,"activeCount":100},[],{"trials":13125,"activeCount":100},[],{"trials":13127,"activeCount":100},[],{"trials":13129,"activeCount":100},[],{"intervention":13131,"totalTrials":126,"cells":13132},"Experimental",{"EARLY_PHASE1":13133,"PHASE1":13135,"PHASE2":13143,"PHASE3":13145,"PHASE4":13147,"NA":13149},{"trials":13134,"activeCount":100},[],{"trials":13136,"activeCount":100},[13137],{"nctId":13138,"briefTitle":13139,"status":149,"phases":13140,"primaryCompletion":814,"completion":8447,"start":4999,"enrollment":100,"conditions":13141,"interventions":13142},"NCT00592215","Second Trimester Labor Induction",[88],[13139],[13131],{"trials":13144,"activeCount":100},[],{"trials":13146,"activeCount":100},[],{"trials":13148,"activeCount":100},[],{"trials":13150,"activeCount":100},[],{"intervention":3626,"totalTrials":126,"cells":13152},{"EARLY_PHASE1":13153,"PHASE1":13155,"PHASE2":13161,"PHASE3":13163,"PHASE4":13165,"NA":13167},{"trials":13154,"activeCount":100},[],{"trials":13156,"activeCount":100},[13157],{"nctId":3620,"briefTitle":3621,"status":106,"phases":13158,"primaryCompletion":3623,"completion":3623,"start":645,"enrollment":164,"conditions":13159,"interventions":13160},[88],[1844],[3613,3626],{"trials":13162,"activeCount":100},[],{"trials":13164,"activeCount":100},[],{"trials":13166,"activeCount":100},[],{"trials":13168,"activeCount":100},[],{"intervention":13170,"totalTrials":126,"cells":13171},"Oral cannabis",{"EARLY_PHASE1":13172,"PHASE1":13174,"PHASE2":13182,"PHASE3":13184,"PHASE4":13186,"NA":13188},{"trials":13173,"activeCount":100},[],{"trials":13175,"activeCount":100},[13176],{"nctId":13177,"briefTitle":13178,"status":106,"phases":13179,"primaryCompletion":813,"completion":813,"start":714,"enrollment":30,"conditions":13180,"interventions":13181},"NCT02165176","Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis",[88],[1844],[13170],{"trials":13183,"activeCount":100},[],{"trials":13185,"activeCount":100},[],{"trials":13187,"activeCount":100},[],{"trials":13189,"activeCount":100},[],{"intervention":13191,"totalTrials":126,"cells":13192},"CBD 1mg\u002FKg",{"EARLY_PHASE1":13193,"PHASE1":13195,"PHASE2":13207,"PHASE3":13209,"PHASE4":13211,"NA":13213},{"trials":13194,"activeCount":100},[],{"trials":13196,"activeCount":100},[13197],{"nctId":13198,"briefTitle":13199,"status":106,"phases":13200,"primaryCompletion":13201,"completion":13201,"start":13202,"enrollment":2091,"conditions":13203,"interventions":13204},"NCT05049733","The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A",[88],"2023-06-01","2022-03-07",[1844],[13191,13205,13206],"CBD 2mg\u002FKg","CBD 4mg\u002FKg",{"trials":13208,"activeCount":100},[],{"trials":13210,"activeCount":100},[],{"trials":13212,"activeCount":100},[],{"trials":13214,"activeCount":100},[],{"intervention":13205,"totalTrials":126,"cells":13216},{"EARLY_PHASE1":13217,"PHASE1":13219,"PHASE2":13225,"PHASE3":13227,"PHASE4":13229,"NA":13231},{"trials":13218,"activeCount":100},[],{"trials":13220,"activeCount":100},[13221],{"nctId":13198,"briefTitle":13199,"status":106,"phases":13222,"primaryCompletion":13201,"completion":13201,"start":13202,"enrollment":2091,"conditions":13223,"interventions":13224},[88],[1844],[13191,13205,13206],{"trials":13226,"activeCount":100},[],{"trials":13228,"activeCount":100},[],{"trials":13230,"activeCount":100},[],{"trials":13232,"activeCount":100},[],{"intervention":13206,"totalTrials":126,"cells":13234},{"EARLY_PHASE1":13235,"PHASE1":13237,"PHASE2":13243,"PHASE3":13245,"PHASE4":13247,"NA":13249},{"trials":13236,"activeCount":100},[],{"trials":13238,"activeCount":100},[13239],{"nctId":13198,"briefTitle":13199,"status":106,"phases":13240,"primaryCompletion":13201,"completion":13201,"start":13202,"enrollment":2091,"conditions":13241,"interventions":13242},[88],[1844],[13191,13205,13206],{"trials":13244,"activeCount":100},[],{"trials":13246,"activeCount":100},[],{"trials":13248,"activeCount":100},[],{"trials":13250,"activeCount":100},[],{"intervention":8302,"totalTrials":126,"cells":13252},{"EARLY_PHASE1":13253,"PHASE1":13255,"PHASE2":13261,"PHASE3":13263,"PHASE4":13265,"NA":13267},{"trials":13254,"activeCount":100},[],{"trials":13256,"activeCount":100},[13257],{"nctId":8294,"briefTitle":8295,"status":873,"phases":13258,"primaryCompletion":8297,"completion":8298,"start":8299,"enrollment":235,"conditions":13259,"interventions":13260},[88],[6323,27],[8302,8287],{"trials":13262,"activeCount":100},[],{"trials":13264,"activeCount":100},[],{"trials":13266,"activeCount":100},[],{"trials":13268,"activeCount":100},[],{"intervention":13270,"totalTrials":126,"cells":13271},"Tenofovir enema",{"EARLY_PHASE1":13272,"PHASE1":13274,"PHASE2":13283,"PHASE3":13285,"PHASE4":13287,"NA":13289},{"trials":13273,"activeCount":100},[],{"trials":13275,"activeCount":100},[13276],{"nctId":13277,"briefTitle":13278,"status":106,"phases":13279,"primaryCompletion":13280,"completion":13280,"start":2381,"enrollment":2091,"conditions":13281,"interventions":13282},"NCT02750540","Optimization of a Tenofovir Enema for HIV Prevention",[88],"2019-05",[3930],[13270],{"trials":13284,"activeCount":100},[],{"trials":13286,"activeCount":100},[],{"trials":13288,"activeCount":100},[],{"trials":13290,"activeCount":100},[],{"intervention":13292,"totalTrials":126,"cells":13293},"[11C]PIB",{"EARLY_PHASE1":13294,"PHASE1":13296,"PHASE2":13304,"PHASE3":13306,"PHASE4":13308,"NA":13310},{"trials":13295,"activeCount":100},[],{"trials":13297,"activeCount":100},[13298],{"nctId":13299,"briefTitle":13300,"status":106,"phases":13301,"primaryCompletion":7286,"completion":7286,"start":2149,"enrollment":2091,"conditions":13302,"interventions":13303},"NCT01826110","PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers",[88],[5015],[13292],{"trials":13305,"activeCount":100},[],{"trials":13307,"activeCount":100},[],{"trials":13309,"activeCount":100},[],{"trials":13311,"activeCount":100},[],{"intervention":13313,"totalTrials":126,"cells":13314},"Buspirone oral",{"EARLY_PHASE1":13315,"PHASE1":13317,"PHASE2":13329,"PHASE3":13331,"PHASE4":13333,"NA":13335},{"trials":13316,"activeCount":100},[],{"trials":13318,"activeCount":100},[13319],{"nctId":13320,"briefTitle":13321,"status":106,"phases":13322,"primaryCompletion":12611,"completion":12611,"start":13323,"enrollment":1582,"conditions":13324,"interventions":13328},"NCT03521960","Buspirone for Opioid Tapering",[88],"2018-05-30",[7107,13325,13326,13327],"Dependency (Psychology)","Pain, Chronic","Opiate Withdrawal Syndrome",[13313],{"trials":13330,"activeCount":100},[],{"trials":13332,"activeCount":100},[],{"trials":13334,"activeCount":100},[],{"trials":13336,"activeCount":100},[],{"intervention":8692,"totalTrials":126,"cells":13338},{"EARLY_PHASE1":13339,"PHASE1":13341,"PHASE2":13347,"PHASE3":13349,"PHASE4":13351,"NA":13353},{"trials":13340,"activeCount":100},[],{"trials":13342,"activeCount":100},[13343],{"nctId":8684,"briefTitle":8685,"status":106,"phases":13344,"primaryCompletion":8447,"completion":8447,"start":901,"enrollment":2717,"conditions":13345,"interventions":13346},[88],[8688],[8690,8691,8692],{"trials":13348,"activeCount":100},[],{"trials":13350,"activeCount":100},[],{"trials":13352,"activeCount":100},[],{"trials":13354,"activeCount":100},[],{"intervention":13356,"totalTrials":126,"cells":13357},"[F18]-ASEM",{"EARLY_PHASE1":13358,"PHASE1":13360,"PHASE2":13371,"PHASE3":13373,"PHASE4":13375,"NA":13377},{"trials":13359,"activeCount":100},[],{"trials":13361,"activeCount":100},[13362],{"nctId":13363,"briefTitle":13364,"status":106,"phases":13365,"primaryCompletion":13366,"completion":13367,"start":13368,"enrollment":921,"conditions":13369,"interventions":13370},"NCT04055467","Brain Imaging in Tobacco Smokers During a Quit Attempt",[88],"2022-10-30","2022-11-30","2019-12-16",[1827,3521],[13356],{"trials":13372,"activeCount":100},[],{"trials":13374,"activeCount":100},[],{"trials":13376,"activeCount":100},[],{"trials":13378,"activeCount":100},[],{"intervention":13380,"totalTrials":126,"cells":13381},"Tipranavir\u002FRitonavir",{"EARLY_PHASE1":13382,"PHASE1":13384,"PHASE2":13393,"PHASE3":13395,"PHASE4":13397,"NA":13399},{"trials":13383,"activeCount":100},[],{"trials":13385,"activeCount":100},[13386],{"nctId":13387,"briefTitle":13388,"status":106,"phases":13389,"primaryCompletion":4854,"completion":4854,"start":8309,"enrollment":22,"conditions":13390,"interventions":13391},"NCT00344123","Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir\u002FRitonavir in Healthy Subjects",[88],[29],[13380,13392],"Rosuvastatin",{"trials":13394,"activeCount":100},[],{"trials":13396,"activeCount":100},[],{"trials":13398,"activeCount":100},[],{"trials":13400,"activeCount":100},[],{"intervention":13392,"totalTrials":126,"cells":13402},{"EARLY_PHASE1":13403,"PHASE1":13405,"PHASE2":13411,"PHASE3":13413,"PHASE4":13415,"NA":13417},{"trials":13404,"activeCount":100},[],{"trials":13406,"activeCount":100},[13407],{"nctId":13387,"briefTitle":13388,"status":106,"phases":13408,"primaryCompletion":4854,"completion":4854,"start":8309,"enrollment":22,"conditions":13409,"interventions":13410},[88],[29],[13380,13392],{"trials":13412,"activeCount":100},[],{"trials":13414,"activeCount":100},[],{"trials":13416,"activeCount":100},[],{"trials":13418,"activeCount":100},[],{"intervention":13420,"totalTrials":126,"cells":13421},"Insorb absorbable staples",{"EARLY_PHASE1":13422,"PHASE1":13424,"PHASE2":13435,"PHASE3":13437,"PHASE4":13439,"NA":13441},{"trials":13423,"activeCount":100},[],{"trials":13425,"activeCount":100},[13426],{"nctId":13427,"briefTitle":13428,"status":873,"phases":13429,"primaryCompletion":3119,"completion":3119,"start":7187,"enrollment":13430,"conditions":13431,"interventions":13433},"NCT01687972","INSORB Versus Subcuticular Sutures at Cesarean Section",[88],187,[13432,2312],"Cesarean Section",[13420,13434],"Absorbable sutures",{"trials":13436,"activeCount":100},[],{"trials":13438,"activeCount":100},[],{"trials":13440,"activeCount":100},[],{"trials":13442,"activeCount":100},[],{"intervention":13434,"totalTrials":126,"cells":13444},{"EARLY_PHASE1":13445,"PHASE1":13447,"PHASE2":13453,"PHASE3":13455,"PHASE4":13457,"NA":13459},{"trials":13446,"activeCount":100},[],{"trials":13448,"activeCount":100},[13449],{"nctId":13427,"briefTitle":13428,"status":873,"phases":13450,"primaryCompletion":3119,"completion":3119,"start":7187,"enrollment":13430,"conditions":13451,"interventions":13452},[88],[13432,2312],[13420,13434],{"trials":13454,"activeCount":100},[],{"trials":13456,"activeCount":100},[],{"trials":13458,"activeCount":100},[],{"trials":13460,"activeCount":100},[],{"intervention":13462,"totalTrials":126,"cells":13463},"Alcohol + Caffeine Beverage",{"EARLY_PHASE1":13464,"PHASE1":13466,"PHASE2":13476,"PHASE3":13478,"PHASE4":13480,"NA":13482},{"trials":13465,"activeCount":100},[],{"trials":13467,"activeCount":100},[13468],{"nctId":13469,"briefTitle":13470,"status":106,"phases":13471,"primaryCompletion":328,"completion":328,"start":6086,"enrollment":1593,"conditions":13472,"interventions":13474},"NCT01289561","Combined Effects of Alcohol and Caffeine",[88],[13473],"Alcohol or Other Drugs Effects",[13462,13475],"Alcohol + Caffeine-placebo",{"trials":13477,"activeCount":100},[],{"trials":13479,"activeCount":100},[],{"trials":13481,"activeCount":100},[],{"trials":13483,"activeCount":100},[],{"intervention":13475,"totalTrials":126,"cells":13485},{"EARLY_PHASE1":13486,"PHASE1":13488,"PHASE2":13494,"PHASE3":13496,"PHASE4":13498,"NA":13500},{"trials":13487,"activeCount":100},[],{"trials":13489,"activeCount":100},[13490],{"nctId":13469,"briefTitle":13470,"status":106,"phases":13491,"primaryCompletion":328,"completion":328,"start":6086,"enrollment":1593,"conditions":13492,"interventions":13493},[88],[13473],[13462,13475],{"trials":13495,"activeCount":100},[],{"trials":13497,"activeCount":100},[],{"trials":13499,"activeCount":100},[],{"trials":13501,"activeCount":100},[],{"intervention":13503,"totalTrials":126,"cells":13504},"Inje cocktail",{"EARLY_PHASE1":13505,"PHASE1":13507,"PHASE2":13521,"PHASE3":13523,"PHASE4":13525,"NA":13527},{"trials":13506,"activeCount":100},[],{"trials":13508,"activeCount":100},[13509],{"nctId":13510,"briefTitle":13511,"status":106,"phases":13512,"primaryCompletion":13513,"completion":13514,"start":13515,"enrollment":33,"conditions":13516,"interventions":13518},"NCT04201197","Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs",[88],"2022-03-16","2022-07-28","2020-11-10",[13517],"Drug-Interactions",[13503,13519,13520],"THC Cannabis extract","THC\u002FCBD Cannabis Extract",{"trials":13522,"activeCount":100},[],{"trials":13524,"activeCount":100},[],{"trials":13526,"activeCount":100},[],{"trials":13528,"activeCount":100},[],{"intervention":13519,"totalTrials":126,"cells":13530},{"EARLY_PHASE1":13531,"PHASE1":13533,"PHASE2":13539,"PHASE3":13541,"PHASE4":13543,"NA":13545},{"trials":13532,"activeCount":100},[],{"trials":13534,"activeCount":100},[13535],{"nctId":13510,"briefTitle":13511,"status":106,"phases":13536,"primaryCompletion":13513,"completion":13514,"start":13515,"enrollment":33,"conditions":13537,"interventions":13538},[88],[13517],[13503,13519,13520],{"trials":13540,"activeCount":100},[],{"trials":13542,"activeCount":100},[],{"trials":13544,"activeCount":100},[],{"trials":13546,"activeCount":100},[],{"intervention":13520,"totalTrials":126,"cells":13548},{"EARLY_PHASE1":13549,"PHASE1":13551,"PHASE2":13557,"PHASE3":13559,"PHASE4":13561,"NA":13563},{"trials":13550,"activeCount":100},[],{"trials":13552,"activeCount":100},[13553],{"nctId":13510,"briefTitle":13511,"status":106,"phases":13554,"primaryCompletion":13513,"completion":13514,"start":13515,"enrollment":33,"conditions":13555,"interventions":13556},[88],[13517],[13503,13519,13520],{"trials":13558,"activeCount":100},[],{"trials":13560,"activeCount":100},[],{"trials":13562,"activeCount":100},[],{"trials":13564,"activeCount":100},[],{"intervention":13566,"totalTrials":126,"cells":13567},"Sirolimus",{"EARLY_PHASE1":13568,"PHASE1":13570,"PHASE2":13582,"PHASE3":13584,"PHASE4":13586,"NA":13588},{"trials":13569,"activeCount":100},[],{"trials":13571,"activeCount":100},[13572],{"nctId":13573,"briefTitle":13574,"status":106,"phases":13575,"primaryCompletion":8036,"completion":2174,"start":2105,"enrollment":164,"conditions":13576,"interventions":13581},"NCT00908466","Sirolimus as Therapeutic Approach to Uveitis",[88],[13577,13578,13579,13580],"Uveitis","Intermediate Uveitis","Posterior Uveitis","Panuveitis",[13566,13566],{"trials":13583,"activeCount":100},[],{"trials":13585,"activeCount":100},[],{"trials":13587,"activeCount":100},[],{"trials":13589,"activeCount":100},[],{"intervention":13591,"totalTrials":126,"cells":13592},"Vitamin D",{"EARLY_PHASE1":13593,"PHASE1":13595,"PHASE2":13606,"PHASE3":13608,"PHASE4":13610,"NA":13612},{"trials":13594,"activeCount":100},[],{"trials":13596,"activeCount":100},[13597],{"nctId":13598,"briefTitle":13599,"status":149,"phases":13600,"primaryCompletion":13601,"completion":13601,"start":2149,"enrollment":100,"conditions":13602,"interventions":13605},"NCT01956864","Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer",[88],"2016-02-11",[13603,13604],"Cirrhosis","Hepatocellular Carcinoma",[13591],{"trials":13607,"activeCount":100},[],{"trials":13609,"activeCount":100},[],{"trials":13611,"activeCount":100},[],{"trials":13613,"activeCount":100},[],{"intervention":13615,"totalTrials":126,"cells":13616},"Truvada alone",{"EARLY_PHASE1":13617,"PHASE1":13619,"PHASE2":13635,"PHASE3":13637,"PHASE4":13639,"NA":13641},{"trials":13618,"activeCount":100},[],{"trials":13620,"activeCount":100},[13621],{"nctId":13622,"briefTitle":13623,"status":106,"phases":13624,"primaryCompletion":13625,"completion":13625,"start":13626,"enrollment":1773,"conditions":13627,"interventions":13630},"NCT04760691","Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW",[88],"2025-03-24","2021-03-01",[24,13628,13629],"Prophylaxis","Transgender",[13615,13631,13632,13633,13634],"Truvada plus Leuprolide 11.25mg intramuscular","Truvada plus Estradiol 1 mg","Truvada plus Estradiol 6 mg","Estradiol 6 mg alone",{"trials":13636,"activeCount":100},[],{"trials":13638,"activeCount":100},[],{"trials":13640,"activeCount":100},[],{"trials":13642,"activeCount":100},[],{"intervention":13631,"totalTrials":126,"cells":13644},{"EARLY_PHASE1":13645,"PHASE1":13647,"PHASE2":13653,"PHASE3":13655,"PHASE4":13657,"NA":13659},{"trials":13646,"activeCount":100},[],{"trials":13648,"activeCount":100},[13649],{"nctId":13622,"briefTitle":13623,"status":106,"phases":13650,"primaryCompletion":13625,"completion":13625,"start":13626,"enrollment":1773,"conditions":13651,"interventions":13652},[88],[24,13628,13629],[13615,13631,13632,13633,13634],{"trials":13654,"activeCount":100},[],{"trials":13656,"activeCount":100},[],{"trials":13658,"activeCount":100},[],{"trials":13660,"activeCount":100},[],{"intervention":13632,"totalTrials":126,"cells":13662},{"EARLY_PHASE1":13663,"PHASE1":13665,"PHASE2":13671,"PHASE3":13673,"PHASE4":13675,"NA":13677},{"trials":13664,"activeCount":100},[],{"trials":13666,"activeCount":100},[13667],{"nctId":13622,"briefTitle":13623,"status":106,"phases":13668,"primaryCompletion":13625,"completion":13625,"start":13626,"enrollment":1773,"conditions":13669,"interventions":13670},[88],[24,13628,13629],[13615,13631,13632,13633,13634],{"trials":13672,"activeCount":100},[],{"trials":13674,"activeCount":100},[],{"trials":13676,"activeCount":100},[],{"trials":13678,"activeCount":100},[],{"intervention":13633,"totalTrials":126,"cells":13680},{"EARLY_PHASE1":13681,"PHASE1":13683,"PHASE2":13689,"PHASE3":13691,"PHASE4":13693,"NA":13695},{"trials":13682,"activeCount":100},[],{"trials":13684,"activeCount":100},[13685],{"nctId":13622,"briefTitle":13623,"status":106,"phases":13686,"primaryCompletion":13625,"completion":13625,"start":13626,"enrollment":1773,"conditions":13687,"interventions":13688},[88],[24,13628,13629],[13615,13631,13632,13633,13634],{"trials":13690,"activeCount":100},[],{"trials":13692,"activeCount":100},[],{"trials":13694,"activeCount":100},[],{"trials":13696,"activeCount":100},[],{"intervention":13634,"totalTrials":126,"cells":13698},{"EARLY_PHASE1":13699,"PHASE1":13701,"PHASE2":13707,"PHASE3":13709,"PHASE4":13711,"NA":13713},{"trials":13700,"activeCount":100},[],{"trials":13702,"activeCount":100},[13703],{"nctId":13622,"briefTitle":13623,"status":106,"phases":13704,"primaryCompletion":13625,"completion":13625,"start":13626,"enrollment":1773,"conditions":13705,"interventions":13706},[88],[24,13628,13629],[13615,13631,13632,13633,13634],{"trials":13708,"activeCount":100},[],{"trials":13710,"activeCount":100},[],{"trials":13712,"activeCount":100},[],{"trials":13714,"activeCount":100},[],{"intervention":13716,"totalTrials":126,"cells":13717},"CS-1000 labeled SVF cells",{"EARLY_PHASE1":13718,"PHASE1":13720,"PHASE2":13729,"PHASE3":13731,"PHASE4":13733,"NA":13735},{"trials":13719,"activeCount":100},[],{"trials":13721,"activeCount":100},[13722],{"nctId":13723,"briefTitle":13724,"status":149,"phases":13725,"primaryCompletion":13726,"completion":13726,"start":714,"enrollment":100,"conditions":13727,"interventions":13728},"NCT02035085","19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction",[88],"2022-06",[10625],[13716],{"trials":13730,"activeCount":100},[],{"trials":13732,"activeCount":100},[],{"trials":13734,"activeCount":100},[],{"trials":13736,"activeCount":100},[],{"intervention":13738,"totalTrials":126,"cells":13739},"Anti-SARS-CoV-2 Human Convalescent Plasma",{"EARLY_PHASE1":13740,"PHASE1":13742,"PHASE2":13753,"PHASE3":13755,"PHASE4":13757,"NA":13759},{"trials":13741,"activeCount":100},[],{"trials":13743,"activeCount":100},[13744],{"nctId":13745,"briefTitle":13746,"status":106,"phases":13747,"primaryCompletion":12424,"completion":13748,"start":13749,"enrollment":7105,"conditions":13750,"interventions":13752},"NCT04377672","Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)",[88],"2021-12-13","2020-05-28",[13751],"SARS-CoV-2 Infection",[13738],{"trials":13754,"activeCount":100},[],{"trials":13756,"activeCount":100},[],{"trials":13758,"activeCount":100},[],{"trials":13760,"activeCount":100},[],{"intervention":13762,"totalTrials":126,"cells":13763},"Intraperitoneal docetaxel",{"EARLY_PHASE1":13764,"PHASE1":13766,"PHASE2":13775,"PHASE3":13777,"PHASE4":13779,"NA":13781},{"trials":13765,"activeCount":100},[],{"trials":13767,"activeCount":100},[13768],{"nctId":13769,"briefTitle":13770,"status":873,"phases":13771,"primaryCompletion":12413,"completion":12413,"start":3530,"enrollment":280,"conditions":13772,"interventions":13774},"NCT04583488","Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis",[88],[13773],"Peritoneal Carcinomatosis",[13762],{"trials":13776,"activeCount":100},[],{"trials":13778,"activeCount":100},[],{"trials":13780,"activeCount":100},[],{"trials":13782,"activeCount":100},[],{"intervention":13784,"totalTrials":126,"cells":13785},"Vaporized THC alone",{"EARLY_PHASE1":13786,"PHASE1":13788,"PHASE2":13798,"PHASE3":13800,"PHASE4":13802,"NA":13804},{"trials":13787,"activeCount":100},[],{"trials":13789,"activeCount":100},[13790],{"nctId":13791,"briefTitle":13792,"status":149,"phases":13793,"primaryCompletion":854,"completion":854,"start":12704,"enrollment":100,"conditions":13794,"interventions":13795},"NCT03832816","Behavioral and Physiological Effects of THC and CBD",[88],[4263],[13784,13796,13797],"Vaporized CBD alone","Vaporized CBD with THC",{"trials":13799,"activeCount":100},[],{"trials":13801,"activeCount":100},[],{"trials":13803,"activeCount":100},[],{"trials":13805,"activeCount":100},[],{"intervention":13796,"totalTrials":126,"cells":13807},{"EARLY_PHASE1":13808,"PHASE1":13810,"PHASE2":13816,"PHASE3":13818,"PHASE4":13820,"NA":13822},{"trials":13809,"activeCount":100},[],{"trials":13811,"activeCount":100},[13812],{"nctId":13791,"briefTitle":13792,"status":149,"phases":13813,"primaryCompletion":854,"completion":854,"start":12704,"enrollment":100,"conditions":13814,"interventions":13815},[88],[4263],[13784,13796,13797],{"trials":13817,"activeCount":100},[],{"trials":13819,"activeCount":100},[],{"trials":13821,"activeCount":100},[],{"trials":13823,"activeCount":100},[],{"intervention":13797,"totalTrials":126,"cells":13825},{"EARLY_PHASE1":13826,"PHASE1":13828,"PHASE2":13834,"PHASE3":13836,"PHASE4":13838,"NA":13840},{"trials":13827,"activeCount":100},[],{"trials":13829,"activeCount":100},[13830],{"nctId":13791,"briefTitle":13792,"status":149,"phases":13831,"primaryCompletion":854,"completion":854,"start":12704,"enrollment":100,"conditions":13832,"interventions":13833},[88],[4263],[13784,13796,13797],{"trials":13835,"activeCount":100},[],{"trials":13837,"activeCount":100},[],{"trials":13839,"activeCount":100},[],{"trials":13841,"activeCount":100},[],{"intervention":13843,"totalTrials":126,"cells":13844},"[11C]DPA-713",{"EARLY_PHASE1":13845,"PHASE1":13847,"PHASE2":13855,"PHASE3":13857,"PHASE4":13859,"NA":13861},{"trials":13846,"activeCount":100},[],{"trials":13848,"activeCount":100},[13849],{"nctId":13850,"briefTitle":13851,"status":873,"phases":13852,"primaryCompletion":3241,"completion":3241,"start":7605,"enrollment":1572,"conditions":13853,"interventions":13854},"NCT03257592","Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States",[88],[5134,5173],[13843],{"trials":13856,"activeCount":100},[],{"trials":13858,"activeCount":100},[],{"trials":13860,"activeCount":100},[],{"trials":13862,"activeCount":100},[],{"intervention":13864,"totalTrials":126,"cells":13865},"Rifampin & midazolam",{"EARLY_PHASE1":13866,"PHASE1":13868,"PHASE2":13878,"PHASE3":13880,"PHASE4":13882,"NA":13884},{"trials":13867,"activeCount":100},[],{"trials":13869,"activeCount":100},[13870],{"nctId":13871,"briefTitle":13872,"status":106,"phases":13873,"primaryCompletion":8340,"completion":3311,"start":814,"enrollment":5229,"conditions":13874,"interventions":13875},"NCT01162486","Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers",[88],[35,801],[13864,13876,13876,13876,13877,13877],"rifapentine & midazolam","rifapentine and midazolam",{"trials":13879,"activeCount":100},[],{"trials":13881,"activeCount":100},[],{"trials":13883,"activeCount":100},[],{"trials":13885,"activeCount":100},[],{"intervention":13876,"totalTrials":126,"cells":13887},{"EARLY_PHASE1":13888,"PHASE1":13890,"PHASE2":13896,"PHASE3":13898,"PHASE4":13900,"NA":13902},{"trials":13889,"activeCount":100},[],{"trials":13891,"activeCount":100},[13892],{"nctId":13871,"briefTitle":13872,"status":106,"phases":13893,"primaryCompletion":8340,"completion":3311,"start":814,"enrollment":5229,"conditions":13894,"interventions":13895},[88],[35,801],[13864,13876,13876,13876,13877,13877],{"trials":13897,"activeCount":100},[],{"trials":13899,"activeCount":100},[],{"trials":13901,"activeCount":100},[],{"trials":13903,"activeCount":100},[],{"intervention":13877,"totalTrials":126,"cells":13905},{"EARLY_PHASE1":13906,"PHASE1":13908,"PHASE2":13914,"PHASE3":13916,"PHASE4":13918,"NA":13920},{"trials":13907,"activeCount":100},[],{"trials":13909,"activeCount":100},[13910],{"nctId":13871,"briefTitle":13872,"status":106,"phases":13911,"primaryCompletion":8340,"completion":3311,"start":814,"enrollment":5229,"conditions":13912,"interventions":13913},[88],[35,801],[13864,13876,13876,13876,13877,13877],{"trials":13915,"activeCount":100},[],{"trials":13917,"activeCount":100},[],{"trials":13919,"activeCount":100},[],{"trials":13921,"activeCount":100},[],{"intervention":13923,"totalTrials":126,"cells":13924},"ADX48621",{"EARLY_PHASE1":13925,"PHASE1":13927,"PHASE2":13935,"PHASE3":13937,"PHASE4":13939,"NA":13941},{"trials":13926,"activeCount":100},[],{"trials":13928,"activeCount":100},[13929],{"nctId":13930,"briefTitle":13931,"status":106,"phases":13932,"primaryCompletion":9139,"completion":9139,"start":4978,"enrollment":1663,"conditions":13933,"interventions":13934},"NCT02447640","PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration",[88],[112],[13923],{"trials":13936,"activeCount":100},[],{"trials":13938,"activeCount":100},[],{"trials":13940,"activeCount":100},[],{"trials":13942,"activeCount":100},[],{"intervention":13944,"totalTrials":126,"cells":13945},"Standard dose Truvada®",{"EARLY_PHASE1":13946,"PHASE1":13948,"PHASE2":13959,"PHASE3":13961,"PHASE4":13963,"NA":13965},{"trials":13947,"activeCount":100},[],{"trials":13949,"activeCount":100},[13950],{"nctId":13951,"briefTitle":13952,"status":149,"phases":13953,"primaryCompletion":1162,"completion":2668,"start":13954,"enrollment":100,"conditions":13955,"interventions":13957},"NCT03834909","Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)",[88],"2022-04",[2312,13956],"HIV-1-infection",[13944,13958],"Pregnancy-adjusted dose Truvada®",{"trials":13960,"activeCount":100},[],{"trials":13962,"activeCount":100},[],{"trials":13964,"activeCount":100},[],{"trials":13966,"activeCount":100},[],{"intervention":13958,"totalTrials":126,"cells":13968},{"EARLY_PHASE1":13969,"PHASE1":13971,"PHASE2":13977,"PHASE3":13979,"PHASE4":13981,"NA":13983},{"trials":13970,"activeCount":100},[],{"trials":13972,"activeCount":100},[13973],{"nctId":13951,"briefTitle":13952,"status":149,"phases":13974,"primaryCompletion":1162,"completion":2668,"start":13954,"enrollment":100,"conditions":13975,"interventions":13976},[88],[2312,13956],[13944,13958],{"trials":13978,"activeCount":100},[],{"trials":13980,"activeCount":100},[],{"trials":13982,"activeCount":100},[],{"trials":13984,"activeCount":100},[],{"intervention":13986,"totalTrials":126,"cells":13987},"Moderately-high dose of psilocybin",{"EARLY_PHASE1":13988,"PHASE1":13990,"PHASE2":14001,"PHASE3":14003,"PHASE4":14005,"NA":14007},{"trials":13989,"activeCount":100},[],{"trials":13991,"activeCount":100},[13992],{"nctId":13993,"briefTitle":13994,"status":106,"phases":13995,"primaryCompletion":13996,"completion":13996,"start":1645,"enrollment":16,"conditions":13997,"interventions":13998},"NCT02145091","Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",[88],"2019-12-26",[112],[13986,13999,14000],"Moderately-low dose of psilocybin","Very-low dose of psilocybin",{"trials":14002,"activeCount":100},[],{"trials":14004,"activeCount":100},[],{"trials":14006,"activeCount":100},[],{"trials":14008,"activeCount":100},[],{"intervention":13999,"totalTrials":126,"cells":14010},{"EARLY_PHASE1":14011,"PHASE1":14013,"PHASE2":14019,"PHASE3":14021,"PHASE4":14023,"NA":14025},{"trials":14012,"activeCount":100},[],{"trials":14014,"activeCount":100},[14015],{"nctId":13993,"briefTitle":13994,"status":106,"phases":14016,"primaryCompletion":13996,"completion":13996,"start":1645,"enrollment":16,"conditions":14017,"interventions":14018},[88],[112],[13986,13999,14000],{"trials":14020,"activeCount":100},[],{"trials":14022,"activeCount":100},[],{"trials":14024,"activeCount":100},[],{"trials":14026,"activeCount":100},[],{"intervention":14000,"totalTrials":126,"cells":14028},{"EARLY_PHASE1":14029,"PHASE1":14031,"PHASE2":14037,"PHASE3":14039,"PHASE4":14041,"NA":14043},{"trials":14030,"activeCount":100},[],{"trials":14032,"activeCount":100},[14033],{"nctId":13993,"briefTitle":13994,"status":106,"phases":14034,"primaryCompletion":13996,"completion":13996,"start":1645,"enrollment":16,"conditions":14035,"interventions":14036},[88],[112],[13986,13999,14000],{"trials":14038,"activeCount":100},[],{"trials":14040,"activeCount":100},[],{"trials":14042,"activeCount":100},[],{"trials":14044,"activeCount":100},[],{"intervention":14046,"totalTrials":126,"cells":14047},"liothyronine",{"EARLY_PHASE1":14048,"PHASE1":14050,"PHASE2":14059,"PHASE3":14061,"PHASE4":14063,"NA":14065},{"trials":14049,"activeCount":100},[],{"trials":14051,"activeCount":100},[14052],{"nctId":14053,"briefTitle":14054,"status":106,"phases":14055,"primaryCompletion":14056,"completion":14056,"start":7668,"enrollment":1593,"conditions":14057,"interventions":14058},"NCT02506751","Open-label Study of Liothyronine in MS",[88],"2017-09-18",[638,9828,9829],[14046],{"trials":14060,"activeCount":100},[],{"trials":14062,"activeCount":100},[],{"trials":14064,"activeCount":100},[],{"trials":14066,"activeCount":100},[],{"intervention":14068,"totalTrials":126,"cells":14069},"SAR 1118 0.1%",{"EARLY_PHASE1":14070,"PHASE1":14072,"PHASE2":14084,"PHASE3":14086,"PHASE4":14088,"NA":14090},{"trials":14071,"activeCount":100},[],{"trials":14073,"activeCount":100},[14074],{"nctId":14075,"briefTitle":14076,"status":873,"phases":14077,"primaryCompletion":5169,"completion":5169,"start":1646,"enrollment":164,"conditions":14078,"interventions":14081},"NCT00936520","SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy",[88],[14079,14080],"Diabetic Macular Edema (DME)","Pars Plana Vitrectomy",[14068,14082,14083],"SAR 1118 1.0%","SAR 1118 5.0%",{"trials":14085,"activeCount":100},[],{"trials":14087,"activeCount":100},[],{"trials":14089,"activeCount":100},[],{"trials":14091,"activeCount":100},[],{"intervention":14082,"totalTrials":126,"cells":14093},{"EARLY_PHASE1":14094,"PHASE1":14096,"PHASE2":14102,"PHASE3":14104,"PHASE4":14106,"NA":14108},{"trials":14095,"activeCount":100},[],{"trials":14097,"activeCount":100},[14098],{"nctId":14075,"briefTitle":14076,"status":873,"phases":14099,"primaryCompletion":5169,"completion":5169,"start":1646,"enrollment":164,"conditions":14100,"interventions":14101},[88],[14079,14080],[14068,14082,14083],{"trials":14103,"activeCount":100},[],{"trials":14105,"activeCount":100},[],{"trials":14107,"activeCount":100},[],{"trials":14109,"activeCount":100},[],{"intervention":14083,"totalTrials":126,"cells":14111},{"EARLY_PHASE1":14112,"PHASE1":14114,"PHASE2":14120,"PHASE3":14122,"PHASE4":14124,"NA":14126},{"trials":14113,"activeCount":100},[],{"trials":14115,"activeCount":100},[14116],{"nctId":14075,"briefTitle":14076,"status":873,"phases":14117,"primaryCompletion":5169,"completion":5169,"start":1646,"enrollment":164,"conditions":14118,"interventions":14119},[88],[14079,14080],[14068,14082,14083],{"trials":14121,"activeCount":100},[],{"trials":14123,"activeCount":100},[],{"trials":14125,"activeCount":100},[],{"trials":14127,"activeCount":100},[],{"intervention":8180,"totalTrials":126,"cells":14129},{"EARLY_PHASE1":14130,"PHASE1":14132,"PHASE2":14138,"PHASE3":14140,"PHASE4":14142,"NA":14144},{"trials":14131,"activeCount":100},[],{"trials":14133,"activeCount":100},[14134],{"nctId":8173,"briefTitle":8174,"status":149,"phases":14135,"primaryCompletion":8176,"completion":814,"start":8177,"enrollment":100,"conditions":14136,"interventions":14137},[88],[5430],[8180,8152],{"trials":14139,"activeCount":100},[],{"trials":14141,"activeCount":100},[],{"trials":14143,"activeCount":100},[],{"trials":14145,"activeCount":100},[],{"intervention":14147,"totalTrials":126,"cells":14148},"Artesunate Suppositories",{"EARLY_PHASE1":14149,"PHASE1":14151,"PHASE2":14167,"PHASE3":14169,"PHASE4":14171,"NA":14173},{"trials":14150,"activeCount":100},[],{"trials":14152,"activeCount":100},[14153],{"nctId":14154,"briefTitle":14155,"status":106,"phases":14156,"primaryCompletion":14157,"completion":14157,"start":14158,"enrollment":1582,"conditions":14159,"interventions":14166},"NCT03100045","Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2\u002F3)",[88],"2021-10-06","2017-04-20",[14160,14161,14162,14163,14164,14165,6521],"HPV-Related Anal Intraepithelial Neoplasia","AIN2\u002F3","Artesunate","Alternative Treatment","Anal Dysplasia","Precancerous Conditions",[14147],{"trials":14168,"activeCount":100},[],{"trials":14170,"activeCount":100},[],{"trials":14172,"activeCount":100},[],{"trials":14174,"activeCount":100},[],{"intervention":14176,"totalTrials":126,"cells":14177},"Pioglitazone",{"EARLY_PHASE1":14178,"PHASE1":14180,"PHASE2":14195,"PHASE3":14197,"PHASE4":14199,"NA":14201},{"trials":14179,"activeCount":100},[],{"trials":14181,"activeCount":100},[14182],{"nctId":14183,"briefTitle":14184,"status":106,"phases":14185,"primaryCompletion":6564,"completion":6564,"start":14186,"enrollment":2151,"conditions":14187,"interventions":14194},"NCT03440034","Study of Pioglitazone in Sporadic Inclusion Body Myositis",[88],"2018-05-22",[14188,14189,14190,14191,14192,14193],"Myositis","Inclusion Body Myositis","Muscular Diseases","Musculoskeletal Disease","Neuromuscular Diseases","Nervous System Diseases",[14176],{"trials":14196,"activeCount":100},[],{"trials":14198,"activeCount":100},[],{"trials":14200,"activeCount":100},[],{"trials":14202,"activeCount":100},[],{"intervention":14204,"totalTrials":126,"cells":14205},"Vaporized THC, limonene, or THC and limonene",{"EARLY_PHASE1":14206,"PHASE1":14208,"PHASE2":14219,"PHASE3":14221,"PHASE4":14223,"NA":14225},{"trials":14207,"activeCount":100},[],{"trials":14209,"activeCount":100},[14210],{"nctId":14211,"briefTitle":14212,"status":106,"phases":14213,"primaryCompletion":14214,"completion":3393,"start":646,"enrollment":14215,"conditions":14216,"interventions":14218},"NCT03609853","Behavioral Pharmacology of THC and D-limonene",[88],"2022-06-28",53,[14217],"D-limonene and THC Pharmacodynamics",[14204],{"trials":14220,"activeCount":100},[],{"trials":14222,"activeCount":100},[],{"trials":14224,"activeCount":100},[],{"trials":14226,"activeCount":100},[],{"intervention":14228,"totalTrials":126,"cells":14229},"NEOX® CORD 1K®",{"EARLY_PHASE1":14230,"PHASE1":14245,"PHASE2":14247,"PHASE3":14249,"PHASE4":14251,"NA":14253},{"trials":14231,"activeCount":100},[14232],{"nctId":14233,"briefTitle":14234,"status":149,"phases":14235,"primaryCompletion":7537,"completion":14236,"start":14237,"enrollment":100,"conditions":14238,"interventions":14244},"NCT03296436","A Pilot Study to Assess the Efficacy of NEOX® CORD 1K® in the Treatment of Complex Diabetic Wounds",[87],"2021-10","2020-01",[14239,14240,14241,14242,14243],"Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)","Diabetic Foot Ulcer","Diabetic Foot","Diabetic Foot Infection","Diabetic Foot Ulcer Mixed",[14228],{"trials":14246,"activeCount":100},[],{"trials":14248,"activeCount":100},[],{"trials":14250,"activeCount":100},[],{"trials":14252,"activeCount":100},[],{"trials":14254,"activeCount":100},[],{"intervention":14256,"totalTrials":126,"cells":14257},"Hydrocortisone",{"EARLY_PHASE1":14258,"PHASE1":14270,"PHASE2":14272,"PHASE3":14274,"PHASE4":14276,"NA":14278},{"trials":14259,"activeCount":100},[14260],{"nctId":14261,"briefTitle":14262,"status":106,"phases":14263,"primaryCompletion":14264,"completion":14264,"start":14265,"enrollment":14266,"conditions":14267,"interventions":14269},"NCT03237689","Effects of Glucocorticoids on Cognition in HIV-infected Women",[87],"2023-09-08","2017-11-20",136,[14268],"Hiv",[14256],{"trials":14271,"activeCount":100},[],{"trials":14273,"activeCount":100},[],{"trials":14275,"activeCount":100},[],{"trials":14277,"activeCount":100},[],{"trials":14279,"activeCount":100},[],{"intervention":14281,"totalTrials":126,"cells":14282},"Prenatal vitamin-mineral containing 3 mg fluoride",{"EARLY_PHASE1":14283,"PHASE1":14296,"PHASE2":14298,"PHASE3":14300,"PHASE4":14302,"NA":14304},{"trials":14284,"activeCount":100},[14285],{"nctId":14286,"briefTitle":14287,"status":106,"phases":14288,"primaryCompletion":1042,"completion":1042,"start":875,"enrollment":14289,"conditions":14290,"interventions":14295},"NCT02536352","Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being",[87],43,[14291,14292,14293,14294],"Preterm Birth","Preterm Labor","Bacteremia","Preterm Premature Rupture of Fetal Membranes",[14281],{"trials":14297,"activeCount":100},[],{"trials":14299,"activeCount":100},[],{"trials":14301,"activeCount":100},[],{"trials":14303,"activeCount":100},[],{"trials":14305,"activeCount":100},[],{"intervention":14307,"totalTrials":126,"cells":14308},"Pioglitazone 30 mg",{"EARLY_PHASE1":14309,"PHASE1":14321,"PHASE2":14323,"PHASE3":14325,"PHASE4":14327,"NA":14329},{"trials":14310,"activeCount":100},[14311],{"nctId":14312,"briefTitle":14313,"status":106,"phases":14314,"primaryCompletion":14315,"completion":14316,"start":14317,"enrollment":7105,"conditions":14318,"interventions":14320},"NCT04300127","Pioglitazone for Idiopathic Gastroparesis",[87],"2025-03-15","2025-03-18","2019-10-24",[14319],"Gastroparesis",[14307],{"trials":14322,"activeCount":100},[],{"trials":14324,"activeCount":100},[],{"trials":14326,"activeCount":100},[],{"trials":14328,"activeCount":100},[],{"trials":14330,"activeCount":100},[],{"intervention":14332,"totalTrials":126,"cells":14333},"Enoxaparin",{"EARLY_PHASE1":14334,"PHASE1":14344,"PHASE2":14346,"PHASE3":14348,"PHASE4":14350,"NA":14352},{"trials":14335,"activeCount":100},[14336],{"nctId":14337,"briefTitle":14338,"status":106,"phases":14339,"primaryCompletion":2149,"completion":2149,"start":8079,"enrollment":14340,"conditions":14341,"interventions":14342},"NCT00894283","Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients",[87],198,[5768,5769],[14332,14343],"Fondaparinux",{"trials":14345,"activeCount":100},[],{"trials":14347,"activeCount":100},[],{"trials":14349,"activeCount":100},[],{"trials":14351,"activeCount":100},[],{"trials":14353,"activeCount":100},[],{"intervention":14343,"totalTrials":126,"cells":14355},{"EARLY_PHASE1":14356,"PHASE1":14362,"PHASE2":14364,"PHASE3":14366,"PHASE4":14368,"NA":14370},{"trials":14357,"activeCount":100},[14358],{"nctId":14337,"briefTitle":14338,"status":106,"phases":14359,"primaryCompletion":2149,"completion":2149,"start":8079,"enrollment":14340,"conditions":14360,"interventions":14361},[87],[5768,5769],[14332,14343],{"trials":14363,"activeCount":100},[],{"trials":14365,"activeCount":100},[],{"trials":14367,"activeCount":100},[],{"trials":14369,"activeCount":100},[],{"trials":14371,"activeCount":100},[],{"intervention":14373,"totalTrials":126,"cells":14374},"Everolimus Oral",{"EARLY_PHASE1":14375,"PHASE1":14386,"PHASE2":14388,"PHASE3":14390,"PHASE4":14392,"NA":14394},{"trials":14376,"activeCount":100},[14377],{"nctId":14378,"briefTitle":14379,"status":106,"phases":14380,"primaryCompletion":14381,"completion":14381,"start":14382,"enrollment":4344,"conditions":14383,"interventions":14385},"NCT05153668","Everolimus Trial in Laryngotracheal Stenosis",[87],"2025-10-23","2022-09-30",[14384],"Idiopathic Subglottic Tracheal Stenosis",[14373],{"trials":14387,"activeCount":100},[],{"trials":14389,"activeCount":100},[],{"trials":14391,"activeCount":100},[],{"trials":14393,"activeCount":100},[],{"trials":14395,"activeCount":100},[],{"intervention":14397,"totalTrials":126,"cells":14398},"Adrenocorticotropic Hormone",{"EARLY_PHASE1":14399,"PHASE1":14410,"PHASE2":14412,"PHASE3":14414,"PHASE4":14416,"NA":14418},{"trials":14400,"activeCount":100},[14401],{"nctId":14402,"briefTitle":14403,"status":106,"phases":14404,"primaryCompletion":14405,"completion":14405,"start":14406,"enrollment":329,"conditions":14407,"interventions":14409},"NCT03727776","Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)",[87],"2023-07-07","2019-08-19",[14408],"Proliferative Vitreoretinopathy",[14397],{"trials":14411,"activeCount":100},[],{"trials":14413,"activeCount":100},[],{"trials":14415,"activeCount":100},[],{"trials":14417,"activeCount":100},[],{"trials":14419,"activeCount":100},[],{"intervention":14421,"totalTrials":126,"cells":14422},"ERCP with Bupivacaine",{"EARLY_PHASE1":14423,"PHASE1":14433,"PHASE2":14435,"PHASE3":14437,"PHASE4":14439,"NA":14441},{"trials":14424,"activeCount":100},[14425],{"nctId":14426,"briefTitle":14427,"status":149,"phases":14428,"primaryCompletion":14429,"completion":14429,"start":14429,"enrollment":100,"conditions":14430,"interventions":14432},"NCT04611958","Intraductal Liposomal Bupivacaine for Chronic Pancreatitis",[87],"2021-07-01",[14431],"Chronic Pancreatitis",[14421],{"trials":14434,"activeCount":100},[],{"trials":14436,"activeCount":100},[],{"trials":14438,"activeCount":100},[],{"trials":14440,"activeCount":100},[],{"trials":14442,"activeCount":100},[],{"intervention":14444,"totalTrials":126,"cells":14445},"Four-Chamber Tartrazine Patch across 3 Body Sites",{"EARLY_PHASE1":14446,"PHASE1":14457,"PHASE2":14459,"PHASE3":14461,"PHASE4":14463,"NA":14465},{"trials":14447,"activeCount":100},[14448],{"nctId":14449,"briefTitle":14450,"status":149,"phases":14451,"primaryCompletion":581,"completion":581,"start":14452,"enrollment":100,"conditions":14453,"interventions":14456},"NCT06800183","Topical Tartrazine for Improved Skin Structure Visualization in Dermatology",[87],"2026-05-11",[112,14454,14455],"Dermoscopy","Optical Imaging",[14444],{"trials":14458,"activeCount":100},[],{"trials":14460,"activeCount":100},[],{"trials":14462,"activeCount":100},[],{"trials":14464,"activeCount":100},[],{"trials":14466,"activeCount":100},[],{"intervention":14468,"totalTrials":126,"cells":14469},"Baclofen",{"EARLY_PHASE1":14470,"PHASE1":14479,"PHASE2":14481,"PHASE3":14483,"PHASE4":14485,"NA":14487},{"trials":14471,"activeCount":100},[14472],{"nctId":14473,"briefTitle":14474,"status":106,"phases":14475,"primaryCompletion":8340,"completion":8340,"start":1762,"enrollment":264,"conditions":14476,"interventions":14478},"NCT00640003","Baclofen Treatment of Ataxia Telangiectasia",[87],[14477],"Ataxia Telangiectasia",[14468],{"trials":14480,"activeCount":100},[],{"trials":14482,"activeCount":100},[],{"trials":14484,"activeCount":100},[],{"trials":14486,"activeCount":100},[],{"trials":14488,"activeCount":100},[],{"intervention":14490,"totalTrials":126,"cells":14491},"Transdermal Androgel",{"EARLY_PHASE1":14492,"PHASE1":14500,"PHASE2":14502,"PHASE3":14504,"PHASE4":14506,"NA":14508},{"trials":14493,"activeCount":100},[14494],{"nctId":14495,"briefTitle":14496,"status":149,"phases":14497,"primaryCompletion":292,"completion":292,"start":4518,"enrollment":100,"conditions":14498,"interventions":14499},"NCT01940718","Androgen Regulation of Priapism in Sickle Cell Disease",[87],[3345,3344,6417],[14490],{"trials":14501,"activeCount":100},[],{"trials":14503,"activeCount":100},[],{"trials":14505,"activeCount":100},[],{"trials":14507,"activeCount":100},[],{"trials":14509,"activeCount":100},[],{"intervention":1046,"totalTrials":126,"cells":14511},{"EARLY_PHASE1":14512,"PHASE1":14518,"PHASE2":14520,"PHASE3":14522,"PHASE4":14524,"NA":14526},{"trials":14513,"activeCount":100},[14514],{"nctId":1038,"briefTitle":1039,"status":149,"phases":14515,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":100,"conditions":14516,"interventions":14517},[87],[1044],[1046,893,892],{"trials":14519,"activeCount":100},[],{"trials":14521,"activeCount":100},[],{"trials":14523,"activeCount":100},[],{"trials":14525,"activeCount":100},[],{"trials":14527,"activeCount":100},[],{"intervention":14529,"totalTrials":126,"cells":14530},"sublingual film with peanut extract",{"EARLY_PHASE1":14531,"PHASE1":14542,"PHASE2":14544,"PHASE3":14546,"PHASE4":14548,"NA":14550},{"trials":14532,"activeCount":100},[14533],{"nctId":14534,"briefTitle":14535,"status":106,"phases":14536,"primaryCompletion":4876,"completion":4876,"start":14537,"enrollment":2081,"conditions":14538,"interventions":14541},"NCT03070561","Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects",[87],"2014-01-14",[2109,14539,14540],"Immunotherapy","Pharmacokinetics",[14529],{"trials":14543,"activeCount":100},[],{"trials":14545,"activeCount":100},[],{"trials":14547,"activeCount":100},[],{"trials":14549,"activeCount":100},[],{"trials":14551,"activeCount":100},[],{"intervention":14553,"totalTrials":126,"cells":14554},"Full Nicotine Cigarettes",{"EARLY_PHASE1":14555,"PHASE1":14566,"PHASE2":14568,"PHASE3":14570,"PHASE4":14572,"NA":14574},{"trials":14556,"activeCount":100},[14557],{"nctId":14558,"briefTitle":14559,"status":106,"phases":14560,"primaryCompletion":14561,"completion":14561,"start":14562,"enrollment":2091,"conditions":14563,"interventions":14564},"NCT04999644","Reduced Nicotine Cigarette Purchasing Decisions",[87],"2023-03-29","2022-02-23",[1827],[14553,14565],"Reduced Nicotine Cigarettes",{"trials":14567,"activeCount":100},[],{"trials":14569,"activeCount":100},[],{"trials":14571,"activeCount":100},[],{"trials":14573,"activeCount":100},[],{"trials":14575,"activeCount":100},[],{"intervention":14565,"totalTrials":126,"cells":14577},{"EARLY_PHASE1":14578,"PHASE1":14584,"PHASE2":14586,"PHASE3":14588,"PHASE4":14590,"NA":14592},{"trials":14579,"activeCount":100},[14580],{"nctId":14558,"briefTitle":14559,"status":106,"phases":14581,"primaryCompletion":14561,"completion":14561,"start":14562,"enrollment":2091,"conditions":14582,"interventions":14583},[87],[1827],[14553,14565],{"trials":14585,"activeCount":100},[],{"trials":14587,"activeCount":100},[],{"trials":14589,"activeCount":100},[],{"trials":14591,"activeCount":100},[],{"trials":14593,"activeCount":100},[],{"intervention":14595,"totalTrials":126,"cells":14596},"Standard analgesia use [Oxygen]",{"EARLY_PHASE1":14597,"PHASE1":14617,"PHASE2":14619,"PHASE3":14621,"PHASE4":14623,"NA":14625},{"trials":14598,"activeCount":100},[14599],{"nctId":14600,"briefTitle":14601,"status":106,"phases":14602,"primaryCompletion":5520,"completion":14603,"start":1772,"enrollment":14604,"conditions":14605,"interventions":14609},"NCT03088306","Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients",[87],"2018-08-31",49,[14606,14607,14608],"Lumbar Spinal Stenosis","Lumbar Spinal Instability","Lumbar Spine Degeneration",[14595,14610,14611,14612,14613,14614,14615,14616],"Standard analgesia use [Hydromorphone]","Standard analgesia use [Volatile Anesthesia]","Standard analgesia use [Fentanyl]","Multi-modal pain management [Acetaminophen + Gabapentin]","Multi-modal pain management [Fentanyl]","Multi-modal pain management [Intravenous Ketamine]","Multi-modal pain management [Valium + Gabapentin]",{"trials":14618,"activeCount":100},[],{"trials":14620,"activeCount":100},[],{"trials":14622,"activeCount":100},[],{"trials":14624,"activeCount":100},[],{"trials":14626,"activeCount":100},[],{"intervention":14610,"totalTrials":126,"cells":14628},{"EARLY_PHASE1":14629,"PHASE1":14635,"PHASE2":14637,"PHASE3":14639,"PHASE4":14641,"NA":14643},{"trials":14630,"activeCount":100},[14631],{"nctId":14600,"briefTitle":14601,"status":106,"phases":14632,"primaryCompletion":5520,"completion":14603,"start":1772,"enrollment":14604,"conditions":14633,"interventions":14634},[87],[14606,14607,14608],[14595,14610,14611,14612,14613,14614,14615,14616],{"trials":14636,"activeCount":100},[],{"trials":14638,"activeCount":100},[],{"trials":14640,"activeCount":100},[],{"trials":14642,"activeCount":100},[],{"trials":14644,"activeCount":100},[],{"intervention":14611,"totalTrials":126,"cells":14646},{"EARLY_PHASE1":14647,"PHASE1":14653,"PHASE2":14655,"PHASE3":14657,"PHASE4":14659,"NA":14661},{"trials":14648,"activeCount":100},[14649],{"nctId":14600,"briefTitle":14601,"status":106,"phases":14650,"primaryCompletion":5520,"completion":14603,"start":1772,"enrollment":14604,"conditions":14651,"interventions":14652},[87],[14606,14607,14608],[14595,14610,14611,14612,14613,14614,14615,14616],{"trials":14654,"activeCount":100},[],{"trials":14656,"activeCount":100},[],{"trials":14658,"activeCount":100},[],{"trials":14660,"activeCount":100},[],{"trials":14662,"activeCount":100},[],{"intervention":14612,"totalTrials":126,"cells":14664},{"EARLY_PHASE1":14665,"PHASE1":14671,"PHASE2":14673,"PHASE3":14675,"PHASE4":14677,"NA":14679},{"trials":14666,"activeCount":100},[14667],{"nctId":14600,"briefTitle":14601,"status":106,"phases":14668,"primaryCompletion":5520,"completion":14603,"start":1772,"enrollment":14604,"conditions":14669,"interventions":14670},[87],[14606,14607,14608],[14595,14610,14611,14612,14613,14614,14615,14616],{"trials":14672,"activeCount":100},[],{"trials":14674,"activeCount":100},[],{"trials":14676,"activeCount":100},[],{"trials":14678,"activeCount":100},[],{"trials":14680,"activeCount":100},[],{"intervention":14613,"totalTrials":126,"cells":14682},{"EARLY_PHASE1":14683,"PHASE1":14689,"PHASE2":14691,"PHASE3":14693,"PHASE4":14695,"NA":14697},{"trials":14684,"activeCount":100},[14685],{"nctId":14600,"briefTitle":14601,"status":106,"phases":14686,"primaryCompletion":5520,"completion":14603,"start":1772,"enrollment":14604,"conditions":14687,"interventions":14688},[87],[14606,14607,14608],[14595,14610,14611,14612,14613,14614,14615,14616],{"trials":14690,"activeCount":100},[],{"trials":14692,"activeCount":100},[],{"trials":14694,"activeCount":100},[],{"trials":14696,"activeCount":100},[],{"trials":14698,"activeCount":100},[],{"intervention":14614,"totalTrials":126,"cells":14700},{"EARLY_PHASE1":14701,"PHASE1":14707,"PHASE2":14709,"PHASE3":14711,"PHASE4":14713,"NA":14715},{"trials":14702,"activeCount":100},[14703],{"nctId":14600,"briefTitle":14601,"status":106,"phases":14704,"primaryCompletion":5520,"completion":14603,"start":1772,"enrollment":14604,"conditions":14705,"interventions":14706},[87],[14606,14607,14608],[14595,14610,14611,14612,14613,14614,14615,14616],{"trials":14708,"activeCount":100},[],{"trials":14710,"activeCount":100},[],{"trials":14712,"activeCount":100},[],{"trials":14714,"activeCount":100},[],{"trials":14716,"activeCount":100},[],{"intervention":14615,"totalTrials":126,"cells":14718},{"EARLY_PHASE1":14719,"PHASE1":14725,"PHASE2":14727,"PHASE3":14729,"PHASE4":14731,"NA":14733},{"trials":14720,"activeCount":100},[14721],{"nctId":14600,"briefTitle":14601,"status":106,"phases":14722,"primaryCompletion":5520,"completion":14603,"start":1772,"enrollment":14604,"conditions":14723,"interventions":14724},[87],[14606,14607,14608],[14595,14610,14611,14612,14613,14614,14615,14616],{"trials":14726,"activeCount":100},[],{"trials":14728,"activeCount":100},[],{"trials":14730,"activeCount":100},[],{"trials":14732,"activeCount":100},[],{"trials":14734,"activeCount":100},[],{"intervention":14616,"totalTrials":126,"cells":14736},{"EARLY_PHASE1":14737,"PHASE1":14743,"PHASE2":14745,"PHASE3":14747,"PHASE4":14749,"NA":14751},{"trials":14738,"activeCount":100},[14739],{"nctId":14600,"briefTitle":14601,"status":106,"phases":14740,"primaryCompletion":5520,"completion":14603,"start":1772,"enrollment":14604,"conditions":14741,"interventions":14742},[87],[14606,14607,14608],[14595,14610,14611,14612,14613,14614,14615,14616],{"trials":14744,"activeCount":100},[],{"trials":14746,"activeCount":100},[],{"trials":14748,"activeCount":100},[],{"trials":14750,"activeCount":100},[],{"trials":14752,"activeCount":100},[],{"intervention":14754,"totalTrials":126,"cells":14755},"Retinoic acid",{"EARLY_PHASE1":14756,"PHASE1":14766,"PHASE2":14768,"PHASE3":14770,"PHASE4":14772,"NA":14774},{"trials":14757,"activeCount":100},[14758],{"nctId":14759,"briefTitle":14760,"status":106,"phases":14761,"primaryCompletion":635,"completion":635,"start":5113,"enrollment":30,"conditions":14762,"interventions":14764},"NCT03491267","Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis",[87],[14763],"Central Centrifugal Cicatricial Alopecia (CCCA)",[14754,14765],"Sham treatment",{"trials":14767,"activeCount":100},[],{"trials":14769,"activeCount":100},[],{"trials":14771,"activeCount":100},[],{"trials":14773,"activeCount":100},[],{"trials":14775,"activeCount":100},[],{"intervention":14765,"totalTrials":126,"cells":14777},{"EARLY_PHASE1":14778,"PHASE1":14784,"PHASE2":14786,"PHASE3":14788,"PHASE4":14790,"NA":14792},{"trials":14779,"activeCount":100},[14780],{"nctId":14759,"briefTitle":14760,"status":106,"phases":14781,"primaryCompletion":635,"completion":635,"start":5113,"enrollment":30,"conditions":14782,"interventions":14783},[87],[14763],[14754,14765],{"trials":14785,"activeCount":100},[],{"trials":14787,"activeCount":100},[],{"trials":14789,"activeCount":100},[],{"trials":14791,"activeCount":100},[],{"trials":14793,"activeCount":100},[],{"intervention":3580,"totalTrials":126,"cells":14795},{"EARLY_PHASE1":14796,"PHASE1":14802,"PHASE2":14804,"PHASE3":14806,"PHASE4":14808,"NA":14810},{"trials":14797,"activeCount":100},[14798],{"nctId":3572,"briefTitle":3573,"status":106,"phases":14799,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":1593,"conditions":14800,"interventions":14801},[87],[3578],[56,3580,3581,3582],{"trials":14803,"activeCount":100},[],{"trials":14805,"activeCount":100},[],{"trials":14807,"activeCount":100},[],{"trials":14809,"activeCount":100},[],{"trials":14811,"activeCount":100},[],{"intervention":3581,"totalTrials":126,"cells":14813},{"EARLY_PHASE1":14814,"PHASE1":14820,"PHASE2":14822,"PHASE3":14824,"PHASE4":14826,"NA":14828},{"trials":14815,"activeCount":100},[14816],{"nctId":3572,"briefTitle":3573,"status":106,"phases":14817,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":1593,"conditions":14818,"interventions":14819},[87],[3578],[56,3580,3581,3582],{"trials":14821,"activeCount":100},[],{"trials":14823,"activeCount":100},[],{"trials":14825,"activeCount":100},[],{"trials":14827,"activeCount":100},[],{"trials":14829,"activeCount":100},[],{"intervention":3582,"totalTrials":126,"cells":14831},{"EARLY_PHASE1":14832,"PHASE1":14838,"PHASE2":14840,"PHASE3":14842,"PHASE4":14844,"NA":14846},{"trials":14833,"activeCount":100},[14834],{"nctId":3572,"briefTitle":3573,"status":106,"phases":14835,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":1593,"conditions":14836,"interventions":14837},[87],[3578],[56,3580,3581,3582],{"trials":14839,"activeCount":100},[],{"trials":14841,"activeCount":100},[],{"trials":14843,"activeCount":100},[],{"trials":14845,"activeCount":100},[],{"trials":14847,"activeCount":100},[],{"intervention":14849,"totalTrials":126,"cells":14850},"Normosol-R",{"EARLY_PHASE1":14851,"PHASE1":14860,"PHASE2":14862,"PHASE3":14864,"PHASE4":14866,"NA":14868},{"trials":14852,"activeCount":100},[14853],{"nctId":14854,"briefTitle":14855,"status":106,"phases":14856,"primaryCompletion":7376,"completion":8079,"start":1762,"enrollment":1663,"conditions":14857,"interventions":14858},"NCT00389311","A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides",[87],[29],[14849,14859],"Nonoxynol-9",{"trials":14861,"activeCount":100},[],{"trials":14863,"activeCount":100},[],{"trials":14865,"activeCount":100},[],{"trials":14867,"activeCount":100},[],{"trials":14869,"activeCount":100},[],{"intervention":14859,"totalTrials":126,"cells":14871},{"EARLY_PHASE1":14872,"PHASE1":14878,"PHASE2":14880,"PHASE3":14882,"PHASE4":14884,"NA":14886},{"trials":14873,"activeCount":100},[14874],{"nctId":14854,"briefTitle":14855,"status":106,"phases":14875,"primaryCompletion":7376,"completion":8079,"start":1762,"enrollment":1663,"conditions":14876,"interventions":14877},[87],[29],[14849,14859],{"trials":14879,"activeCount":100},[],{"trials":14881,"activeCount":100},[],{"trials":14883,"activeCount":100},[],{"trials":14885,"activeCount":100},[],{"trials":14887,"activeCount":100},[],{"intervention":14889,"totalTrials":126,"cells":14890},"Bactrim DS 800Mg-160Mg",{"EARLY_PHASE1":14891,"PHASE1":14907,"PHASE2":14909,"PHASE3":14911,"PHASE4":14913,"NA":14915},{"trials":14892,"activeCount":100},[14893],{"nctId":14894,"briefTitle":14895,"status":149,"phases":14896,"primaryCompletion":14897,"completion":14898,"start":14899,"enrollment":100,"conditions":14900,"interventions":14906},"NCT04230746","Effect of Antibiotics on Urinary Microbiome",[87],"2025-02","2026-02","2023-10",[14901,14902,14903,14904,14905],"Microtia","UTI","Bacteriuria","Antibiotic Resistant Infection","Antibiotics Causing Adverse Effects in Therapeutic Use",[14889],{"trials":14908,"activeCount":100},[],{"trials":14910,"activeCount":100},[],{"trials":14912,"activeCount":100},[],{"trials":14914,"activeCount":100},[],{"trials":14916,"activeCount":100},[],{"intervention":14918,"totalTrials":126,"cells":14919},"Methylergonovine",{"EARLY_PHASE1":14920,"PHASE1":14933,"PHASE2":14935,"PHASE3":14937,"PHASE4":14939,"NA":14941},{"trials":14921,"activeCount":100},[14922],{"nctId":14923,"briefTitle":14924,"status":149,"phases":14925,"primaryCompletion":14926,"completion":855,"start":14927,"enrollment":100,"conditions":14928,"interventions":14932},"NCT03303235","Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections",[87],"2020-10","2020-07",[14929,14930,14931],"Uterine Atony","Uterine Tone Disorders","Postpartum Hemorrhage",[14918],{"trials":14934,"activeCount":100},[],{"trials":14936,"activeCount":100},[],{"trials":14938,"activeCount":100},[],{"trials":14940,"activeCount":100},[],{"trials":14942,"activeCount":100},[],{"intervention":1858,"totalTrials":126,"cells":14944},{"EARLY_PHASE1":14945,"PHASE1":14951,"PHASE2":14953,"PHASE3":14955,"PHASE4":14957,"NA":14959},{"trials":14946,"activeCount":100},[14947],{"nctId":1849,"briefTitle":1850,"status":106,"phases":14948,"primaryCompletion":1852,"completion":1852,"start":1853,"enrollment":1854,"conditions":14949,"interventions":14950},[87],[1665,1856],[1858,1844],{"trials":14952,"activeCount":100},[],{"trials":14954,"activeCount":100},[],{"trials":14956,"activeCount":100},[],{"trials":14958,"activeCount":100},[],{"trials":14960,"activeCount":100},[],{"intervention":14962,"totalTrials":126,"cells":14963},"Blinded Study Medication - Condition 1",{"EARLY_PHASE1":14964,"PHASE1":14978,"PHASE2":14980,"PHASE3":14982,"PHASE4":14984,"NA":14986},{"trials":14965,"activeCount":100},[14966],{"nctId":14967,"briefTitle":14968,"status":149,"phases":14969,"primaryCompletion":3075,"completion":14970,"start":14971,"enrollment":100,"conditions":14972,"interventions":14973},"NCT07043452","Measuring Acute Drug Demand in Humans II",[87],"2027-12-30","2025-11-15",[4263],[14962,14974,14975,14976,14977],"Blinded Study Medication - Condition 2","Blinded Study Medication - Condition 3","Blinded Study Medication - Condition 4","Blinded Study Medication - Condition 5",{"trials":14979,"activeCount":100},[],{"trials":14981,"activeCount":100},[],{"trials":14983,"activeCount":100},[],{"trials":14985,"activeCount":100},[],{"trials":14987,"activeCount":100},[],{"intervention":14974,"totalTrials":126,"cells":14989},{"EARLY_PHASE1":14990,"PHASE1":14996,"PHASE2":14998,"PHASE3":15000,"PHASE4":15002,"NA":15004},{"trials":14991,"activeCount":100},[14992],{"nctId":14967,"briefTitle":14968,"status":149,"phases":14993,"primaryCompletion":3075,"completion":14970,"start":14971,"enrollment":100,"conditions":14994,"interventions":14995},[87],[4263],[14962,14974,14975,14976,14977],{"trials":14997,"activeCount":100},[],{"trials":14999,"activeCount":100},[],{"trials":15001,"activeCount":100},[],{"trials":15003,"activeCount":100},[],{"trials":15005,"activeCount":100},[],{"intervention":14975,"totalTrials":126,"cells":15007},{"EARLY_PHASE1":15008,"PHASE1":15014,"PHASE2":15016,"PHASE3":15018,"PHASE4":15020,"NA":15022},{"trials":15009,"activeCount":100},[15010],{"nctId":14967,"briefTitle":14968,"status":149,"phases":15011,"primaryCompletion":3075,"completion":14970,"start":14971,"enrollment":100,"conditions":15012,"interventions":15013},[87],[4263],[14962,14974,14975,14976,14977],{"trials":15015,"activeCount":100},[],{"trials":15017,"activeCount":100},[],{"trials":15019,"activeCount":100},[],{"trials":15021,"activeCount":100},[],{"trials":15023,"activeCount":100},[],{"intervention":14976,"totalTrials":126,"cells":15025},{"EARLY_PHASE1":15026,"PHASE1":15032,"PHASE2":15034,"PHASE3":15036,"PHASE4":15038,"NA":15040},{"trials":15027,"activeCount":100},[15028],{"nctId":14967,"briefTitle":14968,"status":149,"phases":15029,"primaryCompletion":3075,"completion":14970,"start":14971,"enrollment":100,"conditions":15030,"interventions":15031},[87],[4263],[14962,14974,14975,14976,14977],{"trials":15033,"activeCount":100},[],{"trials":15035,"activeCount":100},[],{"trials":15037,"activeCount":100},[],{"trials":15039,"activeCount":100},[],{"trials":15041,"activeCount":100},[],{"intervention":14977,"totalTrials":126,"cells":15043},{"EARLY_PHASE1":15044,"PHASE1":15050,"PHASE2":15052,"PHASE3":15054,"PHASE4":15056,"NA":15058},{"trials":15045,"activeCount":100},[15046],{"nctId":14967,"briefTitle":14968,"status":149,"phases":15047,"primaryCompletion":3075,"completion":14970,"start":14971,"enrollment":100,"conditions":15048,"interventions":15049},[87],[4263],[14962,14974,14975,14976,14977],{"trials":15051,"activeCount":100},[],{"trials":15053,"activeCount":100},[],{"trials":15055,"activeCount":100},[],{"trials":15057,"activeCount":100},[],{"trials":15059,"activeCount":100},[],{"intervention":15061,"totalTrials":126,"cells":15062},"Itraconazole",{"EARLY_PHASE1":15063,"PHASE1":15073,"PHASE2":15075,"PHASE3":15077,"PHASE4":15079,"NA":15081},{"trials":15064,"activeCount":100},[15065],{"nctId":15066,"briefTitle":15067,"status":106,"phases":15068,"primaryCompletion":15069,"completion":15069,"start":1645,"enrollment":96,"conditions":15070,"interventions":15072},"NCT02120677","Topical Itraconazole in the Treatment of Basal Cell Carcinoma",[87],"2019-01-30",[15071],"Basal Cell Carcinoma",[15061],{"trials":15074,"activeCount":100},[],{"trials":15076,"activeCount":100},[],{"trials":15078,"activeCount":100},[],{"trials":15080,"activeCount":100},[],{"trials":15082,"activeCount":100},[],{"intervention":15084,"totalTrials":96,"cells":15085},"cyclophosphamide",{"EARLY_PHASE1":15086,"PHASE1":15088,"PHASE2":15090,"PHASE3":15124,"PHASE4":15126,"NA":15128},{"trials":15087,"activeCount":100},[],{"trials":15089,"activeCount":100},[],{"trials":15091,"activeCount":100},[15092,15102,15113],{"nctId":15093,"briefTitle":15094,"status":106,"phases":15095,"primaryCompletion":15096,"start":15097,"enrollment":1572,"conditions":15098,"interventions":15100},"NCT00010413","Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus",[89],"2007-08","1999-04",[15099],"Pemphigus",[15084,15101],"filgrastim",{"nctId":15103,"briefTitle":15104,"status":106,"phases":15105,"primaryCompletion":15106,"completion":15106,"start":15107,"enrollment":235,"conditions":15108,"interventions":15112},"NCT00258180","Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy",[89],"2009-02-24","2005-08-15",[15109,15110,15111],"Diarrhea","Gastrointestinal Complications","Unspecified Childhood Solid Tumor, Protocol Specific",[15101,15084],{"nctId":15114,"briefTitle":15115,"status":106,"phases":15116,"primaryCompletion":15096,"start":15117,"enrollment":2119,"conditions":15118,"interventions":15123},"NCT00010387","Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease",[89],"1999-03",[15119,15120,15121,15122],"Anemia, Hemolytic, Autoimmune","Felty Syndrome","Purpura, Thrombocytopenic","Autoimmune Diseases",[15084,15101],{"trials":15125,"activeCount":100},[],{"trials":15127,"activeCount":100},[],{"trials":15129,"activeCount":100},[15130,15139],{"nctId":15131,"briefTitle":15132,"status":149,"phases":15133,"primaryCompletion":15134,"completion":15134,"start":1655,"enrollment":100,"conditions":15135,"interventions":15137},"NCT02441491","Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )",[92],"2024-03-31",[15136],"ROHHAD Syndrome",[15138],"Cyclophosphamide",{"nctId":15140,"briefTitle":15141,"status":106,"phases":15142,"start":15143,"enrollment":1572,"conditions":15144,"interventions":15145},"NCT00010400","Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome",[92],"1997-04",[2218,8774],[15138,15101],{"intervention":2006,"totalTrials":96,"cells":15147},{"EARLY_PHASE1":15148,"PHASE1":15150,"PHASE2":15152,"PHASE3":15158,"PHASE4":15160,"NA":15177},{"trials":15149,"activeCount":100},[],{"trials":15151,"activeCount":100},[],{"trials":15153,"activeCount":100},[15154],{"nctId":9674,"briefTitle":9675,"status":106,"phases":15155,"primaryCompletion":7188,"completion":7188,"start":9677,"enrollment":1572,"conditions":15156,"interventions":15157},[89],[9679],[9665,9681,2006],{"trials":15159,"activeCount":100},[],{"trials":15161,"activeCount":100},[15162,15169,15173],{"nctId":15163,"briefTitle":15164,"status":106,"phases":15165,"primaryCompletion":1645,"completion":1645,"start":900,"enrollment":15166,"conditions":15167,"interventions":15168},"NCT01327677","Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring",[91],137,[3259],[2006,2006],{"nctId":3295,"briefTitle":3296,"status":106,"phases":15170,"primaryCompletion":3298,"completion":3298,"start":3299,"enrollment":3300,"conditions":15171,"interventions":15172},[91],[3302],[2006,3304,1981],{"nctId":1995,"briefTitle":1996,"status":873,"phases":15174,"primaryCompletion":1998,"completion":1999,"start":2000,"enrollment":614,"conditions":15175,"interventions":15176},[91],[2002,2003,1716],[2005,2006],{"trials":15178,"activeCount":100},[15179],{"nctId":3308,"briefTitle":3309,"status":106,"phases":15180,"primaryCompletion":2174,"completion":2174,"start":3311,"enrollment":3312,"conditions":15181,"interventions":15182},[92],[3314,3315],[1981,2006],{"intervention":15101,"totalTrials":614,"cells":15184},{"EARLY_PHASE1":15185,"PHASE1":15187,"PHASE2":15189,"PHASE3":15203,"PHASE4":15205,"NA":15207},{"trials":15186,"activeCount":100},[],{"trials":15188,"activeCount":100},[],{"trials":15190,"activeCount":100},[15191,15195,15199],{"nctId":15093,"briefTitle":15094,"status":106,"phases":15192,"primaryCompletion":15096,"start":15097,"enrollment":1572,"conditions":15193,"interventions":15194},[89],[15099],[15084,15101],{"nctId":15103,"briefTitle":15104,"status":106,"phases":15196,"primaryCompletion":15106,"completion":15106,"start":15107,"enrollment":235,"conditions":15197,"interventions":15198},[89],[15109,15110,15111],[15101,15084],{"nctId":15114,"briefTitle":15115,"status":106,"phases":15200,"primaryCompletion":15096,"start":15117,"enrollment":2119,"conditions":15201,"interventions":15202},[89],[15119,15120,15121,15122],[15084,15101],{"trials":15204,"activeCount":100},[],{"trials":15206,"activeCount":100},[],{"trials":15208,"activeCount":100},[15209],{"nctId":15140,"briefTitle":15141,"status":106,"phases":15210,"start":15143,"enrollment":1572,"conditions":15211,"interventions":15212},[92],[2218,8774],[15138,15101],{"intervention":3304,"totalTrials":614,"cells":15214},{"EARLY_PHASE1":15215,"PHASE1":15217,"PHASE2":15219,"PHASE3":15221,"PHASE4":15227,"NA":15241},{"trials":15216,"activeCount":100},[],{"trials":15218,"activeCount":100},[],{"trials":15220,"activeCount":100},[],{"trials":15222,"activeCount":100},[15223],{"nctId":8075,"briefTitle":8076,"status":106,"phases":15224,"primaryCompletion":8078,"completion":8079,"start":6210,"enrollment":311,"conditions":15225,"interventions":15226},[89,90],[3259,8081],[8083,8064],{"trials":15228,"activeCount":100},[15229,15233],{"nctId":3295,"briefTitle":3296,"status":106,"phases":15230,"primaryCompletion":3298,"completion":3298,"start":3299,"enrollment":3300,"conditions":15231,"interventions":15232},[91],[3302],[2006,3304,1981],{"nctId":15234,"briefTitle":15235,"status":149,"phases":15236,"primaryCompletion":714,"completion":714,"start":714,"enrollment":100,"conditions":15237,"interventions":15240},"NCT01967017","Study of Local Anesthesia as a Method to Decrease IUD Insertion Related Pain",[91],[15238,15239],"IUD Insertion Complication","Pain Control",[3304],{"trials":15242,"activeCount":100},[15243],{"nctId":15244,"briefTitle":15245,"status":873,"phases":15246,"primaryCompletion":6673,"completion":6673,"start":12336,"enrollment":1582,"conditions":15247,"interventions":15250},"NCT02517996","Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis\u002FPainful Bladder Syndrome (IC\u002FPBS)",[92],[15248,15249],"Interstitial Cystitis","Painful Bladder Syndrome",[3304],{"intervention":15252,"totalTrials":235,"cells":15253},"Memantine",{"EARLY_PHASE1":15254,"PHASE1":15256,"PHASE2":15258,"PHASE3":15260,"PHASE4":15262,"NA":15264},{"trials":15255,"activeCount":100},[],{"trials":15257,"activeCount":100},[],{"trials":15259,"activeCount":100},[],{"trials":15261,"activeCount":100},[],{"trials":15263,"activeCount":100},[],{"trials":15265,"activeCount":100},[15266,15272,15279],{"nctId":15267,"briefTitle":15268,"status":106,"phases":15269,"primaryCompletion":4887,"completion":4887,"start":3358,"enrollment":4486,"conditions":15270,"interventions":15271},"NCT00181298","Memantine in Systemic Lupus Erythematosus",[92],[2218],[15252],{"nctId":15273,"briefTitle":15274,"status":106,"phases":15275,"primaryCompletion":224,"completion":2338,"start":11126,"enrollment":1593,"conditions":15276,"interventions":15278},"NCT00294554","Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia",[92],[15277,1888,2026],"Parkinson's Disease",[15252],{"nctId":15280,"briefTitle":15281,"status":873,"phases":15282,"primaryCompletion":7132,"completion":7132,"start":8188,"enrollment":614,"conditions":15283,"interventions":15287},"NCT01078844","Memantine in Adult Autism Spectrum Disorder",[92],[15284,15285,15286],"Autism","Asperger's Disorder","Pervasive Developmental Disorder NOS",[15288],"memantine",{"intervention":7127,"totalTrials":235,"cells":15290},{"EARLY_PHASE1":15291,"PHASE1":15293,"PHASE2":15295,"PHASE3":15305,"PHASE4":15307,"NA":15309},{"trials":15292,"activeCount":100},[],{"trials":15294,"activeCount":100},[],{"trials":15296,"activeCount":100},[15297,15301],{"nctId":7121,"briefTitle":7122,"status":106,"phases":15298,"primaryCompletion":2105,"completion":2105,"start":697,"enrollment":1663,"conditions":15299,"interventions":15300},[89],[7125],[2282,7127],{"nctId":7129,"briefTitle":7130,"status":106,"phases":15302,"primaryCompletion":5585,"completion":5585,"start":7132,"enrollment":1663,"conditions":15303,"interventions":15304},[88,89],[7134,2313],[7136,7137],{"trials":15306,"activeCount":100},[],{"trials":15308,"activeCount":100},[],{"trials":15310,"activeCount":100},[15311],{"nctId":15312,"briefTitle":15313,"status":106,"phases":15314,"primaryCompletion":15315,"completion":15316,"start":1687,"enrollment":184,"conditions":15317,"interventions":15319},"NCT01794689","Mechanisms of Sleep Disruption Hyperalgesia",[92],"2018-01","2019-03-12",[15318,3259],"Sleep Deprivation",[7127,15320],"Saline Placebo",{"intervention":114,"totalTrials":235,"cells":15322},{"EARLY_PHASE1":15323,"PHASE1":15325,"PHASE2":15335,"PHASE3":15337,"PHASE4":15339,"NA":15341},{"trials":15324,"activeCount":100},[],{"trials":15326,"activeCount":100},[15327,15331],{"nctId":104,"briefTitle":105,"status":106,"phases":15328,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":15329,"interventions":15330},[88],[112],[95,114],{"nctId":1910,"briefTitle":1911,"status":106,"phases":15332,"primaryCompletion":1913,"completion":1914,"start":1915,"enrollment":25,"conditions":15333,"interventions":15334},[88],[1844,114],[1844,114],{"trials":15336,"activeCount":100},[],{"trials":15338,"activeCount":100},[],{"trials":15340,"activeCount":100},[],{"trials":15342,"activeCount":100},[15343],{"nctId":15344,"briefTitle":15345,"status":106,"phases":15346,"primaryCompletion":15347,"completion":15348,"start":15349,"enrollment":15350,"conditions":15351,"interventions":15352},"NCT01484340","A Smoking Cessation Trial in HIV-infected Patients in South Africa",[92],"2016-06-30","2017-06-30","2014-03-28",560,[889,24],[114],{"intervention":15354,"totalTrials":280,"cells":15355},"Eszopiclone",{"EARLY_PHASE1":15356,"PHASE1":15358,"PHASE2":15364,"PHASE3":15366,"PHASE4":15368,"NA":15370},{"trials":15357,"activeCount":100},[],{"trials":15359,"activeCount":100},[15360],{"nctId":8684,"briefTitle":8685,"status":106,"phases":15361,"primaryCompletion":8447,"completion":8447,"start":901,"enrollment":2717,"conditions":15362,"interventions":15363},[88],[8688],[8690,8691,8692],{"trials":15365,"activeCount":100},[],{"trials":15367,"activeCount":100},[],{"trials":15369,"activeCount":100},[],{"trials":15371,"activeCount":100},[15372],{"nctId":15373,"briefTitle":15374,"status":106,"phases":15375,"primaryCompletion":3341,"completion":3341,"start":8480,"enrollment":164,"conditions":15376,"interventions":15379},"NCT00374556","Insomnia and Osteoarthritis Study",[92],[15377,15378],"Osteoarthritis","Insomnia",[15354],{"intervention":15381,"totalTrials":280,"cells":15382},"Corticosteroid",{"EARLY_PHASE1":15383,"PHASE1":15385,"PHASE2":15387,"PHASE3":15389,"PHASE4":15391,"NA":15393},{"trials":15384,"activeCount":100},[],{"trials":15386,"activeCount":100},[],{"trials":15388,"activeCount":100},[],{"trials":15390,"activeCount":100},[],{"trials":15392,"activeCount":100},[],{"trials":15394,"activeCount":100},[15395,15405],{"nctId":15396,"briefTitle":15397,"status":149,"phases":15398,"primaryCompletion":15399,"completion":161,"start":12078,"enrollment":100,"conditions":15400,"interventions":15403},"NCT04735185","Stem Cells vs. Steroids for Discogenic Back Pain",[92],"2025-11-30",[15401,15402],"Chronic Low Back Pain","Degenerative Disc Disease",[15381,15404],"Local anesthetic",{"nctId":15406,"briefTitle":15407,"status":106,"phases":15408,"primaryCompletion":12336,"completion":12336,"start":3119,"enrollment":8513,"conditions":15409,"interventions":15411},"NCT01670825","Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia",[92],[15410],"Occipital Neuralgia",[15381,15412],"Local anethestic",{"intervention":5388,"totalTrials":280,"cells":15414},{"EARLY_PHASE1":15415,"PHASE1":15417,"PHASE2":15419,"PHASE3":15421,"PHASE4":15423,"NA":15429},{"trials":15416,"activeCount":100},[],{"trials":15418,"activeCount":100},[],{"trials":15420,"activeCount":100},[],{"trials":15422,"activeCount":100},[],{"trials":15424,"activeCount":100},[15425],{"nctId":5381,"briefTitle":5382,"status":106,"phases":15426,"primaryCompletion":4518,"completion":4518,"start":2185,"enrollment":5384,"conditions":15427,"interventions":15428},[91],[5386],[5368,5388,5389],{"trials":15430,"activeCount":100},[15431],{"nctId":15432,"briefTitle":15433,"status":873,"phases":15434,"primaryCompletion":8446,"completion":8446,"start":5740,"enrollment":264,"conditions":15435,"interventions":15438},"NCT01876992","Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)",[92],[15436,15437,18],"Diabetes","Pre-diabetes",[5388],{"intervention":11920,"totalTrials":280,"cells":15440},{"EARLY_PHASE1":15441,"PHASE1":15443,"PHASE2":15445,"PHASE3":15451,"PHASE4":15453,"NA":15455},{"trials":15442,"activeCount":100},[],{"trials":15444,"activeCount":100},[],{"trials":15446,"activeCount":100},[15447],{"nctId":11912,"briefTitle":11913,"status":106,"phases":15448,"primaryCompletion":11915,"completion":11915,"start":8910,"enrollment":30,"conditions":15449,"interventions":15450},[89],[11917,11918],[11903,11920],{"trials":15452,"activeCount":100},[],{"trials":15454,"activeCount":100},[],{"trials":15456,"activeCount":100},[15457],{"nctId":15458,"briefTitle":15459,"status":149,"phases":15460,"primaryCompletion":4518,"completion":4518,"start":900,"enrollment":100,"conditions":15461,"interventions":15463},"NCT01349556","Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream",[92],[15462],"Medication Reaction",[11920],{"intervention":15465,"totalTrials":280,"cells":15466},"Apixaban",{"EARLY_PHASE1":15467,"PHASE1":15469,"PHASE2":15471,"PHASE3":15473,"PHASE4":15475,"NA":15484},{"trials":15468,"activeCount":100},[],{"trials":15470,"activeCount":100},[],{"trials":15472,"activeCount":100},[],{"trials":15474,"activeCount":100},[],{"trials":15476,"activeCount":100},[15477],{"nctId":15478,"briefTitle":15479,"status":106,"phases":15480,"primaryCompletion":1874,"completion":1874,"start":15481,"enrollment":3446,"conditions":15482,"interventions":15483},"NCT02406885","Apixaban Pharmacokinetics in Bariatric Patients (APB)",[91],"2017-07-19",[11619,18],[15465],{"trials":15485,"activeCount":100},[15486],{"nctId":15487,"briefTitle":15488,"status":106,"phases":15489,"primaryCompletion":15490,"completion":15490,"start":15491,"enrollment":15492,"conditions":15493,"interventions":15495},"NCT04818151","Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data",[],"2021-06-30","2021-01-01",14914,[15494,700],"Venous Thromboembolic Disease",[15496,15465],"Warfarin",{"intervention":7214,"totalTrials":280,"cells":15498},{"EARLY_PHASE1":15499,"PHASE1":15501,"PHASE2":15503,"PHASE3":15509,"PHASE4":15511,"NA":15513},{"trials":15500,"activeCount":100},[],{"trials":15502,"activeCount":100},[],{"trials":15504,"activeCount":100},[15505],{"nctId":7207,"briefTitle":7208,"status":106,"phases":15506,"primaryCompletion":7210,"completion":7210,"start":7211,"enrollment":1593,"conditions":15507,"interventions":15508},[89],[5430],[7198,7214],{"trials":15510,"activeCount":100},[],{"trials":15512,"activeCount":100},[],{"trials":15514,"activeCount":100},[15515],{"nctId":15516,"briefTitle":15517,"status":873,"phases":15518,"primaryCompletion":15519,"completion":15519,"start":15520,"enrollment":126,"conditions":15521,"interventions":15525},"NCT03699618","Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration",[],"2020-01-06","2019-05-29",[15522,15523,15524],"Submacular Hemorrhage","Wet Macular Degeneration","Neovascular Age-related Macular Degeneration",[7214],{"intervention":15527,"totalTrials":280,"cells":15528},"Propofol",{"EARLY_PHASE1":15529,"PHASE1":15531,"PHASE2":15533,"PHASE3":15535,"PHASE4":15537,"NA":15539},{"trials":15530,"activeCount":100},[],{"trials":15532,"activeCount":100},[],{"trials":15534,"activeCount":100},[],{"trials":15536,"activeCount":100},[],{"trials":15538,"activeCount":100},[],{"trials":15540,"activeCount":100},[15541,15548],{"nctId":15542,"briefTitle":15543,"status":106,"phases":15544,"primaryCompletion":6346,"completion":6346,"start":2104,"enrollment":15545,"conditions":15546,"interventions":15547},"NCT01526395","Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital",[92],99,[1754,5173,5134],[15527],{"nctId":15549,"briefTitle":15550,"status":873,"phases":15551,"primaryCompletion":1644,"completion":1644,"start":8575,"enrollment":7105,"conditions":15552,"interventions":15557},"NCT01772537","The Effects of Anesthesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.",[92],[15553,15554,15555,15556],"Thoracic Aneurysm","Aneurysm Stent","Cardiopulmonary Bypass","Abdominal Aneurysm",[15527,15558],"isoflurane",{"intervention":15560,"totalTrials":280,"cells":15561},"broccoli sprout extract",{"EARLY_PHASE1":15562,"PHASE1":15564,"PHASE2":15566,"PHASE3":15577,"PHASE4":15579,"NA":15581},{"trials":15563,"activeCount":100},[],{"trials":15565,"activeCount":100},[],{"trials":15567,"activeCount":100},[15568],{"nctId":15569,"briefTitle":15570,"status":106,"phases":15571,"primaryCompletion":15572,"completion":15572,"start":13036,"enrollment":164,"conditions":15573,"interventions":15575},"NCT01845220","Prevention of Alcohol Intolerance",[89],"2015-07-01",[15574],"Alcohol Sensitivity",[15576],"Broccoli Sprout Extract",{"trials":15578,"activeCount":100},[],{"trials":15580,"activeCount":100},[],{"trials":15582,"activeCount":100},[15583],{"nctId":15584,"briefTitle":15585,"status":106,"phases":15586,"primaryCompletion":7104,"completion":7104,"start":2150,"enrollment":2106,"conditions":15587,"interventions":15588},"NCT00994604","The Effects of Broccoli Sprout Extract on Obstructive Lung Disease",[92],[21,5080],[15560],{"intervention":15590,"totalTrials":280,"cells":15591},"Liposomal bupivacaine",{"EARLY_PHASE1":15592,"PHASE1":15594,"PHASE2":15603,"PHASE3":15605,"PHASE4":15607,"NA":15609},{"trials":15593,"activeCount":100},[],{"trials":15595,"activeCount":100},[15596],{"nctId":15597,"briefTitle":15598,"status":106,"phases":15599,"primaryCompletion":7351,"completion":7351,"start":15600,"enrollment":921,"conditions":15601,"interventions":15602},"NCT04121338","Temporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility",[88],"2019-12-09",[8406],[15590],{"trials":15604,"activeCount":100},[],{"trials":15606,"activeCount":100},[],{"trials":15608,"activeCount":100},[],{"trials":15610,"activeCount":100},[15611],{"nctId":15612,"briefTitle":15613,"status":106,"phases":15614,"primaryCompletion":7015,"completion":7015,"start":7327,"enrollment":15615,"conditions":15616,"interventions":15620},"NCT02762071","Liposomal Bupivacaine for Pain Control After Total Shoulder Arthroplasty",[92],108,[15377,15617,15618,15619],"Arthropathy","Shoulder Pain","Closed Fracture Proximal Humerus, Four Part",[15590,15621],"Interscalene Nerve Block",{"intervention":15623,"totalTrials":280,"cells":15624},"dexamethasone",{"EARLY_PHASE1":15625,"PHASE1":15627,"PHASE2":15629,"PHASE3":15631,"PHASE4":15637,"NA":15639},{"trials":15626,"activeCount":100},[],{"trials":15628,"activeCount":100},[],{"trials":15630,"activeCount":100},[],{"trials":15632,"activeCount":100},[15633],{"nctId":693,"briefTitle":694,"status":106,"phases":15634,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":15635,"interventions":15636},[90],[700],[702,703,704,661,705,706,707],{"trials":15638,"activeCount":100},[],{"trials":15640,"activeCount":100},[15641],{"nctId":15642,"briefTitle":15643,"status":106,"phases":15644,"completion":15645,"start":15646,"enrollment":347,"conditions":15647,"interventions":15649},"NCT00004403","Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis",[92],"2002-03","2000-05",[2742,15648],"Cysticercosis",[15650,15623,15651],"albendazole","phenytoin",{"intervention":4904,"totalTrials":280,"cells":15653},{"EARLY_PHASE1":15654,"PHASE1":15656,"PHASE2":15658,"PHASE3":15660,"PHASE4":15666,"NA":15668},{"trials":15655,"activeCount":100},[],{"trials":15657,"activeCount":100},[],{"trials":15659,"activeCount":100},[],{"trials":15661,"activeCount":100},[15662],{"nctId":4896,"briefTitle":4897,"status":106,"phases":15663,"primaryCompletion":3311,"completion":3311,"start":4899,"enrollment":4900,"conditions":15664,"interventions":15665},[89,90],[4902],[4904,4905,4906],{"trials":15667,"activeCount":100},[],{"trials":15669,"activeCount":100},[15670],{"nctId":3265,"briefTitle":3266,"status":106,"phases":15671,"primaryCompletion":3268,"completion":3119,"start":2185,"enrollment":3269,"conditions":15672,"interventions":15673},[92],[3271,3245],[3273,3204],{"intervention":15675,"totalTrials":126,"cells":15676},"Phenazopyridine",{"EARLY_PHASE1":15677,"PHASE1":15679,"PHASE2":15681,"PHASE3":15683,"PHASE4":15685,"NA":15687},{"trials":15678,"activeCount":100},[],{"trials":15680,"activeCount":100},[],{"trials":15682,"activeCount":100},[],{"trials":15684,"activeCount":100},[],{"trials":15686,"activeCount":100},[],{"trials":15688,"activeCount":100},[15689],{"nctId":15690,"briefTitle":15691,"status":149,"phases":15692,"primaryCompletion":15693,"completion":15693,"start":3299,"enrollment":100,"conditions":15694,"interventions":15696},"NCT02703558","Evaluation of Fluorescein Use During Cystoscopy",[92],"2018-01-10",[15695],"Intraoperative Cystoscopy",[15675,15697],"Fluorescein",{"intervention":15697,"totalTrials":126,"cells":15699},{"EARLY_PHASE1":15700,"PHASE1":15702,"PHASE2":15704,"PHASE3":15706,"PHASE4":15708,"NA":15710},{"trials":15701,"activeCount":100},[],{"trials":15703,"activeCount":100},[],{"trials":15705,"activeCount":100},[],{"trials":15707,"activeCount":100},[],{"trials":15709,"activeCount":100},[],{"trials":15711,"activeCount":100},[15712],{"nctId":15690,"briefTitle":15691,"status":149,"phases":15713,"primaryCompletion":15693,"completion":15693,"start":3299,"enrollment":100,"conditions":15714,"interventions":15715},[92],[15695],[15675,15697],{"intervention":15404,"totalTrials":126,"cells":15717},{"EARLY_PHASE1":15718,"PHASE1":15720,"PHASE2":15722,"PHASE3":15724,"PHASE4":15726,"NA":15728},{"trials":15719,"activeCount":100},[],{"trials":15721,"activeCount":100},[],{"trials":15723,"activeCount":100},[],{"trials":15725,"activeCount":100},[],{"trials":15727,"activeCount":100},[],{"trials":15729,"activeCount":100},[15730],{"nctId":15396,"briefTitle":15397,"status":149,"phases":15731,"primaryCompletion":15399,"completion":161,"start":12078,"enrollment":100,"conditions":15732,"interventions":15733},[92],[15401,15402],[15381,15404],{"intervention":15735,"totalTrials":126,"cells":15736},"11C-para-aminobenzoic acid PET\u002FCT",{"EARLY_PHASE1":15737,"PHASE1":15739,"PHASE2":15741,"PHASE3":15743,"PHASE4":15745,"NA":15747},{"trials":15738,"activeCount":100},[],{"trials":15740,"activeCount":100},[],{"trials":15742,"activeCount":100},[],{"trials":15744,"activeCount":100},[],{"trials":15746,"activeCount":100},[],{"trials":15748,"activeCount":100},[15749],{"nctId":15750,"briefTitle":15751,"status":106,"phases":15752,"primaryCompletion":15753,"completion":15753,"start":15754,"enrollment":1773,"conditions":15755,"interventions":15760},"NCT05611905","Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid",[],"2025-11-08","2023-12-22",[15756,15757,15758,15759],"Renal Excretion","Bacterial Infections","Inflammatory Disease","Oncologic Disease",[15735,15761],"Probenecid",{"intervention":15761,"totalTrials":126,"cells":15763},{"EARLY_PHASE1":15764,"PHASE1":15766,"PHASE2":15768,"PHASE3":15770,"PHASE4":15772,"NA":15774},{"trials":15765,"activeCount":100},[],{"trials":15767,"activeCount":100},[],{"trials":15769,"activeCount":100},[],{"trials":15771,"activeCount":100},[],{"trials":15773,"activeCount":100},[],{"trials":15775,"activeCount":100},[15776],{"nctId":15750,"briefTitle":15751,"status":106,"phases":15777,"primaryCompletion":15753,"completion":15753,"start":15754,"enrollment":1773,"conditions":15778,"interventions":15779},[],[15756,15757,15758,15759],[15735,15761],{"intervention":15781,"totalTrials":126,"cells":15782},"Ozurdex",{"EARLY_PHASE1":15783,"PHASE1":15785,"PHASE2":15787,"PHASE3":15789,"PHASE4":15791,"NA":15793},{"trials":15784,"activeCount":100},[],{"trials":15786,"activeCount":100},[],{"trials":15788,"activeCount":100},[],{"trials":15790,"activeCount":100},[],{"trials":15792,"activeCount":100},[],{"trials":15794,"activeCount":100},[15795],{"nctId":15796,"briefTitle":15797,"status":873,"phases":15798,"primaryCompletion":15799,"completion":15799,"start":15800,"enrollment":12613,"conditions":15801,"interventions":15804},"NCT02688309","Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases",[],"2021-10-28","2015-01-13",[15802,15803],"Macular Edema","Fibrosis of the Retina",[15781],{"intervention":15806,"totalTrials":126,"cells":15807},"Increased dose of amiodarone",{"EARLY_PHASE1":15808,"PHASE1":15810,"PHASE2":15812,"PHASE3":15814,"PHASE4":15816,"NA":15818},{"trials":15809,"activeCount":100},[],{"trials":15811,"activeCount":100},[],{"trials":15813,"activeCount":100},[],{"trials":15815,"activeCount":100},[],{"trials":15817,"activeCount":100},[],{"trials":15819,"activeCount":100},[15820],{"nctId":15821,"briefTitle":15822,"status":149,"phases":15823,"primaryCompletion":7104,"completion":7104,"start":7375,"enrollment":100,"conditions":15824,"interventions":15826},"NCT00721032","Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia",[92],[15825],"Ventricular Tachycardia",[15806],{"intervention":15828,"totalTrials":126,"cells":15829},"HBOC-201",{"EARLY_PHASE1":15830,"PHASE1":15832,"PHASE2":15834,"PHASE3":15836,"PHASE4":15838,"NA":15840},{"trials":15831,"activeCount":100},[],{"trials":15833,"activeCount":100},[],{"trials":15835,"activeCount":100},[],{"trials":15837,"activeCount":100},[],{"trials":15839,"activeCount":100},[],{"trials":15841,"activeCount":100},[15842],{"nctId":15843,"briefTitle":15844,"status":15845,"phases":15846,"conditions":15847,"interventions":15849},"NCT02684474","Expanded Access Protocol Using HBOC-201","NO_LONGER_AVAILABLE",[],[15848],"Anemia",[15828],{"intervention":15851,"totalTrials":126,"cells":15852},"Cyclosporin 0.05% ophthalmic",{"EARLY_PHASE1":15853,"PHASE1":15855,"PHASE2":15857,"PHASE3":15859,"PHASE4":15861,"NA":15863},{"trials":15854,"activeCount":100},[],{"trials":15856,"activeCount":100},[],{"trials":15858,"activeCount":100},[],{"trials":15860,"activeCount":100},[],{"trials":15862,"activeCount":100},[],{"trials":15864,"activeCount":100},[15865],{"nctId":15866,"briefTitle":15867,"status":106,"phases":15868,"primaryCompletion":2127,"completion":2127,"start":15096,"enrollment":1663,"conditions":15869,"interventions":15871},"NCT00987467","Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis",[92],[15870],"Atopic Keratoconjunctivitis",[15851],{"intervention":15873,"totalTrials":126,"cells":15874},"Intravenous sedation",{"EARLY_PHASE1":15875,"PHASE1":15877,"PHASE2":15879,"PHASE3":15881,"PHASE4":15883,"NA":15885},{"trials":15876,"activeCount":100},[],{"trials":15878,"activeCount":100},[],{"trials":15880,"activeCount":100},[],{"trials":15882,"activeCount":100},[],{"trials":15884,"activeCount":100},[],{"trials":15886,"activeCount":100},[15887],{"nctId":15888,"briefTitle":15889,"status":106,"phases":15890,"primaryCompletion":15891,"completion":15891,"start":5960,"enrollment":15892,"conditions":15893,"interventions":15896},"NCT04887285","Virtual Reality as a Substitute for Procedural Sedation During Epidural Steroid Injections",[92],"2023-08-15",146,[15894,15895],"Lower Back Pain","Lumbar Radiculopathy",[15873],{"intervention":15496,"totalTrials":126,"cells":15898},{"EARLY_PHASE1":15899,"PHASE1":15901,"PHASE2":15903,"PHASE3":15905,"PHASE4":15907,"NA":15909},{"trials":15900,"activeCount":100},[],{"trials":15902,"activeCount":100},[],{"trials":15904,"activeCount":100},[],{"trials":15906,"activeCount":100},[],{"trials":15908,"activeCount":100},[],{"trials":15910,"activeCount":100},[15911],{"nctId":15487,"briefTitle":15488,"status":106,"phases":15912,"primaryCompletion":15490,"completion":15490,"start":15491,"enrollment":15492,"conditions":15913,"interventions":15914},[],[15494,700],[15496,15465],{"intervention":15916,"totalTrials":126,"cells":15917},"Tesamorelin",{"EARLY_PHASE1":15918,"PHASE1":15920,"PHASE2":15922,"PHASE3":15924,"PHASE4":15926,"NA":15928},{"trials":15919,"activeCount":100},[],{"trials":15921,"activeCount":100},[],{"trials":15923,"activeCount":100},[],{"trials":15925,"activeCount":100},[],{"trials":15927,"activeCount":100},[],{"trials":15929,"activeCount":100},[15930],{"nctId":15931,"briefTitle":15932,"status":149,"phases":15933,"primaryCompletion":14237,"start":8575,"enrollment":100,"conditions":15934,"interventions":15936},"NCT01788462","Egrifta Replacement and Sleep Disordered Breathing",[],[15935],"Lipodystrophy",[15916],{"intervention":15938,"totalTrials":126,"cells":15939},"Olanzapine",{"EARLY_PHASE1":15940,"PHASE1":15942,"PHASE2":15944,"PHASE3":15946,"PHASE4":15948,"NA":15950},{"trials":15941,"activeCount":100},[],{"trials":15943,"activeCount":100},[],{"trials":15945,"activeCount":100},[],{"trials":15947,"activeCount":100},[],{"trials":15949,"activeCount":100},[],{"trials":15951,"activeCount":100},[15952],{"nctId":15953,"briefTitle":15954,"status":149,"phases":15955,"primaryCompletion":9139,"completion":9139,"start":15956,"enrollment":100,"conditions":15957,"interventions":15959},"NCT02977741","Olanzapine for the Treatment of Refractory Chronic Nausea and Vomiting",[],"2016-11",[11236,15958],"Vomiting",[15938],{"intervention":15961,"totalTrials":126,"cells":15962},"Topical phenylephrine 2.5%",{"EARLY_PHASE1":15963,"PHASE1":15965,"PHASE2":15967,"PHASE3":15969,"PHASE4":15971,"NA":15973},{"trials":15964,"activeCount":100},[],{"trials":15966,"activeCount":100},[],{"trials":15968,"activeCount":100},[],{"trials":15970,"activeCount":100},[],{"trials":15972,"activeCount":100},[],{"trials":15974,"activeCount":100},[15975],{"nctId":15976,"briefTitle":15977,"status":873,"phases":15978,"primaryCompletion":15979,"completion":15979,"start":8543,"enrollment":235,"conditions":15980,"interventions":15982},"NCT02909140","Optimal Method for Mydriasis in Cataract Surgery",[92],"2018-08-15",[15981],"Cataract",[15961,15983,15984,15985],"Topical cyclopentolate 1%","Intracameral Lidocaine 1%","Intracameral 0.2- 0.3ml of epinephrine 1:10,000",{"intervention":15983,"totalTrials":126,"cells":15987},{"EARLY_PHASE1":15988,"PHASE1":15990,"PHASE2":15992,"PHASE3":15994,"PHASE4":15996,"NA":15998},{"trials":15989,"activeCount":100},[],{"trials":15991,"activeCount":100},[],{"trials":15993,"activeCount":100},[],{"trials":15995,"activeCount":100},[],{"trials":15997,"activeCount":100},[],{"trials":15999,"activeCount":100},[16000],{"nctId":15976,"briefTitle":15977,"status":873,"phases":16001,"primaryCompletion":15979,"completion":15979,"start":8543,"enrollment":235,"conditions":16002,"interventions":16003},[92],[15981],[15961,15983,15984,15985],{"intervention":15984,"totalTrials":126,"cells":16005},{"EARLY_PHASE1":16006,"PHASE1":16008,"PHASE2":16010,"PHASE3":16012,"PHASE4":16014,"NA":16016},{"trials":16007,"activeCount":100},[],{"trials":16009,"activeCount":100},[],{"trials":16011,"activeCount":100},[],{"trials":16013,"activeCount":100},[],{"trials":16015,"activeCount":100},[],{"trials":16017,"activeCount":100},[16018],{"nctId":15976,"briefTitle":15977,"status":873,"phases":16019,"primaryCompletion":15979,"completion":15979,"start":8543,"enrollment":235,"conditions":16020,"interventions":16021},[92],[15981],[15961,15983,15984,15985],{"intervention":15985,"totalTrials":126,"cells":16023},{"EARLY_PHASE1":16024,"PHASE1":16026,"PHASE2":16028,"PHASE3":16030,"PHASE4":16032,"NA":16034},{"trials":16025,"activeCount":100},[],{"trials":16027,"activeCount":100},[],{"trials":16029,"activeCount":100},[],{"trials":16031,"activeCount":100},[],{"trials":16033,"activeCount":100},[],{"trials":16035,"activeCount":100},[16036],{"nctId":15976,"briefTitle":15977,"status":873,"phases":16037,"primaryCompletion":15979,"completion":15979,"start":8543,"enrollment":235,"conditions":16038,"interventions":16039},[92],[15981],[15961,15983,15984,15985],{"intervention":16041,"totalTrials":126,"cells":16042},"Evening only administration of insulin glargine",{"EARLY_PHASE1":16043,"PHASE1":16045,"PHASE2":16047,"PHASE3":16049,"PHASE4":16051,"NA":16053},{"trials":16044,"activeCount":100},[],{"trials":16046,"activeCount":100},[],{"trials":16048,"activeCount":100},[],{"trials":16050,"activeCount":100},[],{"trials":16052,"activeCount":100},[],{"trials":16054,"activeCount":100},[16055],{"nctId":16056,"briefTitle":16057,"status":873,"phases":16058,"primaryCompletion":8565,"completion":8565,"start":2105,"enrollment":9563,"conditions":16059,"interventions":16061},"NCT00869414","Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes",[92],[16060,3219],"Type 1 Diabetes",[16041,16062,16063],"Morning only administration of insulin glargine","split dose insulin glargine",{"intervention":16062,"totalTrials":126,"cells":16065},{"EARLY_PHASE1":16066,"PHASE1":16068,"PHASE2":16070,"PHASE3":16072,"PHASE4":16074,"NA":16076},{"trials":16067,"activeCount":100},[],{"trials":16069,"activeCount":100},[],{"trials":16071,"activeCount":100},[],{"trials":16073,"activeCount":100},[],{"trials":16075,"activeCount":100},[],{"trials":16077,"activeCount":100},[16078],{"nctId":16056,"briefTitle":16057,"status":873,"phases":16079,"primaryCompletion":8565,"completion":8565,"start":2105,"enrollment":9563,"conditions":16080,"interventions":16081},[92],[16060,3219],[16041,16062,16063],{"intervention":16063,"totalTrials":126,"cells":16083},{"EARLY_PHASE1":16084,"PHASE1":16086,"PHASE2":16088,"PHASE3":16090,"PHASE4":16092,"NA":16094},{"trials":16085,"activeCount":100},[],{"trials":16087,"activeCount":100},[],{"trials":16089,"activeCount":100},[],{"trials":16091,"activeCount":100},[],{"trials":16093,"activeCount":100},[],{"trials":16095,"activeCount":100},[16096],{"nctId":16056,"briefTitle":16057,"status":873,"phases":16097,"primaryCompletion":8565,"completion":8565,"start":2105,"enrollment":9563,"conditions":16098,"interventions":16099},[92],[16060,3219],[16041,16062,16063],{"intervention":15320,"totalTrials":126,"cells":16101},{"EARLY_PHASE1":16102,"PHASE1":16104,"PHASE2":16106,"PHASE3":16108,"PHASE4":16110,"NA":16112},{"trials":16103,"activeCount":100},[],{"trials":16105,"activeCount":100},[],{"trials":16107,"activeCount":100},[],{"trials":16109,"activeCount":100},[],{"trials":16111,"activeCount":100},[],{"trials":16113,"activeCount":100},[16114],{"nctId":15312,"briefTitle":15313,"status":106,"phases":16115,"primaryCompletion":15315,"completion":15316,"start":1687,"enrollment":184,"conditions":16116,"interventions":16117},[92],[15318,3259],[7127,15320],{"intervention":16119,"totalTrials":126,"cells":16120},"0.5% bupivacaine",{"EARLY_PHASE1":16121,"PHASE1":16123,"PHASE2":16125,"PHASE3":16127,"PHASE4":16129,"NA":16131},{"trials":16122,"activeCount":100},[],{"trials":16124,"activeCount":100},[],{"trials":16126,"activeCount":100},[],{"trials":16128,"activeCount":100},[],{"trials":16130,"activeCount":100},[],{"trials":16132,"activeCount":100},[16133],{"nctId":16134,"briefTitle":16135,"status":106,"phases":16136,"primaryCompletion":2185,"completion":2185,"start":8309,"enrollment":16137,"conditions":16138,"interventions":16140},"NCT00484159","Efficacy and Cost: Benefit Ratio of 0, 1, and 2 Medial Branch Blocks for Lumbar Facet Joint Radiofrequency Denervation",[92],151,[16139],"Low Back Pain",[16119,16141],"2% lidocaine",{"intervention":16141,"totalTrials":126,"cells":16143},{"EARLY_PHASE1":16144,"PHASE1":16146,"PHASE2":16148,"PHASE3":16150,"PHASE4":16152,"NA":16154},{"trials":16145,"activeCount":100},[],{"trials":16147,"activeCount":100},[],{"trials":16149,"activeCount":100},[],{"trials":16151,"activeCount":100},[],{"trials":16153,"activeCount":100},[],{"trials":16155,"activeCount":100},[16156],{"nctId":16134,"briefTitle":16135,"status":106,"phases":16157,"primaryCompletion":2185,"completion":2185,"start":8309,"enrollment":16137,"conditions":16158,"interventions":16159},[92],[16139],[16119,16141],{"intervention":16161,"totalTrials":126,"cells":16162},"Secretin (human synthetic) - ChiRhoClin",{"EARLY_PHASE1":16163,"PHASE1":16165,"PHASE2":16167,"PHASE3":16169,"PHASE4":16171,"NA":16173},{"trials":16164,"activeCount":100},[],{"trials":16166,"activeCount":100},[],{"trials":16168,"activeCount":100},[],{"trials":16170,"activeCount":100},[],{"trials":16172,"activeCount":100},[],{"trials":16174,"activeCount":100},[16175],{"nctId":16176,"briefTitle":16177,"status":106,"phases":16178,"primaryCompletion":5097,"completion":5097,"start":4843,"enrollment":1470,"conditions":16179,"interventions":16182},"NCT00438906","Cancer of the Pancreas Screening Study (CAPS 3)",[],[16180,16181],"Pancreatic Neoplasm","Peutz-Jeghers Syndrome",[16161],{"intervention":16184,"totalTrials":126,"cells":16185},"LTQ",{"EARLY_PHASE1":16186,"PHASE1":16188,"PHASE2":16190,"PHASE3":16192,"PHASE4":16194,"NA":16196},{"trials":16187,"activeCount":100},[],{"trials":16189,"activeCount":100},[],{"trials":16191,"activeCount":100},[],{"trials":16193,"activeCount":100},[],{"trials":16195,"activeCount":100},[],{"trials":16197,"activeCount":100},[16198],{"nctId":16199,"briefTitle":16200,"status":149,"phases":16201,"primaryCompletion":55,"completion":55,"start":16202,"enrollment":100,"conditions":16203,"interventions":16204},"NCT05031416","Developing and Pilot Testing a Remote Smoking Cessation Digital Therapeutic for Individuals With Serious Mental Illness",[92],"2025-06",[889],[16184],{"intervention":16206,"totalTrials":126,"cells":16207},"Teriparatide",{"EARLY_PHASE1":16208,"PHASE1":16210,"PHASE2":16212,"PHASE3":16214,"PHASE4":16216,"NA":16218},{"trials":16209,"activeCount":100},[],{"trials":16211,"activeCount":100},[],{"trials":16213,"activeCount":100},[],{"trials":16215,"activeCount":100},[],{"trials":16217,"activeCount":100},[],{"trials":16219,"activeCount":100},[16220],{"nctId":16221,"briefTitle":16222,"status":873,"phases":16223,"primaryCompletion":714,"completion":16224,"start":3119,"enrollment":16225,"conditions":16226,"interventions":16228},"NCT01656629","Stem Cell Recruitment in Osteoporosis Therapy",[92],"2020-08-07",55,[16227],"Low Bone Density",[16206,16229],"Alendronate",{"intervention":16229,"totalTrials":126,"cells":16231},{"EARLY_PHASE1":16232,"PHASE1":16234,"PHASE2":16236,"PHASE3":16238,"PHASE4":16240,"NA":16242},{"trials":16233,"activeCount":100},[],{"trials":16235,"activeCount":100},[],{"trials":16237,"activeCount":100},[],{"trials":16239,"activeCount":100},[],{"trials":16241,"activeCount":100},[],{"trials":16243,"activeCount":100},[16244],{"nctId":16221,"briefTitle":16222,"status":873,"phases":16245,"primaryCompletion":714,"completion":16224,"start":3119,"enrollment":16225,"conditions":16246,"interventions":16247},[92],[16227],[16206,16229],{"intervention":16249,"totalTrials":126,"cells":16250},"continue warfarin through the procedure",{"EARLY_PHASE1":16251,"PHASE1":16253,"PHASE2":16255,"PHASE3":16257,"PHASE4":16259,"NA":16261},{"trials":16252,"activeCount":100},[],{"trials":16254,"activeCount":100},[],{"trials":16256,"activeCount":100},[],{"trials":16258,"activeCount":100},[],{"trials":16260,"activeCount":100},[],{"trials":16262,"activeCount":100},[16263],{"nctId":16264,"briefTitle":16265,"status":106,"phases":16266,"primaryCompletion":7605,"completion":7605,"start":930,"enrollment":902,"conditions":16267,"interventions":16271},"NCT00721136","Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation",[92],[16268,16269,1497,16270],"Bradycardia","Tachycardia","Valvular Heart Disease",[16249,16272,16273],"Hold warfarin","Warfarin held with heparin transition.",{"intervention":16272,"totalTrials":126,"cells":16275},{"EARLY_PHASE1":16276,"PHASE1":16278,"PHASE2":16280,"PHASE3":16282,"PHASE4":16284,"NA":16286},{"trials":16277,"activeCount":100},[],{"trials":16279,"activeCount":100},[],{"trials":16281,"activeCount":100},[],{"trials":16283,"activeCount":100},[],{"trials":16285,"activeCount":100},[],{"trials":16287,"activeCount":100},[16288],{"nctId":16264,"briefTitle":16265,"status":106,"phases":16289,"primaryCompletion":7605,"completion":7605,"start":930,"enrollment":902,"conditions":16290,"interventions":16291},[92],[16268,16269,1497,16270],[16249,16272,16273],{"intervention":16273,"totalTrials":126,"cells":16293},{"EARLY_PHASE1":16294,"PHASE1":16296,"PHASE2":16298,"PHASE3":16300,"PHASE4":16302,"NA":16304},{"trials":16295,"activeCount":100},[],{"trials":16297,"activeCount":100},[],{"trials":16299,"activeCount":100},[],{"trials":16301,"activeCount":100},[],{"trials":16303,"activeCount":100},[],{"trials":16305,"activeCount":100},[16306],{"nctId":16264,"briefTitle":16265,"status":106,"phases":16307,"primaryCompletion":7605,"completion":7605,"start":930,"enrollment":902,"conditions":16308,"interventions":16309},[92],[16268,16269,1497,16270],[16249,16272,16273],{"intervention":16311,"totalTrials":126,"cells":16312},"Broccoli Sprouts",{"EARLY_PHASE1":16313,"PHASE1":16315,"PHASE2":16317,"PHASE3":16319,"PHASE4":16321,"NA":16323},{"trials":16314,"activeCount":100},[],{"trials":16316,"activeCount":100},[],{"trials":16318,"activeCount":100},[],{"trials":16320,"activeCount":100},[],{"trials":16322,"activeCount":100},[],{"trials":16324,"activeCount":100},[16325],{"nctId":16326,"briefTitle":16327,"status":106,"phases":16328,"primaryCompletion":1655,"completion":1655,"start":5585,"enrollment":2106,"conditions":16329,"interventions":16331},"NCT01522703","Effects of Whole Sprouts on Airway Allergic Inflammation",[92],[2188,21,16330],"Allergy",[16311],{"intervention":16333,"totalTrials":126,"cells":16334},"Lamictal",{"EARLY_PHASE1":16335,"PHASE1":16337,"PHASE2":16339,"PHASE3":16341,"PHASE4":16343,"NA":16345},{"trials":16336,"activeCount":100},[],{"trials":16338,"activeCount":100},[],{"trials":16340,"activeCount":100},[],{"trials":16342,"activeCount":100},[],{"trials":16344,"activeCount":100},[],{"trials":16346,"activeCount":100},[16347],{"nctId":16348,"briefTitle":16349,"status":106,"phases":16350,"primaryCompletion":153,"completion":153,"start":16351,"enrollment":264,"conditions":16352,"interventions":16353},"NCT03774641","A Pilot Study of Prophylactic Management of Lamotrigine in Pregnant Women",[],"2018-12-03",[5173,1754,5135],[16333],{"intervention":16355,"totalTrials":126,"cells":16356},"monitoring of adherence with medication",{"EARLY_PHASE1":16357,"PHASE1":16359,"PHASE2":16361,"PHASE3":16363,"PHASE4":16365,"NA":16367},{"trials":16358,"activeCount":100},[],{"trials":16360,"activeCount":100},[],{"trials":16362,"activeCount":100},[],{"trials":16364,"activeCount":100},[],{"trials":16366,"activeCount":100},[],{"trials":16368,"activeCount":100},[16369],{"nctId":16370,"briefTitle":16371,"status":106,"phases":16372,"primaryCompletion":16373,"completion":16373,"start":183,"enrollment":16374,"conditions":16375,"interventions":16377},"NCT03402802","Steroid Eyedrop Adherence After Trabeculectomy",[],"2021-08-25",92,[331,16376],"Adherence, Patient",[16355],{"intervention":15558,"totalTrials":126,"cells":16379},{"EARLY_PHASE1":16380,"PHASE1":16382,"PHASE2":16384,"PHASE3":16386,"PHASE4":16388,"NA":16390},{"trials":16381,"activeCount":100},[],{"trials":16383,"activeCount":100},[],{"trials":16385,"activeCount":100},[],{"trials":16387,"activeCount":100},[],{"trials":16389,"activeCount":100},[],{"trials":16391,"activeCount":100},[16392],{"nctId":15549,"briefTitle":15550,"status":873,"phases":16393,"primaryCompletion":1644,"completion":1644,"start":8575,"enrollment":7105,"conditions":16394,"interventions":16395},[92],[15553,15554,15555,15556],[15527,15558],{"intervention":16397,"totalTrials":126,"cells":16398},"Dolutegravir 50 MG",{"EARLY_PHASE1":16399,"PHASE1":16401,"PHASE2":16403,"PHASE3":16405,"PHASE4":16407,"NA":16409},{"trials":16400,"activeCount":100},[],{"trials":16402,"activeCount":100},[],{"trials":16404,"activeCount":100},[],{"trials":16406,"activeCount":100},[],{"trials":16408,"activeCount":100},[],{"trials":16410,"activeCount":100},[16411],{"nctId":16412,"briefTitle":16413,"status":106,"phases":16414,"primaryCompletion":16415,"completion":16415,"start":16416,"enrollment":2119,"conditions":16417,"interventions":16418},"NCT03512964","Rapid HIV Treatment Initiation, Access and Engagement in Care",[92],"2020-09-13","2016-11-29",[8270],[16397,16419],"Emtricitabine\u002FTenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]",{"intervention":16419,"totalTrials":126,"cells":16421},{"EARLY_PHASE1":16422,"PHASE1":16424,"PHASE2":16426,"PHASE3":16428,"PHASE4":16430,"NA":16432},{"trials":16423,"activeCount":100},[],{"trials":16425,"activeCount":100},[],{"trials":16427,"activeCount":100},[],{"trials":16429,"activeCount":100},[],{"trials":16431,"activeCount":100},[],{"trials":16433,"activeCount":100},[16434],{"nctId":16412,"briefTitle":16413,"status":106,"phases":16435,"primaryCompletion":16415,"completion":16415,"start":16416,"enrollment":2119,"conditions":16436,"interventions":16437},[92],[8270],[16397,16419],{"intervention":15621,"totalTrials":126,"cells":16439},{"EARLY_PHASE1":16440,"PHASE1":16442,"PHASE2":16444,"PHASE3":16446,"PHASE4":16448,"NA":16450},{"trials":16441,"activeCount":100},[],{"trials":16443,"activeCount":100},[],{"trials":16445,"activeCount":100},[],{"trials":16447,"activeCount":100},[],{"trials":16449,"activeCount":100},[],{"trials":16451,"activeCount":100},[16452],{"nctId":15612,"briefTitle":15613,"status":106,"phases":16453,"primaryCompletion":7015,"completion":7015,"start":7327,"enrollment":15615,"conditions":16454,"interventions":16455},[92],[15377,15617,15618,15619],[15590,15621],{"intervention":16457,"totalTrials":126,"cells":16458},"Gabapentin",{"EARLY_PHASE1":16459,"PHASE1":16461,"PHASE2":16463,"PHASE3":16465,"PHASE4":16467,"NA":16469},{"trials":16460,"activeCount":100},[],{"trials":16462,"activeCount":100},[],{"trials":16464,"activeCount":100},[],{"trials":16466,"activeCount":100},[],{"trials":16468,"activeCount":100},[],{"trials":16470,"activeCount":100},[16471],{"nctId":16472,"briefTitle":16473,"status":106,"phases":16474,"primaryCompletion":714,"completion":813,"start":11915,"enrollment":2340,"conditions":16475,"interventions":16477},"NCT01495923","Steroids Versus Gabapentin",[92],[9449,16476],"Radiculopathy",[16457],{"intervention":16479,"totalTrials":126,"cells":16480},"Simvastatin",{"EARLY_PHASE1":16481,"PHASE1":16483,"PHASE2":16485,"PHASE3":16487,"PHASE4":16489,"NA":16491},{"trials":16482,"activeCount":100},[],{"trials":16484,"activeCount":100},[],{"trials":16486,"activeCount":100},[],{"trials":16488,"activeCount":100},[],{"trials":16490,"activeCount":100},[],{"trials":16492,"activeCount":100},[16493],{"nctId":16494,"briefTitle":16495,"status":106,"phases":16496,"completion":12589,"start":16497,"enrollment":6829,"conditions":16498,"interventions":16499},"NCT00125060","Transesophageal Magnetic Resonance Imaging (MRI) in Conjunction With Lipid Lowering Measures",[92],"2000-08",[6875],[16479],{"intervention":16501,"totalTrials":126,"cells":16502},"Penicillin G, Benzathine",{"EARLY_PHASE1":16503,"PHASE1":16505,"PHASE2":16507,"PHASE3":16509,"PHASE4":16511,"NA":16513},{"trials":16504,"activeCount":100},[],{"trials":16506,"activeCount":100},[],{"trials":16508,"activeCount":100},[],{"trials":16510,"activeCount":100},[],{"trials":16512,"activeCount":100},[],{"trials":16514,"activeCount":100},[16515],{"nctId":16516,"briefTitle":16517,"status":106,"phases":16518,"primaryCompletion":16519,"completion":16519,"start":4844,"enrollment":16520,"conditions":16521,"interventions":16524},"NCT01156740","Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings",[92],"2003-04",558,[16522,16523],"Streptococcal Infections","Pharyngitis",[16501,16525],"Amoxicillin",{"intervention":16525,"totalTrials":126,"cells":16527},{"EARLY_PHASE1":16528,"PHASE1":16530,"PHASE2":16532,"PHASE3":16534,"PHASE4":16536,"NA":16538},{"trials":16529,"activeCount":100},[],{"trials":16531,"activeCount":100},[],{"trials":16533,"activeCount":100},[],{"trials":16535,"activeCount":100},[],{"trials":16537,"activeCount":100},[],{"trials":16539,"activeCount":100},[16540],{"nctId":16516,"briefTitle":16517,"status":106,"phases":16541,"primaryCompletion":16519,"completion":16519,"start":4844,"enrollment":16520,"conditions":16542,"interventions":16543},[92],[16522,16523],[16501,16525],{"intervention":16545,"totalTrials":126,"cells":16546},"Venlafaxine",{"EARLY_PHASE1":16547,"PHASE1":16549,"PHASE2":16551,"PHASE3":16553,"PHASE4":16555,"NA":16557},{"trials":16548,"activeCount":100},[],{"trials":16550,"activeCount":100},[],{"trials":16552,"activeCount":100},[],{"trials":16554,"activeCount":100},[],{"trials":16556,"activeCount":100},[],{"trials":16558,"activeCount":100},[16559],{"nctId":16560,"briefTitle":16561,"status":106,"phases":16562,"primaryCompletion":1761,"completion":3256,"start":6346,"enrollment":96,"conditions":16563,"interventions":16564},"NCT01609348","Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)",[92],[5015,27],[16545],{"intervention":16566,"totalTrials":126,"cells":16567},"Immune checkpoint inhibitor",{"EARLY_PHASE1":16568,"PHASE1":16570,"PHASE2":16572,"PHASE3":16574,"PHASE4":16576,"NA":16578},{"trials":16569,"activeCount":100},[],{"trials":16571,"activeCount":100},[],{"trials":16573,"activeCount":100},[],{"trials":16575,"activeCount":100},[],{"trials":16577,"activeCount":100},[],{"trials":16579,"activeCount":100},[16580],{"nctId":16581,"briefTitle":16582,"status":106,"phases":16583,"primaryCompletion":16584,"completion":16584,"start":16585,"enrollment":16586,"conditions":16587,"interventions":16589},"NCT04898751","Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors",[],"2020-08-31","2008-01-01",2214,[16588],"Cutaneous Toxicity From ICI Therapy",[16566],{"intervention":16591,"totalTrials":126,"cells":16592},"Corrie Hybrid Cardiac Rehabilitation Program",{"EARLY_PHASE1":16593,"PHASE1":16595,"PHASE2":16597,"PHASE3":16599,"PHASE4":16601,"NA":16603},{"trials":16594,"activeCount":100},[],{"trials":16596,"activeCount":100},[],{"trials":16598,"activeCount":100},[],{"trials":16600,"activeCount":100},[],{"trials":16602,"activeCount":100},[],{"trials":16604,"activeCount":100},[16605],{"nctId":16606,"briefTitle":16607,"status":106,"phases":16608,"primaryCompletion":16609,"completion":16609,"start":16610,"enrollment":16611,"conditions":16612,"interventions":16619},"NCT05238103","Impact of a Corrie Cardiac Rehabilitation Program",[92],"2024-10-14","2023-04-03",259,[3302,16613,16614,16615,16616,16617,16618],"Myocardial Infarction","Myocardial Ischemia","Coronary Artery Occlusion","Coronary Artery Stenosis Stent","Bypass Graft Occlusion","Valve Heart Disease",[16591],{"intervention":16621,"totalTrials":126,"cells":16622},"Amniotic membranes",{"EARLY_PHASE1":16623,"PHASE1":16625,"PHASE2":16627,"PHASE3":16629,"PHASE4":16631,"NA":16633},{"trials":16624,"activeCount":100},[],{"trials":16626,"activeCount":100},[],{"trials":16628,"activeCount":100},[],{"trials":16630,"activeCount":100},[],{"trials":16632,"activeCount":100},[],{"trials":16634,"activeCount":100},[16635],{"nctId":16636,"briefTitle":16637,"status":149,"phases":16638,"primaryCompletion":11574,"completion":11574,"start":16639,"enrollment":100,"conditions":16640,"interventions":16646},"NCT03685955","Efficacy of Amniotic Membranes in Complex Genitourinary Reconstruction",[],"2020-03",[7428,16641,16642,16643,16644,16645],"Hypospadias and Epispadias and Other Penile Anomalies","Fistula","Fistula, Urinary","Bladder Exstrophy and Epispadias Complex","Bladder and Bladder Neck Disorders (Excluding Calculi)",[16621],{"intervention":15650,"totalTrials":126,"cells":16648},{"EARLY_PHASE1":16649,"PHASE1":16651,"PHASE2":16653,"PHASE3":16655,"PHASE4":16657,"NA":16659},{"trials":16650,"activeCount":100},[],{"trials":16652,"activeCount":100},[],{"trials":16654,"activeCount":100},[],{"trials":16656,"activeCount":100},[],{"trials":16658,"activeCount":100},[],{"trials":16660,"activeCount":100},[16661],{"nctId":15642,"briefTitle":15643,"status":106,"phases":16662,"completion":15645,"start":15646,"enrollment":347,"conditions":16663,"interventions":16664},[92],[2742,15648],[15650,15623,15651],{"intervention":15651,"totalTrials":126,"cells":16666},{"EARLY_PHASE1":16667,"PHASE1":16669,"PHASE2":16671,"PHASE3":16673,"PHASE4":16675,"NA":16677},{"trials":16668,"activeCount":100},[],{"trials":16670,"activeCount":100},[],{"trials":16672,"activeCount":100},[],{"trials":16674,"activeCount":100},[],{"trials":16676,"activeCount":100},[],{"trials":16678,"activeCount":100},[16679],{"nctId":15642,"briefTitle":15643,"status":106,"phases":16680,"completion":15645,"start":15646,"enrollment":347,"conditions":16681,"interventions":16682},[92],[2742,15648],[15650,15623,15651],{"intervention":16684,"totalTrials":126,"cells":16685},"lipitor",{"EARLY_PHASE1":16686,"PHASE1":16688,"PHASE2":16690,"PHASE3":16692,"PHASE4":16694,"NA":16696},{"trials":16687,"activeCount":100},[],{"trials":16689,"activeCount":100},[],{"trials":16691,"activeCount":100},[],{"trials":16693,"activeCount":100},[],{"trials":16695,"activeCount":100},[],{"trials":16697,"activeCount":100},[16698],{"nctId":16699,"briefTitle":16700,"status":873,"phases":16701,"primaryCompletion":8036,"completion":8036,"start":3342,"enrollment":9563,"conditions":16702,"interventions":16703},"NCT00770679","Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging",[92],[15436],[16684],{"intervention":16705,"totalTrials":126,"cells":16706},"18F-Pretomanid PET\u002FCT",{"EARLY_PHASE1":16707,"PHASE1":16709,"PHASE2":16711,"PHASE3":16713,"PHASE4":16715,"NA":16717},{"trials":16708,"activeCount":100},[],{"trials":16710,"activeCount":100},[],{"trials":16712,"activeCount":100},[],{"trials":16714,"activeCount":100},[],{"trials":16716,"activeCount":100},[],{"trials":16718,"activeCount":100},[16719],{"nctId":16720,"briefTitle":16721,"status":106,"phases":16722,"primaryCompletion":16723,"completion":16723,"start":4544,"enrollment":264,"conditions":16724,"interventions":16725},"NCT05609552","Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET",[],"2025-10-28",[35],[16705],{"intervention":15412,"totalTrials":126,"cells":16727},{"EARLY_PHASE1":16728,"PHASE1":16730,"PHASE2":16732,"PHASE3":16734,"PHASE4":16736,"NA":16738},{"trials":16729,"activeCount":100},[],{"trials":16731,"activeCount":100},[],{"trials":16733,"activeCount":100},[],{"trials":16735,"activeCount":100},[],{"trials":16737,"activeCount":100},[],{"trials":16739,"activeCount":100},[16740],{"nctId":15406,"briefTitle":15407,"status":106,"phases":16741,"primaryCompletion":12336,"completion":12336,"start":3119,"enrollment":8513,"conditions":16742,"interventions":16743},[92],[15410],[15381,15412],{"intervention":16745,"totalTrials":126,"cells":16746},"99m Tc-TM",{"EARLY_PHASE1":16747,"PHASE1":16749,"PHASE2":16751,"PHASE3":16753,"PHASE4":16755,"NA":16757},{"trials":16748,"activeCount":100},[],{"trials":16750,"activeCount":100},[],{"trials":16752,"activeCount":100},[],{"trials":16754,"activeCount":100},[],{"trials":16756,"activeCount":100},[],{"trials":16758,"activeCount":100},[16759],{"nctId":16760,"briefTitle":16761,"status":873,"phases":16762,"primaryCompletion":16763,"completion":16764,"start":16765,"enrollment":7105,"conditions":16766,"interventions":16767},"NCT05236387","Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection",[],"2023-05-23","2023-06-30","2022-03-01",[10625],[16745],{"intervention":16769,"totalTrials":126,"cells":16770},"Blood transfusion",{"EARLY_PHASE1":16771,"PHASE1":16773,"PHASE2":16775,"PHASE3":16777,"PHASE4":16779,"NA":16781},{"trials":16772,"activeCount":100},[],{"trials":16774,"activeCount":100},[],{"trials":16776,"activeCount":100},[],{"trials":16778,"activeCount":100},[],{"trials":16780,"activeCount":100},[],{"trials":16782,"activeCount":100},[16783],{"nctId":16784,"briefTitle":16785,"status":873,"phases":16786,"primaryCompletion":16787,"completion":16787,"start":3256,"enrollment":126,"conditions":16788,"interventions":16790},"NCT02990273","The Utility of Thromboelastography in Cirrhotic Patients Undergoing Endoscopic Procedures",[92],"2021-01-19",[16789],"Cirrhosis, Coagulopathy",[16769],{"intervention":16792,"totalTrials":126,"cells":16793},"Gardasil® Vaccine",{"EARLY_PHASE1":16794,"PHASE1":16796,"PHASE2":16798,"PHASE3":16800,"PHASE4":16802,"NA":16804},{"trials":16795,"activeCount":100},[],{"trials":16797,"activeCount":100},[],{"trials":16799,"activeCount":100},[],{"trials":16801,"activeCount":100},[],{"trials":16803,"activeCount":100},[],{"trials":16805,"activeCount":100},[16806],{"nctId":16807,"briefTitle":16808,"status":106,"phases":16809,"primaryCompletion":7104,"completion":7104,"start":2338,"enrollment":16810,"conditions":16811,"interventions":16813},"NCT00806676","Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease",[92],67,[16812],"Chronic Kidney Disease",[16792],{"intervention":16815,"totalTrials":126,"cells":16816},"Atomoxetine",{"EARLY_PHASE1":16817,"PHASE1":16819,"PHASE2":16821,"PHASE3":16823,"PHASE4":16825,"NA":16827},{"trials":16818,"activeCount":100},[],{"trials":16820,"activeCount":100},[],{"trials":16822,"activeCount":100},[],{"trials":16824,"activeCount":100},[],{"trials":16826,"activeCount":100},[],{"trials":16828,"activeCount":100},[16829],{"nctId":16830,"briefTitle":16831,"status":106,"phases":16832,"primaryCompletion":16833,"completion":16833,"start":16834,"enrollment":1663,"conditions":16835,"interventions":16836},"NCT00286949","Treatment of Executive Dysfunction in Parkinson's Disease",[92],"2008-06-30","2005-01-06",[15277],[16815],{"intervention":16838,"totalTrials":126,"cells":16839},"Alfentanil",{"EARLY_PHASE1":16840,"PHASE1":16842,"PHASE2":16844,"PHASE3":16846,"PHASE4":16848,"NA":16850},{"trials":16841,"activeCount":100},[],{"trials":16843,"activeCount":100},[],{"trials":16845,"activeCount":100},[],{"trials":16847,"activeCount":100},[],{"trials":16849,"activeCount":100},[],{"trials":16851,"activeCount":100},[16852],{"nctId":16853,"briefTitle":16854,"status":106,"phases":16855,"primaryCompletion":5169,"completion":5169,"start":16856,"enrollment":33,"conditions":16857,"interventions":16859},"NCT00991809","Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil",[92],"2009-02",[16858],"Hyperalgesia",[16838,16860],"Diphenhydramine",{"intervention":16860,"totalTrials":126,"cells":16862},{"EARLY_PHASE1":16863,"PHASE1":16865,"PHASE2":16867,"PHASE3":16869,"PHASE4":16871,"NA":16873},{"trials":16864,"activeCount":100},[],{"trials":16866,"activeCount":100},[],{"trials":16868,"activeCount":100},[],{"trials":16870,"activeCount":100},[],{"trials":16872,"activeCount":100},[],{"trials":16874,"activeCount":100},[16875],{"nctId":16853,"briefTitle":16854,"status":106,"phases":16876,"primaryCompletion":5169,"completion":5169,"start":16856,"enrollment":33,"conditions":16877,"interventions":16878},[92],[16858],[16838,16860],{"intervention":16880,"totalTrials":126,"cells":16881},"Psilocybin-assisted treatment",{"EARLY_PHASE1":16882,"PHASE1":16884,"PHASE2":16886,"PHASE3":16888,"PHASE4":16890,"NA":16892},{"trials":16883,"activeCount":100},[],{"trials":16885,"activeCount":100},[],{"trials":16887,"activeCount":100},[],{"trials":16889,"activeCount":100},[],{"trials":16891,"activeCount":100},[],{"trials":16893,"activeCount":100},[16894],{"nctId":16895,"briefTitle":16896,"status":106,"phases":16897,"primaryCompletion":11420,"completion":16898,"start":224,"enrollment":16899,"conditions":16900,"interventions":16901},"NCT01943994","Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study",[92],"2023-11-14",82,[3520],[16880,16902],"Nicotine Replacement Therapy",{"intervention":16902,"totalTrials":126,"cells":16904},{"EARLY_PHASE1":16905,"PHASE1":16907,"PHASE2":16909,"PHASE3":16911,"PHASE4":16913,"NA":16915},{"trials":16906,"activeCount":100},[],{"trials":16908,"activeCount":100},[],{"trials":16910,"activeCount":100},[],{"trials":16912,"activeCount":100},[],{"trials":16914,"activeCount":100},[],{"trials":16916,"activeCount":100},[16917],{"nctId":16895,"briefTitle":16896,"status":106,"phases":16918,"primaryCompletion":11420,"completion":16898,"start":224,"enrollment":16899,"conditions":16919,"interventions":16920},[92],[3520],[16880,16902],{"intervention":16922,"totalTrials":126,"cells":16923},"Amyl Nitrite",{"EARLY_PHASE1":16924,"PHASE1":16926,"PHASE2":16928,"PHASE3":16930,"PHASE4":16932,"NA":16934},{"trials":16925,"activeCount":100},[],{"trials":16927,"activeCount":100},[],{"trials":16929,"activeCount":100},[],{"trials":16931,"activeCount":100},[],{"trials":16933,"activeCount":100},[],{"trials":16935,"activeCount":100},[16936],{"nctId":16937,"briefTitle":16938,"status":149,"phases":16939,"primaryCompletion":6345,"completion":6345,"start":714,"enrollment":100,"conditions":16940,"interventions":16943},"NCT02428959","Diagnostic Utility of Amyl Nitrite in Patients With Suspected Achalasia Undergoing High Resolution Esophageal Manometry (HREM)",[92],[16941,16942],"Dysphagia","Achalasia",[16922],{"intervention":16945,"totalTrials":126,"cells":16946},"Lidocaine patch",{"EARLY_PHASE1":16947,"PHASE1":16949,"PHASE2":16951,"PHASE3":16953,"PHASE4":16955,"NA":16957},{"trials":16948,"activeCount":100},[],{"trials":16950,"activeCount":100},[],{"trials":16952,"activeCount":100},[],{"trials":16954,"activeCount":100},[],{"trials":16956,"activeCount":100},[],{"trials":16958,"activeCount":100},[16959],{"nctId":16960,"briefTitle":16961,"status":106,"phases":16962,"primaryCompletion":16963,"completion":16963,"start":7758,"enrollment":16964,"conditions":16965,"interventions":16968},"NCT04378959","Lidocaine Patch for Neck Pain",[92],"2023-06-02",76,[16966,16967],"Neck Pain","Neck Pain, Posterior",[16945],{"intervention":16970,"totalTrials":126,"cells":16971},"Ergocalciferol",{"EARLY_PHASE1":16972,"PHASE1":16974,"PHASE2":16976,"PHASE3":16978,"PHASE4":16980,"NA":16982},{"trials":16973,"activeCount":100},[],{"trials":16975,"activeCount":100},[],{"trials":16977,"activeCount":100},[],{"trials":16979,"activeCount":100},[],{"trials":16981,"activeCount":100},[],{"trials":16983,"activeCount":100},[16984],{"nctId":16985,"briefTitle":16986,"status":106,"phases":16987,"primaryCompletion":5740,"completion":5740,"start":2185,"enrollment":16988,"conditions":16989,"interventions":16991},"NCT01426347","Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis",[92],139,[16990,8567],"Rheumatoid Arthritis",[16970],{"intervention":1559,"totalTrials":126,"cells":16993},{"EARLY_PHASE1":16994,"PHASE1":16996,"PHASE2":16998,"PHASE3":17000,"PHASE4":17002,"NA":17004},{"trials":16995,"activeCount":100},[],{"trials":16997,"activeCount":100},[],{"trials":16999,"activeCount":100},[],{"trials":17001,"activeCount":100},[],{"trials":17003,"activeCount":100},[],{"trials":17005,"activeCount":100},[17006],{"nctId":1551,"briefTitle":1552,"status":106,"phases":17007,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":17008,"interventions":17009},[92],[678],[680,1559],{"intervention":17011,"totalTrials":126,"cells":17012},"18F-DCFPyL",{"EARLY_PHASE1":17013,"PHASE1":17015,"PHASE2":17017,"PHASE3":17019,"PHASE4":17021,"NA":17023},{"trials":17014,"activeCount":100},[],{"trials":17016,"activeCount":100},[],{"trials":17018,"activeCount":100},[],{"trials":17020,"activeCount":100},[],{"trials":17022,"activeCount":100},[],{"trials":17024,"activeCount":100},[17025],{"nctId":17026,"briefTitle":17027,"status":106,"phases":17028,"primaryCompletion":17029,"completion":17029,"start":875,"enrollment":3394,"conditions":17030,"interventions":17033},"NCT02687139","Study of PSMA-targeted 18F-DCFPyL PET\u002FCT in the Evaluation of Patients With Renal Cell Carcinoma",[92],"2019-04",[17031,17032],"Renal Cell Carcinoma","Kidney Cancer",[17011],{"intervention":17035,"totalTrials":126,"cells":17036},"Fleet Enema",{"EARLY_PHASE1":17037,"PHASE1":17039,"PHASE2":17041,"PHASE3":17043,"PHASE4":17045,"NA":17047},{"trials":17038,"activeCount":100},[],{"trials":17040,"activeCount":100},[],{"trials":17042,"activeCount":100},[],{"trials":17044,"activeCount":100},[],{"trials":17046,"activeCount":100},[],{"trials":17048,"activeCount":100},[17049],{"nctId":17050,"briefTitle":17051,"status":106,"phases":17052,"primaryCompletion":2105,"completion":5585,"start":2186,"enrollment":2081,"conditions":17053,"interventions":17054},"NCT00696618","Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men",[92],[29],[17035,17055,17056],"tap water enema","Normosol-R enema",{"intervention":17055,"totalTrials":126,"cells":17058},{"EARLY_PHASE1":17059,"PHASE1":17061,"PHASE2":17063,"PHASE3":17065,"PHASE4":17067,"NA":17069},{"trials":17060,"activeCount":100},[],{"trials":17062,"activeCount":100},[],{"trials":17064,"activeCount":100},[],{"trials":17066,"activeCount":100},[],{"trials":17068,"activeCount":100},[],{"trials":17070,"activeCount":100},[17071],{"nctId":17050,"briefTitle":17051,"status":106,"phases":17072,"primaryCompletion":2105,"completion":5585,"start":2186,"enrollment":2081,"conditions":17073,"interventions":17074},[92],[29],[17035,17055,17056],{"intervention":17056,"totalTrials":126,"cells":17076},{"EARLY_PHASE1":17077,"PHASE1":17079,"PHASE2":17081,"PHASE3":17083,"PHASE4":17085,"NA":17087},{"trials":17078,"activeCount":100},[],{"trials":17080,"activeCount":100},[],{"trials":17082,"activeCount":100},[],{"trials":17084,"activeCount":100},[],{"trials":17086,"activeCount":100},[],{"trials":17088,"activeCount":100},[17089],{"nctId":17050,"briefTitle":17051,"status":106,"phases":17090,"primaryCompletion":2105,"completion":5585,"start":2186,"enrollment":2081,"conditions":17091,"interventions":17092},[92],[29],[17035,17055,17056],{"intervention":17094,"totalTrials":126,"cells":17095},"18F-FDS PET\u002FCT",{"EARLY_PHASE1":17096,"PHASE1":17098,"PHASE2":17100,"PHASE3":17102,"PHASE4":17104,"NA":17106},{"trials":17097,"activeCount":100},[],{"trials":17099,"activeCount":100},[],{"trials":17101,"activeCount":100},[],{"trials":17103,"activeCount":100},[],{"trials":17105,"activeCount":100},[],{"trials":17107,"activeCount":100},[17108],{"nctId":17109,"briefTitle":17110,"status":106,"phases":17111,"primaryCompletion":16723,"completion":16723,"start":17112,"enrollment":9563,"conditions":17113,"interventions":17116},"NCT05611892","Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients",[],"2022-12-22",[17114,15759,15758,17115],"Enterobacterial Infections","Invasive Fungal Infections",[17094],{"intervention":17118,"totalTrials":126,"cells":17119},"Radiolabeled autologous seminal fluid",{"EARLY_PHASE1":17120,"PHASE1":17122,"PHASE2":17124,"PHASE3":17126,"PHASE4":17128,"NA":17130},{"trials":17121,"activeCount":100},[],{"trials":17123,"activeCount":100},[],{"trials":17125,"activeCount":100},[],{"trials":17127,"activeCount":100},[],{"trials":17129,"activeCount":100},[],{"trials":17131,"activeCount":100},[17132],{"nctId":17133,"briefTitle":17134,"status":106,"phases":17135,"primaryCompletion":5097,"completion":5097,"start":4999,"enrollment":329,"conditions":17136,"interventions":17138},"NCT01053741","Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission",[92],[17137],"Human Immunodeficiency Virus (HIV)",[17118,17139],"Radiolabeled Normosol-R",{"intervention":17139,"totalTrials":126,"cells":17141},{"EARLY_PHASE1":17142,"PHASE1":17144,"PHASE2":17146,"PHASE3":17148,"PHASE4":17150,"NA":17152},{"trials":17143,"activeCount":100},[],{"trials":17145,"activeCount":100},[],{"trials":17147,"activeCount":100},[],{"trials":17149,"activeCount":100},[],{"trials":17151,"activeCount":100},[],{"trials":17153,"activeCount":100},[17154],{"nctId":17133,"briefTitle":17134,"status":106,"phases":17155,"primaryCompletion":5097,"completion":5097,"start":4999,"enrollment":329,"conditions":17156,"interventions":17157},[92],[17137],[17118,17139],{"intervention":17159,"totalTrials":126,"cells":17160},"Mupirocin and Chlorhexidine",{"EARLY_PHASE1":17161,"PHASE1":17163,"PHASE2":17165,"PHASE3":17167,"PHASE4":17169,"NA":17171},{"trials":17162,"activeCount":100},[],{"trials":17164,"activeCount":100},[],{"trials":17166,"activeCount":100},[],{"trials":17168,"activeCount":100},[],{"trials":17170,"activeCount":100},[],{"trials":17172,"activeCount":100},[17173],{"nctId":17174,"briefTitle":17175,"status":106,"phases":17176,"primaryCompletion":17177,"completion":17177,"start":5694,"enrollment":17178,"conditions":17179,"interventions":17182},"NCT02223520","Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial",[92],"2019-10-31",307,[17180,17181],"Staph Aureus Colonization","Staph Aureus Infection",[17159],{"intervention":17184,"totalTrials":126,"cells":17185},"Transdermal Fentanyl",{"EARLY_PHASE1":17186,"PHASE1":17188,"PHASE2":17190,"PHASE3":17192,"PHASE4":17194,"NA":17196},{"trials":17187,"activeCount":100},[],{"trials":17189,"activeCount":100},[],{"trials":17191,"activeCount":100},[],{"trials":17193,"activeCount":100},[],{"trials":17195,"activeCount":100},[],{"trials":17197,"activeCount":100},[17198],{"nctId":17199,"briefTitle":17200,"status":106,"phases":17201,"completion":4808,"start":7177,"enrollment":14215,"conditions":17202,"interventions":17205},"NCT00181246","Efficacy of Transdermal Fentanyl for Chronic Neuropathic Pain",[92],[17203,17204],"Peripheral Neuropathy","Complex Regional Pain Syndromes (CRPS)",[17184],{"intervention":17207,"totalTrials":126,"cells":17208},"Ferumoxytol",{"EARLY_PHASE1":17209,"PHASE1":17211,"PHASE2":17213,"PHASE3":17215,"PHASE4":17217,"NA":17219},{"trials":17210,"activeCount":100},[],{"trials":17212,"activeCount":100},[],{"trials":17214,"activeCount":100},[],{"trials":17216,"activeCount":100},[],{"trials":17218,"activeCount":100},[],{"trials":17220,"activeCount":100},[17221],{"nctId":17222,"briefTitle":17223,"status":149,"phases":17224,"primaryCompletion":14236,"completion":17225,"start":17226,"enrollment":100,"conditions":17227,"interventions":17229},"NCT03777514","Intravenous (IV) Versus Oral Iron Treatment of Iron Deficiency Anemia in the Post-operative Bariatric Surgical Patient",[92],"2022-09","2019-08",[17228],"IDA in the Post-bariatric Surgical Patient",[17207,17230],"Ferrous sulfate",{"intervention":17230,"totalTrials":126,"cells":17232},{"EARLY_PHASE1":17233,"PHASE1":17235,"PHASE2":17237,"PHASE3":17239,"PHASE4":17241,"NA":17243},{"trials":17234,"activeCount":100},[],{"trials":17236,"activeCount":100},[],{"trials":17238,"activeCount":100},[],{"trials":17240,"activeCount":100},[],{"trials":17242,"activeCount":100},[],{"trials":17244,"activeCount":100},[17245],{"nctId":17222,"briefTitle":17223,"status":149,"phases":17246,"primaryCompletion":14236,"completion":17225,"start":17226,"enrollment":100,"conditions":17247,"interventions":17248},[92],[17228],[17207,17230],{"intervention":17250,"totalTrials":126,"cells":17251},"Intralesional Triamcinolone Acetonide",{"EARLY_PHASE1":17252,"PHASE1":17254,"PHASE2":17256,"PHASE3":17258,"PHASE4":17260,"NA":17262},{"trials":17253,"activeCount":100},[],{"trials":17255,"activeCount":100},[],{"trials":17257,"activeCount":100},[],{"trials":17259,"activeCount":100},[],{"trials":17261,"activeCount":100},[],{"trials":17263,"activeCount":100},[17264],{"nctId":17265,"briefTitle":17266,"status":106,"phases":17267,"primaryCompletion":17268,"completion":17268,"start":7327,"enrollment":164,"conditions":17269,"interventions":17271},"NCT02996097","Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids",[92],"2018-06-15",[17270],"Keloid",[17250],{"intervention":17273,"totalTrials":126,"cells":17274},"Healthy volunteers",{"EARLY_PHASE1":17275,"PHASE1":17277,"PHASE2":17279,"PHASE3":17281,"PHASE4":17283,"NA":17285},{"trials":17276,"activeCount":100},[],{"trials":17278,"activeCount":100},[],{"trials":17280,"activeCount":100},[],{"trials":17282,"activeCount":100},[],{"trials":17284,"activeCount":100},[],{"trials":17286,"activeCount":100},[17287],{"nctId":17288,"briefTitle":17289,"status":873,"phases":17290,"primaryCompletion":13036,"completion":13036,"start":4843,"enrollment":10709,"conditions":17291,"interventions":17294},"NCT00796627","Hypoxia-inducible Factor-1 (HIF-1) Regulated Circulating Angiogenic Cells (CACs) Recruitment in Burn Wound Healing",[92],[17292,17293],"Wound Healing","Burns",[17273],{"intervention":17296,"totalTrials":126,"cells":17297},"recombinant human lactoferrin",{"EARLY_PHASE1":17298,"PHASE1":17300,"PHASE2":17302,"PHASE3":17304,"PHASE4":17306,"NA":17308},{"trials":17299,"activeCount":100},[],{"trials":17301,"activeCount":100},[],{"trials":17303,"activeCount":100},[],{"trials":17305,"activeCount":100},[],{"trials":17307,"activeCount":100},[],{"trials":17309,"activeCount":100},[17310],{"nctId":17311,"briefTitle":17312,"status":17313,"phases":17314,"completion":4998,"start":17315,"enrollment":164,"conditions":17316,"interventions":17318},"NCT00377078","Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.","UNKNOWN",[92],"2005-10",[17317],"Clostridium Difficile",[17296]]